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Abstract 
This thesis contributes to the Human Genome Project by adding detail to the 
physical and genetic maps of the human genome, and by identifying a strong 
candidate gene for a form of distal myopathy. 
Genomic clones for the human skeletal muscle genes slow troponin (TNN/1), 
alpha actin (ACTA1), and (3-tropomyosin (TPM2) were isolated for use in the 
fluorescent in situ hybridisation localisation of these genes on the cytogenetic 
map of the human genome. The localisation of these genes made them 
potential candidates for inherited skeletal muscle diseases, including the muscular 
dystrophies investigated here. 
M icrosatellite, VNTR and RFLP markers were used in a search for linkage to a 
novel form of distal myopathy segregating in a Western Australian family. The 
decadic logarithm of the likelihood ratio, or 'lod score' method, was used to 
determine linkage between markers and this distal myopathy gene. A 22.4 eM 
candidate region was identified at 14q11.2. This was the first localisation of a 
distal myopathy gene. The Human Genome Organisation Nomenclature 
Committee reserved MPD1, 'myopathy, distal 1 ', for this form of distal 
myopathy, now known as Laing myopathy. 
The MPD1 candidate region was excluded as the disease gene location for two 
other forms of distal myopathy. Silburn myopathy in 1994, which established 
the genetic heterogeneity of distal myopathy, and Felice myopathy in 1996. 
The exclusion of the MPD1 and French-Canadian OPMD candidate regions as 
disease gene locations for a putative-OPMD segregating in a Western 
Australian family, proved that this disease gene did not lie at 14q11.2. 
iii 
Testing an MPD1 muscle-specific candidate gene for the Laing myopathy 
mutation, the myosin heavy polypeptide 7 gene (MYH7), identified seven 
base changes between the MPD1 proband sequence and the published 
MYH7 eDNA sequence. All of these base changes were found in eight 
unrelated, unaffected Western Australians, therefore none of them were the 
Laing myopathy mutation. Two further differences to the published MYH7 
sequence segregated exclusively with the MPD1 proband. One of these, the 
MYH7 G5073C (cDNA)/G23628C (gDNA) base change, caused a critical 
change to the MYH7 13-myosin heavy chain polypeptide product (13-MyHC). 
An A 1663P 13-MyHC substitution. G23628/C 23628 segregated with Laing 
myopathy in the Western Australian distal myopathy family. This segregation 
was confirmed by a single-strand conformation polymorphism test, then used to 
test 256 unaffected chromosomes. None possessed MYH7C23628. 
Two patients from European distal myopathy families phenotypically similar to 
Laing myopathy, the Voit and Scoppetta families, were tested for the presence 
of MYH7 gDNA G23628/C23628 heterozygosity. Both were homozygous 
MYH7 G23628. One of these patients (Voit) was also tested for MYH7 
eDNA G5073/C5073 heterozygosity. She was homozygous MYH7 G5073. 
An analysis of the effect of the 13-MyHC A 1663P substitution at various levels 
of protein structure strengthened the candidature of MYH7 G5073C as the 
Laing myopathy mutation. It demonstrated the extreme rarity of the 13-MyHC 
A 1663P substitution; it showed that this substitution did have a detrimental 
effect on coiled-coil formation; and it identified ways in which the 13-MyHC 
A 1663P substitution could disrupt myofibrillogenesis or contractility. Future 
research directions are identified and the contribution of this work to evolving 
concepts in muscular dystrophy is evaluated. 
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CHAPTER 1 
INTRODUCTION 
1 
1.0 INTRODUCTION 
Clinical medicine has undergone significant changes during the past ten years as 
molecular genetics has uncovered many mutations causing inherited human 
diseases. Objective confirmation of diagnosis and accurate disease risk-
assessment for asymptomatic individuals have become increasingly available 
for families segregating inherited diseases. Based on these developments, this 
thesis investigated autosomal dominant (AD) muscular dystrophies classified as 
distal myopathy and oculopharyngeal muscular dystrophy (OPMD). 
The distal myopathies comprise a heterogeneous group of disorders showing 
both AD and autosomal recessive (AR) inheritance, with diverse phenotypic 
features and pathological changes (Mastaglia, 1991, pp. 1300-1301 ). They 
share the clinical feature of myopathic weakness beginning in the distal muscles 
of the lower and/or upper extremities (Walton & Gardner-Medwin, 1981, pp. 
505-506). OPMD was first described in 1915 by Taylor (cited in Brais et al., 
1995) who noted progressive vagus-glossopharyngeal paralysis with ptosis 
(eyelid droop) of familial nature. OPMD is now known to have world-wide 
incidence, having been reported in more than 20 countries (Brais et al., 1995). 
Some inherited forms of muscular dystrophy display both OPMD and distal 
myopathy symptoms (Satoyoshi & Kinoshita, 1977). The possibility of allelic 
heterogeneity and/or variable expressivity was one reason for the joint 
investigation of these two types of muscular dystrophy. Gelehrter and Collins, 
(1990, pp. 299 & 311) define allelic heterogeneity as "similar or identical 
phenotypes caused by different mutant alleles at the same genetic locus", and 
variable expressivity as "the variable severity of a genetic traif'. 
2 
1.1 AIMS 
This thesis has five aims. To: 
(i) isolate genomic clones for human skeletal muscle slow 
troponin (TNN/1), alpha actin (ACTA 1) and ~­
tropomyosin ( TPM2) genes, for use in the in situ 
cytogenetic mapping of these skeletal muscle contractile 
protein genes (a candidate approach); 
(ii) localise the disease gene causing a form of AD-distal 
myopathy segregating in a Western Australian family; 
(iii) test the Western Australian distal myopathy candidate 
region as the possible location for two other 
phenotypically different forms of AD-distal myopathy, 
one segregating in a Queensland family, the other in a 
Connecticut family; 
(iv) test the Western Australian distal myopathy candidate 
region and the French Canadian OPMD candidate 
region, as possible locations for a form of AD-OPMD 
segregating in a Western Australian family; 
(v) test muscle-specific candidate genes within the Western 
Australian distal myopathy candidate region for a 
possible disease-causing mutation (the positional 
candidate approach). 
3 
1.2 RATIONALE 
The rationale of this thesis is, "Knowledge of the structure and function of the 
human genome will improve the nosology, diagnosis, prognosis, prevention, 
treatment and future research into the molecular pathology of AD-muscular 
dystrophy''. 
1.2.1 Clinical Heterogeneity 
Until recently, nosology, diagnosis, prognosis and research into the molecular 
pathology of muscular dystrophy ·(MD) was based almost entirely on clinical 
phenotype. Gelehrter and Collins (1990, p. 307) define phenotype as "the 
observed result of the interaction of genotype with environmental factors, the 
observable expression of a particular gene or genes". These same authors 
(1990, p. 303) define genotype as "the genetic constitution of an individual or 
more specifically, the alleles [alternative forms of genes] at specific loci". 
Clinical phenotype usually develops its characteristic signs and symptoms after 
a long chain of causation whose individual events and timing are unknown. 
Under these circumstances, clinical heterogeneity is inevitable with genetically 
identical diseases displaying different symptoms or, conversely, with genetically 
different diseases displaying similar symptoms. In all cases, clinical 
heterogeneity reduces nosologic, diagnostic and prognostic accuracy and 
diminishes research accuracy. 
Until recently, even comprehensive diagnostic testing could not overcome the 
difficulty of clinical heterogeneity. Before the cloning of the gene responsible for 
the human muscular dystrophies, Duchenne and Becker MDs (Koenig et al., 
4 
1987), diagnosis of these diseases was based on family history, clinical 
findings, serum muscle enzyme levels, muscle biopsy, electromyography and 
electrocardiography (Kakulas & Adams, 1985 cited in Laing, 1993, p. 45). 
Despite the thoroughness of this protocol, its major weakne$5 was that all the 
elements relied on phenotypic tests of genotypic status, and phenotype can 
~ be highly variable. At the commencement of this thesis in 1993, all inherited 
forms of distal myopathy and OPMD were diagnosed on the basis of 
phenotype. Diagnostic accuracy for these forms of MD was inevitably 
confounded by clinical heterogeneity. Two approaches had been developed 
to address clinical heterogeneity. The first involved a detailed mathematical 
analysis of clinical observations, the second was based on molecular genetics. 
There have been several mathematical attempts to provide a degree of 
objectivity to clinical diagnosis based on phenotype (Preus & Ayme, 1983; 
van den Anker et al., 1993; Verloes 1995). This later attempt (Verloes, 1995, 
p. 433) submitted fifty-five published cases, belonging to five overlapping 
phenotypically related multiple congenital anomaly syndromes, to principal 
factor analysis, hierarchical clustering and graphical scaling, due to: 
the inability of the human brain to do 'unweighted' and 
unbiased multivariate analysis i.e., the impossibility of 
analyzing a phenotype without some preconceived 
view of what is discriminant and what is secondary and 
also the inability to perceive similarities between cases 
compared for dozens of manifestations. 
Twenty-nine cardinal signs used to define each syndrome were selected for 
analysis. Dendograms derived from cluster analysis showed that the five 
selected syndromes, hydrolethalus, Smith-Lemli-Opitz type II, orofaciodigital 
5 
type VI, holoprosencephaly-polydactyly and Pallister-Hall syndromes, 
evidently constituted independent phenotypic entities as clinically described. 
overlapping cases could usually be placed, unambiguously, into one of these 
categories. In three cases this required revision of the previous Pallister-Hall 
syndrome diagnosis since they "have probably been abusively diagnosed 
because of an undue stress placed on the presence of a CNS hamartoma," 
(Verloes, 1995, p. 441). 
This type of analysis is called numerical syndromology. It produces results 
comparable to the subjective pattern recognition process characterising MCA 
syndrome diagnoses by physicians. Some objective patterns of anomalies 
differing between closely similar syndromes may have been identified. 
Nevertheless, numerical syndromology seems inordinately complex and, from 
the outset, quite limited in expectation. It acknowledges; that it is a heuristic 
process not supported by statistical reasoning, that biased ·selection of data 
rather than causal entity may account for clusters, that it cannot deliver any 
hierarchy of syndromes and that it cannot be expected to solve the problem of 
genetic heterogeneity among phenotypically related cases. 
Numerical syndromology has had limited success at introducing objectivity to 
clinical diagnosis. It can improve the accuracy with which syndromes are 
categorised and described, but that is all. No matter what mathematical model it 
adopts, this approach can never address the underlying causes of the 
syndromes. It can never identify disease genes, those genes that when 
mutated give rise to human disease (Collins, 1992, p. 3). In contrast, molecular 
genetics can identify disease genes, improving disease classification, diagnosis 
and, sometimes, prognosis. 
6 
The process of linking genetic change to clinical phenotype commenced with the 
discovery of disease-causing mutations by Pauling et al. (1949), with each 
newly-discovered mutation suggesting further avenues of research into the 
molecular pathology of the disease that it caused. For these reasons, molecular 
genetics was the approach adopted in this thesis. ·It provided the opportunity 
to make the complexities of clinical heterogeneity less refractory. 
1.2.2 Muscular Dystrophy Nosology 
Human MDs are defined as "those conditions in man in which there is a primary, 
progressive degenerative disease of skeletal muscle. The characteristic 
features include a symmetric distribution of muscular atrophy, an intact nerve 
supply, and the liability to heredo-familial incidence." (Adams, et al., 1962, p. 
78). The distal myopathies and the OPMD investigated in this thesis are MOs. 
MD has become a general term to describe "a group of inherited and 
progressively debilitating myogenic disorders which can be classified into more 
than 20 diseases on the basis of genetic as well as clinical features." (Ozawa et 
al., 1998, p. 421 ). 
The power of molecular genetics to contribute to MD nosology became 
apparent with the cloning of the first major human disease gene identified using 
the 'new genetics', the dystrophin gene (Koenig et al., 1987). Four 
technological advances have contributed most to the identification of disease 
genes: DNA banking technology providing a permanent supply of a family's 
DNA (Neitzel, 1986); the polymerase chain reaction (PCR) (Saiki et al., 1985); 
rapid PCR based linkage studies (Weber & May, 1989); and rapid mutation 
screening technologies (Saiki et al., 1988; Vosberg, 1989; Williams, 1989; 
Bloch, 1991 ). 
7 
The first MDs to be reclassified by molecular genetics were dystrophinopathies, 
the MDs caused by mutations in the dystrophin gene. The phenotypes of 
dystrophinopathies occur "with a wide range of neuromuscular symptoms, and 
neither male sex nor proximal weakness are diagnostic prerequisites for 
consideration of an underlying dystrophin abnormality." (Hoffman & Schwartz, 
1991, p. 175). Table 1.1 (p. 9) shows the early impact of molecular genetics 
on MD nosology. 
Apart from the dystrophinopathies, by 1993 only myotonic dystrophy 
diagnosis could be confirmed by mutation type (Brook et al., 1992). In addition, 
genetic location could be used to confirm disease diagnosis for X-linked 
myotubular myopathy (MTM) (Liechti-Gallati et al., 1991), Emery-Dreifuss MD 
(Gonsalez et al., 1991), facioscapulohumeral MD (FSHD) (Wijmenga et al., 
1992), severe childhood AR-MD (SCAR MD) (Ben Othmane et al., 1992) and 
limb girdle MD (LGMD) (Beckmann et al., 1991; Speer et al., 1992). 
SCARMD has been classified as a subgroup of the AR-LGMD group 
(Bushby & Beckmann, 1995), but debate continues about SCARMD 
nosology (Ozawa et al. 1998, p. 433). 
Table 1.1 also shows that genetic linkage had not been demonstrated in any 
form of distal myopathy or OPMD at the commencement of this project, nor had 
any candidate gene been identified for either of these disorders (MI M 160500 
& MIM 164300; McKusick, 1992). 
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Table 1.1 Muscular Dystrophy Nosology, 1993 
Dystrophy type Identification Cytogenetic Location Gene 
X-Unked recessive 
Dystrophinopathies Koenig et al., 1987 
Duchenne Meryon, 1852 (cited in Partridge, 1993, p. xiii) Xp21.2 Boyd & Buckle, 1986 Dystrophin (DMD) Koenig et al., 1987 
Becker Becker, 1955 (cited in Ozawa, et al., 1998, p. 421) Xp212 Koenig et al., 1987 Dystrophin ~DMD) Koenig et al., 1987 
Quadriceps myopathy Thage, 1965 Xp21.2 Sunohara et al., 1990 Dystrophin DMD) Koenig et al., 1987 
Myalgia and cramps Kuhn et al., 1979 Xp21.2 Gospe et al., 1989 Dystrophin (DMD) Koenig et al., 1987 
Emery-Dreifuss MD Emery & Dreifuss, 1966 Xq28 Gonsalez et al., 1991 
Myotubular myopathy (MTM1) Engel et al., 1968 Xq28 Uechti-Gallati et al., 1991 
Autosomal dominant 
Myotonic dystrophy (DM1) Bell, 1947 19q13.2-q13.3 Harley et al., 1991 CTG repeat expansion Brook et al., 1992 
Facioscapulohumeral MD Tyler & Wintrobe, 1950 
FSHD Wijmenga et al., 1992 4q35 Wijmenga et al., 1992 
Umb-girdle MD (LGMD) Walton & Nalrass, 1954 
LGMD Gilchrist et al., 1988 Sq31-q33 Speer et al., 1992 
LGMD Panegyres et al., 1990 
Bethlem myopathy Bethlem et al., 1976 
Distal myopathy Gowers, 1902 
Welander (WMD) Welander, 1951 
Rnnish Tibial Udd et al., 1991 
Markesbery Markesberyetal., 1974 
Oculopharyngeal MD Taylor, 1915 (cited in Brais et al., 1995) 
OPMD Barbeau, 1965 (cited in Brais et al., 1995) 
Oculopharangodistal myopathy Satoyoshi & Kinoshita (1977) 
Autosomal reciessive 
Severe Childhood AR-MD Kloepfer & Talley, 1958 
SCAR MD Passos-Bueno et al., 1991a & b 13q Ben Othmane et al., 1992 
Umb girdle MD Walton & Natrass, 1954 
LGMD Shokeir & Kobrinsky, 1976 
LGMD Panegyres et al., 1990 
LGMD Beckmann et al., 1991 15q15.1-q21.1 Beckmann et al., 1991 
LGMD Mahjneh et al., 1992 
Congenital MD Batten, 1909 (cited in Markesbury, et al.,1974, p.127) 
*Fukuyama · Fukuyama,et al., 1981 
Merosin deficiency Tomeetal., 1994 
*Walker-Warburg syndrome Warburg, 1976 
*Muscle, eye and brain (MEB) disease Santavuori & Leisti 1980 
Distal myopathy Gowers, 1902 
Miyoshi (MM) Miyoshi et al., 1975 &1986 
Non aka Nonakaetal., 1981 &1985 
Hereditary inclusion 
body myopathy (h-IBM) Askanas & Engel1993 
* with neurogenic involvement 
1.2.3 Molecular Pathology, Diagnosis, Prognosis, 
Prevention and Treatment 
Nosology is a means, not an end. It groups diseases according to perceived 
similarities in pathology. Its precision depends upon knowledge of pathological 
mechanisms. Molecular genetics has been able to identify primary causes of 
inherited disease, the first step in their molecular pathology, by identifying 
disease gene locations and disease-causing mutations. But improved 
knowledge of molecular pathology has not only lead to refined nosology. More 
importantly, it has lead to better diagnosis and prognosis and better methods of 
prevention. This became evident shortly after the cloning of the dystrophin 
gene. 
The dystrophinopathies belong to an allelic series, a term first used by 
McKusick (1973, p. 446) to describe phenotypic diversity of human diseases 
caused by mutations in the same gene. Monaco et at. (1988) demonstrated 
that mutation type could contribute to the severity of dystrophinopathy. They 
linked disease severity and mutation type by discovering that the size or 
location of dystrophin mutations did not correlate with the clinical severity of 
DMD or BMD. In an attempt to explain these observations, Monaco et at. 
(1988) proposed the 'reading frame theory' which hypothesised that disease 
severity was directly correlated to the effect of the genetic lesions on the open 
reading frame (OAF) of messenger RNA (mANA) transcript triplet codons. 
Analysis of the mutations in lymphocyte DNA from many hundreds of DMD 
and BMD patients has shown that severe DMD is predominantly a 
consequence of intragenic deletions that cause translational reading frame shifts 
in the mANA (Koenig et at., 1989; den Dunnen et at., 1989). Stop codons 
generated by these frameshift mutations result in the premature termination of 
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protein synthesis during translation, leading to the production of truncated 
dystrophin molecules lacking a carboxyl terminus. These truncated molecules 
are non-functional and rapidly degraded, explaining the lack of dystrophin in 
these DMD patients. 
Conversely, the deletions or duplications resulting in the less severe BMD 
patients bring together exons that maintain the reading frame, resulting in the 
synthesis of shorter, lower molecular weight semi-functional dystrophin (Koenig, 
et al., 1989; den Dunnen et al., 1989). A large study of 256 deletions along the 
the entire length of the dystrophin gene, found that the 'OAF frameshift theory' 
of Monaco et al. (1988) was consistent with phenotype in 92% of cases 
(Koenig et al., 1989). 
Beggs et al. (1991) confirmed that this was the molecular basis for phenotype 
variability among patients suffering from dystrophinopathies. In addition, these 
authors established that deletions within the amino-terminal domain tended to 
result in low levels of dystrophin and, consequently, a more severe phenotype. 
The phenotypes of patients with deletions or duplications in the central rod 
domain were found to be more variable. While agreeing that the discovery of 
disease-causing mutations could improve diagnosis and prognosis, these 
authors also added a cautionary note, ". . . however, phenotypic variability 
among patients with similar mutations suggests that epigenetic and/or 
environmental factors play an important role in determining the clinical 
progression." (Beggs et al., 1991, p. 54). This caution is revisited several times 
throughout this thesis. 
Prevention of dystrophinopathies, particularly DMD, is achieved by prenatal 
diagnosis allowing known carriers the choice of terminating affected foetuses. 
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The status of male foetuses is most frequently determined by multiplex PCR 
(Chamberlain et al., 1988) because this has the advantage of detecting 98% of 
all dystrophin deletions in about 24 hours (Beggs et al., 1990). 
Dystrophinopathy treatments based on replacement of damaged dystrophin 
have been under development for several years, (Anderson & Kunkel, 1992). 
There are three general approaches: myoblast transplantation, gene therapy 
and genetic therapy. The objective of all these approaches has been to 
increase the quantity of functional dystrophin in affected DMD tissues to levels 
of therapeutic value, effectively ameliorating DMD symptoms to that of BMD. 
The cloning of the dystrophin gene, the substantiation of the 'ORF frameshift 
theory' of Monaco et al. (1988), improved diagnosis, prognosis and prevention 
for the dystrophinopathies and the promise of dystrophin replacement therapy, 
launched an exponential expansion of molecular genetic investigation into the 
MOs. 
The rationale of this thesis was based on the success of these early 
investigations into the molecular genetics of the MOs. The expectation was that 
their success could be repeated, at least in part, for three forms of AD-distal 
myopathy and one form of AD-OPMD. Refinement of distal myopathy and 
OPMD nosology, diagnosis and prognosis appeared an achievable goal. 
Local factors also made the MD investigations in this thesis viable. 
1.2.4 Ascertainment 
Ascertainment of families segregating inherited disorders and the banking of their 
DNA is the first crucial step in any attempt to identify human disease genes. 
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W ithout families containing sufficient numbers of affected individuals, the cloning 
of human disease genes cannot proceed. Geographic isolation and an 
associated low rate of emigration, has led to the establishment of large families 
in Western Australia. Having family members all within one state is an important 
advantage for human disease gene cloning, because ascertainment and the 
banking of DNA is frequently the rate-limiting step of gene localisation. 
Ascertainment in Western Australia is also greatly assisted by world-class 
diagnostic facilities and excellent medical records stretching back to the early 
years of colonisation. The identification of a proband in a large Western 
Australian family presented the possibility of tracing their inherited disease 
backwards and/or forwards through three, four or five generations. Exploiting 
these local advantages, this thesis investigated a large Western Australian 
family segregating a form of AD-distal myopathy over three generations. 
Medical records of this kinship stretched back more than 30 years, all living 
members resided in Western Australia, and, most importantly, this kinship 
contained nine affected members, sufficient to be confident of localising the 
responsible disease gene. 
The ultimate rationale of all molecular genetic investigations into inherited human 
disease is to improve knowledge of their molecular pathology and so develop 
better nosology, diagnosis, prognosis, prevention, and treatments for each 
disease. This investigation into three forms of AD-distal myopathy and one 
form of AD-OPMD was based on this rationale. 
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CHAPTEB2 
HUMAN DISEASE GENES 
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2.0 HUMAN DISEASE GENES 
The search for human disease genes using 'new genetics' began during the 
1980s, driven by a desire to influence the course of genetic disease. As a 
direct result of this ongoing search, high-resolution genetic and physical maps of 
the human genome are now available, and it was predicted that the entire 
sequence of the human genome would be known by the year 2003 (G. 
Sutherland, personal communication, 1997; Collins et al., 1998, p. 687). In fact, 
97% of the human genome sequence became available in July, 2000 (Golden 
& Lemonick, 2000). 
2.1 HUMAN INHERITANCE 
Human phenotype is determined by a mixture of major and minor genetic 
determinants, together with environmental influences (Gelehrter & Collins, 1990, 
pp. 57 & 64; Strachan & Read, 1996, p. 61 ). 
2.1.1 Patterns of Inheritance 
The genotype at a locus often influences human phenotype to the extent that 
non-Mendelian patterns of inheritance result (Ott, 1997, p. 23). Traditionally, 
non-Mendelian human traits have been described as multifactorial, resulting from 
the interplay of multiple environmental factors with multiple genes. Multifactorial 
inheritance has been further subdivided into polygenic and oligogenic inheritance 
(Gelehrter & Collins, 1990, p. 57). Polygenic traits are those determined by 
many genes, called polygenes, each locus having a small effect on the 
determination of a trait (Strachan & Read, 1996, p. 81 ). Oligogenic traits are 
those determined by a small number of genes, called oligogenes, originally 
called 'leading factors' by Wright (1968, cited by Morton & Lio, 1997, p. 17), 
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each having a larger effect on the determination of a trait (Strachan & Read, 
1996, p. 81 ). 
2.1.2 Inherited Disease 
Human diseases with an inherited component (inherited human diseases) are 
classified in the same way as normal traits. Uke these traits, most inherited 
human diseases do not display Mendelian segregation (Lander & Schork, 
1994, p. 2037). Even when Mendelian inheritance is apparent, three common 
confounders of this pattern of disease segregation have been identified: locus 
heterogeneity, where similar phenqtypes are caused by mutations at different 
genetic loci, e.g. retinitis pigmentosa (Kajiwara et al., 1991; Dryja, et al., 1990); 
variable expressivity, where individuals with the same mutant gene show 
variable clinical phenotype, e. g. peripheral neurofibromatosis (von 
Recklinghausen disease) (Collins et al., 1989); and reduced penetrance, where 
only a proportion of those with a disease-causing mutation actually express 
clinical phenotype, e.g. RB1 gene mutations in retinoblastoma (Lohmann, 
1999). 
The majority of common inherited human diseases display a genetic component 
but their pattern of inheritance is unclear. They appear to have their clinical 
phenotype determined by multiple environmental and genetic factors (Ott, 
1997, p. 23). The extent to which these diseases run in families is measured 
by the ratio of recurrence risk in monozygotic twins versus that in dizygotic twins, 
or the ratio of recurrence risk in a sibling versus population incidence (Piomin et 
al., 1994). 
If individual disease liability is normally distributed with higher average liability for 
sibs of affected parents, a disease is classified as polygenic (Falconer, 1981, 
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cited by Strachan & Read, 1996, pp. 486-488), each polygene having a small 
effect on the determination of the disease. The locations of polygenes 
contributing to the expression of polygenic disease are called susceptibility loci 
(Strachan & Read, 1996, pp. 486-491). A recent genomic screen involving 
519 markers and 147 independent affected sib pairs provided evidence that 
one form of autism was a polygenic disease, not an oligogenic one, with more 
than 15 susceptibility loci involved (Risch et al., 1999). Supporting this 
conclusion, other studies involving these same affected sib pairs have excluded 
the suggested oligogenic role of the chromosome 6p histocompatibility 
complex (HLA) loci in the genetic aetiology of autism (Rogers et al., 1999), 
and have excluded the chromosomal region 15q11-q13, also implicated as a 
region harbouring major susceptibility autism gene(s) (Salmon, et al., 1999). 
Inherited human diseases are classified as oligogenic if each locus has sufficient 
effect to be detected by linkage analysis (Morton & Lio, 1997, p. 17). The 
locations of oligogenes contributing to the expression of oligogenic disease are 
called major susceptibility loci (Strachan & Read, 1996, pp. 486-491). Some 
major susceptibility loci for oligogenic diseases have been identified: HLA-8 
susceptibility locus for ankylosing spondylitis (Schlosstein et al., 1973), 
apolipoprotein E (APOE) susceptibility locus for late onset Alzheimer's (Corder 
et al., 1993), and Vitamin D Receptor (VDR) susceptibility locus for 
osteoporosis (Morrison et al., 1994). 
Classification of human inheritance patterns is further complicated by 
observations that oligogenes may operate over a polygenic background and 
that some genes may appear as a Mendelian determinant for one character but 
as a polygene for another. Strachan and Read, (1996, p. 490) have 
suggested that, "between pure Mendelian and pure polygenic characters there 
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lies a whole spectrum of traits governed by major susceptibility loci, possibly 
operating over a polygenic background and sometimes subject to major 
environmental determinants". 
This view sees all human characters and inherited diseases lying along a 
Mendelian- oligogenic- polygenic- environmental continuum. It is a panoramic 
view, but one which lacks important detail because it captures interacting 
environmental and genotypic events through a wide-angled phenotypic lens. 
Through this lens, developed pictures of inherited disease are inevitably blurred 
by clinical heterogeneity. Human molecular genetics has started to improve 
'focus by adding genotypic lenses. 
The cloning of human disease genes is the first step towards uncovering the 
molecular events determining clinical phenotype. Their cloning and analysis 
have already added, and will continue to add, functional detail to contemporary 
phenotype definitions of Mendelian, oligogenic and polygenic inheritance. As 
the cloning of human disease genes progresses, phenotypic descriptions of 
inherited human disease will be supplemented with patho-physiology details, 
based upon improved understanding of mutated gene action. Mechanisms 
underlying the clinical heterogeneity of inherited disease will begin to emerge, 
promoting further research into the molecular pathology of human genetic 
disease. Better treatments for affected individuals will develop at an increasing 
pace. 
2.2 HUMAN GENOME PROJECT 
The cloning of human disease genes in the years 1984-1989 led to three 
observations: that altered gene function was an effective way to identify human 
genes; that the identification of disease-causing mutations improved both the 
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genetic and physical map of the human genome; and the efforts of individual 
laboratories to clone genes, 'one-at-a-time', was wasteful of time and resources. 
These observations first began to emerge in 2 reports published by the 
Department of Energy (DOE) in the USA; 'Technologies for Detecting 
Heritable Mutations in Human Beings" (1985) and, "Report on the Human 
Genome Initiative" (1987). It was these reports that launched the idea of a 
dedicated Human Genome Project (HGP). 
After a series of pilot projects and the involvement of the United States Office 
of Technology Assessment and the United States National Institutes of Health, 
HGP commenced in 1991, governed .by the Human Genome Organisation 
(HUGO) (Strachan & Read, 1996, p. 336). Its major goal was to understand 
the structure of the human genome, its major rationale was the expectation that 
new advances in molecular genetics, would find application in the fields of 
diagnostic and therapeutic medicine (Collins, 1992, pp. 5-6). 
From the DOE reports and pilot projects, three things became apparent: that 
the most effective way to track down the vast majority of human disease genes 
was to develop a high-resolution physical map of the human genome; that this 
could only be built from detailed genetic and physical maps; and that the 
localisation of disease genes on these maps would simultaneously improve 
both maps and lead to the cloning of disease genes. 
2.3 GENETIC MAP OF THE HUMAN GENOME 
For the great majority of disease genes, the first step towards their cloning has 
been their localisation on the genetic map of the human genome. The 
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foundations for genetic mapping were laid when Alfred Sturtevant (1913) 
charted the locations of mutations affecting six Drosophila melanogaster 
developmental genes. He understood neither the biochemical basis of these 
defects nor even that genes were made from DNA. By correlating the co-
inheritance patterns of six X-linked mutations he developed a genetic map 
based solely on abstract mathematical reasoning and not biochemistry: the 
closer two genetic markers were on a chromosome, the more frequent was their 
co-inheritance. 
Sturtevant's abstract mathematical reasoning was the first demonstration of what 
is now called parametric linkage analysis. The HGP is developing a genetic 
map of the human genome based on parametric and nonparametric linkage 
analysis and by identification of allelic association. 
2.3.1 Recombination Fraction 
Recombination fraction, or theta (6}, measures the frequency of crossovers 
between loci, and is defined as the fraction of meiotic events that show a 
recombination between two loci (Gelehrter & Collins, 1990, p. 309). It 
provides a measure of the genetic distance between two markers. If two 
markers are close together, e will be small with a value of zero attained when 
both markers coincide. If they lie further apart, e will be larger with an upper limit 
of 0.5, corresponding to 'recombination' between markers located on non-
homologous chromosomes. Recombination fractions can never exceed 0.5 no 
matter how great the physical distance between them. This is immediately 
obvious for a single crossover and is also true for multiple crossovers (Strachan 
& Read, 1997, pp. 314-315). 
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Haldane (1919) showed that, if crossovers were distributed independently with 
respect to one another, occurring randomly along synapsed diplonema 
chromosomes and having no influence on each other, the number of crossovers 
between two markers was Poisson distributed. By summing alternative terms 
of the Poisson distribution, the probability of an odd number of crossovers 
(evidence of recombination) became: 
e = (1 - e-2d ) 12 
where e is the base of natural logarithms and d is the map distance between the 
markers. This equation became known as Haldane's mapping function because 
it expressed the mathematical relationship between recombination fraction and 
genetic map distance. For small distances, this mapping function reduces to: 
e = d 
reflecting the fact that the possibility of more than one crossover can be 
neglected for closely linked markers. 
Haldane (1919) defined two loci showing 1% recombination (a recombination 
fraction of 0.01) as separated by 1 centiMorgan (eM), in recognition of the 
genetic mapping of the Drosophila sp. fruit fly being carried out by Morgan's 
group at Columbia University. In 1916 Muller wrote a four-part review based 
on his doctoral thesis, "The mechanism of crossing over''. Edwards (1997, p. 
11 ), considered that Morgan's group may have been aware of Haldane's 
mapping function before 1919, and substantiates this view by quoting from the 
second-part of Muller's report: 
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In the case of higher percents of separation (long 
distances), the highest of three frequencies (let us call it 
A C) falls short of the sum of the other two (AB +A C), 
and so it is a smaller number than the distance 
representing it on the diagram, but nevertheless (within 
the normal limits of error) can be calculated from this 
diagram distance A C, for a constant relation was 
discoverable between this hypothetical distance and 
the actual frequency. 
Since Muller's reviews focussed significantly on the work done by Morgan's 
group, it may be that this group actually laid the foundations for linkage 
estimation theory. Unfortunately, Haldane does not refer to Muller's work in his 
paper and Muller's doctoral thesis ca~not be found. Perusal of Muller's thesis 
might have settled the issue of who first developed a genetic mapping function 
(Edwards, 1997, p. 11). 
2.3.2 Genetic Markers 
All forms of genetic mapping use genetic markers, which are defined as, 
"mendelian [sic] characters which are sufficiently polymorphic to give a 
reasonable chance that a randomly selected person will be heterozygous" 
(Strachan & Read, 1996, p 317). 
Five types of polymorphic DNA marker have contributed most to the 
development of the human genetic map: restriction fragment length 
polymorphisms (RFLPs) (Botstein et al., 1980), variable number tandem 
repeat (VNTR) minisatellite polymorphisms (Jeffreys et al., 1985; Nakamura et 
al., 1987), microsatellite polymorphisms (Beckmann, 1988; Weber & May, 
1989) and single nucleotide polymorphisms (SNPs) (Kwok & Gu, 1999). All 
DNA polymorphisms can be associated with genes or can be anonymous 
DNA fragments (D-segments) without gene association. 
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RFLPs and minisatellite VNTRs are now seldom used for genetic mapping. 
RFLPs have only two alleles (the restriction site is present or is not) and so lack 
informativeness. Minisatellite VNTRs have preferential sub-telomeric location 
(de Lange et al., 1990), which excludes large parts of the genome from 
analysis. Also, since minisatellite size ranges from 0.5 kb to 40 kb (Armour, 
1996, p. 172), large alleles will not amplify under standard PCR conditions 
(Saiki et al., 1990). 
For these reasons, microsatellites became the standard tool for developing the 
genetic map of the human genome. They are evenly distributed throughout the 
human genome, are highly polymorphic and arrays of the most commonly used 
sequence for genetic studies, (CA/GT) n where n is greater than 12, are 
estimated to occur approximately 35,000 times or once every 100 kilobase 
(kb) (Weber, 1990). 
More recently, a world-wide effort has commenced to discover several hundred 
thousand SNPs throughout the human genome, each a variation of one 
nucleotide between the DNA sequence of individuals (Collins et al., 1997). 
SNP databases have been developed (Smigielski et al., 2000; 
http://www.ncbi. nlm.nih.gov/SNP), in anticipation that the identification of these 
polymorphic sites will revolutionise molecular diagnosis, accelerate the 
discovery of genes contributing to disease and contribute to 
pharmacogenomics (Pfost et al., 2000). 
2.3.3 Polymerase Chain Reaction 
PCR amplifies short sequences of DNA, in vitro, from template DNA between 
100 base pairs {bp) to 6 kb in length (Saiki et al., 1990). It amplifies template 
DNA approximately one billion times (Mullis, et al., 1986). Standard PCR 
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amplifies picograms (pg) of template DNA (1 0-12 g) to produce micrograms 
(.ug) of of DNA product (10·6 g), which can be routinely sized by agarose gel 
electrophoresis. 
The first step of PCR is the denaturation of template DNA by heating to about 
94oc for approximately 3 minutes on the first cycle, 30-60 seconds on 
subsequent cycles. After the initial denaturation, the reaction is cooled, for 
example, to sooc-ssoc for 1 minute and the primers, present in high 
concentration, anneal to their complementary sequence at the 3' ends of each 
template DNA strand. Optimum ·annealing temperatures vary for different 
primers and template DNA. 
Primers are chemically synthesised oligonucleotides, usually 20-25 nucleotides 
long with a free hydroxyl group present on their 3' ends. They are designed to 
target specific regions in the genome through the laws of probability. If a primer 
has a random sequence of 20 nucleotides, the number of possible sequences 
for a primer of that length is (1/4)20, given that any one of four nucleotides can 
occupy each site. This means that the chance of any 20 nucleotide sequence 
appearing in a 3x1 09 bp double stranded length of DNA is: 2x(1/4)20x(3x1 09), 
making the chance that it will appear twice equal to: 2x(1/4)20x(1/4)20x(3x1 09), 
or approximately 5x10·15. Based on these calculations, each primer is unique in 
the genome by a factor of 1015-1016. In reality, the bulk of the human genome 
comprises DNA of varying degrees of repetitivity, and only 1 0% of it is single 
copy sequence (Cooper, 1995a, p. 1 ). For primers targeting single copy 
sequence, the uniqueness of each primer becomes 1014-1015. 
Notwithstanding these impressive statistics, false priming can still occur. 
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PCR reactions are then heated from their primer annealing temperatures to 
12oc for a length of time which is dependent on amplicon size. Nucleotides are 
present in the reaction mixture. This allows template DNA amplification to occur. 
Nucleotides attach to the 3' hydroxyl group of the primer and extend along each 
template DNA strand by adding complementary nucleotides, and so make 
each strand of the template double stranded. DNA synthesis proceeds in a 5' 
to 3' direction while template DNA strands are 'read' in a 3' to 5' direction (Mullis 
et al., 1986; Saiki et al., 1989). 
Amplification is achieved using thermostable DNA polymerases that withstand 
high temperatures. These are isolated and purified from organisms adapted to 
hot environments, such as the bacterium Therrnus aquaticus. The optimum 
amplification temperature for thermostable PCR DNA polymerases is 12oc, 
and they can withstand the repeated 94oc DNA denaturation cycles which 
follow each amplification cycle (Hayashi, 1994). 
After the initial denaturation, the cycle, 'primer annealing -> DNA amplification -> 
denaturation' is repeated, frequently up to 40 times. Template DNA is 
continuously denatured and amplified, with the new product acting as a template 
for the next. Unless the template DNA is exactly the same size as the product, 
as happens when a gel-purified PCR product is re-amplified, DNA polymerase 
will extend past the other primer but in an arithmetic fashion. In contrast, copies 
of template DNA between the primers increase exponentially and most PCR 
DNA-product is of this defined length. PCR DNA polymerases synthesise 
DNA at a rate of approximately 1 000 bases per minute, achieving a billion fold 
increase in template DNA between the primers after 30-35 PCR cycles (Saiki, 
1990). 
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2.3.4 Unity of Gene Mapping 
All methods of human disease gene localisation share the following similarities. 
All depend upon affected individuals' posterior probabilities (probability after 
pedigree analysis) of being identical by descent (IBD) at genetic markers 
exceeding the prior probabilities (probability before pedigree analysis) of the 
same genetic markers being IBD. All rely upon the decline of IBD segments 
between individuals as genetic relationship diminishes. All are based on 
models, explicit in the case of parametric methods and implicit in nonparametric 
methods. All establish linkage between markers and disease genes by 
identifying a series of recombination fractions equal to zero for the segregation of 
a disease gene and a group of markers. These similarities suggest an 
underlying unity to human gene mapping. This unity was described eleven 
years before HGP got underway, then apparently overlooked (Thompson, 
1997, p. 139). 
2.3.5 Connecting Meioses (m) 
The basic unity of genetic mapping was first emphasised by Edwards (1980) 
who defined genealogy as the number of meioses ( m) connecting individuals. 
Defining genealogy in this way, placed regular families, isolated pairs of 
relatives, populations of individuals related in unknown ways and even whole 
species (huge numbers of families of 1 connected by unknown numbers of 
meioses) all on the same m-continuum. It also linked genealogy to genetic 
distance. Since m determines IBD marker prior probabilities, and all disease 
gene mapping depends upon comparing IBD marker prior probabilities to IBD 
marker posterior probabilities in affected individuals, m is the fundamental unit of 
linkage analysis. 
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Edwards (1997, p. 34) cites Robbins (1918) as having demonstrated that 
allelic association decay was given by (1-0n, where twas the recombination 
fraction (now given the symbol 6) and n was the number of generations. 
Edwards (1980) used Robbins' allelic association decay formula to determine 
that 1 eM DNA lengths retain approximately 50% continuity after 70 generations 
or after about 21 00 years if generation time was 30 years. Defining haplotype 
half-life as the number of segregations required to make prior haplotype 
probability approximately 0.5, the haplotype half-life for 1 eM DNA was about 
70 generations for t (or 6) = 0.01. This was obtained by substituting these 
values in Robbins allelic association decay formula: 
(1 - 0.01 )?0 = 0.9970 = 0.495 
van der Meulen and te Meerman (1997) provided theoretical support for 
Edwards' analysis. Assuming a population growth of 5.5% per generation and 
a quasi-exponential distribution for the number of offspring, the probability 
distribution for the size of the area where no recombination occurs, could be 
calculated from: 
for N meioses and a probability of recombination, t When the expected size 
of this area and its variance are calculated by partial integration, carriers of human 
disease genes that appeared 60 generations ago (approximately 1500 years) 
share, on average, about 5cM DNA with a standard deviation of 8 eM. 
Ten years after Edwards' discussion of allelic association in man, Bishop and 
Williamson (1990) examined the conditional probability of gene IBD: 
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P (relatives lBO at disease locust relatives both affected) 
They considered this as the conditional probability of gene lBO because all 
linkage detection methods are based on the premise that marker loci 
surrounding loci causing or contributing to a disease, are likely to be 
genotypically similar in affected relatives. Bishop and Williamson (1990) 
showed that the probability of gene identity between single loci surrounding 
disease loci, given two affected relatives, depended upon genealogical 
relationship, disease allele frequency and the risk-ratio of the disease 
susceptibility allele as calculated from penetrance probability. The overall result 
of including more parameters in their calculations was the same as Edwards' 
(1980) earlier conclusions. The greater the genealogical distance to a common 
ancestor, the greater the number of meiotic steps, the smaller the conserved 
ancestral segments. 
2.3.6 Likelihood 
One statistic dominates all methods of gene mapping: likelihood (Fisher, 1912, 
1922a). In genetic mapping, probability refers to events yet to be observed, 
likelihood refers to events that have already been observed. In 1912, Fisher 
introduced the concept of likelihood and then developed it into the method of 
maximum likelihood (Fisher, 1922a). Likelihood is the probability of the 
occurrence of results had this probability been calculated before the 
observations were made. In genetics, the value of likelihood depends upon 
the assumed value of the recombination fraction, so likelihood is a function of e 
and can be plotted against it. Fisher's method of maximum likelihood was 
based on his observations that the likelihood function (or graph) contained within 
itself all the relevant information provided by the observations, and that the 
value of e at which likelihood attained its maximum value was a good estimate of 
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the actual value of e. Because likelihoods can reach very high values and are 
difficult to represent on a graph, Fisher chose to plot the natural logarithm of the 
likelihood as a function of e (Fisher, 1922a). 
Fisher (1922b) tested his maximum likelihood method by calculating maximum 
likelihood estimates for eight X-linked Drosophila loci whose order was assumed 
known. The possibility of multiple crossing-over was ignored, making Fisher's 
estimates approximate. Edwards (1989) derived the exact maximum 
likelihood solution for Fisher's work, confirming the power of the original 
calculations. 
There are two types of likelihood calculations. First, when it is possible to 
specify parameters of disease inheritance, it is also possible to predict from 
pedigrees the prior probability that two loci should be linked. The widely 
accepted prior probability that any two loci are linked on the human genome is 1 
in 50, giving a prior probability that they are not linked of 49 in 50 (Strachan and 
Read, 1996. p. 320). Bayes' theorem provides a general method for 
combining probabilities into joint probabilities, allowing the determination of 
posterior probabilities that indicate linkage, conditional on the above accepted 
prior probabilities (Nicholls & Stark, 1971 ). A formal statement of Bayes' 
theorem is: 
P(H~E) = P(Hi) P(EIHi) I I P(Hi) P(EIHi) 
where P(H;) means the probability of the i th hypothesis and P(EI Hi) the 
probability of the evidence E, given the hypothesis H; (Krawczak & 
Schmidtke, 1994, pp. 66-68). In this case, calculation of linkage threshold yields 
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a joint probability of linkage (the overall odds in favour of linkage) as the product 
of prior and posterior linkage probabilities. Posterior probabilities are 
empirically determined, E, in this sampling design. 
Calculating acceptable posterior probabilities from Bayes' theorem for both 
linkage and non-linkage requires specification of an acceptable level of 
significance for joint probability of linkage. The conventional p=0.05 threshold of 
significance, or odds of 20:1, for joint probability of linkage versus non-linkage, is 
universally accepted. Therefore, calculating posterior probabilities from Bayes' 
theorem for linkage and non-linkage is a simple matter of substituting the 
appropriate linkage and non-linkage prior probabilities (1/50 and 49/50) and the 
linkage and non-linkage joint probabilities (20 and 1, as odds). To achieve an 
overall linkage threshold of significance p=0.05, conditional upon the stated prior 
probabilities, the minimum required posterior probability odds that emerge are, 
1000:1/linkage:non-linkage. These are the odds against which genome testing 
data is measured (Blanket al., 1988). 
Second, when it is not possible to specify an explicit disease model, the 
posterior probability of shared genome at the marker loci is compared to the 
prior probability. The probability of obtaining the observed posterior 
probabilities, had the prior probabilities been correct, is a measure of relative 
likelihood since it is derived from the ratio of relative posterior and prior 
probabilities (Smith & Stephens, 1997). Since this a 'model-free' analysis, prior 
probabilities are estimated from what would be expected by random 
segregation. Absolute probabilities· do not change likelihood estimates 
because they are obtained by adjusting the sum of relative posterior and prior 
probabilities to equal 1. For example, the ratio 3:1 could become become 
3/4:1/4. This logic underlies the statistics of all nonparametric linkage detection 
methods. 
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2.3. 7 Two-point Lod Score 
The theory of detection and estimation of linkage was revolutionised by 
Morton's lod score (Morton, 1955). It is based on the Bayesian calculations 
described above and begins by determining Smax. the value of 8 at which the 
likelihood of obtaining the data, L, has its maximum value, or equivalently, at 
which dUd8 = 0. This maximum likelihood is expressed as L(datal8 = 8max). 
Maximum likelihood analysis next calculates the oddS in favour of linkage versus 
non-linkage by computing the likelihood ratio: 
Likelihood ratio (8) = L(datal8 = 8max)/L(datal8 = 1/2) 
where L(datal8 = 1/2) is the likelihood of obtaining the data when 8 = 112 or, 
equivalently, when the disease gene and a marker are unlinked. This ratio gives 
the odds in favour of linkage versus non-linkage with a recombination fraction 
8max· After Morton (1955), likelihood ratios are reported as lod scores, Z, the 
decadic logarithm of: 
L(datal8 = 8max)/L(datal8= 112) 
Critical thresholds for a single test between the disease locus and a marker, a 
two-point lod score, are z = 3.0 and Z = -2.0. Z = 3.0 corresponds 
(approximately) to 1000:1 odds that the disease gene and a marker are linked, 
setting p=0.05. Linkage can be rejected if Z < -2 and values of Z between -2 
and +3 are inconclusive. Specifying parameters for linkage analysis is 
complicated, and the extraction of linkage information from human pedigrees is 
entirely dependent upon computer programs such as LIPED (Ott, 1974), 
LINKAGE (Lathrop eta/., 1985) and ILINK and MLINK (Schaffer, 1996). 
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2.3.8 Multipoint Lod Score 
Almost since its inception, classical genetics has used three-point crosses to 
order linked loci on chromosomes (Sturtevant, 1913). It is based on the 
established premise that the rarest recombinant class is the one that requires the 
most recombinations. For n linked markers, (n-1) crossovers always produces 
the rarest recombinant class which is, therefore, two crossovers for a three-point 
cross. Chromosomal order can be deduced from such linked 
multilocus/multipoint inheritance patterns. An advantage of multipoint linkage 
analysis is that it overcomes limited marker informativeness. Highly informative 
microsatellite markers have reduced this problem, but it still persists in 
pedigrees lacking optimum structure. 
Like two-point lod scores, multipoint lod scores are totally dependent on 
computer programs like VITESSE (O'Connell & Weeks, 1995) and LINKMAP 
(Schaffer, 1996) that move the unmapped disease locus across the linkage 
region from one marker location to the next, calculating the likelihood of obtaining 
the pedigree data, its lod, at and between each marker had the disease gene 
actually been at each point of calculation. Plotting likelihood/multipoint lod as a 
function of map location, produces a curve whose highest peak marks the most 
likely position of a disease locus (Morton, 1995). Conversely, exclusion is 
indicated should a multipoint curve remain below a lod of -2 across a linkage 
region. The same two-point critical thresholds operate for multipoint lod 
analysis. 
The EXCLUDE program (Edwards, 1987) turns negative linkage data into a 
diagram of remaining candidate locations. The value of EXCLUDE is that it 
progressively narrows the range of possible candidate locations during genomic 
testing. 
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2.3.9 Parametric Methods: Co-segregation Linkage Analysis 
Parametric co-segregation linkage analysis involves Mendelian segregation 
within pedigrees, establishes relationships between loci, specifies disease 
inheritance parameters and employs parametric statistics to compare prior and 
posterior probabilities of I BD markers. Disease inheritance parameters 
specified are: mode of inheritance; phase (the combination of alleles, or 
haplotypes, inherited from each parent); mutation rates; allele frequencies; 
extent of phenocopy (environmentally determined phenotypes mimicking a 
genetically determined trait); degrees of penetrance (when 'non-affecteds' are 
included); locus heterogeneity; allelic heterogeneity; variable expressivity; 
interactions for more than one contributory locus; and incomplete ascertainment. 
The greater the degree of specification, the greater the power of parametric 
linkage analysis. For example, Grimm et al. (1994) showed that the male 
mutation rate was about ten times higher than the female mutation rate in families 
segregating DMD point mutations. In deletion DMD families the situation was 
different. DMD deletion mutation rate was about twice as high in females as it 
was in males. Consequently, the specification of mutation rate by sex (in this 
case) increased the power of linkage analysis, improving estimates of wild-type 
and disease allele frequencies. 
Conversely, inability to specify any disease inheritance parameters reduces the 
power of parametric methods by reducing the ability to extract posterior 
probabilities from pedigrees. Inability to specify disease inheritance 
parameters stems from small human pedigree size (insufficient affected 
individuals), imperfect human pedigree structure (missing individuals) and the 
necessary retrospective analysis of all human pedigrees. All of these factors 
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confound the specifi~tion of disease parameters, but sometimes their effect can 
be minimised. For example, when the mode of inheritance of one form of 
severe childhood autosomal recessive muscular dystrophy (SCARMD) was 
uncertain, lod scores were calculated under pure autosomal recessive and co-
dominant models before establishing linkage of autosomal recessive 
SCARMD to 17q12-q21.33 (Roberds et at., 1994). This form of SCARMD is 
also called LGMD2D. 
Major susceptibility loci of oligogenic disease can be identified by co-
segregation linkage analysis (Morton & Lio, 1997, p. 18). Heterogeneous and 
essentially non-Mendelian breast cancer was subjected to this approach. A 
subset of families with an unusually high background level of susceptibility was 
identified and, in these families, breast cancer followed reduced-penetrance 
Mendelian inheritance. Co-segregation linkage analysis mapped a major breast 
cancer susceptibility locus to 17q21 (Hall et at., 1990). 
Mapping the breast cancer major susceptibility locus to 17q21 highlighted major 
difficulties confronting this type of complex segregation analysis. First, 1500 
families were screened to identify the 4-5% of these families with high 
background level of susceptibility and seemingly reduced-penetrance 
Mendelian inheritance (Newman et at., 1988). Genetic versus environmental 
determinants, shared environment versus shared genes and bias of 
ascertainment all confounded heritability estimates and, therefore, the proposed 
co-segregation linkage analysis for these families. Maximum likelihood 
programs struggled to include the correct mix of parameter values and, until it 
succeeded, it was doubtful if the greatest overall likelihood for the observed 
data would emerge (Hallet at., 1990). 
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Ascertainment for breast cancer was difficult but not impossible. For other 
complex diseases like schizophrenia, ascertainment has proven to be the 
greatest stumbling block (Byerley, 1989). The oligogenic diseases most 
amenable to co-segregation linkage analysis are those whose major 
susceptibility locus reveals itself in a subset of affected families, segregating the 
disease in reduced-penetrance Mendelian mode. 
2.3.1 0 Nonparametrlc Methods: Allele-Sharing 
Nonparametric linkage analysis, also called shared segment linkage analysis, is 
not entirely model free, assuming the linear arrangement of genes on 
chromosomes, the Mendelian segregation of loci (although precise mode of 
inheritance is not specified), and assuming that genes affect traits. Shared 
segment linkage analysis is similar to co-segregation analysis in that it focusses 
upon affected individuals in pedigrees, but it is different in that it localises both 
Mendelian and non-Mendelian conditions and never overtly specifies disease 
parameters. 
Nonparametric linkage analysis must be adopted for the analysis of high 
prevalence, genetically influenced human diseases such as asthma, diabetes 
mellitus or psychiatric disorders. Modelling disease parameters for these 
diseases is difficult. Nonparametric linkage analysis compares the observed 
agreement of alleles at a marker locus with the agreement expected by chance. 
The degree of agreement at a marker locus can be measured either by the 
number of alleles identical by state (ISS) or the number of alleles IBD. IBD 
affected sib pair (ASP) (Suarez et al., 1978), and IBS affected pedigree 
member (APM) (Weeks & Lange, 1988, 1992) strategies and their extensions 
are the most commonly used IBD and IBS methods. 
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An ideal sample for ASP analysis consists of n nuclear families, each family 
comprising two affected sibs and and their parents, where both parents 
possess a different heterozygous genotype at each tested marker locus. In this 
sample, sib IBD can be determined unambiguously and, for each marker 
tested, two sibs will have an IBD score of 2 (identical alleles) or 0 (non-identical 
alleles) with a probability of 0.25 and an IBD score of 1 (one identical allele) with 
a probability of 0.5. From this starting position, a range of different ASP 
statistical tests have been developed to distinguish between IBD distributions 
when disease and marker locus are unlinked (Ho) or linked (H1). These methods 
include: IBD proportions, means or goodness-of-fit tests (Blackwelder & Elston, 
1985); correction for incomplete information (Holmans, 1993); inclusion of 
unaffected sibs (Green & Montasser 1988); and for the inclusion of two linked 
marker loci (Knapp et al., 1994) or two unlinked marker loci (Cordell et al., 1995). 
Todd et al., (1987, 1998) used ASP to show that over half of the inherited 
predisposition to insulin-dependent diabetes mellitus (I DDM) (type 1) was 
associated with chromosome 6p21 'high risk' HLA haplotypes. Genome-wide 
ASP scans for linkage of chromosome regions to type 1 diabetes in affected 
families have confirmed this locus and the 11p15 region, containing the insulin 
gene, as type 1 diabetes susceptibility loci (Davies et al., 1994; Todd & Farran, 
1996). ASP analysis has also located four additional but equivocal type 1 
diabetes susceptibility loci at 11 q13, 6q22, 6q27 and 2q33 (Todd & Farran, 
1996). 
The APM method can be used with arbitrary pedigrees and it only requires the 
marker genotypes of the affected individuals within the family. The APM 
method tests whether IBS sharing between all affected relative pairs is 
significantly increased compared to that expected under the null hypothesis. 
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APM has an advantage over ASP methods because it uses information 
obtained from the entire pedigree, but because it does not uniquely determine 
IBD, it has lower power than ASP and other IBD methods (Davis et al., 1996). 
APM is usually combined with other genetic mapping methods as discussed in, 
'Combined Mapping Strategies' (pp. 41-43). 
2.3.11 Nonparametric Methods: Allelic Association 
The fourth type of segment sharing analysis is allelic association. This method of 
genetically mapping diseases examines allelic association in populations. Allelic 
association is defined as any significant association between specific alleles at 
two or more neighbouring loci (Strachan & Read, 1996, p 589). It makes no 
assumptions about disease inheritance and is therefore a nonparametric method 
of gene mapping. It is a method of analysis that only applies to diseases and 
populations where most affected people are descended from a common 
'carrier' ancestor. Possible disease allele locations are identified by finding 
series of alleles in affected individuals, measured two at a time, at a frequency 
above that expected by random segregation. 
Establishing relationships between alleles, and not loci, distinguishes allelic 
association from linkage analysis mapping. This distinction is important because 
allelic association can happen for reasons other than disease allele linkage; 
natural selection favouring a particular combination of alleles at two loci or 
population stratification where those with and those without a disease may, by 
history, be genetically different subsets of their population (Lander & Schork, 
1994, pp. 2041-2042). For these reasons, allelic association analysis is not 
linkage analysis. 
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Allelic association studies can also be distinguished by the fact that linkage 
disequilibrium need not occur around a disease locus. Linkage disequilibrium 
(also sometimes called allelic association) is defined as the non-random 
association of alleles at linked loci (Strachan & Read, p. 593). Strong selection 
against disease phenotype, and/or a high gene mutation rate creating an allelic 
series of disease-causing mutations in a population, will prevent linkage 
disequilibrium. DMD is an example of a disease that does not show linkage 
disequilibrium for both of these reasons. 
Allelic association is rarely detectable beyond 1 eM, even for major genes of 
larger effect (Morton & Lio, 1997, p. 20), therefore it is of uncertain value for 
genome scans (Lonjou et al., 1999, pp. 1625-1626). Its major application is to 
increase map resolution for Mendelian genes and oligogenes within candidate 
regions, and it remains the only practical method to locate polygenes (Morton, 
1998, p. 690). The case-control design study is one allelic association strategy 
to localise Mendelian genes, oligogenes and polygenes. This method tests 
specific candidate alleles in two random samples of unrelated affecteds and 
unrelated controls, defining each group by current and antecedent health states. 
Case-control design studies have repeatedly established an association 
between the HLA-DR2 allele within the major histocompatibility complex 
(MHC) and multiple sclerosis (MS) in different populations (Haines et al., 
1998). Repeating case-control studies in different populations is important 
because the associations they establish may arise as an artifact of migration and 
population admixture (Lander & Schork, 1994, pp. 2041-2042; Morton & 
Collins, 1998, p. 11389). The greatest difficulty confronting this type of 
association study is the risk that the study and control groups are drawn from 
genetically distinct populations. 
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A series of methods have been developed to to circumvent the 'choice of 
control' difficulty posed by population stratification. All of these use parental 
genotypes in place of non-related controls. By this approach, nuclear families 
with one or more affected child are collected and typed at the marker locus. The 
two parental alleles that have not been transmitted to the affected child are 
combined to form the marker genotype of the 'control individual'. The two 
principal methods based on this logic are the haplotype relative risk (HRR) test 
(Falk & Rubenstein, 1987) and the transmission disequilibrium test (TOT) 
(Spielman et al., 1993). 
HRR operates on the basis that the distribution of marker genotypes obtained 
from the non-transmitted parental alleles, in families with a single affected child, is 
identical to the distribution of marker genotypes in the population (Falk & 
Rubenstein, 1987). This is the 'control', and marker frequency in probands and 
controls are compared and tested for significance with a xJ test. 
TOT compares the alleles transmitted by heterozygous parents to their affected 
children with the non-transmitted alleles and permits simultaneous testing for 
linkage and association. The alleles not transmitted to the affected child(ren) 
create an internal 'family-based' control permitting a x2 test estimate of relative 
risk. Thomson (1995, pp. 492-493) has shown that the non-transmitted allele 
sample provides unbiased allele frequency estimates. TOT has been 
extended to the situation of multi-allele marker loci (Sham & Curtis, 1995; 
Bickeboller & Clerget-Oarpouix, 1995) and to 'sib TOT' that uses marker data 
from unaffected sibs instead of from parents (Spielman & Ewens, 1998). Both 
HRR and TOT are applied when other forms of genetic mapping or other types 
of evidence have given some indication of disease gene location (see Section 
2.3.13, pp. 41-43). 
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2.3.12 Resolving Power 
Following Edwards (1980) and Bishop and Williamson (1990), Houwen et al. 
(1994) identified the 'number-of-meiotic-steps' encompassed by different 
sampling designs as: population allelic association studies, 34-1 00 meiotic 
steps; shared segment analysis in groups of families with common ancestor, 9-
34 meiotic steps; homozygosity mapping first and second cousins, 6-9 meiotic 
steps; and sib pair studies, 2 meiotic steps. Effectively, family linkage and 
population association analyses were at opposite ends of a genetic mapping 
m-continuum. 
Close genetic relationships, therefore, provide greater power over larger 
genetic distances because the probability of lBO decline is smaller at a disease 
locus. Linkage detection power is good but map resolving power is necessarily 
low (Thompson,1997, pp. 137 & 139-140). When disease inheritance 
parameter specification is accurate, human genetic mapping by co-segregation 
analysis normally has a highest statistical resolution of 1 eM, which is equivalent 
to a 1% recombination probability (Strachan & Read, 1996, pp. 327 -328). 
Conversely, more distant genetic relationships provide more power over 
smaller genetic distance because the probability of I BD decline is greater at a 
disease locus. With increasing m, linkage detection power declines (smaller and 
smaller conserved sequences) as map resolving power increases 
(Thompson, 1997, p. 137). 1 eM is the genetic distance at which allelic 
association due to sharing of ancestral chromosomes starts to become 
noticeable (Morton & Lio, 1997, p. 20). Therefore, allelic association is only 
useful for gene mapping over distances of 1 eM and less. 
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2.3.13 Combined Mapping Strategies 
All genetic mapping strategies aim to detect linkage. In the balance between 
robustness, power and resolution all have discreet advantages. Attempts to 
analyse pedigrees at 8=1 X 10-3 would be pointless (Boehnke, 1994) as would 
genome scan disequilibrium mapping at 8=1 X1 0-1 (Thompson & Neel, 1997, 
p. 201). Different mapping strategies are exploited concurrently or sequentially 
to refine disease gene localisation. 
Allelic association has proven useful to refine the · location of major disease 
genes established by co-segregation analysis (Lonjou et al., 1999, p. 1621). 
The localisation of disease genes for Huntington disease (HD) (The 
Huntington's Disease Collaborative Research Group, 1993) and cystic fibrosis 
(Riordan, et al., 1989) were refined by the employment of allelic association 
analysis after co-segregation linkage analysis and prior to the positional cloning 
of these disease genes. 
Conversely, linkage analysis can be used to legitimise an allelic association. 
Working with 98 MS families Haines et al. (1998) showed that three highly 
polymorphic markers, HLA-DR, D6S273 and TNFj3,.in the MHC demonstrated 
strong genetic linkage (respective parametric lod scores of 4.60, 2.20 and 
1.24). This confirmed specific association with the HLA-DR2 allele and MS. 
The HLA-DR2 allele, or a nearby disease allele in linkage disequilibrium with the 
HLA-DR2 allele, is, therefore, one of the major susceptibility alleles for 
oligogenic MS. 
Linkage analysis can also refine a candidate region defined by allelic association. 
Houwen et al. (1994) assigned the gene for benign recurrent intrahepatic 
cholestasis (BRIC) to chromosome 18q21 by searching for chromosome 
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segments shared by only four patients, two sibs and two unrelated individuals. 
BRIC is an autosomal recessive liver disease characterised by multiple 
episodes of cholestasis (bile obstructive jaundice) without progression to 
chronic liver disease. Such use of allelic association to localise private diseases 
of genetically isolated populations, is a powerful empirical method for mapping 
disease genes. Sinke et al. (1997) performed co-segregation linkage analysis 
of an expanded sample of 14 BRIC families, using 15 microsatellite markers 
from the 18q21 region. Obligate recombinants in two families placed the BRIG 
gene in a 7cM interval, between markers D18S69 and D18S64. 
Sib pair analysis has difficulty distinguishing true susceptibility loci from false 
positives because it is a low resolution form of analysis (Houwen et al., 1994). 
It can seldom identify chromosomal regions small enough for the identification of 
disease genes. Population allelic associations studies have the potential to 
confirm 'sib pair' susceptibility loci and reduce the size of location, but are only 
justified if there is sufficient evidence from different linkage analyses (Todd & 
Farrall, 1996, pp. 1443-1445). 
APM has been applied to linkage analysis of complex diseases after co-
segregation linkage analysis on informative pedigrees has indicated possible 
locations of (major) susceptibility loci. It has been used to support the 
localisation of (major) susceptibility loci for late-onset familial Alzheimer disease 
(Schellenberg et al., 1993), bipolar disorder (Berrettini et al., 1997; Straub et al., 
1994), pre-eclampsia (high blood pressure during pregnancy) and eclampsia 
(convulsions related to pre-eclampsia) (Harrison, et al., 1997), and 
schizophrenia (Wang et al., 1995). 
HRR and TDT are both used to confirm genetic location or associations. HRR 
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has implicated the dopamine 04 receptor as a susceptibility gene in attention 
deficit hyperactivity disorder (ADHD) (Smalley et al., 1998; Swanson et al., 
1998) and excluded dopamine DRD2 -141 delta C allele as a polymorphism 
associated with schizophrenia (Li eta/., 1998). The dopamine system has long 
been suspected of aetiological involvement in ADHD and schizophrenia, thus 
focusing these HRR tests. TOT has: confirmed the HLA-DR2 allele association 
with MS (Haines et al., 1998); identified increased transmission of allele 4 of 
D18S487 to affected children in type 1 diabetic families (Merriman et al., 1998); 
and verified a population association between IDDM (type 1) and the 'class 1' 
alleles of the region of a 5' flanking tandem-repeat DNA polymorphism adjacent 
to the insulin gene on chromosome 11p (Spielman et al., 1993). 
2.3.14 Genetic Map Limitations 
The methods developed for the analysis of complex traits have not been as 
successful as the parametric methods developed for the linkage analysis of 
Mendelian traits. Thompson (1997, p. 276) has suggested that the increasing 
availability of marker data, and the increasing focus on linkage detection by 
association studies among relatives, or at the population level, may improve the 
discovery of susceptibility loci. However this may not happen. High density 
genetic maps serve to increase haplotype half-life over the shorter genetic 
distances that they can resolve, because the chance of recombination 
simultaneously reduces with genetic distance reduction. Consequently, 
diminishing recombination means that higher and higher density genetic maps 
are not nearly as useful as often argued, requiring an unrealistic number of 
connecting meioses for recombination to occur and therefore add little relevant 
information (J.H. Edwards, personal communication, 1996). 
43 
High-resolution mapping is also constrained by the fact that small conserved 
segments are harder to find than larger conserved segments and require more 
markers for identification. Since the risk of false positives is related to the 
number of markers needed to identify conserved segments, higher resolution 
mapping carries a higher risk of false positives (Strachan & Read, 1996, p. 
501 ). This is a manageable problem for Mendelian conditions which must map 
somewhere on the genetic map, but for association studies there may be no 
association to find, so the risk of false positives increases as the search 
continues. Correction has to be applied to the threshold of significance which is 
set at: 
p = 0.05/n 
where n is the number of independent associations checked (Grove & 
Andreasen, 1982, p. 7). With this correction, the detection ability of association 
studies is reduced to detecting only the strongest of associations. 
There is also evidence that genetic mapping cannot unravel all evolutionary 
complexity, thereby limiting its resolving power. Disease haplotypes larger 
than predicted by Edwards (1980) and van der Meulen and te Meerman 
(1997) have been identified. Evidence of greater extended genomic sharing 
comes from the A455E cystic fibrosis mutation's 25 eM common affected 
haplotype in French Canadian and Dutch populations and the 621 + 1 G--> T 
cystic fibrosis mutation's 14 eM common affected haplotype in French Canadian 
populations (de Vries et al., 1996). This extended genomic sharing may reflect 
too large a recombination fraction in the calculations of Edwards (1980) and van 
der Meulen and te Meerman (1997) or undetected consanguinity in empirical 
studies. 
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Alternatively, the creation and disappearance of haplotypes through repeated 
introduction (de Vries et at., 1996) or during haplotype-recombination-drift 
equilibria (van der Meulen & te Meerman, 1997), may be more complex than 
present models allow. Certainly, the allelic association found around the locus 
for HD paints a complex picture of linkage disequilibrium in one of the best 
characterised human chromosomal regions (MacDonald et at., 1991 ). 
For any two loci, linkage disequilibrium is commonly estimated by the Yule 
coefficient (<I>) (Yule & Engledow, 1914 and Engledow & Yule, 1915 as cited in 
Edwards, 1997, pp. 9-10 and in Krawczak & Schmidtke, 1994, pp. 64-66). 
The Yule coefficient was defined as the absolute value: 
<P = (P1,1- P1,2)/(P1,1 + P1.2- 2-Pu•P1,2) 
where p1,1 and p1,2 denote the frequency of allele A1 on chromosomes bearing 
allele 81 and 82, respectively. When ci> equals 1, maximum possible linkage 
disequilibrium is indicated. Conversely, when ci> equals 0, linkage disequilibrium 
is absent. However when ci> is between 1 and 0, discontinuities can arise that 
are not fully understood. 
In a region spanning 2500 kb around the HD locus, one locus D4895 (defined 
by the probe L 19ps11) showed almost perfect Taql RFLP equilibrium with the 
HD locus (<I>,... 0) despite being within 250kb of the HD locus. Yet the same 
D4S95 locus yielded ci> = 0.35 and ci> = 0.56 for Accl and Mbol RFLPs 
' 
respectively and a more distant locus 04898 (defined by probe 88731) had a 
Sacl RFLP yielding ci> = 0.46 (MacDonald et at., 1991). 
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The lack of steady linkage disequilibrium gradients of allelic association at the HD 
locus do not necessarily invalidate the relationship between genetic distance 
and number of connecting meioses (m). Probably they reflect a complex 
history, involving any one or all of several independent mutations, early 
recombination between disease chromosomes or possibly the origin of some 
marker polymorphisms after the appearance of disease mutations (Strachan & 
Read, 1996, p. 333). 
The resolving power of genetic mapping is limited, but there is a way to 
overcome these limitations. Integration of the genetic and physical map of the 
human genome. Six years after the commencement of HGP, the importance of 
map integration was emphasised by Morton and Lio (1997, pp. 19-20): 
The need for better maps becomes more critical as the 
most striking major loci are cloned. The remaining major 
genes are rarer and may have less obvious candidates. 
Complex inheritance adds the additional complications 
of low penetrance and high heterogeneity. Allelic 
association (linkage dis-equilibrium) can be a powerful 
tool in a sufficiently small region, but not in a larger region 
or with a genome scan unless the density of markers is 
high, since allelic association is rarely detectable beyond 
1 eM even for major genes of larger effect, short history, 
and less heterogeneity. Positional cloning for disease 
genes under complex inheritance cannot succeed unless 
map quality is improved. Linkage cannot determine 
order within 1 eM except in enormous samples, and so 
integration of data from physical and radiation hybrid 
maps is essential. 
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2.4 PHYSICAL MAP OF THE HUMAN GENOME 
The primary goal of all mapping techniques is to identify the locations of genes. 
The genetic map of the human genome does not allow the isolation of genes. It 
gives the relative locations of detectable variations in DNA base sequence. 
Although this allows the positioning of polymorphisms associated with genes 
between flanking markers, it is insufficient information to clone individual genes. 
Unlike the genetic map, the physical map specifies physical distances, not 
statistical distances between markers. HG P is developing a physical map of 
the human genome. At lower levels of resolution its unit of measurement is the 
megabase (Mb), at mid-levels the kb, and at the highest level the bp. The size 
of the autosomal genetic map has been estimated as 2809 eM in males and 
4782 eM in females (Morton, 1991 ). Since the size of the haploid human 
genome is estimated at 3.2 billion nucleotides (3,200 Mb) (Bodmer, 1981), 1 
eM on the sex-averaged genetic map is roughly equivalent to 1 Mb on the 
physical map. Table 2.1 (p. 48) shows methods of physical mapping. Three 
methods were employed and are reviewed. 
2.4.1 Fluorescent in situ Hybridlsation 
Genomic fragments can be physically ordered on a chromosome by 
Fluorescent in situ Hybridisation (FISH) (Montanaro et al., 1991 ; Korenberg et 
al., 1992). After hybridization of specific DNA probes to chromosomes, 
reporter molecules attached to these probes are detected by fluorescently 
labelled affinity molecules. Table 2.1. shows that FISH has been applied to 
metaphase, prometaphase and interphase chromosomes, artificially extended 
chromatin fibre and DNA with increasing resolution. 
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Table 2.1 
Method 
Somatic cell panels 
Flow cytometry 
Chromosome painting 
Chromosome staining 
Comparative mapping 
Physical Mapping 
Translocation and .deletion hybrid panels 
Cytogenetic breakpoint mapping 
*Fluorescence in situ hybridization: 
*metaphase chromosomes 
prometaphase chromosomes 
interphase chromosomes 
artificially extended chromatin fibre 
artificially extended DNA 
Radiation hybrid panels 
*Clone contigs: 
clone fingerprinting: 
repetitive DNA fingerprinting 
IRE-PCR hybridisation 
* STS content mapping 
chromosome walking: 
bidirectional hybridisation 
whole clone-clone hybridisation 
*Automated DNA cycle sequencing 
Highest Resolution 
chromosome 
chromosome 
sub-chromosome 
10Mb 
10Mb 
81Vb 
21'v1> 
51'v1> 
2M> 
50kb 
<5kb 
<5kb 
60kb 
clone size 
clone size 
1 bp 
*Reviewed in this Section, pp. 47-52. *Reviewed in Section 2.5.5.1, 'Mutation Detection', pp. 65-66. 
Authors 
Dubois & Naylor, 1992 
Bartholdi et al., 1987 
Dauwerse et at., 1992 
Buckton et at., 1976 
O'Brien & Graves, 1991 
Abrams et at., 1995 
Chumakov et al., 1992a 
Ireland et al., 1995 
Narahara et al., 1997 
Wilke et al., 1994 
Haaf & Ward, 1994 
van Ommen et al., 1995 
Stanford TNG4 panel, 1997 
Bellanne-Chantelot et al., 1992 
Nelson et al., 1989 
Doggett et al., 1995 
Riley et al., 1990 
Nizetic et al., 1994 
Sears et al., 1992 
FISH was a significant advance on earlier 3H in situ hybridisation methods, 
which suffered from low intensity signal, and were difficult to distinguish from 
background noise. FISH probes can be PCR-amplified genomic STSs of 
>1.0 kb to avoid hybridization to isoforms or pseudogenes (Cayanis et at., 
1998). Alternatively, STSs are used to isolate larger clones from genomic 
libraries for use in FISH (Callen et at., 1990). These larger probes, containing 
up to 40 kb of insert, are preferred because they intensify signal. STSs were 
proposed by Olson et at. (1989) as the common language of the genetic and 
physical map. Each STS is a single-copy, unique sequence of DNA between 
1 00-250 bp. These sequences are easily amplified and unequivocally 
recognised by PCR. They are ·independent of probe used. or mapping 
strategy employed, and have been adopted by human genome mapping 
groups as their universal language. 
2.4.2 Clone Contlgs 
Partial digestion of purified human DNA with restriction endonucleases results in 
a series of overlapping fragments whose size is determined by the restriction 
enzyme cutting frequency. Small fragments (>10 kb) are separated by 
agarose electrophoresis, large fragments by pulse field gel electrophoresis 
(PFGE). To provide a framework for the sequencing of the human genome, 
series of overlapping DNA fragments have been cloned to form DNA libraries. 
Table 2.2 (p. 50) shows commonly used cloning vectors with insert sizes. 
Cloned DNA may be genomic DNA (gDNA) or already part of a DNA library 
such as a chromosome specific-library prepared by flow cytometry (Cotter et 
at., 1989). Purified vectors are digested with the same restriction endonuclease 
and ligated to the overlapping human DNA fragments. 
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Table 2.2 Cloning Vectors (Strachan & Read, 1997, p. 101) 
Cloning Vector Size of Insert Authors 
Plasmid vectors 0-10 kb Okayama & Berg, 1983 
Bacteriophage f.. 
replacement vectors 9-23 kb Sambrook et al., 1989 
Cosmid vectors 30-44 kb Bellanne-Chantelot, 1991 
Bacteriophage P1 70-100 kb Sternberg, 1992 
PAC vectors 130-150 kb Ioannou et al., 1994 
BAC vectors up to 300 kb Shizuya et al., 1992 
YAC vectors 0.2-2.0 Mb Albertstein et al., 1990 
PAC= P1-derived artificial chromosomes; BAC =bacterial 
artificial chromosome; Y AC = yeast artificial chromosomes 
The final stage in the creation of clones for contig construction, is the 
transformation of the host cell with vectors carrying inserted foreign DNA. Y ACs 
are a commonly used eukaryotic vector. They consist of two arms that are 
propagated independently in E. coli as plasmids, pJS97 and pJS98 (Riley et 
al., 1992). Each contains an ampicillin resistance gene, an E. coli replicon to 
propagate as a plasmid, a yeast origin of replication, a yeast telomere and 
several restriction sites including one for C/al at the end of the telomere. pJS97 
also contains a yeast centromere and a pigment suppressor gene that 
suppresses the host strain's production of a red pigment. C/al digestion 
linearises the plasmids and fragments the target DNA. The vector arms 
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therefore each have a C/al tail at one end and a telomere at the other end. 
Ligation of the target DNA and the vector arms produces a Y AC which can 
transform yeast cells. The presence of one pigment suppressor gene, or one 
YAC, per cell makes colonies pink, two or more make them white. Yeast colour 
change is used to monitor the number of Y ACs in a cell and their stability against 
deletions. Unstable colonies have red and pink sectors as some cells lose their 
Y ACs as they divide. 
Cosmids are synthetic cloning vectors possessing desirable features of both 
plasmid and A. phage cloning vectors. The bacteriophage P1 plasmid vector 
comprises P1 lytic genes and a plasmid replicon (Sternberg, 1992). DNA is 
inserted between two vector arms and packaged into a P1 protein coat in vitro. 
Upon injection into a host, the recombinant P1 circularises and can be induced to 
replicate. Recombinant P1 exploits P1 's large size of 11 0-115 kb linear DNA, 
replacing most of this with insert DNA. PACs combine some features of the F-
factor (Hayes, 1953) into the P1 vector (Ioannou et al., 1994), enabling them to 
carry larger inserts. 
The ability of F-factors to carry large foreign DNA fragments is also exploited in 
BAC vectors as are the two F-factor genes, parA and parB, which keep copy 
number down to 1 or 2 per cell (Shizuya et al., 1992). In this way, 
recombination between inserts is reduced, greatly assisting the maintenance of 
large intact eukaryotic DNA in bacterial cells. The frequent repetitive sequences 
found in eukaryotic DNA and the high copy number mean that most other 
bacterial vectors are plagued with structural instability of inserts. Low copy 
number does, however, mean low yield of recombinant DNA. 
Building contigs by linking clones depends upon establishing overlap by 
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common fragment. There are two general ways to develop clone contigs; 
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chromosome walking and clone fingerprinting (Table 2.1, p. 48). Only the clone 
fingerprinting STS content mapping has relevance to this project. 
2.4.2.1 Sequence Tagged Site Content Mapping 
In developing clone contigs, STS content mapping usually involves sequencing 
approximately 300 bases at the end of isolated . clones. Candidate primer 
sequences are identified without GC-rich regions, primers synthesised and an 
STS is identified if only one region of total gDNA is PCR amplified. 
The STS screening of chromosome 16 (Doggett et al., 1995) used Y AC 
library pools based on a Y AC library pooling scheme designed by Balding 
and Torney (1991). This scheme maximised the chance of detecting positive 
clones, false positives and false negatives. Primary pools of clones were 
screened for each STS then secondary pools of STS-positive primary pools 
were screened to identify overlapping clones containing the same STS. Total 
gDNA was used as a positive control for each STS identified. 
550 Los Alamos chromosome 16-specific Y ACs were used in the STS 
screening of chromosome 16. Primary pools of Y ACs contained 36 
chromosome 16-specific Y ACs, 1 0 secondary pools contained 18 of the 
primary pools of Y AC such that each individual Y AC was present in only 5 of 
these 1 0 secondary pools. By identifying STSs present on both Y ACs and 
cosmids, it became possible to close the gaps between the cosmid contigs 
which were, on average, 65 kb before this Y AC STS screening project was 
undertaken (Doggett et al., 1995). 
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2.4.3 Multi-Level Physical Maps 
The integration of genetic maps with low-resolution and high-resolution physical 
maps has resulted in multi-level maps of the human genome accessible at 
different levels of resolution. Doggett et al., (1995) developed an integrated 
low-resolution mega-YAC with a high-resolution cosmid contig mini-YAC map. 
They measured the power of their integrated physical, genetic and cytogenetic 
map of human chromosome 16 as 'completeness ~t resolution', the fraction of 
the chromosome within a fixed distance of mapped points. At resolution of 200 
kb it was 0.88 complete and at resolution of 500 kb it was 0.97 complete. The 
average density or spacing was 1 STS every 160 kb. 
Multi-level physical maps are important for the cloning of human disease genes 
because they are less sensitive to the vagaries of individual maps, each map 
acting as a reference for others (Cohen et al., 1993). The more accurate the 
physical map, the easier it is to isolate transcribed sequences and their 
controlling elements. Multi-level physical maps are accurate physical maps of 
the human genome. They are available at the National Centre for 
Biotechnology Information (NCBI) site, under 'Hot Spot', Human Genome 
Resources (http://www. ncbi. nlm. nih. gov/genome/guidel). 
2.5 CLONING HUMAN DISEASE GENES 
There are four general ways to clone human disease genes: functional cloning, 
position-independent candidate approach, positional cloning, and positional 
candidate approach. Only the last two methods depend upon the genetic and 
physical maps of the human genome, however confidence in functionally cloned 
genes and position independent candidate genes as disease genes is 
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substantially increased if they can be shown to map to the same chromosomal 
region as a disease gene. All four strategies conclude with the identification of 
mutations in cloned genes. All these strategies had to be considered for 
inclusion in this project. All are reviewed. Two were employed. 
2.5.1 Functional Cloning 
Functional cloning requires knowledge of biochemical basis of an inherited 
disease or evidence from functional complementation assay about altered gene 
function. 
2.5.1.1 Oligonucleotides and Antibodies 
Two approaches are possible when the biochemical basis of an inherited 
disease is known. The first involves determining part of the amino acid 
sequence of a defective/deficient protein from partially degenerate 
oligonucleotides corresponding to all possible codon permutations. Screening 
an appropriate complementary DNA (eDNA) library with labelled probe 
comprising a mix of all partially degenerate oligonucleotides enables correct 
eDNA clones to be isolated. These are then used to probe genomic libraries 
for gDNA clones, allowing the complete characterisation of the gene. The factor 
VIII disease gene (FB) responsible for haemophilia A was clonect and then 
characterised in this way (Gitschier et at., 1984). 
The second approach involves raising specific antibodies against the normal 
protein product of a disease gene. These antibodies immune-precipitate 
polysomes containing desired mANA in in vitro protein synthesising systems. 
Converting such mANA to eDNA allows specific eDNA clones to be isolated 
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and the gene characterised. This was how the phenylketonuria (PKU) disease 
gene, phenylalanine hydroxylase (PAH), was cloned. Low tyrosine and high 
phenylalanine plasma concentrations identified hepatic phenylalanine 
hydroxylase as the deficient enzyme in PKU patients (Levy, 1989). 
Antibodies raised against this enzyme led to the full characterisation of this gene 
and the discovery that PKU can be caused by at least 75 allelic variants of the 
phenylalanine hydroxylase (PAH) gene (Cooper & Krawczak, 1994, p. 52). 
2.5.1.2 Functional Complementation 
Functional complementation has been employed to identify human disease 
genes, particularly those involved in DNA repair. Fanconi anaemia (FA) is 
characterised by cellular hypersensitivity to DNA cross-linking agents. On this 
basis it had been tentatively classified as a DNA-repair disorder (Setlow, 
1978). Sensitivity to the DNA cross-linking agents mitomycin C and 
diepoxybutane was exploited by Strathdee et al. (1992a) to identify three new 
FA complementation groups, FA(B), FA(C) and FA(D) from human/hamster 
somatic hybrid panels. A functional complementation method was employed 
to clone cDNAs that corrected the defect of group C cells (Strathdee et al. 
1992b). The eDNA defective in this anaemia was cloned by transfecting the 
FA(C) cell line with a eDNA library inserted into a eDNA expression shuttle 
vector, pREP4. Selection with mitomycin C and diepoxybutane led to the 
identification of eight FA(C) candidates, 
complemented the FA(C) defect. 
three of which specifically 
These cDNAs encoded alternatively processed transcripts of a new gene, 
FACC, which was mutated in group C patients. This FACC polypeptide did 
not contain any motifs common to other proteins and so represented a new 
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gene involved in the cellular response to DNA damage. The function of FACC 
led directly to its cloning. 
2.5.1.3 Muscular Dystrophy Disease Genes 
Functional cloning has only been useful in a few cases of muscular dystrophy, 
one of which was the cloning of the adhalin gene responsible for LGMD2D. It 
was the knowledge that mutated dystrophin-associated-sarcoglycan proteins 
caused forms of muscular dystrophy that led Roberds et al. (1994) to look for a 
mutated protein from this complex in the skeletal muscles of LGMD2D patients. 
A deficiency of the sarcoglycan eomplex protein adhalin (also called a.-
sarcoglycan) was identified, the human adhalin gene mapped to chromosome 
17q12-q21.33 and adhalin eDNA cloned and sequenced to show missense 
mutations segregating with LGMD2D (Roberds et al., 1994). 
2.5.2 Position-Independent Candidate Approach 
Molecular pathogenesis or phenotype similarity (to animals or humans) can 
suggest candidate genes for human disorders independent of knowledge about 
chromosomal locations of disease genes. Case-control allelic association 
studies use this approach to identify suitable candidate alleles for testing as 
oligogenes and polygenes. Disease genes segregating in a Mendelian fashion 
can also be identified in this way. Goebel et al., (1997) described three 
unrelated 'floppy' children with myopathic fibres containing large masses of thin 
myofilaments. The immunological detection of actin in these thin myofilament 
masses suggested that this was a discrete form of congenital myopathy, an 
'actin myopathy' of either sporadic or hereditary type. Recently, mutations in the 
alpha actin gene have been identified in patients with this actin myopathy and 
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with another muscle disease, nemaline myopathy (Nowak, et al., 1999). 
2.5.3 Positional Cloning 
Positional cloning is the strategy employed when nothing is known about the 
altered function of a disease gene. It commences with one of five different 
genetic mapping methods to determine sub-chromosomal localisation of a 
disease gene: cytogenetic deletions or disrupted chromosomal regions; loss of 
heterozygosity (LOH) in somatic disease; co-segregation linkage analysis; 
shared segment linkage analysis; and allelic association between marker 
genotype and disease locus in a population. Often this first stage of positional 
cloning involves application of more than one of these methods. 
The association of cytogenetic deletions and translocations (visible genetic 
markers) with disease has lead to the cloning of disease genes by positional 
cloning. Subtraction cloning of test DNA sequences corresponding to deleted 
Xp21 sequence in a DMD patient were used to identify dystrophin eDNA 
clones (Koenig et al., 1987). Similarly, cloning an Xp21 translocation breakpoint 
in a DMD patient also led to the isolation of the DMD locus (Worton & 
Thompson, 1988). 
LOH allelic imbalance of markers adjacent to deleted disease genes has been 
used to identify chromosomal regions deleted in somatic disease. It has been 
most successful in identifying familial cancers such as oral cancers (Roz et al., 
1996). However, even within its limited area of application, LOH disease gene 
localisation does have its limitations. For example, in the LOH identification of 
the retinoblastoma 13q14 LOH region (Cavenee et al., 1983; Friend et al., 
1986; Lee et at., 1987), homozygous patients provided no information and 
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most tumour samples contained a mixture of tumour and non-tumour tissue, so 
band intensity of one marker allele was decreased rather than lost entirely. In 
addition, the retinoblastoma 13q14 deletion was not retinoblastoma-specific, 
also associating with osteosarcomas (Friend et al., 1987), breast cancer (Lee et 
al., 1988), and small-cell lung cancer (Yokota et al., 1987). 
The cloning of fully penetrant, uniformly expressed, autosomal dominant and 
recessive X-linked disease genes usually comm~nces with co-segregation 
analysis. For these diseases, mutation segregation can be deduced from clinical 
phenotypes and, unlike autosomal recessive diseases, linkage can be 
established in relatively small, non-cOnsanguineous pedigrees. Disease genes 
of this type feature prominently in the human genome map (Bassett et al., 
1997). 
Shared-segment linkage analysis and allelic association analysis are often used 
as the first step in the positional cloning of autosomal recessive and non-
Mendelian disease genes contributing to complex inherited diseases. 
2.5.3.1 Transcript Map of Candidate Regions 
Genetic mapping only gives a crude estimate of candidate region size because 
genetic distances between markers are uncertain. To identify disease gene 
candidates, an ordered contig of clones has to be built across the candidate 
region. The next step of positional cloning is to construct a transcript map of all 
relevant expressed sequences within candidate region genomic clone contigs. 
Genes can be identified because they make RNA, their sequences are 
conserved, they have relatively long open reading frames (OAFs) and they are 
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often associated with CpG islands (Bird, 1986). Based on these characteristics, 
a variety of methods have been developed to clone genes in cloned DNA. 
Collins (1992, p. 6) and Cooper (1995b, p. 58) have identified three general 
approaches for the isolation of novel transcribed sequences: hybridization-
based, function-based and sequence-based. The methods within each of 
these general approaches are identified in Table 2.3 (p. 60). Only one of these 
methods was used in this thesis. 
2.5.3.2 Expressed Sequence Tags 
Adams et al. (1995) reported the di$covery of 58,384 non-overlapping human 
expressed sequence tags ESTs from the analysis of 300 poly-A selected 
eDNA libraries constructed from 37 distinct organs and tissues. Since the 
identification of such a large number of ESTs necessarily required large scale 
sequencing, eDNA library quality was carefully evaluated. To achieve high 
quality control, the sequences of between 1 00-200 clones from each library 
were assessed on seventeen counts. The libraries selected for large scale EST 
analysis were those with a broad diversity of transcripts, no evidence of DNA 
from another organism, no mitochondrial DNA, no ribosomal DNA, and a low 
percentage of clones without insert. 
Sequencing was done from the 5' end of each eDNA clone rather than the 3' 
end since each 5' end was more likely to contain a protein coding sequence, 
enabling database searches to assign putative identifications. This was 
achieved for 11.6% of the identified ESTs. Three genes associated with colon 
cancer were identified in this EST dataset. 
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Table 2.3 Novel Genomic DNA Transcript Identification 
(from Collins, 1992, p. 6 and Cooper, 1995b, p. 58) 
Methods 
Hybrid/sat/on-based 
Northern Blotting 
Inter-species cross hybridisation 
{'zoo blotting') 
Identification of CpG islands 
CpG Island Rescue PCR (IRP) 
Direct eDNA library screening/ 
sequencing 
Subtractive hybridisation 
Heteronuclear eDNA 
library screening 
Homologous recombination 
Direct eDNA selection using 
cosmidsN AC immobilised arrays 
Reverse transcript PCR 
Function-based 
OAF identification by lac-z 
fusion protein expression 
Exon amplification/trapping 
Enhancer/poly A signal trapping 
Gene transfer and 
transcript identification 
Promoter trapping 
Sequence-based 
Exon prediction 
Differential display 
Interspecific comparison 
Database similarity searching 
*Expressed sequence tag 
PCR mapping (EST-PCR) 
References 
Alwine et al., 1977. 
Monaco et al., 1986 
Bird, 1986; 
Brown & Bird, 1987 
Valdes et at., 1994. 
Hochgeschwender et al., 1989; 
Elvin et at., 1990; 
Geraghty et at., 1993; 
Adams et al., 1991; 
Soeda et al., 1995 
Duguid et al., 1988 
Whitmore et al., 1994 
Vollrath et al., 1988; 
Kurnit & Seed, 1990 
Lovett et al., 1991 
Cheng & Zhu, 1994 
Gray et al., 1982 
Duyk et al., 1990; 
Buckler et al., 1991 
Weber et at., 1984; 
Rosenthal, 1987 
Strathdee et al., 1992b 
von Melchner & Ruley, 1989; 
von Me Iehner et al., 1990, 1995 
Fearon et at., 1990 
Liang & Pardee, 1992 
Sargent et al., 1993 
Gish & States, 1993 
Adams et al., 1993 (a & b), 1995; 
Pallavicini et al., 1997 
*Relevant to this thesis and reviewed on pages 59-61. 
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A preliminary EST transcript map of human skeletal muscle has also been 
provided (Pallavicini et al., 1997). This map required the design of 267 pairs of 
specific primers, corresponding to newly identified muscle genes. PCR 
amplification of the GeneBridge 4 radiation hybrid (RH) panel (Gyapay et al., 
1996; http://www-genome. wi. mit.edu/cig-bin/contig/rhmapper.pl), gave a 
precise map position for 230 skeletal muscle ESTs. 
Diverse clone collections/contigs from many physical mapping groups around 
the world are currently being typed by EST content. An international EST 
mapping consortium has been formed to develop a continuum of overlapping 
clones (Collins, 1998). More than 50,000 ESTs are currently being mapped to 
0.1-0.5 Mb intervals, utilising the whole genome RH and Y AC panel 
approaches. The efforts of the international EST mapping consortium will 
undoubtedly lead to the discovery of hundreds (perhaps thousands) of as yet 
unidentified disease genes associated with ESTs. Sequencing overlapping 
clones confirm the localisation of each transcript (Collins, 1998). 
EST identification from eDNA libraries has some limitations. It can be biased 
towards highly expressed genes, fail to distinguish between pseudogenes, 
multigene family members and functional genes and, if poly A purified eDNA is 
used, ESTs in 5' exons can be poorly represented (Towner 1995, pp. 79-80). 
Promoter-tagged site (PTS) databases avoid these limitations by using 
recombinant retroviral gene trap vectors targeting promoter regions (von 
Melchner & Ruley, 1989). Recombinant retroviral gene trap vectors contain a 
reporter gene without a promoter or enhancer. Reporter gene activation 
therefore requires integration into expressed genes in the same transcriptional 
orientation relative to the gene, allowing selection for 51 retrovirus gene trap 
vector integration (von Melchner, et al., 1990; von Melchner & Ruley, 1995). 
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2.5.4 Positional Candidate Approach 
Increasingly, combinations of functional, position-independent and positional 
cloning strategies are being adopted for disease gene isolation. This combined 
strategy was first termed the positional candidate approach by Ballabio (1993). 
It is distinguished from functional, position-independent and positional cloning 
because it identifies disease genes on the basis of both position and function. 
In reality, most of the 84 positional cloning successes listed by Bassett et al. 
(1997) relied upon something other than pure positional cloning. For example, 
the large-scale deletions associated with LOH localisations suggested that likely 
disease gene candidates might be DNA repair enzymes. They were. 
Similarly, it was the knowledge that three forms of autosomal recessive LGMD 
were associated with mutations in various sarcoglycans of the dystrophin-
associated sarcoglycan complex, that led Nigro et al. (1996) to look for, and find, 
a sarcoglycan candidate in the 5q33-34, LG MD2F linkage region previously 
identified by Passos-Bueno et al. (1996). This gene turned out to contain a 
single base deletion. This single base deletion segregated with LGMD2F: in 
AR mode (Nigro et al., 1996). 
The current rapid localisation of human genes has greatly increased the density 
of the human transcript map and accelerated the movement of disease gene 
cloning towards the positional candidate approach. It has already assumed a 
dominant position and with the projected completion of the human genome 
sequence in 2003 (Collins, 1998), the positional candidate approach will 
increasingly dominate human disease gene cloning. 
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Collins overestimated the time required for the completion of the sequence of 
the human genome. The completion of 97% of the sequence of the human 
genome was announced in July 2000 by Craig Venter, the Chief Executive 
Officer of Celera Genomics, and Francis Collins, director of the US National 
Institutes of Health's National Human Genome Research Institute (and as such 
the unofficial head of the publicly funded HGP). The positional candidate 
approach will be one of many beneficiaries of human genome sequence data. 
Gerald Rubin, the vice president for biomedical research at the Howard Hughes 
Medical Institute, describes the human genome sequence as, "written in a 
foreign language. It's a very complicated problem. It's going to be a long time 
coming" (cited by Lemonick, 2000). Even when the human DNA code is 
readable, the enormous problem of discovering what each protein does and 
how it interacts with other proteins and cell components will still remain. Progress 
will be slow, but the implications of this milestone towards genotypic medicine 
are signWicant 
As far as the positional candidate approach is concerned, the human genome 
sequence should accelerate the identification of susceptibility loci and the 
contributing polygenes (defined, p.15) within these loci. This is significant 
because polygenes are involved in the great majority of inherited human 
disease. Yet individually each polygene contributes little to the determination of 
a disease, cannot be localised by co-segregation linkage analysis and presents 
considerable difficulties for segment-sharing linkage analysis and association 
studies. Identifying polygenes is important not only for polygenic disease, but 
also for Mendelian and oligogenic disease operating over polygenic 
background. With the sequence of every human gene available, associations 
between diseases and alleles of candidate genes within susceptibility regions 
will become easier to establish in families, and in the general population. 
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This approach has already demonstrated its usefulness. An association 
between the epsilon 4 allele of the apolipoprotein E gene (A POE) and familial 
late-onset Alzheimer's disease was demonstrated in 15 Swedish late-onset 
Alzheimer's families (p = 0.01), despite the absence of AD linkage to the 
APOE region in these families (two-point linkage analysis), and only weak 
evidence of linkage from APM (Liu eta/., 1996). 
2.5.5 Mutation Detection 
The final step of all human disease gene cloning strategies requires the 
identification of the mutations contributing to each disease. Mutations can be 
translocations, deletions, duplications, repeat expansions, insertions, splice site, 
missense, frameshift or stop codon mutations. They can affect transcribed and 
non-transcribed portions of the genome. 
To detect gross alterations or rearrangements of genes, transcripts are screened 
for mutations by Southern blotting (Southern, 1975), which is often combined 
with PFGE (Fountain et al., 1989), and Northern blotting (Alwine et al., 1977). 
Deletions that include markers adjacent to the disease gene can be recognised 
from marker segregation in pedigrees for both autosomal dominant and 
recessive diseases. PCR methods detect smaller mutations in cloned DNA 
lying inside or outside coding regions. Commonly used mutation detection 
methods are listed in Table 2.4 (p. 65). 
Three of these were relevant to this thesis. 
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Table 2.4 Common PCR Mutation Detection Methods 
Method 
*Direct Sequencing of Transcripts 
Denaturing Gradient 
Gel Electrophoresis 
RNase Cleavage 
Deletion screening ('multiplex PCR') 
Chemical Mismatch Cleavage 
*DNA Single-strand Conformation 
Polymorphism (SSCP) 
RNA SSCP (rSSCP) 
Dideoxy Fingerprinting 
*Repeat Expansion Detection (RED) 
Restriction Endonuclease 
Fingerprinting (REF) 
Heteroduplex Cleavage 
with Bacterial Resolvases 
Authors 
Sanger, 1981. 
Fischer & Lerman, 1983. 
Myers et al., 1985. 
Chamberlain et al., 1988. 
Cotton et al., 1988. 
Orita et al., 1989. 
Sarkar et al., 1992a. 
Sarkar et al., 1992b. 
Schalling et al., 1993. 
Liu & Sommer, 1995. 
Youil et al., 1995. 
*Relevant to this thesis and reviewed on pages 65-69 
2.5.5.1 Direct Sequencing of Transcripts 
Automated DNA sequencing based on the dideoxy sequencing method 
(Sanger, 1981) has now largely replaced the traditional radioisotope versions of 
this sequencing method. Each sequencing reaction contains: the four types of 
deoxynucleoside triphosphates (dNTPs) deoxyadenosine triphosphate 
(dATP), deoxythymidine triphosphate (dTIP), deoxyguanosine triphosphate 
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dGTP, deoxycytidine triphosphate (dCTP) each labelled with a different 
fluorophore; one primer; magnesium; a buffer; and a thermostable DNA 
polymerase. Chain termination occurs when ddNTPs are incorporated because 
they lack a hydroxyl group at the 3' carbon atom of the ribose sugar. The 
concentration of ddNTPs is much lower than that of the dNTPs, consequently 
chain termination occurs randomly. Cycle sequencing (Sears et al., 1992) is a 
PCR type of sequencing reaction that produces good results for double 
stranded DNA (dsDNA). During electrophoresis of sequencing product, a 
monitor records the four different fluorophore signals as a chromatographic 
intensity profile with ATGC translation. 
2.5.5.2 DNA Single-Strand Conformation Polymorphism 
Size and nucleotide sequence determine the folding structure(s) of single~ 
stranded DNA molecules. In conjunction with surface charge density, these 
parameters contribute to electrophoretic mobility and form the basis of a 
mutation detection method called single-strand conformation polymorphism 
(SSCP) analysis (Orita et al., 1989). PCR-amplified ssDNA fragments up to 
200 bases in length (Sheffield et al., 1993) are denatured and snap-chilled. 
These DNA molecules are separated on a non-denaturing polyacrylamide gel 
under constant voltage and controlled ionic strength and temperature to reduce 
conformation changes in polymorphisms. Label may be incorporated during 
PCR amplification (Orita et al., 1989) or polymorphisms causing a mobility shift 
can be detected by ethidium bromide (Hayashi, 1991) or by silver staining 
acrylamide gels (Hoshino et al., 1992). If the underlying reason for an SSCP is 
not known, bands displaying mobility-shift are cut out, re-amplified by PCR, 
and sequenced to detect nucleotide sequence differences between individuals. 
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2.5.5.3 Repeat Expansion Detection 
Allowing for cyclical permutations, DNA can only have 10 discrete trinucleotide 
sequences. Repeats of all these trinucleotide sequences occur throughout the 
human genome, the majority without pathological effect (Fu et al., 1991 ). There 
are two ways in which trinucleotide repeats are known to cause disease. First, 
short meiotically stable repeats have been shown to cause both AD- and AR-
OPMD. Expansion of the normal (GCG)s repeat to a (GCG)g repeat in exon 
1 of the poly(A) binding protein 2 gene (PABP2) causes AD-OPMD (Brais et 
al., 1998). The pathological association of this type of repeat expansion can 
only be established when detected during the sequencing of candidate genes. 
The second type of disease-causing repeat expansion are the meiotically 
unstable repeat expansions involving much larger expansions. Some 
trinucleotide repeats become extremely unstable . above a certain threshold 
length. Their expansion beyond this 'upper maximum limit' causes disease 
These unstable repeats are seldom transmitted unchanged from parent to child. 
Their tendency is to increase rather than to decrease repeat copy number. For 
example, the expansion:contraction odds ratio for the unstable CGG 
expansion in the FMR1 fragile X gene, has been calculated as 64:3 (Fu et al., 
1991 ). These 'dynamic mutations' can cause anticipation (Richards et al., 1992). 
Anticipation describes the tendency of some dominant conditions to become 
more severe in successive generations, often lowering the age at which clinical 
symptoms onset. It is a type of variable expression. The discovery that 
repeat length correlated with severity for many trinucleotide diseases provided 
a powerful diagnostic and prognostic tool for these diseases, including the nine 
CA(3 repeat expansion neurodegenerative disorders: HD; dentatorubral 
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pallidoluysian atrophy (DRPLA); spinal and bulbar muscular atrophy (SBMA); 
dentatorubral-pallidoluysian atrophy (DRPLA); and spinocerebellar ataxia 
(SCA) types 1, 2, 3, 6 and 7 (Koshy & Zoghbi, 1997). 
The repeat expansion detection (RED) technique (Shalling et al., 1993) can 
detect trinucleotide repeats throughout the human genome, including 
pathological trinucleotide repeat expansions. It does not require knowledge of 
affected gene location. Trinucleotide repeat expansions can cause disease 
within coding regions, within transcribed but not translated regions and by 
positional effects on nearby genes. HD is an example of a coding region 
trinucleotide repeat expansion (The Huntington's Disease Collaborative 
Research Group, 1993); myotonic dystrophy, an example of a 3' untranslated 
region (UTA) trinucleotide repeat expansion (although this expansion may not 
only be affecting the DMPK gene in whose 3' UTA it is situated) (Boucher et al., 
1995); and the fragile-X syndromes FRAXA (Pintado et al., 1995) and FRAXE 
(Knight et al., 1993), are examples of trinucleotide repeat expansions having 
positional effects and influencing adjacent genes. 
The RED technique works by hybridising trinucleotide repeat oligonucleotides 
to ssgDNA. Trinucleotide repeat oligonucleotides hybridised to genomic 
trinucleotide repeats are ligated to neighbouring oligonucleotides, producing a 
family of oligonucleotides representative of the trinucleotide repeats present in 
the genomic DNA. Trinucleotide repeat size is determined by electrophoresis 
on a 6% acrylamide gel. Potentially pathological trinucleotide repeat 
expansions (of any motif) are detected by comparison of affected and 
unaffected pedigree members. Assuming full penetrance, pathological 
trinucleotide repeat expansions would be present in the former but not the latter 
for all individuals over age of onset. 
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2.6 CONCLUSION 
Research on mapping and identifying human disease genes interacts with the 
recent thrust of the HGP: the isolation of human gDNA and eDNA clones for the 
construction of high-resolution physical maps. The highest resolution physical 
map, the complete nucleotide sequence of the 3000 Mb nuclear human 
genome, is now near completion. 
This chapter focused on those principles and strategies behind the identification 
of human disease genes that were employed in this thesis. It showed how this 
research contributes to the HG P, through its contribution to the development of 
genetic and physical maps of the human genome. It also showed that the final 
identification of disease genes depends upon the physical map of the human 
genome, a map derived from human eDNA and gDNA clones that, 
predominantly, do not have disease association. This is a timely reminder that 
the term 'human disease gene', is a term derived from the contribution inherited 
disease has made to the identification of human genes. A term, according to 
Mat Ridley (2000, pp. 54-55), with severe limitations: 
Open any catalogue of the human genome and you will 
be confronted not with a list of human potentialities, but 
with a list of diseases, mostly named after pairs of 
obscure central-European doctors. This gene causes 
Niemann-Pick disease; that one causes Wolf-
Hirschhorn syndrome. The impression given is that 
genes are there to cause diseases. . . . Yet to define 
genes by the diseases they cause is about as absurd 
as defining organs of the body by the diseases they 
get: livers are there to cause cirrhosis, hearts to have 
heart attacks and brains to have strokes. It is a 
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measure, not of our knowledge but of our ignorance that 
this is the way the genome catalogues read. It is 
literally true that the only thing we know about some 
genes is that their malfunction causes a particular 
disease. This is a pitifully small thing to know about 
genes, and a terribly misleading one. 
All of this is true. Genes are positive forces. It is mutations that cause disease, 
not genes. Nevertheless, 'this pitifully small thing to know about genes' is what 
this thesis seeks to know, because it is the starting point for far more important 
knowledge. A full understanding of normal gene function. Sometime in the 
future, all genes and their products may be named by what they do, and 
diseases identified by mutation. But for the present, the term 'human disease 
gene' accurately describes what we know, and what we do not know, about the 
majority of human genes. 
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CHAPTER3 
MUSCULAR DYSTROPHY: 
A CANDIDATE APPROACH 
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3.0 MUSCULAR DYSTROPHY: A CANDIDATE APPROACH 
In the early 1990s, the molecular neurogenetic team at ANAl took the view that 
any of the contractile proteins could be disease genes for forms of muscular 
dystrophy. They could easily be mutated in muscular dystrophies not yet 
localised in the genome, or in localised muscular dystrophies whose precise 
genes had not been identified. Of particular interest were the seven contractile 
muscle proteins which account for 20% of all mANA in mature muscle fibres 
(Paterson and Bishop, 1977). The high level of muscle-specific expression of 
these genes, and their central contractile role, made them promising candidate 
genes for muscular dystrophy. The task was to place them on the physical map 
of the human genome as 'candidates in waiting', or as candidates for co-localised 
disease genes of interest to the molecular neurogenetic team at ANA I. 
Predominantly, these were the disease genes for forms of nemaline myopathy 
and distal myopathy. 
This approach had elements of the position independent candidate approach 
(p. 56-57) and the positional candidate approach (pp. 62-64). Like the position 
independent candidate approach, it selected for study genes of perceived 
possible relevance to muscular dystrophy, and without knowledge of their 
location. But then it localised these genes on the human physical map, in this 
case the cytogenetic map This is, of course, the first crucial step of the positional 
candidate approach. Genes must be localised before they can become 
candidates in identified linkage regions. So the approach adopted by the ANAl 
molecular neurogenetic group was a candidate approach. A unique candidate 
approach in that it did not quite fit the definition of the position independent 
candidate approach or the positional candidate approach, yet it had some of the 
essentials of each. With hindsight, this was not surprising. It was developed 
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and adopted when 'Reverse Genetics' was first being renamed 'Positional 
Cloning' (Collins, 1992), and before the terms 'position independent candidate 
approach' and 'positional candidate approach' had been coined. 
The work reported in this chapter was done as a part of this team's effort to 
identify muscular dystrophy disease genes. Of special interest to this thesis 
was the possibility that this work might uncover contractile candidate gene(s) for 
a Western Australian form of distal myopathy discussed in Chapter 4. 
Those involved in this research are identified in the three publications produced 
by this work (see Appendix A). The contribution made in this thesis to the 
cytogenetic localisation of these skeletal muscle contractile genes was the 
isolation of genomic clones for the slow skeletal muscle troponin gene (TNN/1), 
the human skeletal muscle alpha actin gene (ACTA 1) and the ~-tropomyosin 
gene (TPM2). This work was done in collaboration with Dr. Anthony Akkari and 
Mr. Clive Hunt, both of ANAl. Positive clones were then assayed and purified 
by Dr. Anthony Akkari (TNN/1 and ACTA 1) and Mr. Clive Hunt (TPM2) for use 
in the in situ cytogenetic mapping of these skeletal muscle contractile protein 
genes. 
3.1 GENOMIC LIBRARIES 
Genomic clones were isolated by amplifying genomic libraries in suitable 
bacterial host strains followed by plating, lifting, probing, picking and re-
amplification. TNN/1 and ACTA 1 positive clones were isolated from the A.Gem 
11 (Promega) genomic library (a gift from Dr. L. Abrahams). This was available 
at ANRI. TPM2 positive clones were isolated from a A.EMBL3 SP6/T7 
genomic library (CLONTECH) made from partially digested Sat13A I genomic 
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DNA separated on a sucrose gradient. Fragments in the range 8 to 22 kb were 
cloned into the BamH I site of f....EMBL3 SP6/T7. Both Sat.IJA I and BamH I 
generate the same GATC sticky-end overhang. 
3. 1.1 Bacterial Host Strains 
The bacterial host strain for the J....Gem 11 library was Escherichia coli LE392 and 
for the f....EMBL3 SP6m library it was Escherichia coli K802. For genomic 
library amplification, both these libraries exploit the fact that f.... bacteriophage 
adsorbs through maltose receptors in the outer membrane of E. coli, receptors 
which normally transport this oligosaccharide into the cell. Adsorption of f.... 
bacteriophage through maltose receptors is facilitated by magnesium ions. 
3.1.2 Growth Media 
Both host strains of E. coli were grown on Luria-Bertani (LB) broth and LB agar 
plates supplemented with maltose and MgS04. 
LB Broth: Bactotryptone 10 g 
Bacto yeast extract 5g 
NaCI 10 g 
ddH20 to 980ml 
Autoclaved 20 psi for 20 minutes 
Before inoculating with either E. coli LE392 or K802, 1 ml 20% maltose 
(IC12H22011) and 1 ml1 M MgS04 were added to 100 ml of autoclaved LB 
buffer at 37oc. Maltose and MgS04 were filter-sterilised as both breakdown 
at autoclave temperature. 
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LB Agar: Bactotryptone 
Bacto yeast extract 
NaCI 
Bacto agar 
ddH20 to 
Autoclaved 
10 g 
5g 
10 g 
15 g 
965ml 
20 psi for 20 minutes 
1 ml 20% maltose and 1 ml 1 M MgS04 were added per 100 ml LB agar 
broth, just before plates were poured and when its temperature was 
approximately 650C. The recipe was the same for top agarose except that 7 
g of agarose was added in place of the 15 g agar. 
3.1.3 Glycerol Stocks and Inoculation 
Glycerol stocks of each strain were prepared by adding 8.5 ml of stationary 
phase broth to 1.5 ml of glycerol. These were stored at -sooc. All working 
cultures were taken from the glycerol stocks, grown overnight in LB broth with 
maltose and MgS04, and subcultured in the same medium, and allowed to 
achieve high-density exponential growth at 2X1 os bacteria per mi. All cultures 
were incubated at 370C and aerated by shaking at 200 rpm (Centomat H 
shaker), until they had reached the desired cell density. 
3.1.4 Plating Genomic Libraries 
15 em LB agar plates, containing 30 ml LB agar with final concentrations of 10 
mM MgS04 and 0.2% maltose, were left to set for approximately 15 minutes 
after flaming to remove any bubbles. 10 ml maltose/MgS04 supplemented 
LB broth was inoculated with the host strains, LE392 or K802, from glycerol 
stocks and incubated on a shaker at 37oc overnight, then subcultured into 1 0 ml 
75 
of the same maltose/MgS04 LB broth and brought to a cell density of 2X108 
bacteria per mi. In 50 ml capped polypropylene tubes, 200 ~-tl of these 
exponential cultures and 1 ~-tl of diluted stock genomic library were incubated at 
37°C for 20 minutes. The stock genomic library dilution to use was determined 
by a library's titre (see the next section). 10 ml of melted 0.07% 
maltose/MgS04 top agarose·, at approximately 45oc, was added to each 
tube and quickly mixed by inversion. Entire contents were poured on to 
separate maltose/MgSO 4 LB bottom agar plates. These were quickly swirled 
to allow even spreading of the agarose. Bubbles were removed by flaming 
and plates were allowed to cool to room temperature for 10 minutes to let them 
set and for the inoculum to soak into the bottom agar. 
All plates were then inverted to prevent condensation smearing, and incubated 
at 37oc overnight, or until the plaques were just about to make contact with each 
other. This time varied from 8-16 hours. Plates were sealed in parafilm, 
inverted and stored at 4oc. This had the desired effect of arresting lysis before 
scoring. 
3.1.5 Tltering Genomic Libraries 
To be confident of identifying a positive genomic clone, screening had to be 
redundant. This meant that sufficient copies of the human genome had to be 
screened to overcome the possibility that, by chance, positive clones were 
missing from any particular aliquot of a library. Six-fold redundancy was 
adopted as an appropriate screening precaution, and calculated according to the 
formula: 
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human genomes per ~I = 
average number bp per insert x number pfu/~1 
bp in human genome 
In this formula, pfu stands for plaque forming units. The pfu titre was determined 
empirically following the plating protocol described in Section 3.1.4 (pp. 75-76). 
1 o-s, 1 o-7, 1 o-s. and 1 o-9 dilutions of the original library were plated and scored 
to determine pfu. 
3.1.6 Determining Insert Size 
The average size of the human insert for the A.Gem 11 library had been 
determined to be 15 kb (personal communication Dr. A. Akkari, 1993). Insert 
size for the A.EMBL3 SP6/T7 library had to be confirmed from the stated 
CLONTECH range of 8-22 kb. This was achieved by comparison of two uncut 
A.EMBL3 SP6m clones with BamH I, EcoR I and Hind Ill digests. It was 
possible to calculate insert size because BamH I, EcoR I and Hind Ill did not cut 
the vector or the TPM2 STS probe sequence. Therefore, any lane with two or 
more fragments was due to one of these enzymes cutting the non-STS part of 
the insert. Lower molecular weight bands on digest gels were summed to give 
approximate insert sizes. 
3.2 PROBING GENOMIC LIBRARIES 
3.2.1 Lifting Libraries 
Using sterile forceps, labelled 137 mm diameter nylon nucleic acid transfer 
membranes (Hybond-N+, Amersham) were placed on to the top of plated 
genomic libraries. Trapping air bubbles was avoided by allowing the 
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membrane to 'peel down', and spread across the library from its initial point of 
contact. Once in place, membranes were marked by stabbing through them 
into the agar with an 18-gauge needle dipped in printer's black ink. This allowed 
the alignment of the membrane autoradiographs with plates for the identification 
of positive clones. 
After 2 minutes, membranes were carefully peeled off genomic libraries, placed 
plaque-side-up for 2 minutes on 15 x 15 em Whatman 3MM chromatography 
paper soaked in NaOH denaturing solution, which comprised 1.5 M NaCI in 0.5 
M NaOH. Membranes were then placed, again plaque-side-up, for 2 minutes 
on another 15 x 15 em Whatman 3MM paper soaked in Tris neutralising 
solution which comprised 1.5 M NaCI in 0.5 M Tris-HCI (pH 7.5). Finally, 
membranes were placed between two Whatman 3MM papers to blot dry. 
Duplicate lifts were made for all plates by placing a second Hybond-N+ 
membrane on to each plate and marking them with ink in the same locations as 
the first membrane. The lifting protocol was the same for primary and duplicate 
lifts. All membranes were left to dry at room temperature, overnight and in a 
dark place, stacked between Whatman 3MM papers. 
3.2.2 Labelling Probes 
The probes employed to screen the A.Gem 11 and A.EMBL3 SP6ff7 
genomic libraries were available at ANAl. They were: LK603 (Wade et al., 
1990) (a gift from Dr. Larry Kedes) for TNN/1; a PCR amplified STS of the 
ACTA 1 gene (Freeman and States, 1991); and a 1.5 kb TPM2 STS 
manufactured with a common axon IV forward primer and a muscle specific 
exon Vlllsk reverse primer (Hunt et al., 1995). 
78 
The probe labelling system employed was developed by Feinberg and 
Volgelstein (1984). Random hexanucleotides were used to prime the Klenow 
DNA polymerase extension of each probe strand, with a.-32p dCTP to 
internally label probes. This method generated probes of up to 50% of the 
length of the original template, and with specific activity greater than 109 cpm/f.tg 
(Feinberg & Vogelstein, 1984). 
25 ng of DNA template was denatured by heating at 95-1 OOOC for 2 minutes. 
Denatured probes were snap-chilled in an ice-bath to prevent renaturation. The 
labelling reaction was assembled ·on ice and behind a perspex screen by 
adding the following reagents to a 0.6 ml eppendorf tube (final reaction 
concentrations are shown in in brackets): 10 f.tl labelling 5X buffer (1X); 2 f.tl 
mixture of unlabelled dNTP (20 f.tM each); 25 ng denatured DNA template (0.5 
ng/f.tl); 5 f.tl a.-32p dCTP (Bresatec) (50 f.tCi where Ci stands for Curie); 2 f.tl 
acetylated, nuclease free, 10 mg/ml BSA (0.4 f.tg/f.tl); 5 units (u) Klenow 
enzyme (0.1 U/f.tl); sterile ddH20 (Baxter) to final volume 50f.tl. This reaction 
was mixed gently and incubated at 25oc for 60 minutes in a thermal cycler (MJ 
Bresatec), then terminated by heating to 95-1oooc for 2 minutes. Ice-bath 
snap-chilling kept probes single-stranded. EDTA was added to 20 mM. 
Probes manufactured in this way were purified using Sephadex G-50 size-
exclusion chromatography spin columns. The purpose of the size-exclusion 
chromatography spin column was to remove the unincorporated a.-32p dCTP. 
Spin columns were prepared by plugging a 3 ml syringe with a small piece of 
sterile non-absorbent cotton wool. The 3 ml syringe was filled with Sephadex 
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G-50 and compacted until it measured about 2 mi. The plunger was removed 
and discarded. 1 ml STE buffer was added to the top of the Sephadex G-50 
column and the syringe placed in a 15 ml polypropylene conical tube. STE 
buffer comprised: 0.1 M NaCI; 10 mM Tris.CI (pH 8.0); and 1 mM EDTA (pH 
8.0). Spin columns were centrifuged at 2000 rpm for 5 minutes in a Beckman 
T J-6 centrifuge. Syringes were placed in new 15 ml tubes and labelled probes 
were added to the top of the Sephadex column. These were centrifuged at 
2000 rpm for 5 minutes in an International Equipment Company (IEC) HN-5 
'radioisotope' centrifuge. 
Purified probes, the eluents, were pipetted from the 15 ml tubes into 0.6 ml 
eppendorf tubes and denatured by heating to 94oc for 5 minutes. Snap-
chilling on ice for 1 minute kept labelled probes single-stranded. 
The percentage incorporation of a-32p into the probe by random priming was 
checked in two ways. First, the fraction, 'eluent cpmltotal cpm' gave an 
approximate percentage value for incorporation efficiency. Total cpm was 
calculated from: Sephadex column cpm plus eluent cpm. It was a simple matter 
to determine the actual counts incorporated by multiplying the original counts 
added to labelling reaction with incorporation percentage. Since 1 t-tCi contains 
2.2 X 106 counts, the added 50 t-tCi a-32p dCTP contained 1.1 X 108 counts. 
The second estimate of radioisotope incorporation efficiency used PEl cellulose 
thin layer chromatography. An 8 em strip of PEl paper was cut an 'x' was 
marked, in pencil, in the middle of this strip, 1 em from one end. This end was 
designated the bottom of the PEl strip. 0.5 ml of the random priming reaction 
was loaded on to this 'x'. 5 ml of 0.75 M K2H2P04 (pH 3.0) was pipetted into 
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a Coplin jar, and the loaded PEl strip was placed in this jar so that its bottom 
end was in the K2H2P04, with the 'x' just above the solvent level. Only the top 
of the strip touched the side of the jar. The K2H2P04 solvent moved up to the 
top of the PEl strip. The front of the K2H2P04 solvent could be seen quite 
clearly, and the PEl strip was removed from the Coplin jar when this front had 
migrated to within 1 em of the top end of the PEl strip. cpm was measured at 
'x', then up to the solvent front. Since unincorporated a-32p dCTP was 
dissolved in the K2H2P04, while labelled probe was not, probe labelling 
efficiency could be calculated from: 
Probe labelling efficiency= cpm at 'x'/(cpm up the strip+ cpm at 'x') 
If the labelling efficiency was too low, Q-20%, then the random priming reaction 
was repeated using more than the original 25 ng DNA template. 
3.2.3 Pre-hybridlsatlon 
Membranes were placed in a round plastic container with pre-hybridisation 
solution and incubated at 42oc for at least four hours with shaking (Stuart 
Scientific Hybridisation Oven/Shaker). 15 ml of pre-hybridisation solution was 
added per membrane. The ingredients and final concentrations of the pre-
hybridisation solution were: 1 M NaCI; 1 M de-ionised formamide; 50 mM Tris 
pH 7.5; 0.1 mg/ml salmon sperm DNA; and 10% dextran sulphate. 
Autoclaved salmon sperm DNA was boiled at 1 oooc for 5 minutes, snap-
chilled on ice then added to the pre-hybridising solution. This procedure 
fragmented the salmon sperm DNA to a size range of 500-700 bp (Sambrook, 
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1989, 8.15). Formamide was deionised by mixing 5 g AG 501-X8 mixed 
bed resin (Bio-Rad) with every 100 ml formamide. This was gently shaken for 
one hour at room temperature then filtered through 305 mm diameter Postlip 
Paper (Hollingsworth & Vose Co. Ltd). 
The salmon sperm blocks non-specific binding of the probe to the membrane 
(Sambrook et al., 1989, 9.48-9.50); formamide keeps the DNA probe single 
stranded; 10% dextran sulphate increases the rate of hybridisation ten-fold, 
because nucleic acids are excluded from the volume of the solution occupied by 
this polymer, effectively increasing probe concentration; 1 M NaCI maximises 
the rate of annealing of the probe with its target as solutions of high ionic strength 
increase hybridisation; 1% SDS solution is a surfactant that facilitates probe-
target annealing (Sambrook, et al., 1989, 9.47-9.55). Pre-hybridising solution 
was stored at -200C in 40 ml aliquots which were wrapped in alfoil. It was 
considered suitable for use as long as it remained frozen. 
3.2.4 Hybrldlsation 
After 4 hours of pre-hybridisation at 42oc, TNN/1 and ACTA 1 radiolabelled 
probes were added to the pre-hybridised A.Gem 11 membranes and the 
TPM2 radiolabelled probe was added to the pre-hybridised A.EMBL3 SP6/T7 
membranes. Labelled probes were again denatured, this time by boiling with 
6 f.lg salmon sperm DNA. After snap-chilling on ice, this mixture was added to 
the pre-hybridisation solution containing membranes, so that the final activity of 
the hybridisation solution was 1X106 counts per mi. Hybridisation took place at 
42oc for between 16-20 hours, with shaking. 
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At the end of hybridisation, 2XSSC was added to the hybridisation solution to 
triple its volume and this mixture was drained into a flushing sink. The added 
2XSSC reduced the viscosity of the hybridisation solution, thus facilitating its 
removal. sse was made up as a stock 20XSSC: 175.3 g Nael; 88.2 g 
sodium citrate; 800 ml ddH20; pH adjusted to 7.0 with a few drops of a 10M 
NaOH; and final volume set at 1 litre with addition of ddH20. 
Membranes were washed at increasing stringency in the hybridisation tubs until 
membrane cpm fell to 1 0-20 cpm/membrane. This was determined by 
removing membranes and testing them individually with a Geiger counter. The 
first and least stringent wash was in 2XSSC for 15 minutes in a shaking water 
bath at 420e. 75 ml 2XSSe was added per membrane. The second wash 
was in 2X sse and 1% SDS for 15 minutes at 42oe, in a shaking waterbath. 
The third wash, only conducted if activity had not dropped sufficiently, was the 
most stringent wash and carried out in 0.1 X sse and 0.1% SDS, for 15 
minutes in a shaking water bath at 42oe. Washing temperatures were 
increased for membranes with high to very high activity, as this also increased 
washing stringency. 
Membranes were blot dried with Whatman 3MM paper and wrapped in Glad 
Wrap. The duplicate membranes were paired and taped to a large piece of 
Whatman 3MM paper, that was cut to fit the size of the autoradiograph 
cassette. This anchored membranes, preventing movement. The Whatman 
3MM backing paper was fluorescently and asymmetrically marked with three 
distinctly different symbols. The fluorescent marker exposed the X-ray film. 
Membranes were placed in a cassette for autoradiography with Dupont eronex 
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4 X-ray film and Quanta Ill autoradiography intensifying screens, at -8ooc. 
Exposure time was overnight, precise times determined by the activity level of 
membranes. 
3.2.5 Positive Primary Clones 
After developing, films were aligned with membranes to ensure that they had 
not moved. The fluorescent marks were useful in this alignment. Permanent ink 
marks were added to the autoradiographs to match the Indian ink marks on the 
membranes. These permanent ink marks were then used to align 
autoradiographs with agar plates and so identify positive plaques. Only 
plaques that were positive on duplicate lifts were considered for picking. When 
possible, single isolated plaques were picked. In the initial screens this was not 
usually possible due to confluence. Agar plugs normally contained several 
plaques, only one of which was positive. 
Plaques, were picked over a light box and using sterile, Pasteur pipettes. 
Transparent glass pipettes were preferred to disposable tips with their ends cut 
off. The tips of Pasteur pipettes were pushed through the 0.7% agarose top 
agar and into the bottom agar to select positive plaques. Agar plugs were 
removed by suction with a moistened finger held over the open 'bulb end' of 
the pipette. Bulbs had a tendency to suck agar plugs too far into the pipette. 
Agar plugs were placed into a sterile 1.5 ml eppendorf with 200 ~I autoclaved 
SM buffer. Phage eluted from agar plugs into SM buffer. Eluted phage and 
agar plugs were stored at 4oc. SM buffer comprised: 5.8 g NaCI; 2 g 
MgS04.1H20; 50 ml1 M Tris Cl (pH 7.5); 5 ml2% gelatin solution; ddH20 to 
1 litre. These were autoclaved and stored in 50 ml aliquots at room temperature 
(Sambrook et al., 1989, A7). 
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3.2.6 Secondary and Subsequent Screening 
Using the eluted phage from each selected positive plaque, a secondary 
screen was conducted. Phage were re-plated and titered to obtain 200-1 000 
plaques on a 15 em petri dish. This was achieved by placing 1 , 10, and 1 00 t.d 
of the eluted phage from the agar plug into 200 J.tl of the overnight broth. Then, 
1 J.tl of these phage eluates were added to 200 JA-1 of exponential growing E. 
coli LE392 or K802. host bacteria. Suitable density plates were lifted using the 
nylon membranes and rescreened using the same radiolabelled probes and 
same procedures employed in the primary screen. 
Rescreening was repeated until 1 00% of the plaques showed up as positive. 
For some primary plaque clones this would occur after the tertiary screen; for all 
clones this was achieved after four rounds of screening. In the final screen, low 
density plates were prepared with 10-50 plaques, as well as plates with 200-
1 000 plaques. The lower density plates were used to pick positive clones for 
stock, while higher density plates were used to confirm that clones were pure 
clones. Well-isolated positive plaques selected for stock, were picked and 
placed into 200 JA-1 SM buffer. These were stored at 4oc. 
The PCR assay of positive stock clones and the preparation and purification of 
large quantities of high titre positive clone DNA by plate lysate method, was 
conducted by others. Approximately 1 0 JA-g of purified positive clones were 
forwarded to Department of Cytogenetics and Molecular Genetics, Adelaide 
Children's Hospital, for use in FISH. 
85 
3.3 RESULTS 
3.3.1 Genomic Libraries and Probes 
The f...Gem 11 had an original activity of approximately 1 X1 01 o pfU/J.tl (personal 
communication, Dr. L. Abrahams 1993). Repeated titrations, however, showed 
this library to have an average activity of 2.4X108 pfU/J.tl. Genomic libraries lose 
activity over time. The f...EMBL3 SP6/T7 library had a stated activity of 5x1 os 
pfu/J.tl (CLONTECH, 1994). This was its measured activity. It was a recently 
purchased genomic library. 
f...Gem 11 insert was, on average, 15 kb (personal communication, Dr. A. Akkari, 
1993). The TPM2 insert was also approximately this size. Restriction 
digestion showed one positive TPM2 clone insert to be 15 kb while another 
was 16-18 kb. This was in agreement with the CLONTECH range of 8-22 kb 
for genomic cloned fragments of average size 15 kb. For both the f...Gem 11 
and the f...EMBL3 SP6m genomic libraries, an average insert size of 15 kb 
was used to calculate the number of plates needed to achieve six-fold 
redundancy screening. 
Labelling the LK603 probe (Wade et al., 1990) and the ACT A 1 STS probe 
(Freeman and States, 1991) was successful with 25 ng DNA template as 
described in Section 3.2.2 (pp. 78-81 ). However the incorporation of a-32p 
dCTP was too low when 25 ng of purified TPM2 STS was used as labelling 
template DNA. It became necessary to increase the TPM2 STS purified DNA 
template five-fold, to 125 ng, to obtain a satisfactory level of a-32p dCTP 
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incorporation into this probe. Probes used in hybridisation all had a.-32p dCTP 
incorporation greater than 50%. 
3.3.2 Hybrldlsation 
Primary plates were always allowed to grow close to confluence with an 
average of 50 000 pfu/plate. These were ideal for the first screening of the 
duplicate membrane lifts because at this confluence eight plates contained the 
equivalent of one diploid genome (50 000 X 8 X 15 000 bp = 6X109 bp). 
This near-confluence meant that secondary screening always showed that 
primary 'positive plaque' agar plugs contained several plaques, only one of 
which was positive. Figure 3.1 (p. 88) shows the result of a duplicate 
quaternary screen of the J..Gem 11 for positive TNN/1 plaques. 
3.3.3 FISH Localisation 
Under the direction of Dr. David Callen at Department of Cytogenetics and 
Molecular Genetics, Adelaide Children's Hospital, the TNN/1, ACTA 1 and 
TPM2 probes provided by ANAl were used to localise these genes by FISH. 
FISH expertise was not available in Western Australia at that time, so the world-
wide reputation of Dr. Callen's team as FISH localisation experts, made them 
an obvious choice to complete this section of the research. 
The first of these genes to be localised by FISH to 1q32 was TNN/1 (Eyre et 
al., 1993). Figure 3.2 (p. 89) shows the FISH localisation of TNN/1 to 
demonstrate the end-point of this research. Subsequently, ACTA 1 was 
localised to 1 q42 (Akkari et al., 1994) and TPM2 to 9p13 (Hunt et al., 1995). 
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A. 
B. 
Figure 3.1 Autoradiographs of a A.Gem 11 genomic library 
quaternary screen for positive TNN/1 clones. A is the first lift, B the 
duplicate lift. Red arrows identify the positive TNN/1 clones that 
were picked. Low density plates like this one were preferred for final 
selection of 'stock' positive clones. Perimeter 'aligning' dots can be 
seen on each autoradiograph. 
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A. 
B. 
Figure 3.2 A whole metaphase showing in situ hybridisation of 
the biotinylated TNN/1 probe to 1q32. A. Normal male 
chromosomes stained with propidium iodide. Hybridisation sites are 
indicated by arrows. B. The same metaphase stained with DAPI for 
chromosome identification. Photographs kindly provided by H.J. 
Eyre, Department of Cytogenetics and Molecular Genetics, Adelaide 
Children's Hospital. 
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For FISH, all ANAl probes were nick-translated with biotin-14-dATP and 
hybridised in situ to metaphases of two or three normal males. Probe 
concentration was 15 ng/ml. The FISH method was modified from that 
previously described (Callen et al., 1990) in that only two rounds of 
amplification with fluorescein-conjugated avidin and biotinylated goat anti-avidin 
were employed. Chromosomes were stained before analysis with both 
propidium iodide (as counterstain) and, for chromosome identification, with 4', 6 
diamidino-2-phenylindole (DAPI). 
In this thesis, all figures which involved scanning, like Figures 3.1 and 3.2, were 
scanned using a MicroteckX6 scanner, run by Microteck Scan Suite 1.0.1 
software (1998). Images were saved in either MicroFrontier Colourlt (1997) or 
AdobePhotoshop 5.0.2 (1998) using either PICT or JPEG formats. To 
improve the printed image quality of scanned developed X-ray films the, 
brightness/contrast in Colour It was set at + 11/+22, effectively altering the 
background from smoke-grey to blue. 
3.4 CONCLUSION 
The human contractile skeletal muscle genes TNN/1, ACTA1, and TPM2 were 
localised to 1q32 (TNN/1), 1q42 (ACTA 1), and 9p13 (TPM2) on the 
cytogenetic map of the human genome. This made them candidate genes for 
inherited skeletal muscle diseases whose candidate region included one of 
these locations. At the time of completion of this work no muscle diseases had 
been localised to these regions. They were, therefore, candidates 'in waiting' for 
inherited muscle diseases yet to be localised. This included the forms of distal 
myopathy and OPMD discussed in Chapters 4, 5, and 6 of this thesis. 
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Subsequently, mutations have been identified in ACTA 1 (Nowak et at., 2000) 
and TPM2 (Donner et at., 2000), all associated with congenital myopathies, 
especially nemaline myopathy. No disease causing mutations have been 
identified in TNN/1. 
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CHAPTER FOUR 
THE LOCALISATION OF AN 
AUTOSOMAL DOMINANT DISTAL 
MYOPATHY GENE 
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4.0 THE LOCALISATION OF AN AUTOSOMAL 
DOMINANT DISTAL MYOPATHY GENE 
The localisation of a form of AD-distal myopathy segregating in a Western 
Australian kindred is reported here (Aim (ii), p. 3). It launched the molecular 
genetic investigation of the distal myopathies. In line with the rationale of this 
thesis (p. 4), there was the expectation that this work would contribute to 
progressive improvements in the nosology, diagnosis, research, prognosis, 
prevention, and treatment of the distal myopathies. 
4.1 DISTAL MYOPATHY NOSOLOGY 
Gowers (1902) described a 10 year old patient with weakness and wasting of 
the hand, forearm and anterior tibial muscles. By the age of 18, severe wasting 
of the sternomastoids, wasting of the tongue and weakness of the facial muscles 
were also evident. This was the first description of hereditary distal myopathy 
(MIM160500) (McKusick, 1992). 
At the start of this thesis, Markesbery and Griggs (1986, p. 1322) and Barohn 
et al. (1991, p. 1369) had presented the most recent nosologies for distal 
myopathy. Their classifications were similar, both based on the same clinical 
and pathological features and mode of inheritance. They differed in that Barohn 
et al. (1991) expanded the Markesbery and Griggs (1986) classification from 
two late-adult onset forms and one early-adult onset form of distal myopathy, to 
two late-adult onset forms and two early-adult onset forms of distal myopathy. 
As well as grouping distal myopathies by common age of onset, the 
classification of Barohn also grouped distal myopathies by commonality of 
onset-site, mode of inheritance, creatine kinase (CK) levels and muscle biopsy 
results. Table 4.1 (p. 94) groups distal myopathies after Barohn's classification. 
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TABLE 4.1 Nosology of the Hereditary Distal Myopathies (after Barohn eta/., 1991, p. 1369) 
Clinical phenotype Late-Adult Onset, Type 1 Late-Adult Onset, Type 2 Early-Adult Onset, Type 1 Early-Adult Onset, Type 2 
Identification: Welander, 1951 Sumner et al., 1971 (F) Markesbery et al., 1977 (S) Miyoshi et al., 1986 (AR) 
Edstrom et al., 1975 Markesbery et al., 1974 (AD) Nonaka et al., 1981 & 1985 (AR) Kuhn & Schroder 1981 (ARIF) 
Scoppetta et al., 1984 (AR) Galassi et al., 1987 (ARIF+S) 
Inheritance: AD AD&F AR&S AR,ARorF&S 
Age of onset: Overage40 Overage40 20-30 years 15-30 years 
Rrst symptoms: Hand muscles Distal leg muscles, Distal leg muscles, Distal leg muscles, 
anterior compartment anterior compartment posterior compartment 
Progression: Very slow - distal Slow - upper extremities, Rapid - proximal leg muscles, Medium - proximal leg muscles. 
flexors and extensors proximal limb muscles arms, hands, neck then trunk. No atrophy or weakness in 
Tendon reflexes diminished upper extremities 
Cardiomyopathy: No Yes No No 
SerumCK: Normal or slightly Normal or slightly Increased, usually <1 OX 1Q-150X normal 
elevated elevated normal, often 2-5X normal 
Electromyography: Myopathic pattern Myopathic pattern Myopathic pattern Myopathic pattern 
Muscle biopsy : Variable, some Rimmed vacuoles Rimmed vacuoles Dystrophy, no vacuoles, some 
rimmed vacuoles gastrocnemius weakness 
F = Familial; S = Sporadic; X='times'. 
4.2 ASCERTAINMENT OF A WESTERN AUSTRALIAN 
FAMILY SEGREGATING DISTAL MYOPATHY 
Ascertainment of a Western Australian (WA) family segregating a form of distal 
myopathy was conducted in the Neuromuscular Clinic of the Australian 
Neuromuscular Research Institute (ANAl), under the supervision of Professor 
Frank Mastaglia, Professor of Neurology at the University of Western Australia. 
This family was of English/Welsh origin and was described as the WA 
Myopathy Distal family, or the WAMPD family. Nine affected and six 
unaffected WAMPD family members agreed to take part in this study. The four 
generation WAMPD pedigree is consistent with a highly penetrant AD form of 
distal myopathy (Figure 4.1, p. 96). 
4.2.1 Clinical Features 
Onset varied from 4-25 years, with indication of earlier onset in generations Ill 
and IV. This indication may be ascertainment bias coming from two sources. 
First, had the onset of distal myopathy been earlier in II :2 and II :5 (red means 
affected), they might not have reproduced. The very existence of this distal 
myopathy family could be a source of ascertainment bias. 
Second, the earlier onset of distal myopathy in 111 :2 and in her children, IV:1, 
IV:2, IV 4 and IV:5, made the segregation of this disease quite apparent and 
caused 1112 to draw clinical attention to her family's condition. If distal myopathy 
onset had been later in 111:2 and her children, this family may not have identified 
itself. 
Either or both of these sources of ascertainment bias could explain the apparent 
earlier onset of distal myopathy in generations Ill and IV. 
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CD 
(J) 
I: 1 1:2 1:3 1:4 
+ 
II: 1 I I :2 11:3 11:4 II :5 11:6 11:7 11:8 
121 /14 / 7 1 
Ill: 1 111:3 111:4 Ill :5 111:6 Ill :7 
I 25 / 19 / 
IV:1 I V:2 IV:3 IV:4 IV:5 IV:6 IV:7 IV:8 IV :9 IV:10 
Figure 4.1 Pedigree of a Western Australian family segregating distal myopathy (the WAMPD family). Squares denote males, circles 
females, lines through squares or circles indicate 'deceased', and diamonds identify individuals of unknown sex. Blackened symbols and 
red numbers indicate individuals affected by distal myopathy. The half-blackened symbol shows an individual who, by history, was 
probably affected by distal myopathy. An 'N' in the centre of the symbol denotes 'unaffected by distal myopathy' while a'?' in the centre of 
the symbol denotes 'unknown status'. The arrow identifies the proband, II I : 2. Each individual marked with a cross ( + ) was examined 
clinically, had an immortalised lymphocyte cell line established, and contributed DNA for linkage analysis. The boxes at the top left-hand 
side of affected participants contain: their mother's age at the time of their conception/ the reported age of onset of their distal myopathy 
symptoms/ and their ~ J u~ "' 1r , . AD inheritance of high penetrance was indicated. 
Excluding ascertainment bias, there are four other explanations for the apparent 
earlier onset of distal myopathy in generations Ill and IV: anticipation caused by 
an unstable trinucleotide repeat expansion (Fu et al., 1991); anticipation caused 
by meiotically stable trinucleotide expansion (Brais et al., 1998); maternal age 
effect; and effects of other genes. Two events in the WAMPD pedigree 
indicate possible effects of maternal age and/or other genes on the age of distal 
myopathy onset. 
The progressively earlier age of distal myopathy onset in the siblings/step· 
siblings IV:1, IV:2, IV:4 and IV:5, correlate with increasing maternal age of 111·2, 
as shown in Figure 4.1 . The mothers age at conception versus the age of distal 
myopathy onset for these individuals, was: IV'1 (25/19), IV·? (27/13}, IV:4 
(36/5) and IV (38/4). From a study of 17 affected sibling pairs born to 
mothers with myotonic dystrophy, Andrews and Wilson (1992) discovered 
that, in 13 of the 17 sibling pairs, later-born affected children suffered more 
severe disease than their first-born siblings. They displayed significantly more 
neonatal feeding difficulties, a later age when first sitting alone, a later age when 
first walking alone, and a higher incidence of scoliosis. The greater the age 
difference between affected sibs, the greater the difference in their disease 
severity, suggesting that increasing maternal age was a factor in the relative 
disease severity of affected children. 
The two older step-siblings, IV·1 and IV:2, and the two younger step-siblings, 
IV 4 and IV:5, had different fathers, 111 :1 and 111 :3 respectively. These older 
step-siblings did not develop symptoms until their mid- to late-teens, the age at 
which their affected mother became symptomatic. Because Ill :2 had two 
partners, each of whom fathered two affected children, there is a potential link 
between paternal genetic contribution and age of onset of distal myopathy. 
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Unfortunately, the putative maternal age effect and paternal genetic contribution, 
confound each other in this pedigree. 
Muscle weakness first presented with selective weakness of the toe extensors 
and ankle dorsiflexors, resulting in bilateral foot drop. This form of distal 
myopathy onsets in the anterior compartment of the leg which contains: the 
tibialis anterior (dorsiflexes and inverts the foot); the extensor hallucis 
(dorsiflexes and inverts the foot, extends the great toe); extensor digitorum 
longus (extends the toes II-V); peroneus tertius ( dorsiflexes and inverts the 
foot). 
The degree of weakness in the anterior tibial muscle groups was variable. 
Weakness of the ankle evertors and inverters was difficult to evaluate in the 
presence of weak dorsiflexion. Some degree of weakness of neck flexors was 
present in all cases and was associated with mild to moderate atrophy of the 
sternomastoid muscles, particularly the sternal head. Selective weakness of the 
long finger extensor muscles was present. The finger flexors and intrinsic hand 
muscles were relatively unaffected, but certain proximal muscle groups such as 
the hip abductors and external rotators and shoulder abductors were mildly 
affected. 
Table 4.2 (p. 99) shows the pattern of muscle weakness in the nine affected 
members of this family. Although progression was gradual, there was 
eventually a moderate degree of incapacity. The oldest living affected family 
member, II ·' , was initially diagnosed as suffering from distal myopathy in 1969, 
yet was still walking when re-examined in 1992, although he had developed 
difficulty maintaining an erect posture. The pattern of muscle weakness in the 
WAMPD family most closely resembles that described by Gowers (1902) in 
his original report of distal myopathy. 
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Table 4.2 Distribution of muscle weakness In 9 distal 
myopathy Individuals in the WAMPD family 
Muscle Group *MRC Grades 
Neck sternomastoids 2 - 4+ 
Shoulder flexors 3+ - 5 
abductors 3+ - 5 
Wrist flexors 4+ - 5 
Finger flexors 4 - 5 
extensors 1+ - 5 
abductors 3+ - 5 
adductors 4 - 5 
Thumb flexors 4 - 5 
extensors 3+ - 5 
abductors 4 - 5 
opposition 3+ - 5 
Trunk flexors 2+ - 5 
Hip flexors 4 - 5 
extensors 4 - 5 
abductors 4+ - 5 
adductors 4 - 5 
external rotators 4 - 5 
Ankle dorsiflexors 0 - 4 
invertors 4 - 4+ 
evertors 2+ - 5 
Toe extensors 0 - 4 
flexors 3+ - 5 
Remaining muscle groups were grade 5 in all subjects. 
*Medical Research Council Grades: 0 = no contraction; 1 = flicker or 
trace of contraction; 2 =active movement with gravity eliminated; 3 = 
active movement against gravity; 4 =active movement against gravity 
and resistance; 5 =normal power (Brooke eta/., 1983). 
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Electromyography and nerve conduction studies were performed in 111:2, 11 :2 
and IV:2 by Dr Tim Day of the Neuromuscular Clinic, ANAl. Recordings 
showed striking myopathic motor unit potential changes; low amplitude, brief 
duration units, with many polyphasic units. A full, low amplitude (<0.5mV) 
interference pattern was recorded, particularly in affected distal limb muscles and 
to a lesser extent in some proximal muscles. Occasional spontaneous 
fibrillation potentials and positive waves were present in some affected muscles 
in 111:2. In all affected individuals, deep tendon reflexes were preserved and the 
plantar responses were flexor. There was no myotonia (a disorder of the 
muscle fibres that results in abnormally long contractions), no sensory 
impairment or other neurological abnormalities. Motor and sensory nerve 
conduction studies in the upper and lower limbs were normal. Serum CK levels 
were elevated in three affected individuals (21 6-531 U/1), according to the 
Gilboa and Swanson (1976) definition of normal serum CK level as, 'lower than 
180U/I'. U stands for unit. 
An open biopsy taken from the left vastus lateralis muscle in 111 :2 showed 
occasional necrotic and regenerating fibres, excessive variation in fibre size, 
increased numbers of fibres with internal nuclei, occasional angulated atrophic 
fibres and nuclear clumps (Figure 4.2A, p. 101 ). One feature characteristic of 
some other forms of distal myopathy was not observed. This was rimmed 
vacuoles (RVs). Most forms of distal myopathy have RVs (Table 4.1 , p. 94). 
The failure to observe RVs could have been due to sampling limitations. 
The NADH-TR histochemistry preparations showed only non-specific changes 
in the more lightly and variably stained moth-eaten type I fibres, but increased 
enzyme activity in the more darkly stained angulated atrophic type II 
fibres(Figure 4.28). 
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A. 
B. 
Figure 4.2 Vastus lateralis biopsy from 111 :2 showing: 
A. Excessive variation in myofibril size and nuclear clumps 
(haemotoxylin and eosin X400). B. Darkly stained 
angulated atrophic type II fibres and moth-eaten type I 
fibres (NADH-TR X400). The vastus lateralis predominantly 
consist of type II, fast-twitch fibres. 
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Dystrophin and desmin immuno-histochemistry were normal. Desmin storage 
has been described in a form of AD-distal myopathy (Horowitz & Schmalbruch, 
1994). A 1969 biopsy of the left tibialis anterior muscle from 11 :2 showed 
evidence of end-stage disease with extreme muscle fibre atrophy, many central 
nuclei and nuclear clumps, and increase or replacement of endomysia! 
connective tissue. 
4. 2. 2 DNA Extraction 
Blood samples were taken and immortalised cell lines established for the 15 
participating family members, marked + in Figure 4.1 (p. 96). Venous blood 
samples were split 50:50 into lithium-heparin and EDTA tubes for immediate 
. 
DNA isolation by conventional phenol-chloroform or salt precipitation techniques 
(Miller et al., 1988), and for lymphocyte isolation and immortalisation with 
Epstein-Barr virus (Neitzel, 1986). DNA extraction and lymphocyte 
immortalisation was performed by medical scientists at the Department of 
Neuropathology, Royal Perth Hospital. 
4.3 CO-SEGREGATION LINKAGE ANALYSIS 
Table 1.1 (p. 9) showed that genetic linkage had not been demonstrated in any 
form of distal myopathy at the start of this study, nor had distal myopathy 
candidate gene(s) been identified (McKusick, 1992). Since information 
necessary for functional cloning was unavailable for all forms of distal myopathy, 
co-segregation linkage analysis was the chosen method tor disease gene 
localisation. The WAMPD pedigree contained enough affected members to 
be reasonably confident of achieving linkage. 
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4.3.1 Genetic Markers 
Genetic markers were identified from a comprehensive linkage map of the 
human genome (NIH/CEPH Collaborative Mapping Group, 1992), a second-
generation linkage map of the human genome (Weissenbach et al., 1992), the 
Cooperative Human Linkage Center (CHLC), 'CHLC REPORT (Murray et al., 
1993), and from the Genome Database (GOB, 1993; 
http://gdbwww.gdb.org/). 97 polymorphic markers spread over all autosomes 
were tested for the fifteen WAMPD family members taking part in the study. 
DNA polymorphisms with a D-number were anonymous DNA fragments (0-
segments), other markers were associated with genes. The legend of Table 
B4.1 (Appendix B) defines acronyms for marker associated with genes. From 
chromosome 1 to 22, the markers tested against the WAMPD pedigree were: 
01880, 01864, 018223, 018185, 018176, CAP, 018104, AT3, and 
ACTN2; APOB, 02844, HOXD4, and 028102; 0381307, 0381304, 
0381285, 0381278, 0381279, 0381282, 0381262, and 0381311; 
D4845(HD), 048174, and 048171; 058268, 058112, 05839, APC, and 
058210; DMDL; 078472, 078435, 078474, GCK, 078440, and CF; 
088166, 08884, 088198, 8CA1, and 088200; 098104, · 09815, and 
09853; 010828; 0118875, D118873,CD3D, andD118836; D12843,and 
012860; 013871, and RB1; 014872,014850, MYH7, 014864,014854, 
014849, 014852, 014876, 014853, 014874, 014848, 014881, 
014845, 014851, and 014813; TPM1, and 015887; 0168291, 0168292, 
0168287, 0168295, 0168298, 0168300, 0168308, 0168265, 
0168186, 0168301, 0168260, 0168266, and 0168305; 017830, 
0178122, GX-Aiu, HOXB6, and 017826; 018840, and 018851; 019875, 
APOC2, and OM; 020866; 0218210, and 0218213; 0228258. 
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Probes for genotyping the 4 VNTR markers D2S44, D10S28, D14S13 and 
D17S26 were purchased from Promega. They were labelled with a.-32p. 
dCTP by random priming method as described in Section 3.2.2 (pp. 78-81). 
For each participating family member, 4 11g of gDNA was digested overnight 
with Haelll (Amersham) and digest fragments separated by 0.8% agarose gel 
electrophoresis. Bio-Rad Mini-Sub Cells or Wide Mini-Sub Cells were used 
to run gels. A Bio-Rad PowerPac 1000 generated electrophoresis power. 
Gels were alkali transferred to Hybond N+ nylon membranes (Amersham) 
using aTE 80 TransVac vacuum blotter (Hoefer) attached to a PV 100 Red-
Evac Vacuum/Pressure Module (Hoefer). The pre-hybridisation of these 
vacuum blots and subsequent hybridisation to labelled probes followed the 
protocols described in Sections 3.2.3 and 3.3.3 (pp. 81-83). Dried and 
probed vacuum blots were placed in radiography hypercassettes (Amersham) 
with Cronex 4 film (Du Pont) and exposed for 7-1 0 days at -8ooc with single 
intensifying screens. 
A Cyclone Plus DNA Synthesiser (Milligen/Biosearch) was used to synthesise 
primers for the 89 microsatellite (Weber & May, 1989) and 4 non-microsatellite 
PCR polymorphisms (APOB, AT3, HD, D17S30). Primer sequences were 
obtained from the GOB (1993; http://gdbwww.gdb.org/). Internal labelling was 
the chosen method for labelling microsatellites. It was simpler, and kinasing trials 
did not improve low repeat microsatellites autoradiographs, the hardest 
microsatellites to score. 
Microsatellite PCR conditions for a reaction volume of 20111 were as follows: 4111 
5 X buffer (335 mM Tris-HCI [pH 8.8] at 250C; 83 mM (NH4)2S04; 100 11M of 
each of the the four dNTPs; 0.2 111 25 mM MgCI2; 50 ng of each primer; 0.1 111 
104 
a-32P dCTP (3,000 Ci/mM, Amersham); 50 ng target DNA; and 0.5 unit (u) Tth 
polymerase (Biotech International). The reactions were overlaid with mineral oil 
and the cycling conditions were based on two patterns. Using a GENATQ 
thermal cycler (Pharmacia): 94oc for 5 minutes to denature; 580C for 6 minutes 
to anneal and elongate. This initial cycle was followed by 34 cycles of 94oc for 
1 minute and 580C for 6 minutes. Using an MJ thermal cycler (Bresatec): 940C 
for 3.5 minutes to denature; ssoc for 1 minute to anneal; 720C for 1 minute to 
elongate. This initial cycle was followed by 34 cycles of 94oc for 30 seconds, 
ssoc for 1 minute and 720C for 1 minute. When necessary, annealing 
temperatures were increased to improve primer specificity and yield. PCR 
reaction conditions for non-microsatellite polymorphisms were similar to those 
described for microsatellite PCR polymorphisms, except a-32P dCTP was not 
included in the non-microsatellite PCR reaction mix. 
Depending on comb size, 4-8 J.tl aliquots of microsatellite PCR products were 
mixed with an equal volume of formamide loading buffer and electrophoresed 
on standard 4% or 6% acrylamide denaturing sequencing gels (Sambrook et al., 
1989, 6.49 & 13.47-13.53). Allele size determined gel acrylamide percentage, 
4% used for alleles averaging <250 bp. Either an SE 1600 Poker Face II 
Nucleic Acid Sequencer (Hoeffer) or a Vertical Sequencing Gel (Bio-Rad) were 
used to run gels. Electrophoresis power was supplied by a Bio-Rad 
PowerPac 3000. Gels were washed in a 4:1 (v:v) methanol:glacial acetic acid 
fixative; partially dried at room temperature; lifted with Whatman 3MM paper cut 
to size; and completely dried at 80°C in a vacuum Slab Gel Dryer (Savant). 
Levels of a-32P dCTP incorporation were measured by passing a Geiger 
105 
counter over dried gels. Gels were placed in 24 em X 30 em autoradiography 
hypercassettes (Amersham, Australia) with Cronex 4 film (Ou Pont). Films 
were exposed at -8ooc for between two hours to several days with a single 
intensifying screen. Exposure time was determined by levels of a.-32P dCTP. 
5 J.ll aliquots of the 4 non-microsatellite PCR products (APOB, AT3, HO, 
017S30) were electrophoresed in 2% agarose. Bio-Rad Mini-Sub Cell or 
Wide Mini-Sub Cell were used to run gels. Electrophoresis power was 
supplied by a Bio-Rad PowerPac 1000. Gels were stained with ethidium 
bromide (EtBr) (1 J.lg/J.tl); viewed with a UVTM-40 Mighty Bright UV 
Transilluminator (Hoeffer); and photographed with a OS-34 fixed focal length 
Polaroid camera loaded with Polaroid 667 film. 
Figure 4.3 (p. 1 07) shows the microsatellite 022S258 gel and the VNTR, 
017S26 gel. Screening the WAMPO genome ran from chromosome 22 to 
chromosome 1, so the 2 markers in Figure 4.3 were among the first markers 
tested. Figure 4.4 (p. 108) shows the microsatellite 048174 gel and the 
VNTR 02S44 gel, which were among the last markers to be tested. All 
autoradiograph gel images in figures throughout this thesis were enlarged 
horizontally to accommodate pedigree numbers and alleles. 
4.3.2 Two-point Linkage Analysis 
Two-point linkage analysis was carried out for all family members on these 97 
marker loci using the computer program LIPEO (Ott, 1974) to apply the method 
of maximum likelihood and lod scores (Morton, 1955). All family members 
were included in this analysis because the pedigree indicated high penetrance 
of this form of distal myopathy (Figure 4.1, p. 96). 
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A. 
B. 
~ 
D22S258 
Family Members 
_. 
B 11 .5 111 :6 IV 9 111 :7 IV:10 111:4 11 ·2 11:3 IV:1 IV2 1112 IV:3 IV:4 IV:5 111 :3 
--
B 4.5 6,5 6,3 1,3 5,1 4,3 4,5 2,3 ~.4 3,4 4,3 5,3 4,3 5,4 4,5 • 
0228258 Genotypes 
017S26 
Family Members 
11 :5 11 :2 11 :3 111 '6 111:7 111 :2 111:3 B 111:4 IV·9 IV:10 IV·1 IV:2 IV:3 IV·4 IV:5 8 
-
-
~-
-
- ~---
- -
-
. 1,1 6,8 4.4 3,3 1,8 2,7 8 1,8 4,3 4,3 1,1 5,1 5,8 2,1 7,8 8 
017826 Genotypes 
C. WAMPD Pedigree 
111 :1 
IV:1 
3,4 
1,1 
11 :2 
4,5 
1,1 
4,3 
1 ,8 
IV:2 IV:3 
3,4 5 ,3 
5 ,1 5 ,8 
11 :3 
2 ,3 
6 ,8 
111:3 
4 ,5 
2 ,7 
IV:4 
4,3 
2 , 1 
11:4 
111:4 
4,3 
1,8 
Ill :5 
11 :5 11 :6 
4 ,5 
IV:S IV:6 IV7 IV8 
5 ,4 
7,8 
111 :6 
6,5 
4 ,4 
IV:9 
8 ,3 
4 ,3 
111:7 
1,3 
3 ,3 
IV:10 
5 ,1 
4,3 
Figure 4.3 Microsatellite 0228258 and VNTR 017826 segregation in 
the WAMPO pedigree. A. 0228258 autoradiograph. B. 017826 
autoradiograph. Both A and B incorporated a.-32P dCTP and were 
electrophoresed on 6% acrylamide gels. Red numbers indicate affected 
individuals; B means 'blank'. On the 017826 gel and the WAMPO pedigree, the 
genotype -,- indicates a failed marker. C. The segregation of 0228258 and 
0 17826 genotypes in the 15 participating (+) WAMPO pedigree members. 
Where possible, paternal alleles are shown on the left. 
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A. 045174 
~ 
Family Members 
8 11 :5 11:2 11:3 111 :6 111 :7 111:2 111 :3 111 :4 IV·9 IV:10 IV:1 IV:2 IV:3 IV·4 IV:5 
..1 2,3 2,3 2,5 4,2 4,5 2,5 3,4 2,5 4,5 4,5 5,5 5,2 1 ,5 32 3,2 ~ 
048174 Genotypes 
B. D2S44 
Family Members 
~ . 
11 :5 11 :2 11 :3 11 1.6 111:7 111"2 111:3 8 111:4 IV:91V:10 IV:1 IV:2 IV:3 IV:4 IV:5 
._ 
-
-
-
~ 4~-4,5 2,3 7,5 1 ,8 5,2 9,10 8 2.5 5,8 5,8 6,2 6,5 3,2 9,2 9,~ 
02844 Genotypes 
C. WAMPD Pedigree 
112 11:3 
2,3 2,5 
4,5 2,3 
0 
111:1 I' 111:2 111:3 
2,5 3,4 
5,2 9,10 
+ + 
IV:1 IV:2 IV:3 IV:4 
5,5 5,2 1,5 3,2 
6,2 6,5 3,2 9,2 
11:4 
111:4 111:5 
2,5 
2,5 
+ 
IV:5 IV:6 IV:7 
3,2 
9,2 
115 11:6 
2,3 
4,5 
IV:8 
111:6 
4,2 
7,5 
+ 
IV:9 
4,5 
5,8 
111:7 
4,5 
1,8 
IV:10 
4,5 
5,8 
Figure 4.4 Microsatellite 04817 4 and VNTR 02844 segregation in the 
WAMPO pedigree. A . 048 174 autoradiograph showing (CA)n replication 
slippage 'stutter bands'. These can make the results for dinucleotide repeat 
markers hard to read. B. 02844 autoradiograph. A and B incorporated a-32P 
dCTP and were electrophoresed on 6% acrylamide gels. Red numbers 
indicate affected individuals; B means 'Blank'. C. The segregation of 048174 
and 02844 genotypes in 15 participating (+) WAMPO pedigree members. 
Where possible, paternal alleles are shown on the left. 
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The chromosomal positions of loci were estimated from NIH/CEPH 
Collaborative Mapping Group (1992) linkage maps, and data from the 'CHLC 
REPORT' (Murray et al., 1993 & 1994). Two markers on chromosome 8 gave 
positive two-point lod scores of over 1.00. 08884 gave a lod score of 1.11 (8 
= 0.00) and 088200 a lod score of 1.09 (8 = 0.00). These two markers were, 
however, only informative in one branch of the family and other markers on 
chromosome 8, 088166 and 088198, showed multiple recombinants for both 
branches of the family. Thus, significantly negative lod scores were obtained for 
these markers, making chromosome 8 unlikely as the site of this distal myopathy 
disease locus. 
More strongly positive two-point lod scores were obtained with markers on 
chromosome 14. 014850, MHY7 and 014864 showed no recombinants and 
yielded respective two-point lod scores of 2.31, 2.60 and 2.60. The cardiac 
myosin beta chain gene, MYH7, has two microsatellite markers, MYH7.1 and 
MYH7.2. These microsatellites were informative for different parts of the 
pedigree, so MYH7.1 and MYH7.2 were haplotyped to obtain the two-point 
lod score of 2.60 for the 'MYH7 microsatellite'. The family structure precludes a 
two-point lod score of 3 or greater. Table 84.1 in Appendix B shows the two-
point LIPEO generated lod scores for all family members. 
4.3.3 Marker Haplotypes from D14S72 (q11} to 
D14S76 {q11-q32} for the WAMPD Family 
Figure 4.5 (p. 110) shows the WAMPO family's marker haplotypes from 
014872 ( q 11) to D 14876 ( q11-q32) requiring the least number of 
recombinations. Paternal haplotypes are shown on the left. Because DNA 
from 1:2 and 1:3 was not available, phase was uncertain for 11:2 and 11 :5. 
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11.2 11.3 11.4 11 .5 11 .6 
.Mw:km. L.Qg (~=Q) 
?25? 5 4 72 5? 014S72 ·3.13 
6 6 33 6 6 014$50 2 31 
2 1 43 2 l MYH7 2601 1 ?. 3 1 1 2 D14S64 2.60 
1 5 51 1 r; 014S54 0 49 
34 42 3 5 D14S49 ·2.49 
5 1 34 5 1 014S52 ·99.99 
43 55 43 014S76 ·99.99 
111.1 111.3 111 .4 111.5 Ill ~ 111.7 
55 ?1 5? 24 4 2 4 3 
l 3 ?· . ? 63 5 6 4 3 
1 4 2 3 23 3 I 44 
3 3 3 11 . 3 23 
5 3 5 15 5 4 5 
4 4. 4 5 34 45 51 
1 4 4 5 53 5 1 ?5 3? 
3 5 5 1 45 4 3 ?5 3? 
IV 1 IV2 IV.3 IV.4 IV.5 IV.6 IV.? IV.8 IV9 IV.10 
45 45 35 ...., 15 , 55 23 4 4 
~ ~ l 2 s1 73 ?i16' ~1 61 6 3 54 .2 11 34 • 3 1 3 1 1 4 3 4 1 2 4 '2 43 3 2 3 2 2 3 32 
3 b 2 5 25 5 5 .., li§ 5 5 54 
54 * 44 44 54 ..J* 54 51* ? 4 5. 7 .... 64 2 1 24 54 51· 1 5 55 
5 5 23 25 1 5 1 5 35 45 
Figure 4.5 Identification of the MP01 candidate region. Genotypes 
of the WAMPO family shown for marker loci spanning the chromosome 14 
region, 014872 (q11) to 014876 (q11-q32). Where possible, paternal 
haplotypes are shown on the left. Question marks (?) indicate 
haplotype/recombination uncertainty due to insufficient meioses. Haplotypes 
were based on minimum number of recombinations. Using all the family data, 
the segregation of alleles in four markers, 014850(6), MYH7( 1), 014864(2), 
and 014854(5), produced positive two-point lad scores (8=0). MP01 
haplotype is shown in red. Paternal allele and maternal allele comparisons 
that define the [MP01 candidate region by recombination. * identify other 
'minimum-recombinant' recombinations. 
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Based on a report from II·? that his mother, 1:3, had the 'family walk' and from her 
death certificate listing, 'Muscular dystrophy' as a cause of death (dated and 
signed 22 April 1965, by G.B. Mortlock, Registrar, Adelaide, South Australia), 
the right-hand haplotypes of 11 :2 and 11 ·5 are assumed to be from 1:3. Phase 
was also uncertain for individuals 11:3, 111:3 and 111 :7 who married into this 
pedigree. 
The co-segregating alleles 014850 (6), MHY7 (1 ), 014864 (~).and 014854 
(5) and the positive two-point lod scores for these markers (shown in Figure 4.5 
& Table B4.1, Appendix B), indicated that this haplotype was segregating with 
the disease. Comparison of the alleles at the centromeric marker 014872 in 
111 · ' and IV· ..1 (marked ), and the alleles at the telomeric marker 014849 in II 2 
and 111 · (marked ), identify the recombinations that define the candidate region 
for this form of distal myopathy. 
4.3.4 Multipoint Linkage Analysis 
Multipoint linkage analysis at 100% 80% and 50% penetrance was performed 
by Helen Kozman, Department of Cytogenetics and Molecular Genetics, 
Adelaide Children's Hospital, using the CRIMAP version 2.4 package as 
previously described by Mulley et al. (1993). All the data for 014872, 
014850, MYH7, 014864, 014854 and 014849, and assuming 100% 
penetrance, yielded multipoint lod scores of 3.00 for the 'MYH7 microsatellite' 
(MYH 7.1 & 7.2 haplotyped) and 2.99 for 014864. A multipoint lod score of 
2.80 was obtained for MYH7 at a penetrance of 80%. These multipoint lod 
scores, shown in Figure 4.6 (p. 112), along with the lack of significant linkage 
elsewhere in the genome, confirm the region from 014872 to 014849 as the 
likely location for this distal myopathy disease gene. 
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Figure 4.6 Multipoint analysis for the markers D14S72, 
D14850, MYH7, D14864, D14854 and D14849 assuming 100%, 
80% and 50% penetrance. 
4.2.6 EXCLUDE 
Analysis of the combined LIPED data in Table 84.1 (Appendix B) for all 
markers and all family members was performed using the EXCLUDE program 
(Edwards, 1987). This was performed to determine the likelihood that the distal 
myopathy gene in this family lay on chromosome 14, and to estimate the 
proportion of the genome excluded as the possible site for the disease gene. 
Running the EXCLUDE program for the entire data set gave a probability of 
99.9% that this distal myopathy disease gene lay on chromosome 14. 
112 
Running the EXCLUDE program for the affecteds-only data set, controlled for 
the possibility of reduced penetrance. It too gave a probability of 99.9% that 
the gene responsible for the WAMPD AD-distal myopathy lay on 
chromosome 14. The WAMPD affecteds-only EXCLUDE results are 
presented in Figure 4. 7. 
:L i! 4 5 
& 7 B g :LD u :Li! 
r 
13 14 15 1& 1? 18 
19 i!D i!1 i!i! 
Figure 4.7 WAMPD family 'affecteds-only' exclusion map based 
on all the 'affected' data in Table 84.1 (Appendix B). Excluded regions 
of chromosomes are shown as thin straight lines and regions not excluded 
as shaded curves. 
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Running the EXCLUDE program for the data set minus the data for 
chromosome 14 showed, in an affecteds only analysis, that at least 50% of the 
genome had been excluded as the possible site of the disease gene in this 
family. This is shown in Figure 4.8. 
1 4 s 
l ~ 
& 7 B g ill 11 U! 
I I , r 
1::1 14 15 1Ei 17 1B 
r l l 
19 21] 21 22 
Figure 4.8 WAMPD family 'affecteds-only' exclusion map with 
the chromosome 14 'affected data' removed from the data in Table 
84.1 (Appendix B). Excluded regions of chromosomes are shown as 
thin straight lines and regions not excluded as shaded curves and 
rectangles. 
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On the basis of this EXCLUDE data, and the multipoint lod scores, the HUGO 
Nomenclature Committee reserved MPD1, 'myopathy, distal 1 ', for this form of 
distal myopathy. It is now called 'Laing myopathy' (Voit et al., 1998; Barohn et 
al., 1999). These results have been reported in brief (Meredith et al., 1994a & 
b) and in full (Laing et al., 1995b). 
4.4 REFINEMENT OF THE MPD1 LINKAGE REGION 
At the time of localisation, the sex-averaged distance of the MPD1 linkage 
interval was estimated to be 28.5 eM from the 'CHLC REPORT' (Murray et al., 
1993) and as 31 eM on the CEPH Consortium map (Cox et al., 1995) (Figure 
4.9, p. 116). If the estimated 2500 human muscle genes (Paterson & Bishop, 
1977) are evenly spread through the 3000 eM human genome, then 
approximately 25 will be located in the 28.5-31 eM MPD1 candidate region. 
Refinement of the initial MPD1 candidate region had the potential to reduce the 
number of muscle candidate genes for Laing myopathy. 
4.4.1 New Genetic Markers 
Seven new microsatellite markers within the MPD1 candidate region were 
identified from the 'CHLC REPORT' (Murray et al., 1994), the 1993-94 
Genethon human genetic linkage map (Gyapay et al., 1994) and from GOB 
(1994; http://gdbwww.gdb.org/). One marker, D14S283, was at the 
centromeric end of the MPD1 candidate region between 014872 and 
D14S50. The remaining six markers, D14S264, D14S80, D14S275, 
D14S262, D14S252, and D14S257 were at the telomeric end of the MPD1 
candidate region, between D14S49 and D14S64. These markers were tested 
against the WAMPD family using the microsatellite protocol described in 
Section 4.3.1 (pp. 104-1 06). 
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A B 
pter ___. qter pter_.. qter 
% eM Markers % eM Markers 
0.0 0.0 140HT 
3.6 6.0 AI'JG 
0.0 0.0 014$72 5.4 9.0 014872 
2.0 3.2 014850 7.8 13.0 014850 
8.4 14.0 TCAA 
9.6 16.0 014800 
4.2 6.6 MYH7 10.8 18.0 MYH7 
7.6 12.0 014S64 13.9 23.0 014864 
8.6 13.6 014$26 15.1 25.0 014826 
10.1 16.0 014880 16.9 28.0 014880 
13.2 20.9 014$54 19.9 33.0 014854 
18.0 28.5 014$49 24:1 40.0 014849 
22.4 35.4 014$69 25.9 43.0 014$70 
28.3 47.0 014875 
26.8 42.3 014824 28.9 8.0 0148306 
30.7 51.0 014847 
34.3 57.0 PYLG 
38.0 63.0 014852 
34.2 54.1 014$66 40.4 67.0 014866 
44.0 73.0 014863 
41.1 65.0 014857 44.6 74.0 014$298 
46.4 77.0 0148540 
48.1 76.1 014S77 50.6 84.0 014877 
49.6 78.4 014S43 51.2 85.0 014S71 
51.8 86.0 014843 
50.2 79.3 014S76 52.4 87.0 014876 
51.1 80.9 014S53 53.0 88.0 014853 
52.8 83.5 014S42 54.2 90.0 014874 
57.8 91.3 014$55 58.4 97.0 014855 
58.6 92.7 014$48 59.6 99.0 014848 
65.5 103.6 014881 65.7 109.0 014881 
67.1 106.0 P1 67.5 112.0 P1 
68.7 114.0 AAGf 
70.5 117.0 014862 
70.0 110.7 014$45 71.7 119.0 014845 
71.5 113.1 014851 72.9 121.0 014851 
77.7 129.0 014878 
77.4 122.4 UT699 78.9 131.0 014822 
79.6 125.8 014$13 79.5 132.0 014813 
80.1 133.0 014821 
83.6 132.1 014S27 83.1 138.0 014827 
86.7 137.0 01481 85.5 142.0 CK8 
89.2 141.1 014882 86.7 144.0 AKT1 
92.3 145.9 014819 88.6 147.0 014817 
93.4 147.7 IGHJ 89.2 148.0 014881 
94.4 149.3 014823 92.2 153.0 014820 
93.4 155.0 014823 
100.0 158.1 014$20 100.0 166.0 IGH 
Figure 4.9 Chromosome 14 sex-averaged genetic linkage maps. 
A. Redrawn from CHLC Report (Murray et al., 1993). B. Redrawn from 
Cox et at. (1994). Markers common to both maps are aligned when they 
are in the same order. Percentage(%) and eM pter ______. qter indicates 
the degree of register between these maps. 
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Figure 4.10 (p. 118) shows the electrophoresis autoradiographs for 0148257 
(the most distal marker within the MP01 candidate region) and 0 148262 (the 
most informative marker with the highest two-point lod score of 2.9 at 8=0). 
Figure 4.11 (p. 119) shows the 2 microsatellites, 0148283 (proximal) and 
014849 (distal), now defining the MP01 candidate region. 
4.4.2 Final Two-point Linkage Analysis 
The WAMPO family's marker haplotypes from 014872 (q11) to 014876 
(q11 -q32) are presented in Figure 4.12 (p. 120). Recombination was detected 
at the centromeric marker 0148283 in 111:2 and IV:9. This excluded that portion 
of the original MP01 candidate region between 014872 and 0148283. 
Linkage analysis with the remaining 6 MP01 candidate region markers did not 
reveal further recombination. Figure 4.12 shows the MP0 1 disease haplotype 
as: " 1-2-1-1-2-1-3-5·1 . 
All linkage data available for 0 14872 (q11) to 014876 (q11-q32) is presented 
in Table 4.3 (p. 121 ). Microsatellite 0148262 was fully informative and 
achieved this family's theoretical maximum two-point lod score of 2.9. 
The MP01 candidate region between 0148283 and 014849 is currently 
estimated to be 22.4 eM GB4 GeneMap'98 (NCBI, 1999; 
http://www.ncbi.nlm.nih.gov/). Since this map estimates that the original 
014872 to 014849 MP01 candidate region was 27.8 eM, running 7 new 
markers in this interval effected a 5.4 eM reduction of the original MP01 
candidate region. 
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A. D14S257 
Family Members 
~ _. 
11 :5 111 :6 IV 9 111 :71V:10 111:4 112 11:3 IV.1 IV:2 1112 IV:3 IV:4 IV:5 111:3 B 
2,1 1,1 1,3 1,3 1,1 2,4 2,1 4,5 3,1 2,1 1,4 2,4 1,1 3,1 1,3 B 
... 
0148257 Genotypes 
B. D14S262 
~-- Family Members _.. 
11 :5 111:6 IV:9 111:7 IV:10 111:4 11 :2 11:3 IV:1 IV2 1112 IV:3 IV:4 IV:5 111 :3 B 
4,1 2, 1,4 4,4 2,4 4,4 4,1 3,4 3,1 4,1 1,4 4,4 4, 1 4,1 2,4 -~ 
~- --,..--
0148262 Genotypes 
C. WAMPD Pedigree 
11 :2 11 :3 11 :4 11 :5 11 :6 
2,1 4,5 2,1 
4,1 3,4 4,1 
+ 
Ill :1 ~ 111 :2 111:3 111:4 11 1:5 111 •6 111 :7 
1,4 1,3 2,4 1,1 1,3 
1,4 2,4 4,4 2,1 4,4 
+ + + + 
IV:1 IV·? IV:3 IV:4 IV:5 IV:6 IV:7 IVB IV:9 IV:10 
3,1 2,1 2,4 1 '1 3,1 1,3 1.1 
3,1 4,1 4,4 4,1 4,1 1,4 2,4 
Figure 4.10 Microsatellites 0148257 and 0148262 segregation in the 
WAMPO pedigree. A. 0148257 autoradiograph, the most distal marker within 
the linkage region. B. 0148262 autoradiograph, the most informative marker 
within the linkage region. Both A and B incorporated a-32P dCTP and were 
electrophoresed on 6% acrylamide gels. Red numbers indicate affected 
individuals; disease haplotype alleles are printed in red; 8 means 'Blank'. C. 
Segregation of 01 48257 and 0148262 alleles in 15 participating(+) WAMPO 
pedigree members. Where possible, paternal alleles are shown on the left. 
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A. 0145283 
• 8 11:5 111:6 1\i 
Family Members 
~ 
111:71V:10 111:4 11:2 11:3 IV . . IV_ Ill IV:3 IV:4 IV·5 111:3 
.I 1,4 4,1 1 ,4 4,4 4,4 1,3 1,4 2,3 4,4 4,4 4,2 2,2 3,4 3,4 1,3 .... 
0148283 Genotypes 
B. 014549 
Family Members 
~ . 
11:5 111:6 IV;9 111:7 IV:10 111:4 11:2 11:3 IV:1 IV:2 111:2 IV:3 IV;4 IV·S 111:3 B 
3.5 4,5 5,1 1,5 4,5 3,4 3,4 4,2 5,4 4,4 4,4 4,4 5,4 4, 5 5,4 B 
.... 
C. WAMPD Pedigree 
111:1 
112 
1,4 
3,4" 
Ji m"' 
4,2 
4,4 
014849 Genotypes 
11:3 
2,3 
4,2 
111:3 
1,3 
4,5 
IV:4 
3,4 
5,4 
+ 
IV:5 
3.4 
5,4 
11:4 
111:4 111:5 
1,3 
3,4 
IV:6 IV:7 
11:5 11:6 
1,4 
3,5 
111:0 111:7 
4,1 4,4 
4,5• 1,5 
IV:8 IV:9 IV:10 
•1,4 4,4 
5,1 4,5 
Figure 4.11 Microsatellite markers defining the MP01 candidate region. A. 
a deliberately over-exposed 0148283 autoradiograph to determine I genotype. 
Other genotypes determined by shorter exposure. B. 014849 autoradiograph. 
A and B incorporated a-32P-dCTP and electrophoresed on 6% acrylamide gels. 
Red numbers indicate affected individuals; B means 'Blank'. C. segregation of 
0148283 and 014849 alleles in participating (+) WAMPO pedigree members. 
Paternal alleles are shown on the lett. Paternal allele and maternal allele 
comparisons that define MP01 candidate region by recombination. 
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Figure 4.12 Refinement of the MP01 candidate region. 
Participating individuals+ . Genotypes of the Laing myopathy family are 
shown for marker loci spanning the chromosome 14 region, 014S72 
(q11) to 014876 (q11-q32). Where possible, paternal alleles are 
shown on the left. Using all the family data, the segregation of alleles in 
ten markers, 014550(6), MYH7(1), 014864(2), 0148264(1), 
014880(1), 0148275(2), 0148262( 1), 0148252( .... ), 014854(b) 
and 0145257( 1 ), produced positive two-point lod scores (6=0). 
Haplotypes were based on minimum number of recombinations. 
Question marks(?) indicate haplotype/recombination uncertainty due to 
insufficient meioses. Paternal allele and maternal allele comparisons 
that define, the 1 MP01 candidate region by recombination. * identify 
other 'minimum-recombinant' recombinations. 
'Minimum-recombination' haplotypes are not all the same as shown in 
Figure 4.5 (p. 110). This happens because more information was 
available for haplotype construction in Figure 4.1 0 than was available 
for this task in Figure 4.5. lndividuallll.3 exemplifies this effect. 
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"l"J 1 4 1 1 3 2 2 2 2 1 3 2 3 2 2 2 4 3 3 1 4 1 4 4 4 1 4 1 1 4 2 4 3 3 3 3 3 1 l 1 3 1 3 L3 1 3 1 3 5 2 5 2 5 5 5 5 5 5 5 5 4 ~-l~ 2 1 2 4 3 1 3 1 1 3 1 1 4 4 4 54 * 54 51* ? 4 5* ? 6 4 2 1 2 4 5 4 5 1 * 1 5 5 5 
5 5 2 3 2 5 1 5 1 5 35 4 5 
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Table 4.3 L/PED generated two-point lod scores between the MPD1 disease locus and loci lying within and flanking 
thel MPD 1 candidate reg~ on chromosome 14. Analysis includes data from all family members. 
Olrorrosorre Recombination Fraction (8) 
%pter-qter Locus 0.00 0.001 0.01 0.05 0.1 0.20 0.3 0.4 
14.08 D14S72 -3.13 -1.56 -0.59 0.030 0.23 0.31 0.26 0.15 
14.10 D14:S283 - 1.93 -0.35 0.60 1.14 1.24 1.11 0.81 0.43 
14.10 D14S50 2.31 2.31 2.27 2.12 1.93 1.51 1.06 0.57 
14.11 MYH7 2.60 2.59 2.55 2.36 2.12 1.61 1.08 0.53 
14.15 D14S64 2.60 2.59 2.55 2.36 2.12 1.61 1.08 0.53 
14.15 D14S264 2.60 2.59 2.55 2.36 2.12 1.61 1.08 0.53 
14.17 D14S80 1.71 1.71 1.68 1.57 1.42 1.11 0.77 0.41 
14.18 D14S275 2.31 2.31 2.27 2.12 1.93 1.51 1.06 0.57 
14.18 D14S262 2.90 2.89 2.85 2.64 2.38 1.82 1.22 0.61 
...... 
1\) 
...... 
14.18 D14S252 1.05 1.05 1.03 0.95 0.86 0.65 0.45 0.23 
14.20 D14S54 0.49 0.49 0.47 0.41 0.34 0.21 0.1 0.03 
14.20 D14S257 1.99 1.99 1.96 1.81 1.61 1.21 0.79 0.37 
-14.22 D14S49 -2.49 -1.25 -0.30 0.30 0.47 0.49 0.36 0.19 
14.37 D14S52 -99.99 -3.41 -1 .45 -0.22 0.17 0.32 0.23 0.10 
14.50 D14S76 -99.99 -6.39 -3.42 -1.46 -0.72 -0.17 0.01 0.05 
14.52 D14S53 -99.99 -3.31 -1 .38 -0.14 0.27 0.49 0.44 0.27 
14.54 D14S74 -99.99 -99.99 -0.02 0.55 0.69 0.66 0.52 0.30 
14.58 D14S48 -99.99 -0.47 0.49 1.00 1.06 0.87 0.56 0.26 
14.63 D14S81 0.20 0.20 0.20 0.15 0.11 0.04 0.01 0.00 
14.69 D14S45 -99.99 -2.20 -1.21 -0.57 -0.34 -0.15 ·0.07 -0.02 
14.70 D14S51 -99.99 -3.77 -1.80 ·0.54 -0.10 0.15 0.16 0.08 
14.78 014S13 -99.99 -1.61 -0.63 -0.03 0.15 0.20 0.13 0.04 
%pter-qter originally determined from from NIHICEPH Collaborative Mapping Group (1992), then progressively updated from CHLC Reports (Murray et al., 
1993 & '94), Cox et al. (1994) and "The National Centre For Biotechnology Information" GB4 GeneMap'98 (http://www.ncbi.nlm.nih.gov/) 
4.5 REPEAT EXPANSION DETECTION 
In 1994, a fellow doctoral candidate, David Chandler, visited Dr. Martin 
Schalling's Clinical Genetics Laboratory at the Karolinska Hospital in Stockholm, 
to receive instruction in the RED technique, first published by Schalling et al. 
(1993). With purified DNA provided by this doctoral candidate, the WAMPD 
family was screened in Schalling's laboratory for all possible 10 trinucleotide 
repeat expansion motifs. All were excluded. A GAG expansion was detected 
but it was present in all 15 family members (personal communication, David 
Chandler, 1994). 
4.6 CONCLUSION 
The distal myopathy segregating in this Western Australian family does not fit 
the distal myopathy nosologies proposed by Markesbery and Griggs (1986, 
p. 1322) or by Barohn et al. (1991 , p. 1369) (Table 4.1, p. 94). Under these 
nosologies, the earliest onset of distal myopathy was, 'Early-Adult Onset 
Types I and II'. In the WAMPD family, onset has been detected as early as 
age 4 {IV·5, Figure 4.1, p. 96). Also, in the Barohn et al. (1991) distal 
myopathy nosology, both early-adult onset types were autosomal recessive 
whereas the WAMPD family displays AD inheritance. Furthermore, the clinical 
pattern and rate of progression of Laing myopathy was unique, showing 
elements of both 'late-Adult Onset Types I and II' and 'Early-Adult Onset 
Type 1 • of the Barohn nosology. Chapters 4 and 9 also consider distal 
myopathy nosology. 
Indications that the onset of this form of distal myopathy is earlier with the 
passage of generations were discussed. Six possible causes were noted, two 
relating to ascertainment bias and four other causes. Only one of these 
possible causes has been has been excluded; anticipation caused by an 
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unstable trinucleotide repeat expansion. The apparent earlier onset of distal 
myopathy in generations Ill and IV shown in Figure 4.1 (p. 96) remains 
unexplained. 
The linkage of MP01 to a 27.8 eM interval at 14q11.2 was the first localisation of 
a distal myopathy (Meredith et al., 1994; Laing et al., 1995b). The identification 
of recombination(s) that would significantly reduce the MP01 candidate region, 
required more affected WAMPO family members or more families segregating 
Laing myopathy. Such family members or families were not available. 
Consequently, only small refinements of MP01 were possible. These were 
entirely dependent upon the generation of new markers between the two 
proximal and two distal candidate region markers, 0148283 and 014850, and 
014849 and 0148257 respectively. 
The refinement of the MP01 region was achieved by running 7 new 
microsatellite markers within the MP01 candidate region. These new markers 
reduced the size of this candidate region to 22.4 eM, a 5.4 eM reduction of the 
original MP01 candidate region. This was equivalent to a reduction of 
approximately 5 muscle-specific MP01 candidate genes (Paterson & Bishop 
1977), from about 25 genes to about 20 genes. 
The linkage analysis performed on this family segregating Laing myopathy had 
approached its limit of refinement. 
FOOTNOTE 
As distal myopathy linkage regions were identified, medical scientists at the 
Department of Neuropathology, Royal Perth Hospital, tested the WAMPD 
family with markers located within these regions: the chromosome 2 Miyoshi 
candidate region; the chromosome 9 Nonaka myopathy candidate region. The 
Miyoshi and Nonaka candidate region markers are listed in Chapter 5 (p. 152). 
In addition, they tested the WAMPD family with markers within the chromosome 
5q31 candidate region of an AD-distal myopathy with vocal cord and 
pharyngeal weakness (AD-VCPMD) (MPD2) (Feit et al., 1998). The 
chromosome 5 markers were: 0581995, D58658, and 0581972. All of the 
Miyoshi, Nonaka and Feit candidate region markers showed recombination in the 
WAMPD family. All generated significantly negative lod scores. The MPD1 
gene did not reside in any of these d1stal myopathy candidate regions, 
strengthening its localisation to chromosome 14q. 
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CHAPTER FIVE 
EXCLUSION OF THE MPD1 
CANDIDATE REGION FOB TWO 
OTHER AD-DISTAL MYOPATHIES 
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5.0 EXCLUSION OF THE MPD1 CANDIDATE REGION 
FOR TWO OTHER AD-DISTAL MYOPATHIES 
The MPD1 candidate region could be further refined by testing for linkage in 
other pedigrees segregating Laing myopathy. Refinement would occur if 
recombination was detected within the MPD1 candidate region in affected 
individuals. There was a practical difficulty with this approach: identifying 
sufficient pedigrees segregating Laing myopathy. Since linkage detection 
power in pedigree analysis is good, but map resolving power is low, several 
large pedigrees of this type would be required to significantly reduce the MPD1 
candidate region. 
Laing et al. (1995b, p. 422) described Laing myopathy as quite distinct from 
the better known distal myopathies found in Scandinavia and Japan, "with 
phenotypic features closely resembling those described in Gowers's [sic] 
original report (Gowers 1902)". Likening Laing myopathy's clinical phenotype 
to a 1902 report of this disease, and only to this 1902 report, suggested that 
Laing myopathy a was rare form of distal myopathy. The best hope of refining 
the MPD1 candidate region Would be to discover sufficient Laing myopathy 
pedigrees, -preferably through a founder effect some 200-300 years ago 
followed by restricted emigration. 
Although geographical isolation restricts emigration from Western Australia, 
colonisation of this state did not begin until 1829 and the Laing myopathy family 
moved to Western Australia during the early years of the twentieth century. The 
excellent medical records of this state did not contain evidence of further 
individuals in Western Australia suffering from Laing myopathy. The possibility 
of refining the MPD1 candidate region with other Laing myopathy Western 
Australian pedigrees appeared unlikely. 
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In addition, the apparent rareness of Laing myopathy made the task of 
identifying and accessing Laing myopathy families living in other parts of the 
world a formidable task. As briefly noted in Section 4.6 (p. 123), when the 
MPD1 candidate region was first identified we were not aware of any 
descriptions of other families segregating distal myopathy phenotypically similar 
to Laing myopathy. 
The genetic testing of further distal myopathy . pedigrees was, therefore, 
restricted to two outcomes. First, if distal myopathy pedigree(s) containing 
sufficient affected individuals became available for genetic testing, then the 
discovery of novel distal myopathy candidate regions would be possible. 
Second, if distal myopathy pedigree(s) became available for genetic testing 
but lacked sufficient affected members for disease gene localisation, then the 
exclusion of the MPD1 candidate region might be possible. Either way, it was 
possible that the genetic heterogeneity of the distal myopathies could be 
established. 
Two further families segregating AD-distal myopathy were sent to us for 
analysis once the MPD1 localisation was published. One of these families 
resided in Queensland, Australia, the QMPD family, the other in Connecticut, 
USA, the CMPD family. Neither pedigree had sufficient affected members to 
establish linkage with the universally accepted p=0.05 threshold of significance, 
or odds of 20:1 for the joint probability of linkage versus non-linkage. 
The genetic testing of these families was, therefore, restricted to the possibility 
of establishing genetic heterogeneity for the distal myopathies. 
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5.1 AUTOSOMAL DOMINANT DISTAL MYOPATHY 
SEGREGATING IN A QUEENSLAND FAMILY 
Seven affected and six unaffected members of the QMPD family agreed to 
participate in genetic testing (Figure 5.1, p. 128). The QMPD pedigree 
indicated that this family was segregating an AD form of distal myopathy of 
relatively high penetrance. Those participating members of the QMPD family 
were ascertained and genetically tested as a part of this distal myopathy 
exclusion project. 
5. 1.1 Ascertainment 
Clinical features of the QMPD family were ascertained by Dr. Peter Silburn, 
Department of Neurology, Princess Alexandra Hospital, Brisbane, Queensland, 
Australia. Onset was in the second decade, always being clinically apparent by 
the time affected individuals reached the early part of their third decade. 
In the seven affected individuals, there was a fixed pattern of cramps then 
weaknesses, progressing: deltoid weakness, weak dorsiflexion of wrists; mild 
weaknesses of finger flexion; and variable weakness of facial musculature. In 
addition, four of the seven affected individuals, 111:4, IV 2, IV:4, and IV:6, 
spanning the age range 23-46 years, showed signs of cardiomyopathy. 
Variable expressivity was also apparent in other ways. 
The proband, Ill 4, who had a history of progressive wea~ness and lethargy, 
presented with recent onset of dysphagia for solids and liquids. She was 
unaware of any other specific muscle problems. Examination revealed marked 
bilateral wasting of the hands and feet and sternocleido-mastoids. 
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1:~ 1:2 1:3 1:4 
II:~ 11:2 11:3 11:4 11:5 11:6 11:7 11:8 11:9 11:10 
+ + + 
Ill :1 111 :2 Ill :3 111:4, 111:5 Ill :6 111:7 111:8 Ill :9 111:10 111 :11 
+ + + + 
? ? 
IV:~ IV:2 IV:3 IV:4 IV:5 IV:6 IV:? IV:8 IV:9 IV:10 IV:11 
? 
V:1 V:2 V:3 
Figure 5.1 Pedigree of a Queensland family (QMPD) segregating distal myopathy. Squares denote males, circles females, lines 
through squares or circles indicate 'deceased', and diamonds individuals of unknown sex. Shaded symbols and red numbers indicate 
individuals affected by distal myopathy, half-shaded symbols show individuals who, by history, were 'probably affected' by distal 
myopathy. An 'N' in the centre of the symbol denotes 'unaffected by distal myopathy', while a'?' in the centre of the symbol denotes 
'unknown disease status'. The proband (111:4) is indicated by an arrow. Each individual marked with a cross(+) had an immortalised 
lymphocyte cell line established and contributed DNA for exclusion analysis. AD inheritance of relatively high penetrance was indicated. 
Mild weakness was present in wrist dorsiflexion and finger extension but with 
preservation of finger flexion. There was also: mild weakness of dorsiflexion of 
the feet, with weakness of plantar and mid-hip flexion; mild weakness of 
shoulder abduction and neck flexion and severe symmetrical facial weakness; 
depressed deep tendon reflexes in the upper limbs and absent in the lower 
limbs. Plantar responses were flexor. 
CK levels were normal on multiple occasions. Nerve conduction studies of 
sensory and motor nerves were also normal. EMG, particularly of the first dorsal 
interosseous and extensor digitorum brevis (EDB), demonstrated small 
amplitude, polyphasic units with an early full interference pattern. There was no 
spontaneous activity and no myotonia was present. 
Proband biopsy samples were obtained from the EDB and deltoid muscle. 
Histologically, EDB showed intermixed hypertrophic and atrophic fibres with 
rounded contours and increased numbers of central nuclei. There was 
preservation of the normal proportion and distribution of fibre types. No 
angulated fibres or other changes of denervation were seen. The interstitium 
showed increased fibrous tissue and fatty infiltration. There were no RVs or 
inclusion bodies and no significant inflammation. Deltoid muscle appeared 
normal. The pathologists, Dr. R.J. Conrad and Dr. A. E.G. Tannenberg (also of 
the Department of Neurology, Princess Alexandra Hospital, Brisbane) 
concluded that the histology of the EDB muscle was consistent with a diagnosis 
of, "Non-Scandinavian distal myopathy, late-adult-onset type" (personal 
communication, 1994). 
A transthoracic echocardiogram (TTE) of the proband demonstrated marked left 
ventricular dilation with septal thinning and hypokinesis (reduced movement). 
Atria were normal. Cardiac conduction defects were not found. Unfortunately 
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this patient died of multiple organ failure in an intensive care unit, due to a self-
administered overdose of digoxin and an angiotension converting enzyme 
inhibitor. Post-mortem biopsy samples were obtained from the quadriceps, 
gastrocnemius, biceps brachialis, and EDB. Biopsy samples were not 
obtained for the heart. 
In the quadriceps, type II muscle fibre atrophy was present. A rare atrophic 
fibre with small RVs was also present. In the biceps, the findings were similar 
although more atrophic fibres containing RVs were present. 
In the gastrocnemius, there was increased variation of muscle fibre diameter with 
hypertrophied, normal and atrophic fibres in a haphazard distribution. Interstitial 
fibrosis was present around some severely atrophic fibres and the atrophic 
fibres were of both types. A rare fibre showing muscle fibre splitting was 
present. No inflammation was seen and there was no evidence of denervation. 
Severe signs of myopathy were seen in EDB and foot muscles showing 
fibrous and fatty replacement, more numerous RVs, small cytoplasmic inclusion 
bodies and internal nuclei. lmmunoperoxidase staining for desmin bodies was 
negative and ragged red fibres were not seen. as previously noted (p 1 02), 
desmin bodies have been associated with AD-distal myopathy, particularly 
when distal myopathy was associated with cardiomyopathy (Horowitz & 
Schmalbruch, 1994). 
For individuals, IV:2, IV. t, IV Sand JV:6, EMG confirmed the myopathic pattern 
described for the proband 111.4 with early, full interference pattern on minimal 
effort. TIE also showed that cardiomyopathy was significantly present in IV:2, 
revealing a thin hypokinetic septum, left ventricular dilatation and moderate left 
130 
ventricular dysfunction. The remainder of the heart of IV:2 was preserved. 
Finally, TTE revealed mild septal hypokinesis and mild reduction in left 
ventricular function in IV:4 and mild mid-basal septal hypokinesis in IV:6. 
Atypical of other affected family members, the proband 111·4 also manifested 
possible myopathy of external ocular muscles as determined by slow saccadic 
eye movements in the vertical and horizontal planes, and incomplete saccades 
in the horizontal plane. CNS disturbances would have to be excluded before 
these abnormal saccadic movements could be taken as clear evidence of ocular 
myopathy. Swallow assessment with video fluoroscopy demonstrated 
reduced propulsion in the pharynx and oesophagus with decreased peristalsis 
consistent with muscular weakness. These atypical symptoms of the proband 
are also associated with OPMD (Victor et al., 1962) and oculopharyngodistal 
myopathy (Satoyoshi & Kinoshita, 1977). 
In this thesis, the AD-distal myopathy segregating in the QMPD family is 
described as 'Silburn myopathy'. 
The publication of the 14q11 .2-q13, OPMD candidate region spanning the 
markers D14S283-D14S50-MYH7. 1 for a French-Canadian form of 
oculopharyngeal MD (OPMD) (Brais et al. , 1995), revealed an overlap of this 
candidate region with the D14S283-D14S49 MPD1 candidate region (Laing et 
at. 1995b). This report, and phenotype overlap between Silburn myopathy 
and OMPD, strengthened the perception that a form or forms of distal 
myopathy, OPMD or oculopharyngodistal myopathy might belong to allelic 
series. Therefore, the OPMD-Iike symptoms of the QMPD proband, Ill :4, 
effectively increased the incentive to conduct the Silburn myopathy MPD1 
exclusion project. 
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5.1.2 Genetic Markers 
Blood samples were taken and immortalised cell lines were established for the 
13 family members who volunteered to participate in the study. DNA 
extraction was identical to that described in Section 4.2.2 (p. 102). The 
segregation of 11 chromosome 14 genetic markers was determined for the 
QMPD family: D14S72, MYH7.1, D14S64, D14S80, D14S54, D14S49, 
D14S76, D14S53, D14S48, D14S45 and D14S51. Primer synthesis, a-32P 
dCTP labelling, PCR conditions, thermal cyclers used, electrophoresis and gel 
exposure to film were described in Section 4.3. 1 (pp. 104-1 06). 
Figure 5.2 (p. 133) shows an MPD1 candidate region microsatellite marker, 
D14S64, as tested on the Silburn myopathy family. 
5.1.3 Chromosome 14 Two-point Linkage Analysis 
Two-point linkage analysis was carried out for the QMPD family as described for 
the WAMPD family in Section 4.3.2 (pp. 106-1 09). Table 5.1 {p. 134) shows 
QMPD 'affecteds-only' two-point LIPED (Ott, 1974) lod scores for all of the 
tested chromosome 14 markers. An 'affecteds-only' analysis was adopted to 
control for reduced penetrance. The maximum possible 'affecteds-only' two-
point lod score for this family was 1.5. 
Significantly negative lod scores (<-2.0 at 8=0) were obtained for the genetic 
markers: D14S72, MYH7.1, D14S64, D14S80, D14S49, D14S53, D14S48, 
D14S45 and D14S51. Three of these genetic markers, MYH7. 1, D14S64, 
014880, were within the MPD1 candidate region. 
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A. 014564 
Family Members .. - __. 
IV:2 IV:4 IV:S 111 :2 IV:6 111:4 11 :7 111:5 IV:9 IV:10 111 :7 111 :9 111 :11 8 
J .2 4,2 3,1 1,2 1,3 1,3 1,2 1,2 2,3 2,3 1,3 1,2 1,2 ~ 
014864 Genotypes 
B. QMPD Pedigree 
+ 
11:6 11:7 
3.2 
+ 
111.1 1112 111:3 111.5 
1,2 
111.6 111.7 111.8 111.9 111:10 11111 
1,2 1,3 1,3 1.2 1,2 
IV:1 IV2 IV:3 IV.4 IV 5 IV.6 IV:7 IV:8 IV:9 IV:10 
3,2 4,2 3,1 3, 1 2.3 2,3 
Figure 5.2 Segregation of the MP01 candidate region 
microsatellite, 014864, in the QMPO pedigree. A. Microsatellite 
014864 autoradiograph. 014864 incorporated a-32P dCTP and was 
electrophoresed on 6% acrylamide gel. B. The segregation of 014864 
alleles in 13 participating (+) QMPO pedigree members. Where 
possible, paternal alleles are shown on the left. 
Comparison of affected genotypes shows why an 'affecteds-only' 
negative lod score of -99.99 (9=0) was obtained for co-segregation of 
014864 with the Silburn myopathy disease gene. The affected 
individuals Ill?, Ill , 1111 1 , IV 2, IV 4, IV 5 and IV 6 do not share a 
common allele. In fact, only one of the four affected grandchildren, IV.5, 
definitely received a 014864 allele (1) from their 'probably affected' 
grandfather, 11:6. Grandchild IV·6 may have received this 014864 allele 
from 11 :6. 
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Table 5.1 LIPED generated two-point lod scores between QMPD disease locus and loci lying withi n and flanking 
the [MPD 1 candidate region1 on chromosome 14. Analysis includes data from affected individuals only. 
Ouorrosorre Recombination Fraction (8) 
%pter-qter Locus 0 .00 0.001 0.01 0.05 0.1 0.20 0.3 0.4 
14.08 014872 -99.99 -7.45 ·4.5 -2.44 -1 .6 -o.79 -0.37 -o.13 
-
-
-- -
0.07 1 14.11 MYH7.1 -99.99 -1.99 -1 .01 -0.36 -o.12 0.05 0.09 
14.15 014864 -99. 99 -4.99 -3.01 -1.64 -1 .08 -o.55 -o.28 -o.11 
I 
14.17 014880 -3.50 -2.45 -1 .5 -0.83 -o.56 -0.29 -0.14 -0.04 
14.20 014854 0.13 0.12 0.12 0.09 0.05 0.01 -o.01 -o.D1 
14.22 014849 -99.99 ·1.70 -o.71 -0.08 0.13 0.25 0.23 0.15 
14.50 014876 0.13 0.13 0.12 0.10 0.08 0.05 0.02 0.01 
14.52 014853 -99.99 -7.69 -4.70 -2.64 -1.78 -o. 95 - 0.50 -0.21 
14.58 014848 -99.99 -7.50 -4.51 -2.47 -1.63 -o.88 -o.so -o.24 
14.69 014845 -99.99 -10.21 -6.26 -3.50 -1 .23 -1 .23 -o.63 -0.25 
14.70 014851 -2.80 -1.76 0.81 -0.18 0.27 0.14 0.14 0.08 
%pter-qter originally determined from from NIH/CEPH Collaborative Mapping Group (1992), then progressively updated from CHLC Reports (Murray et al., 
1993 & 1994), Cox et al. (1994) and "The National Centre For Biotechnology Information" GB4 GeneMap'98 ( 1998). An 'affecteds-only' 
EXCLUDE map for the QMPO family (see, Figure 5.5, p. 139) was generated from this data and the data in Appendix B, Table 85.1 . 
Both 014854 and 014876 achieved the positive lod score of 0.13 (6=0). 
014854 lies within the MP01 candidate region while 014876 lies distal to 
014849, the marker defining the distal end of the MP01 candidate region. The 
positive lod scores for 014854 and 014876 arose because they were 
uninformative markers, each with 0.0 equivalent number of recombinants and 
0.4 equivalent number of informative meioses. The informativeness of all the 
QMPO markers and the lod scores for linkage between the Silburn myopathy 
disease locus and other loci in the genome, are presented in Table 85. 1, 
Appendix B. 
Figure 5.3 (p. 136) shows QMPO chromosome 14 haplotypes based on 
minimum recombination. These haplotypes do not support the linkage of any 
chromosome 14 markers to the Silburn myopathy disease locus. It is 
noticeable that both the markers with positive lod scores, 014854 and 
014876, were close to markers generating significantly negative two-point lod 
scores for co-segregation with the Silburn myopathy disease locus (Table 5.1, 
p. 134). 
5.1.4 Partial Genome Screen 
Further exclusion of the QMPO from regions of the genome was undertaken in 
preparation for future distal myopathy gene localisation. This work was 
completed knowing the Laing myopathy MP01 location but before this location, 
or any other distal myopathy disease gene locations, were published. 
Accordingly, the segregation of polymorphic markers was not targeted at 
genetic loci which have subsequently been identified as distal myopathy 
candidate regions. These are discussed in Section 5.2.5 (pp. 150-152). 
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Figure 5.3 Genotypes of participating ( +) QMPO pedigree members for marker loci spanning I MP01 candidate region. ! 
Haplotypes were based on minimum number of recombinations. Where possible, paternal haplotypes are shown on the left. 
Italicised haplotypes were deduced, not determined. * indicate 'minimum-recombinant' recombinations. Question marks(?) indicate 
haplotype/recombination uncertainty due to insufficient meioses. 
In an 'affecteds-only' analysis, the segregation of 014854, a MP01 candidate region microsatellite, and 014876, a microsatellite distal 
to the MP01 candidate region, both produced the same positive two-point lod score of 0 13 (8=0). This happened because both 
the 014854(2) and the 014876(5) alleles were present in every affected person, sometimes in homozygous genotypes (2,2) and 
(5,5). However, inspection revealed that: (i) the co-segregation of the 014854(2) and 014876(5) alleles in affected individuals and 
without recombination (on the same haplotype) was, from 11.7 (unknown disease status) to 111.2, and then from 1112 to IV.2 and IV.4; (ii) 
similarly, the co-segregation of the 014854(2) and 014876(5) alleles in affected individuals and on the same haplotype was, from 
11.6 (probably affected) to 111.2 and Ill 4 and from 111.2 to rv.5. Therefore, the 014854(2) and 014876(5) alleles do co-segregate to 
and from affected individuals but do so on two different haplotypes. In addition, this cosegregation was not exclusive to affected 
individuals and also included those of 'unknown disease status', and 'probably affected individuals', a fact not included in the affecteds-
only analysis. 
The possibility of linkage of the 8ilburn myopathy disease gene to either or both of these markers was further dispelled by inspection 
of unaffected haplotypes. 014854(2) and 014876(5) co-segregate from 11.6 (probably affected) to 111.5 (ascertained unaffected) 
while 014854(2) and 014876(5) co-segregate from 11.7 (unknown disease status) to 111.9 (ascertained unaffected). 
Linkage of the 8ilburn myopathy gene to either of these markers or to the MP01 candidate region were both refuted. 
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The segregation of 29 polymorphic markers spread over the autosomes 1, 2, 
4, 5, 6, 7, 8, 13, 15, 17, 19, 20 and 21 was recorded for the 13 QMPD family 
members taking part in the study. DNA polymorphisms with a D-number were 
anonymous DNA fragments (D-segments), other markers were associated with 
genes. The Table B5.1 legend (Appendix B) defines the acronyms for 
markers associated with genes. From chromosome 1 to 21, the markers tested 
against the QMPD pedigree were: D18164, D18223, D18187 D18185, 
D18242, and ACTN2; APOB, and D28102; D4S174, and D4S171; 
D5S268, D5S112, D5S127, and D5S399; SCA1, and DMDL; D7S531, 
D7S472, D7S517, and D78483; D8S198; D13S71; TPM1, and D15S87; 
GX-Aiu; DMCTG; D20S66; D218213; and D21S171. 
Primer synthesis, 32P dCTP labelling, PCR conditions, thermal cyclers used, 
electrophoresis and gel exposure to film for the partial genome screen of 
QMPD were as described in Section 4.3.1 (pp. 104-106). Figure 5.4 (p. 138) 
shows a representative microsatellite marker, GX-Aiu on chromosome 17, from 
this partial genome screen of the QMPD family. 
Table B5.1 (Appendix B) shows 'affecteds-only' two-point LIPED generated 
lod scores for linkage between the Silburn myopathy disease gene and all the 
40 markers tested on the QMPD pedigree. 
5.1.5 EXCLUDE 
Analysis of the combined LIPED data for all 40 markers for the affected family 
members was performed using the EXCLUDE program (Edwards, 1987; 
8arfarazi et al. 1989). The 'affecteds-only' EXCLUDE map for the Silburn 
myopathy family, presented in Figure 5.5 (p.139), was generated from the 
'affecteds' data in Table 95.1 (Appendix B). 
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Figure 5.4 Segregation of chromosome 17 microsatellite GX-Aiu 
in QMPD pedigree. A. GX-Aiu microsatellite autoradiograph. The GX-
Aiu microsatellite incorporated a-32P dCTP and was electrophoresed on 
6% acrylamide gel. B. Segregation of GX-Aiu alleles in participating ( +) 
QMPD pedigree members. Where possible, paternal alleles are shown 
on the left. 
Comparison of affected genotypes shows why an affecteds-only 
negative lod score of -99.99 (8=0) was obtained for co-segregation of 
GX-Aiu with the Silburn myopathy disease gene. Grandchildren IV·2, 
1 v 4 and IV 6 all received GX-Aiu allele 1 from their 'probably affected' 
maternal grandfather, 11.6, while grandchild IV.5 did not receive a GX-Aiu 
allele from this grandfather. In addition, daughter 111.11 received the GX-
Aiu allele 2 and not allele 1 from her 'probably affected' father, II :6. 
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The MPD1 candidate region was excluded as a location for the gene causing 
Silburn myopathy, confirming the genetic heterogeneity of the distal 
myopathies first suggested by the two-point lod scores presented in Table 5.1 
(p. 134). 
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Figure 5.5 'Affecteds-only' exclusion map for the QMPD family based on 
data in Table 85.1 (Appendix B). Excluded regions of chromosomes are 
shown as thin straight lines, regions not excluded are shown as shaded 
curves or rectangles. 
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5.2 AUTOSOMAL DOMINANT DISTAL MYOPATHY 
SEGREGATING IN A CONNECTICUT FAMILY 
Four affected and five unaffected members of the CMPD pedigree agreed to 
participate in genetic testing as shown in Figure 5.6 (p. 141). Like the QMPD 
family, there were too few affected individuals for localisation of the CMPD 
disease gene, but exclusion of the MPD1 candidate region was possible. 
5.2.1 Ascertainment 
The four affected and five unaffected participants from this autosomal dominant 
distal myopathy kindred were examined by Dr. Kevin Felice, Department of 
Neurology, University of Connecticut School of Medicine, Farmington, USA 
(Felice et al., 1999). Those affected showed similar patterns of weakness, but 
displayed varying severity. 
The proband, 111 :2, in Figure 5.6 was a male with progressive foot drop first 
noticed at age 35 years. The initial problems included frequent tripping and 
difficulty with stair climbing. This is usually a sign of proximal muscle weakness 
and not due to the onset of foot drop. By the time of clinical ascertainment, he 
was using a cane and bilateral ankle foot orthoses. Other problems included 
progressive exertional dyspnoea (laboured breathing), bilateral cataract surgery 
at age 44 (capsular cataracts), hypertension and gouty arthritis (deposition of uric 
acid and urates in joints). 
The examination of 111 :2 at age 57 revealed that muscle bulk and tone were 
normal in the upper extremities. Strength of 111:2 at age 57 was determined 
according to MAC Grades (Brooke et al., 1983) a scale running from 0 (no 
contraction) to 5 (normal power) (see, Table 4.2, p. 99, for all MAC Grades). 
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V:1 V:2 V:3 V:4 
Figure 5.6 Pedigree of a Connecticut family (CMPD) segregating distal myopathy. Squares denote males, circles females, 
and lines through squares or circles indicate 'deceased'. Shaded symbols and red number indicate individuals affected by distal 
myopathy, half-shaded symbols show individuals who, by history, were 'probably affected' by distal myopathy. An 'N' in the 
centre of the symbol denotes 'unaffected by distal myopathy'. The proband ( 111'2) is indicated by the arrow. Each individual 
marked with a cross ( +) had an immortalised cell line established and contributed DNA for exclusion analysis. Individuals 11:7. 111:2, 
IV:1, IV:2, 111:1, 111:3, IV:3 and IV:7 were clinically ascertained. Individuals 1:2. 11:1, 11:2, 11:4, 11:6, 11:8, IV:6, IV:8, IV:9, V:1, V:2, V:3 and 
V:4 were not examined but, by history, appeared to be, or were, unaffected by distal myopathy. Similarly, history indicates that 
individuals 1:1. 11:3 and 11:5 were probably affected by distal myopathy. AD inheritance was indicated. 
Strength was found to be normal in the upper extremities except for weakness 
of the arm extensors (3), finger extensors (4}, and the part of the flexor 
digitorum profundus controlling digits V (2). The forced vital capacity was 1. 7 
litre (30% of predicted). There was marked foreleg and foot muscle atrophy. 
111:2 needed to push off with both hands to stand from a chair. The gait was 
unsteady with a combined waddle and steppage quality. The MAC-graded 
lower limb muscle strength was: hip flexors (3); knee extensors (4); foot 
dorsiflexors (1); plantar flexors (2); toe flexors (1); and toe extensors (1). CK 
concentration was 534 U/1. This was raised above 'normal' <180 U/1 level as 
defined by Gilboa and Swanson (1976). 
Concentric needle electromyography (CNE) revealed slightly increased 
insertional activity, rare fibrillations and positive waves, and increased recruitment 
of short duration, low amplitude, polyPhasic motor unit action potentials (i.e. 
myopathic recruitment). A left vastus lateralis muscle biopsy disclosed non-
specific myopathic changes including increased variation in fibre size, increased 
internalised nuclei, and mildly increased endomysia! fat and connective tissue. 
Rare necrotic fibres were present. No abnormal inclusions or vacuoles were 
present. 
Many clinical measurements in this patient were normal. He denied double 
vision, swallowing problems, weight loss, muscle cramps, sensory loss or 
paresthesias, passage of dark coloured urine, exercise or cold-induced 
weakness, or voiding difficulties. The heart and lung sounds were normal. There 
were no dysmorphic features, scapular winging, scoliosis or foot deformities. 
The cranial nerve examination was normal with no weakness of eyelid, ocular, 
facial, pharyngeal, lingual (tongue) or neck muscles. There was no sternocleido-
mastoid muscle atrophy. There was no myotonia, and pathological reflexes 
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were not present. Anti-nuclear antibody titre and thyroid stimulating hormone, 
carnitine, lactate and aldolase levels were all normal. Sensory examination, 
electrocardiogram (ECG), sensory and motor nerve conduction, repetitive 
motor nerve stimulation studies and chest X-ray were all normal. The vastus 
lateralis muscle biopsy revealed no RVs, inclusions, cores or rods or abnormal 
storage of lipid or glycogen. EM showed normal looking mitochondria with no 
abnormal inclusions or filaments. 
The son of 111.2, IV·1 (Figure 5.6) appeared to have an earlier onset of this 
family's form of distal myopathy and began to notice weakness at age 20, while 
he was in the army. He recalled having difficulty walking on his heels, performing 
sit-ups and push-ups and having difficulty in running. The leg weakness 
progressed slowly to the point that he reported recent occasional falls due to leg 
and foot weakness. Other problems · included a protuberant abdomen, 
exaggerated lumbar lordosis and small bilateral capsular cataracts. 
The examination of IV:1 at age 35 revealed a normal upper extremity muscle 
strength except for mild finger extensor weakness. The forced vital capacity 
was 4.5 litre (82% of predicted). The gait had both a waddling and steppage 
quality. There was moderate foreleg and foot muscle atrophy. The MAC-
graded lower limb muscle strength was as follows: hip flexors (3); knee flexors 
(5); knee extensors (5); foot dorsiflexors (3); plantar flexors (4); toe flexors (2); 
and toe extensors (2). He was able to stand on his toes but not his heels. 
Nerve conduction studies revealed absent peroneal compound muscle action 
potentials with otherwise normal sensory and motor studies. CNE revealed 
rare fibrillations, positive waves, and myopathic-type recruitment in proximal 
and distal limb muscles. 
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Uke his father, IV:1 had many normal clinical measurements. In particular 
dysmorphic features and scapular winging were absent and there was no ocular, 
facial, lingual, pharyngeal or neck muscle weakness. Electrocardiogram (ECG) 
and sensory examinations were normal. 
The daughter of the 111:2, IV 2 (Figure 5.6) presented with a milder form of the 
family's distal myopathy. She was remarkable only in that she could not walk on 
her heels, her foreleg and foot muscles were thin, and, in the lower extremities, 
there was a mild weakness of the hip flexors and foot and toe extensors. All 
the other phenotype variables ascertained for 111 ·2 and IV:1, were found to be 
normal for 1\ :2 . 
11:7, the mother of 111·? and grandmot~er of I 1:1, and IV:.. was 83 when 
ascertained and admitted to a mild difficulty climbing stairs for the past 2-3 years. 
The examination was remarkable for moderate difficulty standing from a chair, 
inability to heel-walk and mild to moderate weakness of the hip flexors and foot 
dorsiflexors. 
Although not examined, history indicates that individuals 1:1, 11 :3 and 11 :5 (Figure 
5.6) were probably affected by distal myopathy. Individuals 111 :1, 111.3, IV:3 
and IV:7 were clinically ascertained and found to be unaffected by distal 
myopathy. In addition, individuals 1:2, 11:1, 11:2, 11 :4, 11:6, 11:8, IV:6, IV:8, IV:9, 
V:1, V:2, V:3 and V:4 were not examined but, by history, appeared to be, or 
were, unaffected by distal myopathy. 
In this thesis, the AD-distal myopathy segregating in the CMPD family is 
described as 'Felice myopathy'. 
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5.2.2 Genetic Markers 
Blood samples were taken and immortalised cell lines were established for the 
9 family members who volunteered to participate in the study. DNA extraction 
was identical to that described in Section 4.2.2 (p. 1 02). 
DNA studies for the myotonic dystrophy CTG repeat expansion on 19q13 
were negative. These were performed by Athena Laboratories, Worcester, 
MA (Felice et al., 1999). The chromosome 14 markers run for this CMPD 
family were: D14S72, D14S283, D14S264, D14S80, D14S262, D14S252, 
D 14S257, D14S49 and D14S253. Primer synthesis, 32P dCTP labelling, 
PCR conditions, thermal cyclers, electrophoresis, and gel exposure to film were 
all conducted as described in Section-4.3.1 (pp. 104-106). 
5.2.3 Chromosome 14 Two-point Linkage Analysis 
Two-point linkage analysis was carried out for the CMPD family as described for 
the WAMPD and QMPD families. Table 5.2 (p. 146) shows the CMPD 
'affecteds-only' two-point LIPED generated lod scores for all tested 
chromosome 14 markers. An 'affecteds-only' analysis was adopted to control 
for reduced penetrance. 
Significantly negative lod scores (<-2.0) were obtained for 7 of the 9 genetic 
markers: D14S72, D14S283, D14S80, D14S262, D14S257, D14S49, and 
D14S253. Three of these markers, D14S80, D14S262 and D14S257, were 
within the MPD1 candidate region. 
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Table 5.2 LIPED generated two-point lod scores between CMPD disease locus and loci lying within and flanking 
the!MPD1 candidate region! on chromosome 14. Analysis includes data from affected individuals only. 
01rorrosorre Recombination Fraction (8) 
%pter-qter Locus 0.00 0.001 0.01 0.05 0.1 0.20 0.3 0.4 
14.08 014$72 -3.70 -2.38 -1.40 -0.72 -0.44 -0.19 -0.08 -Q.02 
14;10 014$283 -3.40 -3.39 -3.10 -1.98 -1.39 -o.8o -Q.44 -0.19 
14.15 0148264 0.30 0.30 0.29 0.26 . 0.22 0.13 0.06 0.02 
14.17 014S80 -3.40 -3.39 -3.10 -1.98 -1.39 -0.80 -Q.44 -0.19 
14.18 014$262 -3.30 -3.30 -3.05 -1.98 -1.39 -o.8o -Q.44 -0.19 
14.18 014$252 0.30 0.30 0.29 0.26 0.22 0.13 0.06 0.02 
14.20 014$257 -3.40 -3.39 -3.10 -1.98 -1.39 -0.80 -0.44 -Q.19 
14.22 014849 -3.40 -3.39 -3.10 -1.98 -1.39 -o.8o -0.44 -Q.19 
14.25 014$253 -3.00 -3.00 -2.85 -1.96 -1.39 -Q.79 -0.44 -Q.19 
%pter-qter originally determined from from NIHICEPH Collaborative Mapping Group (1992), then progressively updated from CHLC Reports (Murray et al., 
1993 & 1994), Cox et al. (1994), Genethon Human Genome Research Centre Genetic Maps (1993-1996) and "The National Centre For Bio-
technology Information" GB4 GeneMap'98 (1998). 
Two of the 9 markers run against the CMPD family, D14S264 and D14S252, 
achieved the positive lod score of 0.3 (8=0). Both these markers lay within the 
MPD1 candidate region. The positive lod scores for D14S264 and D14S252 
arose because they were uninformative markers, each with 0. 0 equivalent 
number of recombinants and 0.9 equivalent number of informative meioses 
(see Table B5.1, Appendix B). Figure 5.7 (p. 148) shows the genotypes of 
CMPD pedigree members for marker loci spanning the MPD1 candidate 
region. The legend to Figure 5.7 argues that that haplotypes based on 
minimum recombination do not support linkage of these markers to the Felice 
myopathy disease locus. In addition, Figure 5.7 and Table 5.2 show that these 
markers are close to, or coincident with, markers generating significantly negative 
two-point lod scores for co-segregation with the Felice myopathy disease locus. 
5.2.4 Multipoint Linkage Analysis: MPD1 Candidate Region 
Multipoint linkage analysis (Mulley et al., 1993) was performed using the 
affected data presented in Table 5.2. This was conducted by Dr. Joachim 
Hallmayer, Centre for Clinical Research in Psychiatry, Department of Psychiatry, 
University of Western Australia, Graylands Hospital, Mount Claremont, 
Western Australia. Multipoint lod scores were calculated between a putative 
disease locus and and a marker locus using the program GENEHUNTER 
(Kruglyak et al., 1996). 
Distances on chromosome 14 were obtained from the maps in Gyapay et al. 
1994, and the on-line map of the Co-operative Human Linkage Centre (1997; 
http:/ltpg.nci.nih.gov/CHLCI). In the multipoint linkage calculations, the disease 
gene frequency was assumed to be 0.001. Since the number of affected 
family members was not large enough to draw any firm conclusions in regard to 
the penetrance, penetrance was set to 70%. 
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Figure 5.7 Genotypes of of participating (+) CMPO pedigree 
members for marker loci spanning the MP01 candidate region. 
Haplotypes were based on minimum number of recombinations. 
Where possible, paternal haplotypes are shown on the left. Italicised 
haplotypes were deduced, not determined. * indicate 'minimum-
recombinant' recombinations. 
In an 'affecteds-only' analysis, the segregation of the candidate region 
markers 0148264 and 0148252, produced a positive two-point lod 
score of 0 30 (&.=0). This happened because both the 0148264(3) 
and the 0148252(4) alleles were present in every affected person. 
However, inspection revealed that, without recombination: (i) the co-
segregation of 0148264(3) and 0148252( ) on the same 
haplotype was, from 11 .8 (who married into the family and by history 
was unaffected) to 1'12, and then from h• to , ' and I . L and to 
IV.7 (ascertained unaffected); (ii) similarly the co-segregation of the 
0148264(3) and 0148252(4.) alleles co-segregate from II 7 to 111.3 
(ascertained unaffected). Therefore, the 0148264(3) and 
0148252(4) alleles do co-segregate but do so on two different 
haplotypes and to-and-from affected and unaffected individuals. This 
could only be determined by haplotype analysis, and was obscured 
by 'affecteds-only' analysis 
Linkage of the Felice myopathy gene to either of these markers or to 
the MP01 candidate region were both refuted. 
11.7 11 .8 
Lod (8=Ql Marker 
-3.7 014872 3 1 23 
-3.4 
-
l214S283 4_2 34 ~0.3 0148264 3 2 1 3 1 3.4 014880 32 1 1 
-3.3 0148262 1 2 3 1 
0.3 0148252 4 2 4 3 
-3.4 0148257 41 33 
-3.4 014849 1 4 25 
-3.0 0148253 22 1 2 
+ + + 
111.1 111.2 ' 111.3 
13 21 33 
rn 
3 2 44 
3 2 11 3 54 1 2 1 3 
33 32 1 1 
14 4 2 3 4 
21 31 34 
34 24 51 
22 1 2 22 
IV. 1 IV.2 IV.3 IV.4 IV.5 IV.6 IV.? 
23 * 11 11* 23 23 
_31 , 33 ~ ..3-L _31 3 1 32 r 2 1 '3 1 1 4 15 24 1 4 33 33 23 33 44 41 ill 4 4 31 32 1 1 1 31 
24 23 44 44 24 
1 2 12 22 22 1 2 
148 
Two sets of multipoint linkage analysis calculations were performed: either the 
phenotypic status of unaffected individuals was considered unknown; or 
phenotypic information of unaffected individuals was included. All informative 
MPD1 candidate region markers demonstrated recombinations with affected 
individuals in the pedigree (Felice et al., 1999, p. 63). Figure 5.8 shows that the 
lod scores obtained from the multipoint analyses, under either model, were less 
than -2.0 for the entire MPD1 candidate region. The MPD1 candidate region 
was excluded by multipoint linkage analysis as the Felice myopathy disease 
gene location, confirming the indication of distal myopathy's genetic 
heterogeneity implicit in the data already presented in Table 5.2 (p. 146). 
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Figure 5.8 Multipoint linkage analysis of distal myopathy at 70% 
penetrance in a single family from Connecticut against fixed maps of 
markers on chromosome 14, obtained as described in Section 5.2.4 (pp. 
147 & 149). Graph A : Phenotype of unaffected individuals assumed 
unknown. Graph B : Phenotype of unaffected individuals assumed known. 
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5.3 LAING, SILBURN AND FELICE MYOPATHIES 
Table 5.3 (p. 151) compares the essential features of Laing, Silburn and Felice 
myopathies. It shows that the clinical features of Laing myopathy were more 
similar to Felice myopathy than to Silburn myopathy. Mode of inheritance, first 
symptoms, EMG, lack of cardiomyopathy, progression and biopsy findings 
were all similar for Laing and Felice myopathies. Onset age, pattern of 
weakness and CK levels differed. 
Silburn myopathy and Laing myopathy were similar in their mode of inheritance, 
age of onset and EMG data but different in their first symptoms, pattern of 
weakness, rate of progression, CK levels, biopsy findings the presence of 
cardiomyopathy and in the OPMD symptoms in the Silburn myopathy 
proband (seep. 131 ). 
5.4 THREE OTHER DISTAL MYOPATHY LOCI 
Six other forms of distal myopathy have been assigned to three distinct loci 
since the localisation of Laing myopathy to the MPD1 candidate region (Laing 
et al., 1995b). Linkage of the AR Miyoshi myopathy (MM) to chromosome 
2p12-p14 was achieved shortly after MPD1 localisation (Bejaoui et al., 1995). 
More recently, a newly described distal anterior compartment myopathy has 
been linked to the same 2p12-p14 locus (lila et al., 1998). Tibial muscular 
dystrophy (TMD) and late-onset distal myopathy of Markesbury have both 
localised to 2q31-33 (Haravuori et al., 1998a & 1998b). Finally, an AR distal 
myopathy, Nonaka myopathy, has been localised to 9p1-q1 (lkeuchi et al., 
1997) .. deltoid weakness, weak dorsiflexion of wrists; mild weaknesses of finger 
flexion; and variable weakness of facial musculature 
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Table 5.3 Laing, Silburn and Felice myopathies. 
Distal myopathy lnfanVearly- Early-adult Early-adult 
childhood onset onset onset 
(Laing (Silburn (Felice 
myopathy, 1995) myopathy) myopathy) 
Inheritance: AD AD AD 
Earliest onset: 4 years Second decade Third decade 
First symptoms: Distal leg 
muscles in the 
deltoid weakness Distal leg 
muscles in the 
the anterior anterior 
compartment compartment 
Progression: Slow: to Variable, slow Slow: to knee 
neck flexors, Q[ fast: to wasting and finger 
finger extensors, of hands, feet and extensors, 
then to proximal sternocleido- then to 
hip adbuctors, mastoids, then proximal hip 
external rotators to weakness of flexors 
and shoulder external ocular 
abductors and bulbar 
muscles 
Cardiomyopathy: No: but one Yes: No 
autopsy report biventricular 
of 'Myocardial failure 
degeneration' 
Serum CK: Normal or 1.3-6.3X normal 
slightly elevated 
EMG: Myopathic Myopathic Myopathic 
pattern pattern pattern 
Muscle biopsy: Variable, Hyper & atrophic, Variable, 
no vacuoles fibres, fibrous & no vacuoles 
observed fatty infiltration observed 
Locus: 14q11-q13 NOT at: NOT at: 
14q11-q13 14q11-q13, 
9p1-q1' 
2p12-p14, or 
2q31-33 
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The CMPD family was tested by Medical Scientists at the Department of 
Neuropathology, Royal Perth Hospital, with genetic markers covering each of 
these distal myopathy candidate regions. Their results were reported with the 
work described above (Felice et al., 1999, pp. 63-65) and are briefly detailed 
here due to their relevance to distal myopathy nosology. The markers run were: 
028286, 028145, 0282111, 028291, and 028303 for the 2p12-p14 
Miyoshi distal myopathy candidate region; 028389, 0282273, 028364, 
028148, and 028300 for the 2q31-33 TMD and late-onset Markesbury distal 
myopathy candidate region; and 098276, 098248, 09843, and 098319 for 
the 9p1-q1 Nonaka myopathy candidate region. 
Multipoint linkage analysis between Felice myopathy disease locus and genetic 
marker data in these locations was similar to that performed for the MPD1 
candidate region; the disease gene frequency was assumed to be 0.001, 
penetrance was set to 70% and calculations were carried out by alternately 
including or ignoring unaffected phenotypic status. Although the distances 
between markers on chromosome 9 were fixed in the same way as those in the 
MPD1 candidate region, the distances between markers on chromosome 2 
were fixed according to the maps given in Gyapay et al., (1994), Bashir et al. 
(1996) and and the on-line map of the Gemethon Human Genome Research 
Centre (1993-1996). 
Lod scores obtained from the multipoint analyses under either model, were less 
than -2 for virtually the entire 2p12-p14, 2q31-33 and 9p1-q1 distal myopathy 
candidate regions (Felice et al., 1999, p. 63). With the MPD1 candidate region, 
these distal myopathy candidate regions were, therefore, excluded as locations 
for the disease gene causing Felice myopathy. The existence of a further distal 
myopathy locus for this form of distal myopathy seemed likely, further increasing 
the extent of distal myopathy genetic heterogeneity (Felice et al., 1999, p. 65). 
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5.5 CONCLUSION 
Clinical and pathological features of Silburn and Felice myopathies differed in 
some respects from each other and from Laing myopathy. However, as the 
dystrophinopathies first showed, allelic series can be quite diverse in clinical and 
pathological features. This was discussed in, 'Muscular Dystrophy Nosology' 
(Section 1.2.2, pp. 7-9). Therefore, the clinical and pathological distinctions 
between these three myopathies did not exclude the possibility that all of them, 
or any two of them, belonged to an allelic series. It did not even exclude the 
possibility that all of them, or any two of them, were caused by the same 
mutation. 
Liu et at. (1998) found that an ATC->GTC missense at 4265 mutation in the 
2p13 dysferlin gene (DYSF), gave rise to MM and AR-distal anterior 
compartment (tibial) myopathy (DMAT) in the same Italian family. Moreover, in 
two Spanish families the same DYSF mutation, a deletion of G at 5966, 
resulted in MM in one of these families but DMAT in the other. DMAT was first 
described by lila et at. (1998). The implications of the dysferlin findings for MD 
nosology, and nosology in general, are discussed further in Chapter 9. 
The exclusion of the MPD1 candidate region as the location for both the Silburn 
and Felice myopathy disease gene(s), established unequivocally that Laing 
myopathy did not belong to an allelic series which included either or both the 
Silburn myopathy or the Felice myopathy. The simultaneous exclusion of the 
Felice myopathy disease gene by fellow workers from the candidate regions for 
Miyoshi myopathy, tibial muscular dystrophy and Nonaka myopathy, indicated 
the existence of a further distal myopathy locus (Felice et at., 1999, p. 65). 
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These discoveries launched a revised genetic classification of the distal 
myopathies (Felice et al., 1999, pp. 64-65) which had some differences to the 
one presented in Table 4.1 (p. 94). The genetic classification of the distal 
myopathies will be further considered in Chapter 9. 
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6.0 EXCLUSION OF THE MPD1 AND OPMD CANDIDATE 
REGIONS FOR A PUTATIVE-OPMD SEGREGATING 
IN A WESTERN AUSTRALIAN FAMILY 
On-line Mendelian Inheritance in Man (OMIM, 164300) (1999) cites Taylor 
(1915) as the first to describe progressive vagus-glossopharyngeal paralysis 
with ptosis (eyelid droop) characteristic of OPMD. This was observed in a 
family of French-Canadian extraction. Taylor's report went largely unnoticed for 
about 50 years during which time those with similar clinical phenotype were 
classified as 'ocular myopathy' cases, particularly after the extensive review of 
ocular myopathies by Kiloh and Nevin, (1951). 
The modern study of OPMD began when Victor et al. (1962) described a 
Jewish family from Eastern Europe segregating an AD condition, presenting late 
in life and characterised by dysphagia caused by swallowing muscle failure and 
progressive ptosis with predominant involvement of the levator palpebrea. 
These authors recognised the primary myopathic nature of the disease by 
giving it its present name. Hayes (1963) confirmed the observations of Taylor 
(1915) and Victor et al. (1962) by adding two generations to Taylor's 1915 
pedigree. Nevertheless, confusion between ocular myopathies and OPMD 
continued. In 1965 Bray et al. reviewed the literature from 1948-1964 on 'ocular 
myopathies with and without dysphagia'. Forty-three of 148 cases of ocular 
myopathy discovered by these authors, had dysphagia. Although the age of 
onset, familial incidence and weakness of muscle groups of the ocular 
myopathies with and without dysphagia were quite different, all continued to be 
described as forms of ocular myopathy. 
Unequivocal confirmation that OPMD was a distinct disease entity, was finally 
made by a full autopsy study of an Italian OPMD patient (Rebeiz et al., 1969 
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cited in Bouchard et al., 1997, pp. 157~158). In 1980, Tome and Fardeau 
strengthened OPMD as a distinct disease entity by identifying 8.5 nm 
intranuclear tubular filament inclusions (INI) in OPMD skeletal muscle. These 
authors asserted that INI had to be present for OPMD diagnosis. 
Subsequently, INI have become the specific skeletal muscle, histological marker 
for OPMD (Tome et at., 1993). 
From the first modern description of OPMD by Victor et al., 1962 to the 
identification of a specific OPMD INI (Tome & Fardeau, 1980), OPMD gradually 
became recognised as a unique classical muscular dystrophy whose diagnosis 
depended upon the presence of AD segregation, late-onset dysphagia and 
progressive ptosis, generally after age 45, and 8.5 nm diameter skeletal muscle 
INI (Tome & Fardeau, 1980). Based on these diagnostic criteria, OPMD was 
subsequently reported in more than 20 countries and was considered by Brais 
et al. (1995) to have a world-wide incidence. The largest ethnic group 
segregating OPMD are a French-Canadian OPMD population with a highest 
frequency of 1fi500 in the Saguenay-Lac St Jean region (De Braekeleer, 
1991 ). Bouchard (1997) cites the demographic analysis of Barbeau (1966) as 
revealing that this OPMD population was founded by a single ancestor who 
migrated during the 1600's. 
6.1 OPMD NOSOLOGY 
Throughout the establishment of OPMD as a unique classical muscular 
dystrophy with stringent diagnostic requirements, questions about its 
homogeneity have been raised. First, it has been frequently noted that: OPMD 
is a rather generalised dystrophy, with broader clinical phenotype than its 
diagnostic criteria; RVs of likely autophagic nature may or may not be present 
157 
(Tome et al., 1997); mitochondrial abnormalities can be associated with some 
stages of OPMD (Pratt & Meyers, 1986; Goas et al., 1991); and the issue of 
neurogenic involvement in the aetiology of this disease remains unsettled 
(Hardiman et al., 1993). 
Second, reports of 'OPMD' that do not meet all OPMD diagnostic criteria include 
those: with mitochondrial abnormalities but lacking INI, AD (Pauzner et al., 1991) 
and AR (Schroder et al., 1995); with myopathic dystrophic features and 
associated neurogenic involvement (Linoli et al., 1991); with AR inheritance and 
adult onset (Nishimura et al., 1991); with AR inheritance and childhood onset 
(Lacomis et al., 1991); and with AR inheritance in an Ashkenazi Jewish family of 
Hungarian descent (Fried et al., 1975). In this thesis, these forms of OPMD are 
described as putative-OPMDs because they are repeatedly described by 
authors as forms of OPMD, despite the fact that they did not fulfil the accepted 
OPMD diagnostic criteria (Tome et al., 1993). 
Third, clinical phenotypes have been recognised which manifest both OPMD 
and distal myopathy symptoms. All taxonomies have difficulty with 
'intermediate' forms like these 'OPMD-distal myopathy phenotypes' and 
eventually respond by evolving new classifications with inclusive categories for 
persistent 'intermediates'. Nosology is no exception. Oculopharyngodistal 
myopathy was proposed as a separate disease entity to describe the 
intermediate OPMD-distal myopathy phenotypes (Satoyoshi & Kinoshita, 
1977). 
The OPMD-distal myopathy phenotype was occasionally present in the 
investigations reported here, never to the extent that the proposed classification 
of oculopharyngodistal myopathy would apply, but sufficiently prominent to 
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highlight the overlap of the distal myopathy and OPMD phenotypes. In this 
context, oculopharyngodistal myopathy is reviewed. 
6.1.1 Oculopharyngodlstal Myopathy 
Satoyoshi and Kinoshita (1977) reported an autosomal dominant myopathy 
consisting of slowly progressive ptosis and extraocular palsy, weakness of the 
masseter, facial, and bulbar muscles, as well as distal involvement of the limbs 
starting around 40 years of age or later. Autopsy disclosed no remarkable 
change in the central or peripheral nervous system, and muscle biopsy 
specimens from all patients showed myopathic patterns without any specific 
change. To distinguish this disease, and all diseases displaying both OPMD 
and distal myopathy symptoms, Satoyoshi and Kinoshita proposed the term 
'oculopharyngodistal myopathy'. 
Whether the oculopharyngqdistal myopathy classification survives or 
disappears as a part of MD nosology, will depend on the strength of 
supporting clinical and molecular evidence. Retrospective support can be 
found in the literature. Distal myopathies with clinical phenotype overlapping 
that of OPMD had been reported before 1977. Two examples are given. 
Gowers' original description of distal myopathy, which most closely resembled 
Laing myopathy (Laing et al., 1995b), displayed the OPMD characteristics of 
an inability to raise eyebrows and a weakness in closing eyes. Frontales were 
powerless, orbiculares were much weaker than normal (Gowers, 1902). 
Schotland and Rowland (1964) described a family displaying ptosis, 
dysphagia and weakness and wasting of face, neck and distal limb muscles. 
Both OPMD and distal myopathy symptoms were present. Amato et al. 
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(1995) consider that Schotland and Rowland's cases were suffering from what 
Satoyoshi and Kinoshita (1977) later called oculopharyngodistal myopathy. 
Subsequent to the Satoyoshi and Kinoshita (1977) oculopharyngodistal 
myopathy proposal, reports of OPMD with distal myopathy characteristics are 
also represented in the literature. Vita et al. (1983) described an OPMD with 
distal spread involving twelve individuals over three generations of an Italian 
family. They were remarkable in that all had ptosis; dysphagia, nasal voice and 
difficulty in walking. The distribution of muscle weakness in a 50 year old male 
proband and in one of his sisters, was proximal in the upper but distal in the 
lower limbs, confirming the existence of a relationship between OPMD and 
distal myopathy. 
Distal limb myopathy with onset at 30 years, followed by the development of 
progressive ptosis, external opthalmoplegia (affecting muscles that move the 
eye) and pharyngeal myopathy was reported in a 37-year-old Melanesian man 
from the Gulf Province of Papua New Guinea (Scrimgeour & Mastaglia, 1984). 
Two of this patient's sisters were affected, exhibiting ptosis and external 
ophthalmoplegia but without apparent distal muscle involvement or dysphagia. 
Their ages of onset were 35 and 25 years. A familial myopathy with variable 
expressivity was suggested. 
Amato et al. (1995) describe a 19 year old female patient with early onset 
dysarthria (poor pronunciation) and dysphagia followed by distal extremity 
weakness, ptosis, progressive external opthalmoplegia and finally recurrent 
episodes of intestinal pseudo-obstruction. Autosomal dominant inheritance was 
suggested on the basis of bilateral ptosis in the paternal grandfather. Her gait 
was remarkable for bilateral foot drop with ankle dorsiflexors muscle strength 
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scoring 3- on the Medical Research Council's scale of 0 (no strength) to 5 (full 
strength) (Brooke et al., 1983; Table 3.2, p. 82). In Laing myopathy patients, 
dorsiflexors MAC muscle strength range was 0-4. 
The evaluation of this patient by Amato et al. (1995, pp.844-845), excluded 
diseases characterised by ptosis with or without opthalmoplegia; desmin 
storage myopathy, mitochondrial myopathies, myotonic dystrophy, 
neuromuscular junction disorders, dysthyroid myopathy and the congenital 
centronuclear, nemaline rod and central core myopathies. It also excluded 
diseases characterised by intestinal pseudo-obstruction; DMD, 
facioscapulohumeral MD and familial visceral myopathies. Unlike Laing 
myopathy, this patient had RVs but lacked 13-18 nm cytoplasmic 
tubulofilaments accumulations sometimes found in the distal vacuolar 
myopathies (Amato et al.; 1995, p. 845). She also lacked the amyloid 
deposition and 8.5 nm tubulofilaments specific for OPMD (Tome et al., 1993). 
Amato et al., (1995, p. 846) concluded: 
Whether oculopharyngodistal myopathy is a variant 
of OPMD or a distinct neuromuscular disorder that 
merges in the spectrum of the other vacuolar 
myopathies is not known. Rimmed vacuoles and 
13-18 nm cytoplasmic tubule-filaments have been 
observed in some but not all cases. 
Overlap of OPMD and distal myopathy clinical phenotypes reported in the 
literature have also been encountered in this thesis. For example, the proband 
111.4 of the Silburn myopathy family (Figure 5.1, p. 128) displayed weakness of 
external ocular muscles much like that reported by Gowers (1902) in his first 
report of distal myopathy. This patient also possessed reduced propulsion in 
the pharynx and oesophagus with decreased peristalsis consistent with 
muscular weakness (p. 131). Both symptoms are characteristic of OPMD. 
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The slow emergence of OPMD as a distinct disease entity, its generalised 
dystrophic nature, persistent reports of conditions resembling, but failing to 
meet all OPMD diagnostic criteria, and the identification of intermediate OPMD-
distal myopathy phenotypes, all led to nosological uncertainty. The fact that 
there is only one accepted MD classification, OPMD, and one tentative MD 
classification, oculopharyngodistal myopathy, to describe these clinically diverse 
MD diseases, clearly indicates the incompleteness of this part of MD nosology. 
The growing number of putative-OPMD and oculopharyngodistal myopathy 
diseases· in the clinical literature serves only to exacerbate matters. Genetic 
analysis offers a way to break this nosological impasse. 
6.1.2 Molecular Genetics and OPMD Nosology 
The identification of the Laing myopathy MPD1 candidate region and the 
publication of the 14q11.2-q13, 5cM OPMD candidate region, spanning the 
markers D14S283-D14S50-MYH7.1 for a French-Canadian form of OPMD 
(Brais et al., 1995), made it possible to test these candidate regions as 
possible candidate regions for the putative-OPMD segregating in a Western 
Australian family. The candidate region for the French Canadian form of OPMD 
was subsequently reduced to a 1.5 eM region between D14S283 and 
MYH7.1 (Brais et al., 1998). Overlap between the clinical phenotypes of the 
French Canadian OPMD and WAOPMD's putative-OPMD, and between this 
putative-OPMD and Laing myopathy made the testing of these candidate 
regions appear particularly worthwhile. 
The genetic classification of distal myopathy and OPMD had begun. There was 
no reason why the genetic differentiation of distal myopathy, OPMD, putative-
OPMD and oculopharyngodistal myopathy should not also begin. 
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6.2 AN AUTOSOMAL DOMINANT PUTATIVE-OPMD 
SEGREGATING IN A WESTERN AUSTRALIAN FAMILY 
Three affected and eight unaffected members of the WAOPMD pedigree 
agreed to participate in genetic testing (Figure 6.1, p. 164). The pedigree 
indicated AD-OPMD segregation. Like the QMPD and CMPD families, there 
were too few affected individuals for the localisation of the WAOPMD disease 
gene, but exclusion of the French-Canadian OPMD and the MPD1 candidate 
regions were possible. 
6.2.1 Ascertainment 
Ascertainment of the WAOPMD family was conducted in the Neuromuscular 
Clinic of the Australian NeuromuscuJar Research Institute, Nedlands, Western 
Australia, under the supervision of Dr. T. Day. Individuals 111.8, IV " and 1\ 6 of 
the WAOPMD family were clinically examined and diagnosed as affected with 
OPMD symptoms. 
The proband, 111.8 was aged 75 years old at the time of her most recent 
examination. The proband was remarkable with: severe weakness of facial and 
palatal muscles; moderate to severe restriction of ocular movements with slow 
saccadic velocities; bilateral ptosis (which had been partially treated by surgery); 
neck flexion weakness; bilateral distal weakness; wasting in both upper and 
lower limbs; and bilateral foot drop like that found in Laing myopathy (p. 98). 
This last symptom again reinforced the frequently recorded overlap between 
distal myopathy and of OPMD. 111.8 was unstable when walking and liable to 
fall. Since proximal muscle strength was normal, this may indicate the presence 
of CNS or neuropathic problems. Electron microscopy (EM) was performed 
on the muscle biopsy of this patient but IN Is were not detected. 
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+ 
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Figure 6.1 Pedigree of a Western Australian family (WAOPMD) segregating putative-OPMD. Squares denote males, circles females, lines 
through squares or circles indicate 'deceased'. Shaded symbols and rea numbers indicate individuals affected by OPMD, half-shaded symbols 
indicate individuals 'probably affected' by OPMD. The proband, 111.8, is indicated by an arrow. The box at the top left-hand side of participant's 
symbols contains their :~ ... ..-see .ar1r P. t. 1118, IV.3 and IV.6 were clinically examined and diagnosed as affected. Ages at which affected 
individuals first noticed OPMD symptoms were not ascertained. History indicates that 11.3, 111.4 and IV.5 were 'probably affected' by putative-OPMD. 
Each individual marked with a cross(+) had an immortalised cell line established and contributed DNA for exclusion analysis. AD inheritance was 
indicated. Since AD-OPMD generally onsets after age 45, this relatively late onset effectively conferred 'unknown disease status' on V.3, V.4, V.5, 
V.6, V. 7 and, possibly, on IV.11. Thus, the resolving power of this exclusion analysis was diminished. 
The failure to detect INis may have been due to due to sampling problems as 
INI detection is a difficult and time-consuming task requiring considerable 
experience (Bouchard et al., 1998). Until INI are identified in WAOPMD 
muscle, this disease can only be classified as 'putative-OPMD'. 
At age 43 individual IV.3 noticed weakness of both eyes with bilateral 
droopiness. Within a year she began to complain of swallowing difficulty. This 
was followed by weakness of lower limbs and difficulty climbing stairs. It is 
probable that the 'weakness of lower limbs' and the 'difficulty in climbing stairs' 
are not related since the latter is usually a sign of proximal muscle weakness. 
By age 49 her voice became hoarse and sometimes unintelligible. There was 
occasional blurring of vision and double vision. Upon examination at age 52, 
bilateral ptosis, nasal voice, weakness of pharyngeal muscles and mild 
weakness of mainly proximal musculature, were all identified. EMG recorded 
small short duration units, myopathic potentials, in both upper and lower limbs. 
EM was not performed on the IV.3 muscle biopsy. 
From age 47, individual IV.6 noticed increasing ptosis of both eyelids. Two 
years later he noticed a slightly nasal voice and possible droop in the corners of 
the mouth. Examination at age 50 noted: bilateral ptosis of moderate degree, 
mild restriction of eye movements in all directions with gaze-paretic nystagmus, 
slightly slowed saccadic movements, and a nasal voice. There was minimal 
weakness of lips and no muscle wasting or weakness in upper and lower limbs. 
Distal musculature was quite normal. EM was not done on IV 6 muscle biopsy. 
6.2.2 Genetic Markers 
Blood samples were taken and immortalised cell lines were established for the 
11 family members who volunteered to participate in the study (Figure 6.1, p. 
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164). DNA extraction was identical to that described in Section 4.2.2 (p. 102). 
For the WAOPMD family, the segregation of 14 chromosome 14 genetic 
markers was determined: D14S72, D14S283, MYH7.1, MYH7.2, D14S64, 
D14S264, D14S80, D14S275, D14S262, D14S252, D14S54, D14S257, 
D14S49 and D14S53 
Primer synthesis, a-32P dCTP labelling, PCR conditions, thermal cyclers used, 
electrophoresis and gel exposure to film were described in Section 4.3.1 (pp. 
104-106). Figure 6.2 (p. 167) shows the markers lying at the proximal and 
distal ends of the MPD1 candidate region, D14S283 and 014849. D14S283 
also lies at the proximal end of the French-Canadian OPMD candidate region. 
Figure 6.3 (p. 168) shows D14S252, a marker lying within the MPD1 candidate 
region. Figure 6.4 (p. 169) displays the genotypes of WAOPMD pedigree 
members for 14 tested marker loci spanning the MPD1 and French-Canadian 
OPMD candidate regions. 
6.2.3 Chromosome 14 Two-point Linkage Analysis 
Two-point linkage analysis was carried out for the WAOPMD family as 
described for the Laing myopathy family (p. 89). Table 6.1 (p. 170) contains 
chromosome 14 two-point LIPED generated lod scores for all affected 
WAOPMD family members for all of the markers run on this family. An 
'affecteds-only' analysis was adopted to control for reduced penetrance. 
Significantly negative lod scores (<-2.0 at 8=0) were obtained for 12 of the 14 
genetic markers tested, 8 of which (those marked *) were within the MPD1 
candidate region; D14S72, D14S283, MYH7.1*, MYH7.2*, D14S64*, 
D14S264*, D14S80*, D14S275*, D14S252*, D14S257*, D14S49 and 
D14S53. The two positive lod scores were for D14S262* and D14S54*. 
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Figure 6.2 Segregation of the microsatellite markers 0148283 
and 014S49 in the WAOPMO family. 014S283 and 014849 lie at 
the proximal and distal ends of the MP01 candidate region. A. 
0148283 autoradiograph. B. 014849 autoradiograph. A and B 
incorporated a.-32p dCTP and were electrophoresed on 6% 
acrylamide gels. Red numbers indicate affected individuals; 8 means 
'Blank'. C. Segregation of 0148283 and 014849 alleles in the 11 
participating ( +) WAOPMO pedigree members. Where possible, 
paternal alleles are shown on the left. 
Comparison of affected genotypes shows why an 'affecteds-only' 
negative lod scores of -2.83 (8=0) were obtained for co-segregation 
of both 014S283 and 014849 alleles with the WAOPMO disease 
gene. Affected individuals 111:8 , IV:3 and IV:u do not all share a 
common allele for either 0148283 or 014S49. In addition, individuals 
IV~ and IV r inherited different alleles from their 'probably affected' 
father, 111.4, for both of these markers. 
A. 0145283 
Family Members 
111 :5 111 :8 IV:3 IV·6 IV:7 IV:11 V:3 V:4 V:5 V:6 V:7 B 
3,5 2,4 2,5 4,5 3,4 1,2 ?,3 4,3 5,3 5,3 5,4 B 
0148283 Genotypes 
B. D14S49 
Family Members 
111:5 111 :8 IV:3 IV:6 IV:7 IV:11 V:3 V:4 V:5 V:6 V:7 B 
7,5 3,5 4,7 3,7 1,6 2,5 3,1 3,1 7,1 7,1 3,6 B 
014849 Genotypes 
C. WAOPMD Pedigree 
111.6 111.7 111.8 ' 
2,4 
3,5 
o--
IV.1 IV.2 IV.3 IV.4 IV.5 IV.ti IV.7 IV.8 IV.9 IV.10 
2,5 
4,7 
V.3 
?,3 
3,1 
V.4 
4,3 
3,1 
4,5 
3.7 
V.5 
5,3 
7,1 
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1,6 
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5,3 5,4 
7,1 3,6 
IV.11 
1,2 
2.5 
A. D14S252 
Family Members 
B 111:5 111 :8 IV:3 IV.6 IV:? IV:11 V:3 V:4 
~ 1,3 1,3 1,1 1,3 2,3 2,3 3,3 3,3 
B. WAOPMD Pedigree 
111.4 
0148252 Genotype 
111.5 
1,3 
111.6 
V:5 V:6 V:7 
1,3 1,3 2,3 .. 
111.7 1118 , 
3,3 
IV.1 IV.2 IV.3 
1,1 
IV.4 IV.5 N .6 
1,3 
IV.7 
2,3 
IV.8 IV.9 IV.10 IV.11 
V.3 
3,3 
V.4 
3,3 
V.5 
1,3 
2,3 
V.6 V.7 
1,3 1,2 
Figure 6.3 Segregation of the microsatellite marker 0148252 in 
the WAOPMO family. A. 0148252 autoradiograph. The 0148252 
microsatellite incorporated a-32p dCTP and was electrophoresed on a 
6% acrylamide gel. Red numbers indicate affected individuals; B means 
'Blank'. B. The segregation of 0148252 alleles in the 11 participating(+) 
WAOPMO pedigree members. Where possible paternal alleles are 
shown on the left. 
Comparison of affected genotypes shows why an affecteds-only 
negative lod score of -2.8 (9=0) was obtained for co-segregation of 
0148252 with the WAOPMO disease gene. Affected individuals 111:8, 
IV.3 and IV:6 do not all share a common 0148252 allele. 
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Figure 6.4 Genotypes of participating (+) WAOPMO pedigree members for marker loci spanning the MP01 Icandidate 
region (Laing et al., 1995) and the refined French-Canadian OPMO candidate region (Brais et al., 1998). The box at the 
top left-hand side of participant's symbols contains their ge at ascertainment. Haplotypes are based on minimum number of 
recombinations. Where possible paternal haplotypes are shown on the left. * indicate possible recombinations. Question marks 
(?) indicate haplotype/recombination uncertainty due to insufficient meioses. 
In an 'affecteds-only' analysis, the co-segregation of the microsatellite marker alleles 014S262(1) and 014S54(1 ), produced the 
positive two-point lod scores of 0.30 and 0.18 respectively (8 = 0) in the MP01 candidate region. Both the 0148262(1) and the 
014854(1) alleles were present in every affected person. Nevertheless, these positive lod scores are artifacts of the 'affecteds-
only' analysis. 
Haplotypes based on minimum recombination do not support linkage of these markers to the WAOPMO disease locus. 
Inspection reveals that, without recombination, the key co-segregations were: (i) 0148262(1) and 014854(1) from 111.8 (affected) 
to IV.11 (so far unaffected) and (ii) 0148262(1) and 014854( .. ) from 111.5 (unaffected) to IV.3 and IV.6 (both affected) and then on 
to V.5 and V.6 (so far unaffected). Affected individuals 11 1.8, v.o.J and IV.6 and the 'probably affected' 111.4, do not share a common 
0148262-014854 haplotype in the MP01 candidate regions. Therefore, positive 'affecteds-only' positive lod scores for MP01 
markers 0148262 and 014854, do not indicate linkage to the WAOPMO disease locus. 
111.6 111.7 Marker ~ 
1 1 ? 3 1? D14S72 -2.83 
35 2 D14S283 -2.83 
t 3 3 l l.1Y'A7'1 -2.76 2 3 MYH7.2 -2.62 
3 3 D14S64 -2.76 
1 2 D14S264 -2.81 
1 5 I o .... ., -2.96 3 4 D14S275 -2.65 
1 1 D14S262 0.30 
3 3 D14S252 -2.80 
1 2 D14S54 0 .18 
2 1 5"3~ ~14S257 14S49 -2.62.J -2.83 
2 2 014$53 -2.73 
IV.1 IV.2 IV.3 IV.4 IV.S IV.6 IV.? IV.B IV.9 IV.10 IV.11 
41 1 1 55 2 1 * ? 
~ 2....§ 4...5 :L 
..1:..2... ' 0) 23 3 3 31 "1 3 CD 22 3 2 31 2 2 
43 33 21 2 3 
33 2 3 32 
r· 32 52 63 1 1 3 1 4 1 32 4 3 1 1 1 1 32 1 1 1 1 3 1 32 2 3 2 1 2 1 1 2 1 1 
2.L 4.... L2L 3_2_ 
47 7 1 6 2 5 
3 2 2 
V.1 V.2 V.3 V.4 V.5 V.6 V.7 
1 5 1 5 1 5 1 5 
4...3... 5 ~ 5 3 54 
33 
3 3 1 
3 3 3 1 
33 23 2 3 2 1 
13 2 32 3 2 3 1 23 33 3 3 3 2 
56 26 2 6 
43 1 3 1 3 
1 1J 1 3 3 
1 3 1 2 
133 1~ 1 3 .,1 2 2 1 1 1 1 1 2 2 H--- 42 4 2_. 1 3 - 7 7 1 .,3 6 
1 2 32 *1 2 32 
Table 6.1 LIPED generated two-point lod scores between the WAOPMD disease locus and loci lying within and flanking 
the!MPD1 candidate region !on chromosome 14. Analysis includes data from affected individuals only. 
Olrorrosorre Recombination Fraction (8) 
%pter-qter Locus 0.00 0.001 0.01 0.05 0.1 0.20 0.3 0.4 
14.08 014S72 -2.83 -2.38 -1 .55 -o.84 -o.54 -o.25 -0.1 -o.02 
14.10 D14S283 -2.83 -2.38 -1.55 -o.84 -o.54 -o.25 -Q.1 -o.02 
-- -- - - -- -- - -- --
I 14.11 MYH7.1 -2.76 -2.31 -1 .47 -o.79 -o.5o -0.23 -0.09 -o.02 
I 14.11 MYH7.2 -2.62 -2.07 -1.21 -0.56 -Q.31 -o.12 -o.o4 -o.01 
I 14.15 014864 -2.76 -2.31 -1.47 -o.79 -0.50 -Q.23 -o.09 -0.02 
14.15 D14S264 -2.81 -2.12 -1 .22 -o.57 -o.32 -o.11 -o.03 -o.01 
14.17 014S80 -2.96 -2.51 -1 .67 -o.94 -o.61 -o.28 -o.11 -o.03 
14.18 014S275 -2.65 -2.11 -1 .25 -0.60 -o.35 -o.14 -0.5 -0.01 
14.18 D14S262 0.30 0.29 0.28 0.25 0.2 0.12 0.05 0.01 
14.18 D14S252 -2.80 -2.13 -1 .24 -o.59 -o.33 -o.12 -0.04 -o.01 
14.20 D14S54 0.18 0.18 0.18 0.15 0.12 0.07 0.03 0.01 
I 14.20 D14S257 -2.62 -2.07 ·1 .21 -o.56 -Q.31 -Q.12 -0.04 -Q.Q1 
-
--
14.22 014S49 -2.83 -2.38 -1.55 -o.84 -o.54 -o.25 -0.1 -o.02 
14.52 D14S53 -2.73 -2.05 -1.15 -o.5o -o.26 -o.07 -o.01 0.00 
%pter-qter originally determined from from NIH/CEPH Collaborative Mapping Group (1992), then progressively updated from CHLC Reports (Murray et al., 
1993 & 1994 ), Cox et al. (1994) and "The National Centre For Biotechnology Information" G84 GeneMap'98 (http:/ /www.ncbi.nlm.nih.gov/) 
The MPD1 candidate region markers 0148262 and 014854 achieved 
positive lod scores of 0.30 and 0.18 respectively (8=0). The positive lod 
scores for 0148262 and 014854 arose because they were uninformative 
markers, with 0.0 equivalent number of recombinants and, respectively, 0.9 and 
0.5 equivalent number of informative meioses. Figure 6.4 (p. 169) shows that 
haplotypes based on minimum recombination do not support linkage of these 
markers to the WAOPMD disease locus. In addition, both these markers were 
close to markers generating significantly negative. two-point lod scores for co-
segregation with the WAOPMD disease locus (Table 6.1, p. 170). The data 
presented in Table 6.1 could only be considered as the first indication of OPMD 
genetic heterogeneity, if INI are fou.nd in skeletal muscle biopsies from affected 
WAOPMD family members. 
Figure 6.5 (p. 172) presents the EXCLUDE (Edwards, 1987) results for the 
WAOPMD family. It confirms that the WAOPMD disease locus does not lie in 
either the French-Canadian OPMD or MPD1 candidate regions. 
6.3 CONCLUSION 
The relatively late onset of this disease reduced the number of available 
informative meioses. This diminished the resolving power of the WAOPMD 
pedigree analysis. Nevertheless, it was possible to establish that the disease 
gene causing this putative-OPMD is not located in the Laing myopathy MPD1 
or French-Canadian OPMD candidate regions. This result cannot be taken to 
demonstrate locus heterogeneity for. AD-OPMD until it has been demonstrated 
unequivocally that this family segregates OPMD. For this to happen, INI must 
be shown to be associated with this family's disease. Conclusions about 
OPMD locus heterogeneity cannot be drawn from the work reported here. 
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Figure 6.5 'Affecteds-only' exclusion map for the WAOPMD 
family based on data in Table 6.1 (p. 170). Excluded regions of 
chromosomes are shown as thin straight lines, regions not excluded 
as black shaded rectangles. 
Although the genetic heterogeneity of OPMD could not be established, the 
exclusion of chromosome 14 as the disease gene location for the WAOPMD 
form of putative-OPMD has started to unravel the complex genotype-
phenotype relationships between inherited distal myopathy, oculopharyngo-
distal myopathy, putative-OPMD and OPMD with INI. 
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CHAPTER SEVEN 
LAING MYOPATHY: 
POSITIONAL CANDIDATE APPROACH 
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7.0 LAING MYOPATHY: 
POSITIONAL CANDIDATE APPROACH 
Linkage region genes become candidate genes if they are expressed in 
affected tissue before the onset of disease, or if uncertainty exists over the 
timing and/or place of their expression. Tissue-specific genes are the most 
conspicuous candidate genes, but disease genes need not have tissue-specific 
expression. The expansion of the normal (GCG)s repeat to a (GCG)g repeat 
in exon 1 of the PABP2 gene to cause AD-OPMD (Brais et al., 1998) is one 
example of a muscular dystrophy disease gene that is expressed in many 
other tissues. 
At the time of its identification, the a- and ~-cardiac myosin heavy chain genes 
(MYH genes), MYH6 (MIM 160710) and MYH7 (MIM 160760), were the 
only two muscle-specific genes known to lie within the MPD1 candidate region. 
These are still the only two muscle-specific genes listed in the MPD1 candidate 
region by 'Genomic Research', University of Padua (2000; 
http://grup.cribi.unipd.itlmusclelindex.html). The candidature of MYH6 and 
MYH7 for Laing myopathy was assessed by considering the expression 
patterns and disease associations of each of these genes. Investigating 
disease associations can give insights into how proteins work, and so assist in 
the evaluation of disease candidature. 
7.1 MYH6 LAING MYOPATHY CANDIDATURE 
Laing myopathy onsets in the anterior compartment of the leg. The earliest 
recorded onset was in early childhood (see, pp. 95-98). For MYH6 to be a 
strong candidate gene for this disease, it must be expressed in affected 
muscles during the embryonic, foetal, infant or early childhood stages of human 
development. 
174 
7 .1.1 MYH6 Expression 
The candidature of MYH6 for Laing Myopathy is supported by the timing and 
location of its expression in skeletal muscle. Pedrosa-Domellof and Thornell 
(1994) collected samples from upper and lower limbs from two foetuses at 
each of 10, 11, 14, 16, 18, 20 and 25 weeks of gestation (wG). Serial sections 
of whole limb (10-14 wG) and the dissected biceps and triceps brachii, 
quadriceps, tibialis anterior, . extensor digitorum longus, soleus and 
gastrocnemius muscles (16-25 wG) were investigated by light microscope 
immunocytochemistry. Using a monoclonal antibody specific for human and rat 
a-cardiac myosin heavy chain (MyHC), Pedrosa-Domellof and Thornell (1994, 
p. 77), identified a-cardiac MyHC in human muscle spindle intrafusal fibres. 
They concluded that MYH6 is expressed in the tibialis anterior and the extensor 
digitorum longus, during weeks 1 0-25 of gestation. This work was not confirmed 
by the identification of cardiac a-MyHC mANA in affected tissue. 
Nevertheless, it established MYH6 as a candidate gene for Laing Myopathy. 
MYH6 was expressed before the first onset of Laing myopathy, and it was 
expressed in affected muscles, the tibialis anterior and the extensor digitorum 
longus. 
7.1.2 MYH6 Mutations and Disease 
An examination of how mutations in M YH6 might cause Laing myopathy, 
showed that its expression in intrafusal fibres was unlikely to cause this disease. 
These encapsulated bundles of small-diameter muscle fibres receive both 
sensory and motor innervation. They monitor changes in muscle length which 
are transduced into proprioceptive signals by afferent neurones and transmitted 
to the central nervous system (CNS) (Matthews, 1981 ). 
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Myopathy has never been associated with mutations in human muscle spindle 
genes. Muscle spindle absence or failure in mammals causes loss of 
proprioception, not myopathy. Ernfors et at., (1994) used immuno-
cytochemistry to detect muscle spindles in wild type mice, and neurotrophin-3-
deficient (NT-3) mice. Homozygous NT-3 mutant mice tacked muscle spindles, 
while heterozygous NT-3 mutant mice contained approximately half the wild 
type complement of muscle spindles. 
Significantly, the histology of the soleus muscles of normal mice, heterozygous 
NT-3 mutant mice and homozygous NT-3 mutant mice were identical in all other 
respects. There were no signs of myopathy in the soleus sections of the 
homozygous NT-3 mutant mice (Ernfors et at., 1994, Figure 2, p. 506). The 
limb ataxia and inability to position the extremities property in homozygous NT-
3 mutant mice was due to toss of proprioception, not myopathy. 
Since a tack of muscle spindles did not result in myopathy in NT -3 homozygous 
mice, it seems improbable that the malfunctioning of one muscle spindle gene, 
MYH6, could cause myopathy in humans. This, and the fact that a-MyHC has 
never been detected in the mammalian extrafusat fibres (Watro & Kucera, 
1999, p. 182), made MYH6 a weak candidate gene for Laing myopathy. 
7.2 MYH7LAING MYOPATHY CANDIDATURE 
For MYH7 to be a candidate gene for Laing myopathy, its product, ~-cardiac 
MyHC, would have to be have to be present in muscle tissue of the anterior 
leg compartment before or during early childhood. 
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7.2.1 MYH7 Expression 
There are no reports of ~-cardiac MyHC expressed in human muscle spindles, 
even in a recent publication investigating MyHC expression patterns in unusual 
intrafusal fibres (Soukup & Thornell, 1999). 
The expression of MYHl in the extrafusal fibres in primary and secondary 
myotubes during human embryogenesis and foetal development has been 
investigated in selected upper leg muscles (Hughes et al., 1993). Its 
expression in the anterior compartment of the leg during embryogenesis and 
foetal development has not been investigated. 
Using immunocytochemistry (Hughes et al., 1993) detected a C-terminal ~­
cardiac MyHC epitope while primary myotubes were forming during weeks 6 
to 8 of embryogenesis. In addition, when serial sections of week 17 human 
foetal vastus lateralis muscle were exposed under hybridisation conditions to 
random-primed, digoxigenin labelled, 3' untranslated human ~-cardiac MyHC 
eDNA probes, mRNA containing the unique 3' untranslated region of the human 
~-cardiac MyHC was only present in the same extrafusal fibres that contained 
C-terminal ~-cardiac MyHC (Hughes et al., 1993, p. 190). 
The detection of ~-MyHC epitopes in upper leg skeletal muscle during human 
gestation by Hughes showed that MYHl was expressed before the onset of 
Laing myopathy in the type of tissue affected by this disease. This finding did 
not positively identify MYHl as a candidate gene for Laing myopathy. 
Nevertheless, the lack of information about its expression in affected tissue 
before the onset of this disease meant that MYHl could not be excluded as a 
candidate gene for Laing myopathy. 
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7.2.2 MYH7 Mutations and Disease 
Four observations are relevant to MYH7 candidature for Laing myopathy. First, 
numerous reports have associated MYH7 mutations with hypertrophic 
cardiomyopathy (CMH) (Vikstrom & Leinwand,1996; Redwood et al., 1999). 
Laing myopathy patients do not have CMH. Second, some mutations that 
cause CMH also have a skeletal muscle phenotype (Lankford et al. 1995). 
Third, MYHl mutations have been found to show variable expressivity, 
causing central core disease (CCD) skeletal muscle pathology, with or without 
CMH (Fananapazir et al., 1993). Thus, mutations in MYHl could cause skeletal 
muscle disease without CMH. 
Fourth, Laing myopathy onsets in muscles in which fast-twitch fibres 
predominate. In this study, myopathy was detected in the vastus lateralis, a 
muscle dominated by type II, fast-twitch fibres (Figure 4.2, p. 101). However, 
the expression of MYH7 appears to occur predominately in slow-twitch fibres 
(Jandreski et al., 1987). Alternatively, lzumo et al. (1986, p. 597-598) reported 
high levels of ~-MyHC mRNA in the fast-twitch diaphragm muscle of the rat, 
Rattus norgevicus. The possibility that MYH7 is also selectively expressed in 
human fast-twitch fibres cannot be excluded. 
Consideration of these points left uncertainty about the Laing myopathy 
candidature of MYH7, with one important exception. The association of 
mutated forms of MYH7 with skeletal muscle pathology, made the candidature 
of MYHl stronger than that of MYH6. In the absence of any other muscle-
specific genes, the MYH7 eDNA of the WAMPD proband, 111.2, was tested for 
the Laing myopathy mutation. 
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7.3 LAING MYOPATHY MUTATION: TESTING MYH7 
The detection of disease-causing mutations often involves the examination of 
exonic sequences. The simultaneous amplification of multigene family 
members can confound this examination. Epp et al. (1993) determined the 
entire 4,484 bp intergenic region between MYH6 and MYH7. They showed 
that the MYH6 and MYH7 genes were arranged head-to-tail, with the MYH7 
gene located 5' to the MYH6 gene. MYH6 and MYH7. were probably 
formed by the duplication of an ancestral gene. · They retained significant 
homology, so their simultaneous amplification was a distinct possibility. 
7.3.1 Methods 
Testing MYH7 for a Laing myopathy mutation involved: RNA extraction from 
skeletal muscle; skeletal muscle eDNA manufacture; MYH7 amplification, 
purification and sequencing from this template eDNA; MYH7 amplification, 
purification and sequencing from template lymphocyte gDNA; and the SSCP 
screening of MYH7 exon 35 amplified from lymphocyte gDNA. 
7.3.1.1 RNA Extraction from Skeletal Muscle 
RNA was isolated from a quadriceps biopsy taken from the proband, 111.2, of 
the WAMPD family (Figure 3.1, p. 78). This biopsy (D4292522) was 
collected at the Department of Pathology, Sir Charles Gairdner Hospital, Perth, 
Western Australia. Quadriceps biopsies from eight unrelated individuals who 
were unaffected by Laing myopathy were supplied by the Department of 
Neuropathology, Royal Perth Hospital. Demographic information was not 
provided, so these individuals were broadly classified as 'Western Australian 
residents'. All biopsy muscle tissue was placed in liquid nitrogen immediately 
upon collection, then stored at -8ooc. 
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Two grinding methods were used. Initially, a frozen muscle biopsy was placed 
under liquid nitrogen and approximately 50 mg of muscle tissue was cut from it. 
Fatty or connective tissue was avoided. The muscle samples were ground to a 
powder in the mortars, using an electric screwdriver to drive steel pestles. The 
steel mortars were engineered in a steel block, while the steel pestles were 
carefully engineered to fit into these steel mortars. 0. 1% (vlv) Valcorin 
(dimethylcarbonate; Bayer AG) was used to wash all implements that were not 
autoclaved, including the mortars and pestles. The mortars and pestles were 
cooled to -800C and placed under liquid nitrogen upon removal from the -80°C 
freezer, prior to their use in grinding muscle tissue. The second grinding method 
used the same technique to obtain 50 mg samples of frozen muscle tissue, but 
these were then placed in Valcorin treated glass test tube mortars on dry ice. 
Hand-operated sintered-glass pestles were used to disrupt the muscle tissue. 
This was an easier method and was used for approximately 50% of the muscle 
RNA extractions. 
At the completion of grinding by either method, powdered muscle was 
transferred into 0.75 ml TAl-REAGENT (Molecular Research Centre, Inc.) in a 
1.5 ml eppendorf tube. The TAl-REAGENT RNA extraction method is a 
modification of the guanidinium thiocynate and acidic phenol method 
(Chomczynski, 1993). The homogenised muscle tissue was left to stand in 
TAl-REAGENT for five minutes at room temperature. 0.2 ml chloroform was 
then added to each tube and all were shaken vigorously for 15 seconds. These 
samples were allowed to stand for 15 minutes at room temperature before 
centrifugation at 13000 rpm for 15 minutes at 4oc. Centrifugation throughout 
RNA and DNA preparation was done in an Eppendorf Centrifuge 5415C, tube 
lid-hinges were always upwards. An 18-tube rotor was used for 1 .5 ml tubes 
while a 24-tube rotor was used for 0.65 ml tubes. 
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The mixture of homogenised muscle tissue, TAl-REAGENT and chloroform 
separated into three layers: a lower, red, phenol-chloroform organic phase; an 
interphase; and a colourless aqueous upper phase. DNA and proteins were in 
the organic phase and interphase, while RNA remained exclusively in the 
aqueous phase. The aqueous phase was transferred into a new 1.5 ml 
eppendorf tube and mixed with 0.5 ml isopropyl alcohol. These samples were 
stored at room temperature for 1 0 minutes, then centrifuged at 13000 rpm for 
20 minutes at 4°G. RNA appeared as a gel-like pellet at the bottom each 
eppendorf tube, on the side directly under the lid-hinge. 
The supernatant was carefully removed from the tube and the RNA pellet 
vortexed in 1 ml 75% ethanol for 15 seconds, then centrifuged at 7500 rpm for 
5 minutes at 4oc. The supernatant was again removed and RNA pellets 
allowed to 'almost dry' at room temperature with eppendorf tube lids open. 
The drying of pellets was monitored throughout to avoid complete drying, as 
this greatly decreases RNA solubility. RNA pellets were dissolved in 50 J.tl 
ddH20 (Baxter) by incubating for 12 minutes at sooc, then stored in a freezer 
at -800C. 
7.3.1.2 Skeletal Muscle eDNA Manufacture 
The enzyme reverse transcriptase uses the 3' end of short double stranded 
regions on mANA to initiate the synthesis of complementary DNA (Retzel et al, 
1980). The double stranded region was provided by adding hexamer 
oligodeoxyribonucleotides of random sequence (Promega), and allowing them 
to anneal to the mANA. Their random sequence meant that these random 
hexamers annealed at many sites along the the mANA sequence. 
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Muscle eDNA was manufactured as follows: 5 J.tl template mANA, 4 J.tl of 
random hexamers (250 ng/J.tl) and 7 J.tl ddH20, were heated to gooc, snap-
chilled and condensation spun down with a pulse spin at 13000 rpm. This step 
removed all double stranded RNA loops.· 6 J.tl Promega RT (Reverse 
Transcriptase) buffer, 6 J.tl dNTPs (5 mM) and 2 J.tl Maloney murine Leukaemia 
virus-AT (MMLV-Rn were then added. The reaction tube was held at room 
temperature for 5 minutes, 37oc for 1 hour and 900C for 2 minutes (to make 
sscDNA). It was snap-chilled on ice to retain single-strandedness, then 
condensation was spun down with a pulse spin at 13000 rpm. Since MMLV-
RT (Promega) is RNase H minus, the product of this eDNA reaction contains 
template mANA. 
The presence of eDNA in these preparations was assayed by amplifying a 
section of the copper zinc superoxide dismutase (SOD1) eDNA. A strong 
signal indicated that a eDNA preparation was suitable template for MYH6 and 
MYH7 amplification. A 20 f.ll, standard SOD PCR reaction comprised: 4 J.tl5 X 
buffer; 50 ng each SOD primer (1 J.tl); 5 J.tl template eDNA; 8.9 ~-tl ddH20; and 
0.5 u Tth polymerase (0.1 ~-tl) (Biotech International). Each ml of 5X buffer 
contained: 500 J.tl 10X Tth buffer (supplied with the enzyme); 400 J.tl 25 mM 
MgCI2; 40 J.tl25 mM dNTPs; and 60 J.tl ddH20. This buffer provided the 'low-
stringency' reaction concentrations of 2 mM MgCI2 and 200 J.tM dNTP, 
considered appropriate for this assay. 
SOD1 PCR reactions were initially denatured at 94oc for 2 minutes 30 
seconds. Followed by 34 cycles of: 30 seconds denaturation at 94oc; 45 
seconds primer annealing at s8oc; and 45 seconds amplification at 720C. 
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7.3.1.3 MYH6 and MYH7 Primer Design 
Table C7.1 in Appendix C presents a comparison of the MYH6 (Epp et at., 
1993) and the MYH7 (Jaenicke et at., 1990) exon sequences, both of which 
were derived from their published genomic sequences. The application 
program used to make this comparison was SeqEd, Version 1.0.3 
(Myers, 1992: Applied Biosystems International) (ABI). MYH6 and MYH7 
cDNAs do not have coincident base numbers because these genes have 
different lengths of 5' and 3' untranslated regions, and MY H 7 has four deleted 
codons compared to M YH6. However, for the purposes of comparison, they 
are aligned in Table C7.1, even although this has the effect of 'misnumbering' 
the bases of both these genes. The complete exonic sequence of MYH7 is 
I 
6008 bp while that of MYH6 is 5939 bp. 
Comparison of the 5939 bp of the MYH6 eDNA to the 6008 bp of the MYH7 
eDNA revealed 635 bp differences where these sequences overlapped, 
equivalent to a 1 0. 7% difference (635/5939). Similarly, comparison of the 
5820 bp translated region of MYH6 (including the stop codon) to the 5808 bp 
translated region of MYH7 revealed 554 bp differences, equivalent to a 9.52% 
difference (554/5820). The 12 bases in the four deleted codons of MYH7 
were included in this comparison, because they were important for transcript 
identification and primer design. A comparison of the 1939 amino acids of a-
MyHC coded by MYH6 to the 1935 amino acids of ~-MyHC coded by 
MYH7, also presented In Table C7.1, showed there to be 142 different 
residues, equivalent to a 7.32% difference (14211939). 
The 92.68% homology between human a- and ~-MyHC determined in this 
way was close to the 93.2% identity reported for mammalian cardiac a- and 
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f}-MyHC isoforms (Weiss, 1999, et al., p. 63). These authors also report that 
mammalian cardiac MyHC isoforms have only 77-81% identity with the MyHC 
skeletal isoforms. MYH6 and MYH7 had greater homology with each other 
than to the other known MYH genes. The design of primers around differences 
between MYH6 and MYH7was the most stringent approach possible. 
The genetic code and the universal single-letter amino acid code in Table C7.2 
in Appendix C, allowed a detailed examination of Table C7.1. This showed 
that only 196 of the 635 bp differences between MYH6 and MYH7 caused 
amino acid codon changes. There were more base changes (196) than actual 
amino acid alterations (142) because the four deleted codons in MYH7 
contributed 12 bases to the 196 base differences between these genes but 
only 'changed' 4 amino acids, and because some codons contained more than 
one base change, each of which independently altered amino acid sequence. 
It was possible that the Western Australian individuals under investigation might 
not possess all of the 493 'neutral' nucleotide differences and that some novel 
'neutral' nucleotide differences might be present in this population. Accordingly, 
primers for PCR amplification and sequencing for both MYH6 and MYH7 were 
designed around the maximum number of sequence differences between 
these genes. In particular, each primer was designed such that its 3' base 
differed to the equivalent base in the other cardiac MYH gene, and wherever 
practicable, MYH6/MYH7 amino acid codon changes were included in exonic 
primers. It was thought unlikely that exonic primers designed in this way would 
amplify other members of the MYH multigene family. In addition to these 
eDNA exonic MYH6 and MYH7 primers, two intronic MYH7 primers were 
designed to amplify MYH7 exon 35 from lymphocyte gDNA. 
184 
7.3.1.4 MYH6 Primers 
To ascertain the risk of simultaneously amplifying MYH6 and MYH7, the 
possible expression of the MYH6 gene in biopsied muscle spindles was 
tested by designing two primers specific for MYH6. Table 7.1 identifies the 
two MYH6 primers designed to specifically amplify MYH6. Both the forward 
primer, MYH6 1838F, and the reverse primer, MYH6 2127R, each had five 
differences to the equivalent sequences in MYH7, and both their 3' bases were 
different to equivalent bases in MYH7. The MYH6 1838F<--->2127R 
amplicon was called amplicon 12. 
1-
Table 7.1 
Primer 
1838F 
2127R 
MYH6 cDNA/Exonlc Primers 
Sequence 
5'-C ATC C TG GGC TGG CTG C AA AAA-3' 
5'-C CAT CAC CCC TGG AG CTT C l.G-3' 
-
All primers are identified by their 5' base number. This is the same 
number as the complementary MYH6 exonic base number. 
Translated MYH6 primer sequences are shown in DNA 'codons', 
referred to as codons throughout the rest of this thesis since RNA 
codons are not discussed. Black identifies identical bases in M YH6 
(Epp et al., 1993) and MYH7 (Jaenicke et al. , 1990). Red identifies 
base differences resulting in different amino acids in a- and ~-MyHC. 
Blue identifies base differences not altering amino acids in a-MyHC 
when compared to ~-MyHC. 
7.3.1.5 MYH7 Primers 
Table C7.3 in Appendix C presents the double-stranded sequence of MYH7 
and locates the primers used to manufacture amplicons of this gene. Table 7.2 
(p. 186) shows the exonic MYH7 primers used. It identifies base differences 
between MYH6 and MYH7 which altered amino acid codons and those base 
changes which did not change the amino acid sequence. 
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Table 7.2 MYH7 cDNAIExonic Primers 
Ampllcon Primers Primer Sequences 
1 42F 5'-cmttcdcat~-fccao-3' 
1041R 5'-T GGT CT CC TTG GGA G AT GAA T-3' 
2 887F 5'-T CTG GAA AAA TCC AGA GTT ATI-3' 
2015R 5'-GGA CGA GCC TTT C TT GGC C TT G-3' 
3 1943F 5'-C CTG TTT GCC AAC TAT GCT GGG-3' 
3404R 5'-CTT CTG C AG CTG GCT GC C GAG G-3' 
4 3335F 5'-A GAC TTI GAG CTG AAT GCT CTC-3' 
3894R 5'-C AGA ACG C TG GGT CTC C TC CGC-3' 
5 3832F 5'-GC CGG ACC TTG GAA GAC CAG ATG-3' 
4659R 5'-C ATG GAT AGT CTT TCC GC T GGA-3' 
6 4610F 5'-G ATC TCC GAC TTG ACT GAG CAG TTG-3' 
5975R 5'-ctcccaagga~gttacacag-3' 
7 1145F 5'-A GGC G C ATC ATG CAC TTT GGA-3' 
1589R 5'-GTA CTC CTC CTG CTC CAG CAC A-3' 
8 1472F 5'-C GCT GGC TIC GAG ATC TTC GAT-3' 
2091R 5'-A GTG GGG ATG GGT GGA GCG CAA-3' 
9 4550F 5'-T GAG GAG TCC CTG GAA CAT CTG-3' 
5072R 5'-ACG GAC TGC ATC GTC CAG CTG A-3' 
10 4897F 5'-AG ACA CGC AGC CGC AAC GAG GC-3' 
5354R 5'-CTT GGC CTT CTC CTC AGC A TT C -3' 
= 
396F 5'-AAC CTC AAG GAT CGC TAC GC'C T-3' 
2248F 5'-GG TAT CGC ATC CTG AAC CCA GC' -3' 
2492F 5'-A AAG CTG CTG GAA CGT AGA GAC T-3' 
2782F 5'-CA GAT GCT GAG GAG CGC TGT GAT-3' 
3137F 5'-C AAC AC C CTG ACT AAG GC C AAA-3' 
3335F 5'-A GAG TTI GAG CTG AAT GCT CTC-3' 
5268F 5'-AAG AAG ATG GATGCT GAC CTG T-3' 
365R 5'-T CAG CAT GGC CAT GTC CTC GAT T-3' 
61 1R 5'-C AG GAT GGA CTG GTT TTC TC TG -3' 
2639R 5'-GG A GGC CAT CTC CTT CTC TC T T-3' 
3143R 5'-GGT GTI GAC CTT GTC C TC CTC GG-3' 
3998R 5'-GCC TCG GGT CAG CTG GGA GAT C -3' 
5680R 5'-TG C AG CCG CAG CAG GTT TTT C C -3' 
f----
5' MYH7 exonic base numbers used to identify primers. Lower-case identifies 
5'-UTR and 3'-UTR primer sequences. Translated MYH7 primer sequences 
shown in uppercase and in codons. Black identifies bases that were identical 
in published MYH6 sequence (Epp et al., 1993) and published MYHl 
sequence (Jaenicke et al., 1990). Red identifies base differences between 
MYH6 and MYH7 that cause different amino acids to be present in a-MyHC 
and ~-MyHC. Blue identifies base differences coding for the same amino 
acids in a-MyHC and ~-MyHC. 
Primers shown above the grey line were used for amp/icon manufacture and 
sequencing, while those below the line were used only for sequencing. 
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The MYH7 primers in Table 7.2 contained the maximum MYH6/MYH7 
sequence differences, given the need to space primers appropriately and to 
avoid complications such as intra- and/or inter-primer complementation. 
The segregation of a base change in MYH7 exon 35 in WAMPD family 
members was determined using lymphocyte gDNA as a template. This was 
available for all the participants in this study as ident~ied in Figure 3.1 (p. 78). 
Table 7.3 shows the MYH7 gDNA intronic primers designed to target intron 34, 
primer MYH7 23531F, and intron 35, primer MYH7 23825R. The product of 
MY H 7 23531 F<->23825R was called amplicon 11 . It contained MY H 7 ex on 
35 
Table 7.3 MYH7 gDNA lntronlc Primers 
-
Primer Sequence 
23531F 5 '-aggtgcc:tttagtgaagggaao-3' 
23825R 5 '-tcaggaatgagcaggggagctg-3' 
1--
5' MYH7 intronic base numbers used to identify primers. 
Lower-case was employed for intronic sequences. Black 
identifies identical bases in MYH6 (Epp et al., 1993) and 
MYH7 (Jaenicke et al., 1990). Blue identifies base 
differences between MYH6 and MYH7. 
7.3.1.6 DNA Amplification Conditions 
MYH6 amplicons were obtained using standard-PCR, while MYH7 amplicons 
were prepared using both standard and XL-PCR conditions. A 20 ~1. standard 
MYH6/MYH7 PCR reaction comprised: 4 ~15 X buffer; 50 ng each primer (1 ~I 
of each); 5 ~I template eDNA or 5 ~~ of a 1140 dilution of an MYH7 amplicon 
187 
(when this was used as starting template DNA), or 5 J.tl template gDNA (50 
ng); 8.9 111 ddH20; and 0.5 u Tth polymerase (0.1 J.tl) (Biotech International). 
Each ml of 5X buffer contained: 500 J.tl 1 OX Tth buffer (supplied with the 
enzyme); 200 J.tl 25 mM MgCI2; 10 J.tl 25 mM dNTPs; and 290 J.tl ddH20. 
This buffer provided the 'medium-stringency' reaction concentrations of 1 mM 
MgCI2 and 50 J.tM dNTP, considered appropriate for the specific amplification of 
MYH6 and MYH7 amplicons. 
All standard-PCR reactions were initially denatured at 94oc for 2 minutes 30 
seconds. This was followed by 34 cycles of: 30 seconds denaturation at 94oc; 
45 seconds at the chosen annealing temperature; and 45 seconds amplification 
at 720C. Annealing temperatures were determined from Oligo, Version 5.1 
(Rychlik, 1996: National Biosciences Inc., Plymouth, USA) (NBI). If the Oligo 
program recommended a two-step protocol, the annealing/amplification time 
was increased to 1 minute. 
For reaction volumes of 25 f..ll, extra long PCR (XL-PCR) were: 3 J.tl 3.3X 
reaction buffer; 2 J.tl5 mM dNTPs; 50 ng of forward and reverse primers (1 J.tl of 
each); 1.1 J.tl magnesium acetate (MgOAc) (25 mM); 6.9 J.tl ddH20; and 5 J.tl 
template eDNA. The MgOAc and 3.3X buffer were provided by Perkin Elmer. 
A drop of paraffin was placed on to the top of each reaction mix. Towards the 
end of the primary denaturation step, a mixture of 0.5 J.tl XL-r(recombinant)Tth 
polymerase (Perkin Elmer); and 4.5 J.tl 3.3X buffer (Perkin Elmer) was added 
through the paraffin to each reaction. This 'hot-start' method was employed to 
preserve the XL-rTthpolymerase. 
188 
All XL-PCR reactions were initially denatured at 94oc for 2 minutes 30 
seconds. This was followed by two sets of 20 cycles. The first set of 20 cycles 
comprised 15 seconds at 94oc and 8 minutes at the chosen 
annealing/amplification temperature. The second set of 20 cycles comprised 15 
seconds at 94oc and 8 minutes plus a 15 second increment per cycle at the 
chosen annealing/amplification temperature. The annealing/amplification 
temperature was initially set at 680C, but this was lowered to improve yield 
where necessary. 
All amplification conditions are presented in Table 7.5 in Section 7.3.2.7 (p. 
201 ), where it was possible to align amplification conditions, amplicons, 
sequencing primers and bases sequenced. All PCR products were assayed 
by electrophoresis on 2% agarose gels, run at 80V for 1 hour. 
7.3.1. 7 DNA Purification 
QiaQuick buffers and spin-columns (Qiagen) were used to purify PCR 
products. A volume of PB buffer 5 times the volume of PCR was added to 
each completed PCR. This mixture, generally 120 ~1. was loaded on to a spin-
column sitting in a collecting tube and centrifuged at 13000 rpm for 1 minute. 
Since DNA binds to the spin-column matrix, the flow-through was discarded. 
700 ~I of 20% PE buffer (in ethanol) was placed on top of each spin-column 
and these were centrifuged for 1 minute at 13000 rpm. The flow-through was 
discarded and the columns were centrifuged again for 1 minute at 13000 rpm to 
collect and discard any remaining PE buffer. 
Spin-columns were then transferred into labelled 1.5 ml eppendorf tubes, 30-
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50 1-11 of ddH20 added to the centre of each spin-column, and the columns 
centrifuged for 1 minute at 13000 rpm for the last time. The volume of ddH20 
added was determined by the concentration of DNA estimated from gel band 
intensity on PCR assay gels. 30 1-11 ddH20 was added for lowest DNA 
concentrations increasing to 50 1-11 ddH20 for the highest DNA concentrations. 
DNA bound to the spin-column matrix dissolved in this ddH20 as it moved 
through the column into the supporting eppendorf tube in the last centrifugation. 
This purification method removed all PCR reagents and DNA fragments smaller 
than 1 00 bases in length. 
7.3.1.8 DNA Sequencing Reactions 
The ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit 
(PE Biosystems) was used to sequence amplicons. This kit, based on the 
dideoxy sequencing method (Sanger, 1981 ), provided AmpliTaqDNA 
Polymerase FS, dye terminators, deoxynucleoside triphosphates, MgCI2 and 
buffer, all in a single tube. A 10 f.ll, Big Dye sequencing reaction comprised: 4 1-11 
Ready Reaction (also known as 'terminator mix'); 50 ng (1 f.ll) of either a forward 
or a reverse primer; 2-4 1-11 of template dsDNA; and 1-3 1-11 ddH20. DNA 
sequencing reactions require 100-200 ng template dsDNA (BigDye Terminator 
Cycle Sequencing Protocol (nd), p. 3-2). The concentration of purified dsDNA 
MYH6 and MYH7 was estimated from band intensity on agarose gels, 
measured against standards of known concentration. The volumes of template 
DNA and ddH20 added to sequencing reactions were adjusted according to 
these estimated DNA concentrations. When necessary, purified dsDNA was 
concentrated by vacuum centrifugation to a minimum volume of 1 0 f.' I, enough 
for one forward and one reverse reaction. 
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Excess dye terminators make base calling difficult during electrophoretic analysis 
of sequencing reactions. Unincorporated dye terminators were removed from 
sequencing extension products by ethanol/sodium acetate precipitation. 2 t-tl of 
3 M sodium acetate (pH 4. 6) and 50 t-tl of 95% ethanol were added to each 
completed sequencing reaction. Tubes were shaken and left to stand at room 
temperature for 5 minutes, then centrifuged for 45 minutes at 13000 rpm. 
Supernatants were discarded, 150 t-tl of 70% ethanol added to each pellet and 
tubes centrifuged· at 13000 rpm for ten minutes. Supernatants were again 
discarded and pellets briefly dried at 650C in a thermal cycler. These were 
forwarded to the research assistant in charge of sequencing at ANRI, Lori 
Blechynden. Extension products were analysed by electrophoresis on an ABI 
373 Automated DNA Sequencer with a BigDye Filter Wheel Upgrade. 
Sequencing chromatograms were then imported into SeqEd, Version 1.0.3 
(Myers, 1992: ABI) for further analysis. 
7.3.1.9 SSCP Screening of MYH7gDNA 
MYH7 amplicon 11, 23531 F<~>23825R, was amplified from lymphocyte 
gDNA template, using standard PCR (Section 7.3.1.6, pp. 187~188) with an 
annealing temperature of 640C. Eight trial SSCP gels established the most 
suitable conditions for screening an MYH7 amplicon 11 polymorphism 
segregating with Laing myopathy. For 12% and 8% gels, the trials were: 19:1 
(acrylamide:bisacrylamide) at 40C and 350V; 29:1 at 40C and 280V; 75:1, at 
room temperature (-220C) and 200V; 99:1 at room temperature and 130V. 
All SSCP gels were run over four hours in TBE (pH8.3) gel~running buffer. The 
gel most clearly discriminating the G23628/C23628 SSCP was the 8%, 19:1 
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gel run at 350V in the cold room (-40C). Further optimisation was achieved by 
buffer replacement to maintain electrophoresis temperature below 220C. 
Electrophoresis tanks were XCell Sure Lock (Novex) and gels were either 
silver-stained (Bassam et al., 1991) or stained with Sybr Gold (Molecular 
Probes Inc. USA). 
7.3.2 Results 
This section reports the isolation of skeletal muscle RNA, the PCR amplification 
of MYH6 and MYH7, the sequences of MYH6 and MYH7 amplicons and the 
differences between the published and the determined sequence of the 
WAMPD, 111:2 MYH7. 
7.3.2.1 Skeletal Muscle RNA 
The success of RNA extraction was estimated from the bands on an agarose 
gel. This check was necessary because, unlike DNA, RNA is unstable due to 
its adjacent 2' OH group and 3'-5' phosphodiester bond. At alkaline pH, the 2' 
hydroxyl group acts as a nucleophile, transesterifying the 5' hydroxyl and 2'-3' 
phosphodiester bond, which breaks the RNA polymer into fragments 
(Sambrook et al., 1989, 7.3 & 7.6). At neutral pH, RNA is also degraded by 
RNases, present through contamination or within the starting tissue. 
Good preparations of RNA were distinguished by the presence of two clearly 
defined bands of ribosomal RNA (rRNA) and another low molecular weight 
broader band of transfer RNA (tRNA) at 75-120 nucleotides. These bands 
were used to determine the quality of an RNA sample. Figure 7.1 shows 
representativeTRI-REAGENT RNA extractions from human muscle. 
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SIZE MARKER 
SPP1 Phage 
DNA digested 
with EcoR1 
Nucleotides 
8510 --
2810 --
1950 --
1510 --
1160--
980--
720 --
480--
360--
LANE 2 3 4 5 6 7 
Figure 7.1 RNA extractions from human muscle 
using the TAl-REAGENT method. 
8 
The presence of three bands in RNA extractions is 
accepted as an indication that all forms of RNA are intact, an 
important consideration since mANA does not appear as a 
discrete band. Its variable molecular weight and its low 
representation (1-5%) in the total RNA present, make 
mANA only visible as a background smear. The first of 
these extractions, in lane 3, was considered to be of 
insufficient quality to use as a template for eDNA 
manufacture, even although there was a background smear. 
The other three RNA extractions, in lanes 4, 6 and 7, were 
used to manufacture eDNA. In these lanes, mANA can be 
seen as a background smear. A 2% agarose gel was 
loaded and run at 100 volts for 1 hour. Lanes 1, 2 and 8 
were not loaded. 
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7.3.2.2 Skeletal Muscle eDNA 
Figure 7.2 shows representative copper zinc superoxide dismutase (SOD1) 
products amplified from eDNA manufactured from Laing myopathy quadriceps 
muscle biopsy and unaffected quadriceps muscle biopsy. The SOD1 test was 
the only method used to determine the suitability of eDNA preparations as 
template for MYH6 and MYHl amplifications. They were not quantified 
spectrophotometrically. 
SIZE MARKER 
SPP1 Phage 
DNA digested 
with EcoR1 
Nucleotides 
8510--
2810--
1950--
1510--
1160--
980--
720--
480--
~ 360--
LANE 2 3 4 5 6 7 8 
Figure 7.2 The copper zinc superoxide dismutase (SOD1) test to 
ascertain the success of eDNA manufacture. 
Lane 1 failed, all other lanes succeeded. The SOD1 products in lanes 2-
4 (440 bp) were made using template eDNA manufactured from different 
RNA extractions from the quadriceps of the WAMPD Laing myopathy 
proband, 111.2. The SOD1 products in lanes 5-8 were made using 
template eDNA manufactured from the quadriceps RNA of three 
individuals who were unaffected by Laing myopathy, and who were 
unrelated to each other or to the WAMPD family. A 2% agarose gel was 
loaded and run at 1 00 volts for 1 hour. 
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7.3.2.3 MYH6 Amplification 
The M YH6 1838F and 2127R primers (Table 7.1, p. 185) were selected 
because the 246 bp MYH6 sequence between the 3' ends of these primers, 
amplicon 12, contained 62 differences to the equivalent bases in MYH7, 
including one deleted MYH7 codon. These 62 differences are shown in Table 
7.4 (p. 196). 1838FMYH6 and 2127RMYH6 primers gave amplicons of the 
right size (290 bp) from template muscle eDNA for 111.2, the WAMPD proband, 
and from muscle eDNA for 8 unrelated, unaffected individuals. 
7.3.2.4 MYH6 Amplicon Sequencing 
Table 7.4 shows four sequences: the published sequences for MYH6 
amplicon 12; the equivalent published MYH7 sequence; the determined 
MYH6 amplicon 12 sequence for eight unrelated, unaffected individuals; and the 
determined MYH6 amplicon 12 sequence for the WAMPD proband, 111.2. All 
MYH6 amplicon 12 sequences were identical. Figure 7.3 (p. 197) presents 
part of the sequencing chromatograms for the MYH6 amplicon 12. It shows the 
chromatograms for the bases 1947-1982 for the WAMPD proband, 111.2, and 
for an unaffected, unrelated individual. 
Table 7.4 and Figure 7.3 prove that MYH6 was expressed in the biopsy of 
quadriceps muscle used in this project. The M YH6 amplicon 12 was amplified 
from this starting source of eDNA, proving that MYH6 mANA was present. 
Real differences between affected and unaffected MYH7 sequences could be 
obscured and/or apparent differences created by the simultaneous amplification 
of MYH6 and MYH7. The MYH7 primers listed in Table 7.2 (p. 186) were 
designed with as many MYH6/MYH7 sequence differences as practicable, 
specifically to avoid this very real possibility. 
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Table 7.4 MYH6 amp/Icon 12 sequences. The sequence of the 
WAMPD proband, 111.2, and 8 unaffected Individuals 
compared to the equivalent published sequences for 
MYH6 and MYH7. 
5' --------Primer 1838FMYH6 --- ->3' 
GATG GTGGGGTGGGTG GAA AAA Base 
Affected( III.2)MYH6 Primer sequence not determined AAC AAG GATCCTCTC 1874 
8 Unaffected MYH6 from thechroma_!_ogram AAC AAG GATCCTCTC 11 
Published MYH6 C ATC CTGGGCTGGCTG GAA AAA AAC AAG GATCCTCTC 11 
Published MYH7 C ATC A TT GGC TGG CTG GAG AAG AAC AAG GAT CCT CTC 1889 
Affected( II1.2)MYH6 AAC GAG ACT GTT GTG GCC CTG TAG GAG AAG TCC TCC 1910 
8 Unaffected MYH6 AAC GAG ACT GTT GTG GCC CTG TAG GAG AAG TCC TCC 11 
Published MYH6 AAC GAG ACT GTT GTG GCC CTG T AC GAG AAG TCC TCC 11 
Published MYH7 AAT GAG ACTGTCGTGGGCTTG TAT GAG AAG TCT TCC 1935 
Affected( Ill 2)MYH6 CTC AAG CTC A TG GCC ACT CTC TTC TCC TCC T AC GCA 1946 
Unaffected MYH6 CTC AAG CTC A TG GCC ACT CTC TTC TCC TCC T AC GCA 11 
Published MYH6 CTC AAG CTC A TG GCC ACT CTC TTC TCC TCC T AC GCA 11 
Published MYH7 CTCAAGTTG CTCAGCACCCTGTTT GCCAACTAT GCT 1971 
iJYF- 0::: ue ce shr I ' - · Ul - r (I 
Affected( Ill 2}MYH6 ACT GC:C GAT ACT GGGGAC AGT GGT AAA AGC AAA GGA 1982 
8 Unaffected MYH6 ACT GC:C GAT ACTGGGGAC AGTGG'T AAA AGCAAAGGA 1982 
Published MYH6 .C GC:C GAT ACTGG3Gt-r AGT <Y'T AAA A. GCAAAGGA 1982 
Published MYH7 GGG GCT GAT GCG CCT +++ ATT GAG AAG GGC AAA GGC 2004 
Affected(III.2)MYH6 GGC AAG AAA AAGGGCTCA TCCTTC GAG ACG GTGTCG 2018 
8 Unaffected MYH6 GGC AAG AAA AAG GGC TCA TCC TTC GAG ACG GTG TCG 11 
Published MYH6 GGC AAG AAA AAG GGC TCA TCC TTC GAG ACG GTG TCG 11 
Published MYH7 AAG GCC AAG AAA GGC TCG TCC TTT GAG ACT GTG TCA 2040 
Affected( II1.2)MYH6 GCT CTC CAC CGG GAA AAT CTC AAC AAG CTA ATG ACC 2054 
Unaffected MYH6 GCT CTC CAC CGG GAA AAT CTC AAC AAG CTA ATG ACC 11 
Published MYH6 GCT CTC CAC CGG GAA AA T CTC AAC AAG CT A ATG ACC 11 
Published MYH7 GCT CTG CAC AGG GAA AAT CTG AAC AAG CTG ATG ACC 2076 
Affected( 111.2)MYH6 AAC CTG AGG ACC ACC CAT CCT CAC TTT GTG CGT TGC 2090 
8 Unaffected MYH6 AAC CTG AGG ACC ACC CAT CCT CAC TTT GTG CGT TGC 11 
Published MYH6 AAC CTG AGGACCACCCAT CCT CACTTTGTGCGTTGC 11 
Published MYH7 AAC TTG CGC TCC ACC CAT CCC CAC TTT GT A CGT TGT 2112 
3'<-------- Primer 2127RMYH6 ---- 5' 
GCC TTG GGA GGT CCC GAG TAG G 
Atfected( III 2)MYH6 ATC ATC CCC AAT GAG Primer sequence not determined 
8 Unaffected MYH6 ATC ATC CCC AAT GAG from the chromatogram 
Published MYH6 ATC ATC CCC AAT GAG CGG AAG GCTCCA GGG GTG ATG G 2127 
Published MYH7 ACT ATC CCT AAT GAG ACA AAG TCT CCA GGC GTG ATG G 2149 
MYH6 and MYH7 sequences presented in codons. Blue: sequence differences 
between MYH6 and MYH7which do not alter amino acids. Red: sequence differences 
between MYH6 and MYH7which alter amino acids. 1112: WAMPD proband. Unaffected: 
by Laing myopathy and unrelated to 111.2. 8 'unattecteds' had the same MYH6 sequence. 
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A. 1947.-- -------------------..1982 
Mm7 GGGG C T G A T G C G CC T +++ A TT G A GA GGG C ~A GG C 
• 
B. 1947 ~ MYH6 1982 
CT G C C G T A C T G G G G 1\C A GT G GT AAA • GC !:\A ~GG 1\ 
~ J 
I I ~ I 
_£~ ~~ v .J V. tJ\tJ'vY ~~ 1~ 
Figure 7.3 Chromatogram for the MYH6 bases, 1947-1982. A. The 
chromatogram of the WAMPD Laing myopathy proband, 111.2. Above this 
chromatogram is the published sequences for MYH6 and MYH7. identify 
MYH6 and MYH7 sequence differences; the box identifies a codon deleted 
in MYH7. B. The chromatogram of an unaffected, unrelated individual, with 
the same MYH6 sequence as the published sequence and the WAMPD 
Laing myopathy proband, 1112 sequence. 
7.4.2.5 MYH7 Amplification 
Initially, six overlapping amplicons of MYH7 were generated by standard and 
XL-PCR. They were: 42F-1041R (1), 887F-2015R (2), 1943F-3404R (3), 
3335F-3894R (4), 3832F-4659R (5), and 4610F-5972R (6). Figure 7.4 (p. 
198) compares standard-PCR and XL-PCR products for these am pi icons. 
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Nucleotides 
8510 
2810---1 
1950 
1510 
1160 
980---1 
720 
480 
360 ---1 
SPP1 Phage 
DNA digested 
with EcoR1 . 
LANES 1 2 3 4 5 6 7 8 9 10 11 12 13 
Figure 7.4 The original six MYH7 amplicons {p. 197) are 
identified by red numbers on the gel. XL-PCR and standard-PCR 
amplicons were run in pairs with XL products always on the left of 
each amplicon pair. Standard-PCR did not amplify amplicon 6 very 
successfully. An illegitimate amplicon (?) was identified in the 
standard-PCR amplicon 1, lane 2, which was not present in the XL-
PCR amplicon 1 in lane 1. This illegitimate amplicon persisted up to 
a standard-PCR annealing temperature of 640C, at which annealing 
temperature it had a stronger signal than that of the legitimate 1 kb 
amplicon 1. 
The illegitimate amplicon in lane 2 was band-stabbed (Wilton, et al., 1997), re-
amplified using the MYH7 primers 42F<->1041 Rat a standard-PCR annealing 
temperature of 64°C. The product was QiaQuick purified (Qiagen) and 
sequenced using the reverse primer 1041 R. Figure 7.5 (p. 199) shows the 
chromatogram of the last twenty-two 3' bases of this illegitimate 42F<->1041R 
amplicon. 
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853 ... MYH7 Base Numbers v4 
' A. G A G T T G G C A T C T G C G C A T ~ G 
" 
• 
B. c c c T T T c c T c A T C T G l G C A c 
c. . c c 1 l 1 c c l c " T c 
• G l G c A c 6 
,-- ~ r,_, ~ ~ I ,.--, 1,-, ,--, r-, ,....-
[\ I I A 
I I I d \ I I \ i \ \ '~ 1\ 
Figure 7.5 The reverse sequence chromatogram of the illegitimate 
42F<-> 1041 R amplicon over its last twenty-two 3' bases. 
For comparison, three sequences are aligned along the top of this 
chromatogram. A. The published sequence of MYHl for bases 853-
874. B. The sequence of primer 42F. C . The reverse sequence 
chromatogram of the illegitimate 42F<-> 1 041 R amplicon. identify 
base differences between the published MY H 7 sequence (A) 
(Jaenicke et al., 1990), the primer MYH7 42F sequence (B) and the 
determined reverse sequence of the illegitimate amplicon (C). It can be 
seen that MYH7 primer 42F exactly matches the 42F<->1041R 
illegitimate amplicon sequence over its last twenty-two 3' bases. 
I 
1 
The sequence of the illegitimate amplicon in lane 2 (Figure 7.4) showed that it 
was 189 bases long. Apart from its 22, 3' bases, it had the same sequence as 
MYHl from base 875 to the limit of good sequence at base 1021. This fact, 
and the fact that the last 22, 3' bases matched perfectly with the primer MYHl 
42F, proved that the illegitimate 42F<->1041R amplicon, was produced by the 
'false-priming' of primer MYHl 42F at bases 853-874. Given that primer 
MYHl 42F had only 12 complementary bases with the published 853-874 
MYH7 base sequence, this false-priming was quite remarkable. It was even 
more remarkable in that the 3' base of primer MYH7 42F was not 
complementary to the MYH7 base 87 4. 
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7.3.2.6 MYH7 Ampllcon Sequencing 
Table 7.5 (p. 201) lists the MYH7 amplicons selected for sequencing, the 
annealing and amplification temperatures used to make each amplicon and the 
bases successfully sequenced in each amplicon. It includes the original six 
amp I icons shown in Figure 7.4 (p. 198) and four further amplicons, 1145~ 1589 
(7), 1472-2091 (8), 4550-5072 (9) and 4897~5354 (10). Two of these 
amplicons, 7 and 9 were necessary to clarify sequence in the areas of overlap 
between· amp Iicon 2 and 3 and between amplicons 5 and 6. The other two 
amplicons, 8 and 9, were necessary to clarify sequence within amplicons 2 and 
6. All amplicons were purified using the QiaQuick spin-column method before 
setting up sequencing reactions. 
Internal sequencing primers were designed as required. These were identified 
in Table 7.2 (p. 186). The purpose of using ten overlapping amplicons as 
sequencing templates was to reduce the risk of simultaneous amplification of 
MYH6 amplicons or other MYH amplicons. The presence of MYH6 transcripts 
and the false-priming of 42F (Figures 7.3 & 7.5) had shown how easily this 
could occur. The fact that many regions of MYH6 and MYH7 were conserved 
added to this concern. Once the sequence of the 5' and 3' ends of MYH7 
amplicons 1~10 had been determined, it was clear that they were MYH7 
amplicons, therefore suitable as sequencing templates for all M YH7 primers. 
7.3.2.7 Base Differences In Western Australian MYH7 eDNA 
Table 7.6 (p. 202) lists seven base differences between the published eDNA 
sequence for MYHl and that determined for nine individuals: the Laing 
myopathy proband (WAMPD 111.2), and eight unrelated, unaffected Western 
Australian residents. 
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Table 7.5 MYH7 Amp/Icon Sequencing 
Template DNA PCR Annealing/ Sequencing Bases 
(amp Iicon) Amplification (OC) Primer Sequenced 
42-1041 (1) XL-680C 365R 42-335 
42-1041 (1) XL-680C 42F 74-501 
42-1041 (1) XL-680C 611 A 402-590 
42-1041 (1) XL-680C 396F 437-866 
42-1041 (1) XL-680C 1041R 589-1001 
887-2015 (2) XL-660C 887F 930-1481 
1145-1589 (7) 590Cn2oC 1145F 1175-1651 
887-2015 (2) XL-660C 1589R 1186-1553 
887-2015 (2) XL-660C . 2015R 1470-1974 
1472-2091 (8) 680C (2 step) 1472F 1512-1602 
1472-2091 (8) 680C (2 step) 2091R 1779-2061 
1943-3404 (3) XL-680C 1943F 1969-2493 
1943-3404 (3) XL-680C 2639R 2185-2613 
1943-3404 (3) XL-680C 2248F 2377-2645 
1943-3404 (3) XL-680C 2492F 2517-2979 
1943-3404 (3) XL-680C 3143R 2722-3102 
1943-3404 (3) XL-680C 2782F 2815-3080 
1943-3404 (3) XL-680C 3404R 2904-3380 
1943-3404 (3) XL-680C 3137F 3182-3403 
3335-3894 ( 4) 600Cn2oc 3335F 3365-3812 
3335-3894 (4) 600C/720C 3894R 3418-3855 
3832-4659 (5) 610C/720C 3832F 3879-4270 
3832-4659 (5) 610C/720C 3998R 3832-3962 
3832-4659 (5) 610C/720C 4659R 4187-4617 
4550-5072 (9) 590C/720C 4550F 4577-4995 
4550-5072 (9) 590Cn2oC 5072R 4610-5050 
4610-5972 (6) XL-660C 4610F 4636-5063 
4897-5354 (10) 6CfJC/720C 5354R 4910-5326 
4897-5354 (1 0) 600Cn2oc 4897F 4934-5224 
4610-5972 (6) XL-660C 5680R 5277-5624 
4610-5972 (6) XL-660C 5268F 5308-5658 
4610-5972 (6) XL-660C 5975R 5533-5934 
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Table 7.6 MYH7 eDNA Sequence Differences In 
Nine Western Australian Residents 
Altered MYH7 Published Determined E~ivalent Amino Acid 
Base/Codon MYH7Codon MYH7Codon M~ 6Codon 
275/63 ACT ACC ACC All Threonine 
1787/567 CGA CGC CGC All Arginine 
1932/616 TIG C TG CTC All Leucine 
2132/682 GGC GGG GGC All Glycine 
2837/917 GCT GCC GCC All Alanine 
2913/943 TIG CTG TIG All Leucine 
3456/1124 TCC GCC GCC Serine (TCC) 
Alanine (GCC) 
Neutral changes to published MYHl bases (Jaenicke et al. , 1990) are 
indicated in blue. The T3456G MYHl base change causes the ~-MyHC 
S1124A amino acid change. Published MYH6 bases, Epp et al. (1993). 
Since the primary objective of this sequencing project was to determine the 
MYHl eDNA sequence of WAMPD 111.2, unaffected, unrelated individuals 
were only sequenced over regions where differences were observed between 
the published MYH7 eDNA sequence and that determined for WAMPD 111.2. 
Figure 7.6 (pp. 203-204) shows that all seven base changes listed in Table 7.6 
were found as homozygotes. The T3456G difference to the published MYHl 
eDNA sequence was found in all the Western Australian residents tested and so 
could not be a disease-causing mutation. This base difference in MYHl was 
the same as the published sequence for MYH6 and meant that the published 
~-MyHC had an uncharged polar serine at residue 1124 while the Western 
Australian form of ~-MyHC (and a.-MyHC) had non-polar alanine at this residue. 
The change was ~-MyHC S1124A. 
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A. Baae 275. 
C G C C G 
B. Base 1787. 
MYH7codon 63: ACT->ACC. MYH6= ACC. All threonine. 
' A G l A C C G A G A G G C I A 
r 
MYH7codon 567: CGA->CGC. MYH6=CGC. All arginine. 
' 
G A G C C A 1 C G C I A A T I A T C I A~ G G 
C. Base 1932. MYH7codon 616: TTG->CTG. MYH6=CTC. All leucine. 
' I T c c l c T c l A G c r G c T c 1 ~ G c 1 A c 
Figure 7.6 Differences to the published MYH7 eDNA sequence 
(Jaenicke et al., 1990) detected in the MYH7cDNA sequences of the WAMPD 
Laing myopathy proband, 111.2, and in nine unaffected, unrelated WA residents. 
' identify base changes; I separate codons. 
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Figure 7.6 (continued) 
D. Base 2132. MYH7codon 682: GGC->GGG. MYH6=GGC. All glycine. 
' Gi l C TIC C Al 5 6 G 6 l GI G l ~ ~ ~ j C I C C C l ( l 6
1 6 
MYH7codon 917: GCT->GCC. MYH6=GCC. All alanine. 
' 
G G G G C C I A G G T G A G G A 
' 
F. Base 2913. MYH7codon 943: TTG->CTG. MYH6 = TTG. All leucine. 
' l A A G C G C I A A G C T G G A A G 
G. Base 3456. MYH7codon 1124: TCC->GCC. MYH6=GCC=sameas the 
'WA MYH7codon'. TCC=serine (polar residue); GCC=alanine (non-polar residue). 
G 6 c T G 6 A 6 ! C C G G c G 
' identifies base changes; I separates codons 
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Apart from the T3456G base change, all the other base changes in Table 7.6 
were neutral DNA polymorphisms. Their neutrality meant that it was unlikely that 
they could be disease causing mutations, a fact confirmed by their presence in 
eight unrelated, unaffected individuals. This confirmation was important because 
neutral base changes can cause disease, if, for example, they create cryptic 
splice sites (Richard & Beckmann, 1995). 
The determined base change at MYH7 position 1932, MYH7 codon 616, was 
of interest because it identified itself as the likely ancestral '616' codon for M YH6 
and MYH7. The Western Australian MYH7 616 codon (C TG) had only one 
base change to the published M YH7 616 codon (TTG), while the published 
equivalent MYH6 codon (CTC ) had two base changes. Given that MYH6 and 
MYH7 almost certainly arose by duplication of a common ancestor (Epp et al., 
1993), and that these are highly conserved genes (Weiss et al., 1999), the 
ancestral '616' codon was probably the codon found in the Western Australian 
group. This conclusion follows from the observation that only the Western 
Australian CTG codon connects these three codons with just two neutral base 
changes: TTG<--CTG-->CTC . It is also possible that one, or both, of the 
I I I I 
published codons are in error. 
7.3.2.8 Base Differences In WAMPD Proband MYH7 eDNA 
Table 7.7 (p. 206) identifies two differences to the published MYH7 sequence, 
which were only found in the eDNA of WAMPD Laing Myopathy proband. 
Figure 7.7 (p. 206) shows that both these changes were found as 
heterozygotes with the published sequence. The base change at position 
3105 altered codon 1007 in WAMPD 111.2 from the published CTG to TTG but 
this codon change did not alter amino acid 1007, leucine, in ~-MyHC. 
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Table 7.7 MYH7 Sequence Differences In Proband 111.2 
Altered MYHl Published Determined Equivalent Amino Acid 
Base/Codon MYH7Codon MYH7Codon MYH6Codon 
3105/1007 CTG CTG!TTG CTG All Leucine 
5073/1663 GCC GCC/CCC GCC Alanine (GCC) 
Proline (C CC) 
Neutral changes to published MYH7 bases (Jaenicke et al. , 1990) are 
indicated in blue. The MYH7 base change causing ~-MyHC A 1663P 
indicated in red. Published MYH6 bases from Epp et al. (1993). 
A . Base 3105. MYH7codon 1007: CTG-> CTG & TIG. MYH6= CTG. Allleucine. 
' A C 
1 C A A C A G G C T N G G A I G C' 
B. Base 5073. MYH7codon 1663: GCC->GCC & CCC. MYH6=GCC. GCC = 
alanine (non-polar residue); CCC= proline (non-polar residue). 
' T C 1 C G T N C C l A A C l 
Figure 7.7 Differences to the published MYH7 eDNA sequence (Jaenicke et 
al., 1990) detected only in the MYH7 eDNA sequences of the WAMPD Laing 
myopathy proband, 111.2. l identifies base changes; I separates codons. 
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The MYH7 C3105T change was not observed in unaffected, unrelated 
Western Australians. However, it was a neutral change and it did not create a 
cryptic splice site since it occurred in the sequence GCT TIG GAT. It was 
unlikely to be a disease causing mutation and was not investigated further. Its 
discovery was significant because it was the first heterozygous base 
encountered in the WAMPD 1113 MYH7 sequence. It was the first indication 
that two alleles were being sequenced. The MYH7 G5073C base change in 
exon 35, was not present in any of the tested unrelated, unaffected eDNA. It 
caused the ~-MyHC amino acid substitution, A1663P. This was a significant 
change. Residue 1663 was in a a-helical section of ~-MyHC . Proline has a 
reputation as an 'a-helix breaker' (Schimmel & Florey, 1968). 
7.3.2.9 MYH7 gDNA G23628C Segregation In WAMPD Family 
In gDNA, M YH7 G236281 is equivalent to MYH7 eDNA G5073C' . To 
establish whether MYH7 gDNA G23628C segregated with all WAMPD family 
members or with the Laing myopathy affected family members alone, the entire 
WAMPD family was tested, by sequencing, for MYH7 exon 35 G23628C 
heterozygosity. gDNA was available for all WAMPD family members. MYH7 
G23628C is located 12 bases into exon 35. Exon 35 is 204 nucleotides in 
length, from base 23595 to base 23798 in MYH7 gDNA. The amplification 
and sequencing of the MYH7 exon 35 PCA product, amplicon 11 , was carried 
out with the intronic primers 23531 F and 23825A (Table 7.3, p. 187), at an 
annealing temperature of 640C. 
Figure 7.8 (p. 208), Figure 7.9 (p. 209) and Figure 7.10 (p. 210) all show the 
segregation of MYH7 G23628C heterozygosity with Laing myopathy. 
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"' 0 (X) 
I: 1 1:3 1:4 
+ 
II: 1 11:2 11:3 11:4 11:5 11:6 11:7 11:8 
TCCGTNCCAAC TCCGTGCCAAC TCCGTNCCAAC 
+ + + 
Ill: 1 ;t lll:2 Ill :3 Ill :4 Ill :5 Ill :6 Ill :7 
TCCGTNCCAAC TCCGTGCCAAC TCCGTGCCAAC TCCGTNCCAAC TCCGTGCCAAC 
+ 
IV:1 IV:2 IV:3 IV:<il IV:5 IV :6 IV:7 IV:8 IV:9 IV :10 
TCCGTNCCAAC TCCGTNCCAAC TCCGTGCCAAC TCCGTNCCAAC TCCGTNCCAAC TCCGTNCCAAC TCCGTGCCAAC 
Figure 7.8 The segregation of the gDNA, MYHl 23623-23633 base sequence in the WAMPD pedigree. SeqEd, Version 
1.0.3 (Myers, 1992: ABI) was used to convert chromatograms into nucleotide sequences. The N23628 base segregating with 
Laing myopathy was a G/C heterozygote which the ABI 373 DNA Sequencer could not call. Figure 7.9 (pp. 209) shows five 
WAMPD MYHl chromatograms from bases 23623 to 23633, while Figure 7.10 (p. 21 0) shows the segregation of MYHl 23623-
23633 in the WAMPD pedigree, from 111.2 to IV:1 and IV:3. 
Figure 7.9 The chromatograms of MYH7 gDNA sequence 
23623<->23633 in selected members of the WAMPD family. 11.2, 
11 1.2, 111.4, IV.1 and IV.3 are shown. Red pedigree numbers identify 
Laing myopathy individuals. Sequencing template was made from 
lymphocyte gDNA with primers 23531 F and 23825R. 
' identifies heterozygous gDNA base 23628, in affected individuals; 
separates codons. 
WAMPD Pedigree 
11 '2 11:3 11 :5 11 :6 
Ill :4 Ill :5 111 :6 111 :7 
+ + + + + 
IV:1 IV:2 IV:3 IV:4 IV:S IV:6 IV7 IV8 IV:9 IV:10 
11:2 
T c c 
111:2 (daughter of 11 :2) 
T C I C 
111:4 (son of 11 :2) 
T C c 
IV:1 (son of 111:2) 
T C I C 
IV:3 (daughter of 111:2) 
T C I C 
gDNA 23628 T 
G T I N 
gDNA23628 T 
G T I N 
gDNA 23628 T 
G T I G 
gDNA23628 T 
G T I N 
gDNA 23628 T 
G T I G 
I 
Figure 7.9 
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c c I A A c I 
c c I A A c I 
c c I A c I 
c C I A A c I 
c c I A A Cl 
111:1 
T c c G T N c c A c 
1\) 
--4 
0 + \ 
IG23628t 
IV:1 
T T N c c c T c c G c c A A c 
Figure 7.10 The segregation of MYH723623-23633 in the WAMPD pedigree, from 111.2 to IV:1 and IV:3. The chromatogram is not shown. 
7 .3.2.1 0 Testing Two European Distal Myopathy Families for 
MYH7 eDNA G5073C/gDNA G23628C 
The discovery of MYH7 G23628C segregating in other distal myopathy 
families would strengthen its claim to being the Laing myopathy mutation. At 
the time of its discovery we were aware of European distal myopathy families 
with phenotypes similar to Laing myopathy. These were the five Italian families 
reviewed by Scoppetta at al. (1995), and the German family reported by Voit 
at al. (1998). The Voit fami ly and one of the Scoppetta families have also 
been reviewed more recently (Voit et al., 2001 ). The five Scoppetta distal 
myopathy families had a remarkably homogeneous clinical picture with AD 
inheritance, onset in infancy or childhood with peroneal muscles weakness, 
benign progression, possibl~ late involvement of muscles other than tibia-
peroneal muscles, usually normal serum CK, EMG evidence of primary 
myogenic damage and morphological findings of non-specific myopathy. 
These authors described this form of distal myopathy as infantile AD-distal 
myopathy. 
The Voit distal myopathy family comprised a father and his three children from 
two marriages. All were affected by distal myopathy. The father's distal 
myopathy onset at 15 months when it was noticed that he fell frequently. 
Subsequently, he could walk and run but never walk on his heels. In the third 
decade, weakness of hand extensors and finger extensors developed 
followed by hip extensor and generalised muscle weakness in the fourth 
decade. All his three children had infantile onset of distal myopathy, marked by 
weakness of the tibialis anterior and toe extensor muscles. Magnetic 
Resonance Imaging revealed complete wasting of the tibialis anterior and toe 
extensor muscles in his 15 year old daughter. These authors described this 
form of distal myopathy as AD infantile onset tibial myopathy. 
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The AD mode of inheritance, the age of onset and the pattern of muscle 
involvement of these European distal myopathy families was similar to that of 
Laing myopathy. Testing them for MYH7 G23628C and /or gDNA/G5073C 
eDNA heterozygosity appeared worthwhile. In addition, and importantly, these 
families did not show exclusion of the MPD1 region of chromosome 14 by 
linkage analysis (Professor Dr.Thomas Voit, personal communication, 2000). 
Professor Voit, Director, Paediatric Clinic of the University of Essen, Germany, 
forwarded the gDNA of one affected individual in one of the Italian (Scoppetta) 
distal myopathy families and the gDNA and eDNA from one affected member 
of the German (Voit) distal myopathy family. These were tested in the same 
way as Laing myopathy DNA was 'tested for the MYH7 eDNA G5073C, and 
gDNA G23628C. Neither co-segregated eDNA G5073C/gDNA G23628C 
with their distal myopathy (Figure 7.11, p. 213). 
7.3.2.11 SSC P Screening of MYH7 gDNA for G23628C 
Figure 7.12A (p. 214) shows the WAMPD family SSCP gel for MYH7 gDNA 
amplicon 11. The conditions employed were described in Section 7.3.1.9 (pp. 
191-192). The segregation of an SSCP with Laing myopathy was evident. A 
comparison of all the WAMPD sequences for the MYH7 gDNA amplicon 11, 
showed G23628C to be the only sequence difference between affected and 
unaffected WAMPD family members. The observed SSCP was caused by 
G23628C segregating with Laing myopathy. 
A further 122 unrelated unaffected individuals were tested by SSCP for MYH7 
G23628C. Figure 7.12 B and 17.12 C (both p. 214) show two typical SSCP 
gels loaded with 23531 F<->23825R M YH7 gDNA amplicon 11 from unrelated 
individuals, all of whom were unaffected by Laing myopathy. 
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Figure 7.11 MYH7 eDNA amplicon 10 and MYH7 
gDNA amplicon 11 sequences for two European families 
segregating early onset AD-MPD. Chromatograms for the 
M YH7 eDNA bases 5068-5078 and for the M YH7 gDNA 
bases 23623-23633 are shown. 
A. The MYH7 eDNA amplicon 10 sequence of one MPD 
affected member in a German distal myopathy family (Voit) 
showed that this individual was homozygous MYH7 G5073. 
This agreed with the published sequence (Jaenicke et al., 
1 990). Reverse sequence is shown. 
B. The MYH7 gDNA amplicon 11 sequence using template 
gDNA from the same affected German family member, 
confirmed that this individual was homozygous M Y H 7 
G23628. Reverse sequence is shown. 
C. The MYH7 gDNA amplicon 11 sequence from an MPD 
affected member of an Italian family (Scoppetta), also showed 
that this individual was homozygous M YH7 G23628. 
Reverse sequence is shown. 
From these results it was concluded that neither this German 
distal myopathy family (Voit et al., 1998), nor this Italian distal 
myopathy family (Scoppetta et al., 1995), segregated the 
MYH7 eDNA G5073C/gDNA G23628C heterozygosity with 
their form(s) of distal myopathy. 
' identifies base changes; I separates codons. 
A. German Early-Onset AD-MPD (Voit) - eDNA amplicon 10. 
' T c I c G T I G c c I A A c l 
B. German Early-Onset AD-MPD (Voit) - gDNA amplicon 11 
T C I C G T l ~ C C I A A Cl 
C. Italian Early-Onset AD-MPD (Scoppetta) - gDNA amplicon 11 
T c I c G T ~ C c I A A c I 
I 
Figure 7.11 
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Figure 7.12 Screening MYH7 gDNA 23531 F<->23825R amplicon 
11 for the G23628C SSCP. This SSCP is visible in the bottom band of 
each of these gels. 
A. Shows the segregation of the MYH7 G23628C SSCP in the 
WAMPD family with Laing myopathy (red pedigree numbers). This gel 
was silver stained. IV·9 was of interest because it appeared as if he may 
have been homozygous C 23628, even although sequencing had 
previously shown this individual to be heterozygous G23628C . PCR 
mutations are rare, but they do occur. However, sequencing the actua11V:9 
amplicon 11 (23531 F<->23825R) used on this SSCP gel showed that 
IV:9 was G23628C heterozygous. The entire sequence of this IV·9 
amplicon was identical to all other Laing myopathy individuals. 
11 :2 11 :3 11 :5 11 :6 
111:4 111 :5 111 '6 111:7 
+ + + + + 
IV:1 IV:2 IV:3 IV ~4 IV:5 IV:.6 IV7 IV8 IV9 IV:10 
B. An MYH7 G23628C SSCP gel of the MYH7 gDNA amplicon 11 
showing 12 unaffected, unrelated individuals. Unaffected individuals were 
numbered from 1 N to 122N. This was the first 'unaffected' gel, showing the 
SSCP results for individuals 1 N-12N. The positive control was WAMPD 
Laing myopathy individual ll.2. This gel was stained with Sybr Gold. 
C An MYH7 G23628C gel showing the SSCP results for individuals 
80N-89N. This gel was also stained with Sybr Gold. Initially one positive 
control was loaded on each SSCP gel, but this was expanded to 3 
positive controls to increase confidence. One of the positive controls used 
on this gel was individua11V:9. This time, the G23628C SSCP could be 
ident~ied in IV:9. Such is SSCP. 
A. 
11:5 11:2 11:3 111:6 111:7 111:2 111:3 111:4 IV:9 IV:10 IV:1 IV:2 IV:3 IV:4 IV:S 
B. 
1N 2N 3N 4N 5N 6N 11:2 7N 8N 9N 10N 11N 12N 
c. 
11:5 80N 81 N 82N 83N 84N 85N IV:1 86N 87N 88N 89N IV:9 
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A total of 256 unaffected chromosomes were tested for the MYH7 SSCP 
G23628C segregating with Laing myopathy. This sample comprised 122 
unrelated, unaffected individuals and the six unaffected WAMPD family 
members. None were found to have this SSCP. 
In addition, ten of the unaffected, unrelated individuals were sequenced over the 
MYH7 amplicon 11 from base 23531 to 23825. These were individuals 2N, 
6N, 12N, 21 N, 39N, 53N, 76N, 82N, 92N, and 1 OON. None showed 
G23628C heterozygosity, confirming the validity of the SSCP test. 
7.4 CONCLUSION 
Testing MYH7 eDNA of the WAMPD proband, 111.2, for a Laing myopathy 
mutation, identified seven base differences between the WAMPD 111.2 
sequence and the published eDNA sequence for MYH7. All of these 
differences were found in eight unrelated, unaffected Western Australian 
residents. None of them could be disease-causing. 
Two further differences to the published M YH7 sequence segregated 
exclusively with eDNA of WAMPD 111.2. An MYH7 C31 05T base change and 
an MYH7 G5073C . Only the MYH7 G5073C in exon 35, caused a significant 
change to (3-MyHC, resulting in an A 1663P substitution in a repeating a-helical 
section of the (3-MyHC rod. The significance of this change was that proline has 
been described as an 'a-helix breaker' (Schimmel & Florey, 1968) Sequencing 
demonstrated that gDNA G23628/C 23628 heterozygosity segregated with 
Laing myopathy in the WAMPD pedigree. This segregation was confirmed by 
an SSCP test which was then used to test a total of 256 unaffected 
chromosomes. None of these controls showed G23628/C23628 
heterozygosity. 
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Two patients from European distal myopathy families, phenotypically similar to 
Laing myopathy (Voit and Scoppetta), were tested for the presence of MYH7 
gDNA G23628/C 23628 heterozygosity. One of these patients (Voit) was 
also tested for MYH7 c DNA G5073/C5073 heterozygosity. The gDNA of 
both patients was homozygous G23628. The eDNA of the Voit family patient 
was homozygous G5073. 
Chapter 8 evaluates the M YH7 G5073C base change as the Laing myopathy 
mutation. 
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CHAPTER EIGHT 
MYH7G5073C: THE LAING MYOPATHY 
MUTATION OR A BABE POLYMORPHISM? 
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8.0 MYH7G5073C: THE LAING MYOPATHY MUTATION 
OR A RARE POLYMORPHISM? 
The ~-MyHC A 1663P substitution segregating with Laing myopathy raises the 
question, 'Could the (3-MyHC A 1663P substitution cause Laing myopathy?' It 
was the most important question raised by this thesis. It is addressed in this 
chapter. 
The effect of the (3-MyHC A 1663P substitution wiil be analysed in two ways. 
First, a survey of disease-causing mutations in MYH genes and other relevant 
sarcomeric genes, will be conducted to gauge the likelihood that this substitution 
could cause Laing myopathy. Difficulties confronting the (3-MyHC A 1663P 
Laing myopathy candidature and possible disease mechanisms will be 
identified and analysed. Second, the possible effect(s) of the (3-MyHC 
A 1663P substitution will be deduced from first principles: at the primary, 
secondary, quaternary structural levels of ~-MyHC and at superstructural level 
of the thick filament. Future research directions for Laing myopathy may be 
indicated by either, or both, of these analyses. 
8.1 LAING MYOPATHY: SARCOMERIC GENE MUTATIONS 
Laing myopathy has three important identifying characteristics relevant to this 
analysis. It is not associated with heart disease; it is a skeletal muscle 
myopathy; and it affects specific muscles. MYH disease-causing mutations with 
any of these characteristics are of most interest, especially if they occur in the 
LMM region of the MyHC molecule. This analysis starts, therefore, by asking a 
series of questions about mutations. in MYH7, then it broadens its enquiry to 
include other myosins and other sarcomeric genes. 
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8.1.1 Do MYH7 Mutations Have a Cardiac Phenotype? 
(3-MyHC is the predominant ventricular isoform, and mutations in (3-MyHC 
cause hypertrophic cardiomyopathy (CMH) (Redwood et al. , 1999). Any 
aetiology for Laing myopathy based on the MYH7 G5073C mutation, must 
be able to explain why heart disease has not been detected in affected 
WAMPD individuals. 
CMH is a genetically and phenotypically heterogeneous disease associated 
with mutations in nine sarcomeric protein genes (listed in Table 8.1 pp. 225, 
where these genes are more fully considered). Mutations in MYH7 cause 
CMH1 (MIM:192600). All CMH1 mutations segregate in an AD fashion, and 
all lie in the first 2847 bases (949 codons) of the 5805 coding bases in MYH7. 
The structure of myosin II helps to explain why this is observed. 
I 
essential 1 
l~ht cha.ns I 
t+-termlnal I 
end ol myosin : 
heavy ella ns 1 
I 
I 
head tall 
S1 S2 
HMM 
c-tenrunal 
end ol myosin 
heavy chains 
Figure 8.1 A schematic synopsis of the myosin II hexamer. 
Identified are the myosin light chain binding sites and the products of 
proteolytic digestion: the HMM and LMM fragments and the S1 and 
S2 subfragments. HMM and LMM stand for heavy and light 
meromyosin. Scanned from Wolfe (1993, p. 462). 
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The two (3-MyHC monomers in MyHCs comprise one proteolytic fragment, 
the LMM fragment and two proteolytic subfragments 81 and 82. These 
fragments/subfragments are not functionally significant, but are still widely used 
for descriptive purposes. 
The 81 subfragment consists of the globular head, the convertor domain and an 
a-helical neck region. The globular head is the catalytic/motor domain of the 
MyHCs. It contains sites for binding actin, ATPase, a nucleotide binding cleft for 
binding ATP, and a long narrow D464-M495 communication/transducer domain 
between the ATP and actin binding sites (Weiss et al., 1999, p. 64). The 
globular head connects to the second communication/transducer domain, the 
convertor domain, which runs from residue 706 to 771 and appears to 
communicate activity at the nucleotide binding site to the next section of MyHC 
molecule, the 783-843 residue a-helical neck region. The essential light chain 
(ELC), and the regulatory light chain, (RLC) bind to the a-helical neck region. 
The neck region functions as a lever arm, the length of which is correlated with the 
power stroke size and velocity of movement (Uyeda et al., 1996). 
The 82 subfragment comprises the N-terminal one-third of the rod and contains 
a myosin binding protein-C binding site at its N-terminal end, and a hinge-like 
region at its C-terminal end. The hinge-like region facilitates movement of the 
neck and head during a power stroke (Weiss et al., 1999, p. 70). The C-
terminal two-thirds of the rod, the LMM fragment, is responsible for MyHC self-
association and forms the backbone of the thick filament (Weiss et al., 1999, p. 
70). It commences between residues 1203 and 1282, its starting point 
depending on specificity of cleaving enzyme. 
Figure 8.2 superimposes CMH1 mutations on an MYH7 cartoon to produce a 
codon mutation map. 
220 
232 249 1 9 
' 
190 
• • • 250 
s 
1 
s 
u 
8 
F 
R 
A 
G 
M 
E 
N 
T 
I 
s 
2 
s 
u 
B 
F 
R 
501 
751 
GLOBULAR HEAD - CATAlYTIC DOMAIN 
? 
349 • 
513 584 006 
• • • 
... 
GLOBULAR HEAD · CATAL YTlC DOMAIN 
na 797 837 
• • 
DMAINJ u·hellcal neck region 
... , ~ ... 837 
771 ELC ALC 
BIND BINDING 783~ :- ~ ~ 837 
006 808 
~ 11203 
~ 1001•'----------------------------~. 
N 
T 
I 
750 
1204L--.... 
• I 1250 
L 
M 
M 1251 ._ .................................... .. 1500 
F 
A 
A 
~ 1501 E ...... ~ ............................ .... 1750 
N 
T I 1751 1 11935 ~~----~ .................... ~. 
Figure 8.2 Superimposition of CMH1 mutations on a cartoon of the 
MYH7 gene. Mutations were identified from the Human Gene Mutation 
Database (2000; http://archive.uwcm.ac.ukluwcm/mg/ hgmdO.html). In this 
codon mutation map, red numbers identify codons with missense mutations 
while green numbers identify the two known CMH1 codon deletions. All 
other numbers are MYH7 codoni{J-cardiac myosin residue numbers. 
221 
Figure 8.2 shows that 27 different CMH1 mutations can result in heart disease. 
Since 21 of these CMH1 mutations lie in the head of ~-MyHC, between 
MYH7 eDNA bases 25-2847, it follows that CMH is predominantly caused by 
disruption of the functions carried out by the head, or S1 subfragment, of ~­
MyHC (Vikstrom & Leinwand, 1996). Kelly and Strauss (1994) suggested that 
MYH7 mutations represent dominant negatives by disturbing contractile 
function, despite the remaining normal allele producing normal protein. Nishi et 
al., (1995) showed that while an MYH7 missense mutation caused CMH1, a 
MYH7 nonsense mutation segregating in the same pedigree had no effect. 
This showed that nuii-MYH7 alleles do not produce CMH1. 
On the basis of many in vivo and in vitro motility assays of ~-MyHC A403Q 
and in vitro motility assays of many other CMH1 mutations, Redwood et al. 
(1999, p. 25) concluded that CMH1 mutations appear to lead, "to a primary 
hypocontractile state, which, in turn, provides a stimulus for the development of 
compensatory hypertrophy. . . . The most straightforward hypothesis for the 
pathogenesis of the disease is that the reduced force provides a stimulus for 
compensatory hypertrophy." 
This analysis was encouraging for the candidature of MYH7 G5073C as the 
Laing myopathy mutation, because all but six of these CMH mutations were in 
the globular head of the ~-MyHC molecule. The six CMH mutations that were 
in the rod region could also be explained in a way that did not compromise the 
likelihood of MYH7 G5073C as the Laing myopathy mutation. These 
mutations were at codons 870, 908, 924, 929, 935 and 949. Gruen and Gautel 
(1999) discovered a binding site towards the N-terminal end of the myosin 
binding protein-C (MyBP-C), which had high affinity for the S2 region of the 
MyHC rod, in the 126 residues immediately following the head tail junction. All 
of the six ~-MyHC S2 rod region CMH1 mutations lie in the MyBP-C binding 
222 
f 
.. 
region. Binding studies involving wild type MyBP-C and MYHl with the 
mutations R870H and E924K showed that these MYHl mutations greatly 
reduced binding of MyBP-C to the J3-MyHC 82 rod region. Gruen and Gautel 
concluded that the disruption of the MyBP-C binding site by the six 82 rod 
region CMH1 mutations, was the cause of CMH1 in these patients. 
8.1.2 Do MYH7 Mutations Cause Skeletal Muscle Myopathy? 
A myopathy was discovered during the histological examination of soleus 
biopsies taken from CMH1 patients in five kindr~ds. These kindreds were 
segregating four different MYHl mutations (Fananapazir etal., 1993, pp. 3994-
3997). Twelve patients showed mild myopathic changes, four showed 
moderate myopathic changes: variation in fibre size, hypertrophic fibres with 
internal nuclei, increased connective tissue, splitting of muscle fibres, and 
occasional necrotic fibres. Clinical or electrophysiological signs of myopathy 
were not described. The J3-MyHC amino acid substitutions associated with 
soleus muscle myopathy were, L908V (in the 82 rod), R403Q, and G256E. 
Of special interest to this project was the observation that the (3-MyHC 82 rod 
substitution, L908V, segregated from a father with CMH1 phenotype and with 
soleus muscle myopathic changes to his daughter and son who were 33 and 27 
years old respectively at the time of their ascertainment. Both the daughter and 
the son showed muscle myopathic changes, but not CMH1 phenotype. The 
son had three children, two daughters and one son aged 5, 4, and 2. All these 
children had soleus muscle central core phenotype. Muscle central core 
phenotype is also a variably expressed part of nemaline myopathy (Afifi et al., 
1965) and malignant hyperthermia (Frank et al., 1978). In this CMH1 kindred it 
is therefore apparent that the (3-MyHC L908V substitution has co-segregated 
with unspecified muscle myopathic changes and CMH1 phenotype, with 
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unspecified muscle myopathic changes alone and with soleus muscle central 
core phenotype. Echocardiogram was used to determine the presence or 
absence of CMH1 phenotype. Fananapazir (1993) also found that soleus 
muscle central core phenotype was present in a further 7 of 8 patients with the 
L908V substitution, 5 of 8 patients with the R403Q substitution, 1 of 3 patients 
with the G741 R substitution, and in the 1 patient with the G256E substitution. 
Although Laing myopathy has defined myopathic features and has not been 
associated with muscle central core phenotype, the investigations of 
Fananapazir (1993) show that MYH7 mutations can cause skeletal muscle 
pathology without CMH1 phenotype. 
Lankford et al. (1995) compared the contractile properties of single soleus 
muscle slow-twitch muscle fibers in normal controls to those of patients with 2 
distinct CMH1 mutations. They found that fibers from 13-MyHC G741 R 
patients, had decreased maximum velocity of shortening (39% of normal) and 
decreased isometric force generation (42% of normal). Fibers from 13-MyHC 
R403Q patients showed lower force/stiffness ratio (56% of normal) and 
depressed velocity of shortening (50% of normal). Both of these mutation-
containing fibers displayed abnormal force-velocity relationships and reduced 
power output. Therefore, mutations in M YH 7 affect the contractile properties of 
skeletal muscle. This agrees with the later conclusion of Redwood et al. (1999; 
cited on p. 222) that CMH1 is a contractile disorder. The observed variably 
expressed myopathy and central core histology may be secondary 
consequences of altered contractile properties. 
8.1.3 Which CMH Disease Genes are Associated 
with Skeletal Muscle Myopathy? 
Nine CMH genes have been identified and are listed in Table 8.1. 
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Table 8.1 Cardiomyopathy Hypertrophic, Familial (CMH) 
and Associated Disease Genes. 
Gene Protein/ Number of First Reports 
(CMH) Polypeptide Mutations* 
MYH7 Myosin heavy 27 Geisterfer-Lowrance 
(CMH1) polypeptide 7, 
cardiac muscle, ~ 
et al. (1990) 
TNNT2 Troponin T2, cardiac 11 Thierfelder et al. (1994) 
(CMH2) 
TPM1 Tropomyosin 1 alpha 4 Thierfelder et al. (1994) 
(CMH3) 
MYBPC3 Myosin binding 28 Bonne et al. (1995) 
(CMH4) protein, cardiac Watkins et al. (1995) 
TNN/3 Troponin I, cardiac 5 Kimura et al. (1997) 
(CMH7) muscle isoform 
MYL3 Myosin, light chain, 2 Poetter et al. (1996) 
(CMH8) alkali; ventricular 
and skeletal slow 
TTN Titin 1 Satoh et al. (1999) 
(CMH9) 
MYL2 Myosin, light chain 2; 
regulatory ventricular 
5 Poetter et al. (1996) 
ACTC Actin, a, cardiac 1 Mogensen et al. (1999) 
muscle 
* as listed in HGMD (2000) 
Note that CMH5 was assigned to a 'wastebasket' category for forms of CMH not 
linked to any known loci; CMH6 was assigned to hypertrophic cardiomyopathy 
associated with Wolff-Parkinson-White Syndrome; CMH associated with 
mutations in MYL2 and ACTC have not yet been given CMH numbers. 
A PubMed search (http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?) linking all 
CMH genes with 'myopathy' produced only two positive responses. The first 
was eight articles linking MYH7 and myopathy, the second, four articles linking 
TTN and myopathy. An examination of the MYH7 articles showed that six of 
them related to the localisation of the French Canadian form of OPMD, one was 
the Laing et al. (1995b) localisation of MPD1 and one was the Fananapazir et al. 
(1993) report discussed above. An examination of the four titin references 
found that three did not directly link titin to myopathy (Fougerousse et al., 1998; 
Pelin et al., 1997; Muller-Seitz et al., 1993). The only article which linked titin to 
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myopathy was one authored by Udd et al. (1998), where titin was identified as 
a 'superior TMD candidate'. Three months prior to the Udd article, Haravuori et 
al., (1998a) had reported the results of linkage analysis on four different Finnish 
AD-TMD families. They found a common chromosome 2q31 core haplotype 
segregating with affecteds. This was indicative of one major ancient founder 
mutation for AD-TMD in Finland. Multipoint likelihood calculations, combined 
with haplotype and recombination analyses, restricted the TMD locus to a 
chromosomal region of - 1cM. Udd et al. (1998, p.331) comment: 
There are not many interesting genes in the 2q31 locus, 
which is about 1 eM in size. One known gene is the major 
candidate, namely the gene encoding the giant muscle 
gene titin (former name connectin) (Labeit et al., 1995). 
One of the main functions of titin is to keep the contractile 
elements of the sarcomere in place during the variations of 
the functional state of the muscle fibre. It also binds a 
large number of other muscle proteins and is responsible 
for muscle elasticity. . . . Titin has many properties making 
it a highly interesting candidate for TMD. It has several 
sites for differential splicing causing different isoforms to 
appear in different muscles (Labeit et al., 1997). This 
might be relevant for the selective involvement of 
muscles in anatomically restricted myopathies. 
The last sentence of this quotation was most apposite. In 1999 Satoh et al. 
identified in a CMH patient, a G to T transversion in titin codon 740, changing 
this codon from CGC (arginine) to CTC (leucine). This mutation increased the 
binding affinity of titin to alpha-actinin in the yeast two-hybrid assay, suggesting 
that the G2219T titin mutation may cause CMH in this patient by altering its 
affinity to alpha-actinin. Characterisation of titin transcripts from cardiac and 
skeletal muscles show that cascades of axon-skipping events produce titins 
with distinct structures, which confer distinct elastic properties on muscle types 
(Freiburg et al., 1999; Centner et al., 2000). So it appears quite possible that 
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the differential splicing of titin might not only explain the regional distribution of 
this distal myopathy, but could also explain the lack of CMH in TMD patients. 
The splicing-out of the putative TMD mutation in cardiac isoforms could explain 
the absence of CMH, or other cardiac phenotypes, in TMD patients. 
There is no evidence to suggest that differential splicing could explain the 
absence of CMH in Laing myopathy patients. A PubMed search for ~-cardiac 
myosin identified 720 articles, none describing ~-cardiac myosin genes as 
differentially spliced in any of the many organisms studied. There is only one 
report of alternate splicing occurring in a-cardiac MyHC and that involved the 
inclusion or exclusion of the glutamine residue at position 1931 in rat a-cardiac 
MyHC (Sindhwani et al., 1994). Differential splicing does not contribute to the 
anatomical restriction of Laing myopathy and cannot be· invoked to explain the 
absence of CMH1 in these patients. However, the restricted phenotype of a 
mutation can be explained in other ways such as the timing of gene expression 
or tissue-specific factors. The latter is discussed in the next section. 
8.1.4 Do Substitutions in the ~-MyHC LMM Rod Region 
Cause Defects in Specific Muscles? 
Kronert et al. (1995) determined the molecular and ultrastructural defects 
associated with three homozygous-viable MyHC mutations of Drosophila 
melanogaster. These mutations caused a dominant flightless phenotype but 
allowed relatively normal assembly of indirect flight muscle myofibrils. As a 
result of myofibril 'hypercontraction', the contents of the indirect flight muscle 
myofibers were pulled to one end of the thorax as the sarcomere progressively 
ruptured with adult aging. All three mutations caused single amino acid changes 
in the LMM region of the myosin rod. Two changed the same GAG codon 
(glutamic acid) to an AAG codon (lysine) while the third affected an amino acid 
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five residues away, changing CGC codon (arginine) to CAC codon (histidine). 
The amino acid substitutions were E1555K and R1561H. Both of these altered 
residues were conserved in nematode, chicken, and rat muscle myosins, in one 
human non-muscle myosin (now called myosin 9), and in human ~-MyHC (see 
Table 8.2, p. 234, where the organisation of the MyHC rod is presented). In~­
MyHC these residues were E1553 and R1559 and were positioned 102 and 
107 residues N-terminal to the P1663 substitution segregating with Laing 
myopathy. Drosophila melanogaster and human. LMM rods are two residues 
'out-of-register' at this part of their amino acid sequence. 
Drosophila melanogaster is unique in that its multiple forms of muscle MyHC are 
encoded by a single copy gene (Bernstein et al, 1983). Drosophila uses 
alternative RNA splicing to produce all the isoforms required by the functionally 
different muscles in Drosophila (George et al., 1989). The mutations described 
by Kronert (1995) were in exon 16 of the Drosophila MyHC gene and were 
found to be associated with age-dependent, site-specific degradation of 
MyHC. They were also associated with a failure to accumulate phosphorylated 
forms of flightin, a specific protein found in indirect flight muscle previously 
localised to the thick filament. Kronert et al. considered it remarkable that these 
single amino acid changes in the LMM section of the MyHC rod could cause 
severe defects and that these severe defects were only apparent in indirect 
flight muscles. All other muscles were normal. They concluded (pp. 121-122): 
The simplest explanation is that flightin binds to myosin 
where the mutations described in this paper have been 
mapped, and that binding is required for phosphorylation. 
Ferguson et al. (1994) recently showed that a possible 
analogue of flightin in Lethocerus indicus [a water bug] 
does indeed bind to thick filaments, most likely near the 
end of the myosin rod. Flightin interaction with myosin 
might permit proper muscle contraction/relaxation to occur, 
a process that is disrupted in the Drosophila rod mutants. 
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8.1.5 Does the LMM Rod Region of Human p-MyHC Interact 
with Other Molecules? 
Okagaki et al., (1993) established that the skeletal muscle MyBP-C, bound to 
the LMM section of the myosin rod. The last 102 amino acids of MyBP-C was 
involved in LMM binding. This means that there are at least two regions on the 
~-MyHC rod to which MyBP-C binds; at this site and at the myosin S2 site 
associated with CMH 1 which was discussed in Section 8. 1 (pp. 222-223). 
Gilbert et al. (1996) found that one truncated mutant of MyBP-C, only lacking 
the myosin binding domain, produced a clear dominant-negative disruption of 
myofibril assembly. These authors performed transfection studies in skeletal 
muscle myoblasts with constructs encoding truncation mutants of MyBP-C. This 
finding was relevant to the present study for three reasons. 
First, it opened up the possibility that mutations in the MyHC rod might have 
the same dominant negative effect as the truncated MyBP-C. The site(s) on 
the myosin LMM rod to which MyBP-C binds, is/are unknown. Second, the 
cardiac MyBP-C isoform contains a unique 28 residue insertion, not found in 
skeletal muscle MyBP-C, which is abundant in proline and charged residues 
(Redwood et al., 1999: Gruen & Gautel, 1999). Were MyBP-C involved in 
Laing myopathy pathogenesis, the absence of a cardiac phenotype in this 
disease could be a direct result of the differences between skeletal and cardiac 
muscle MyBP-C isoforms. 
Finally, the same MyBP-C high-affinity LMM-binding domain also binds to titin 
but with lower affinity (Gruen & Gautel, 1999). Thus the rod region of p-MyHC 
molecules is closely bound to titin by MyBP-C. Could these two distal 
myopathies be linked by the failure of MyBP-C to bind to ~-MyHC in Laing 
myopathy and to titin in TMD? Other possible connections between the distal 
myopathies are considered in Chapter 9, Section 9.2. 
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8.1.6 Do Other MYH Mutations Cause Skeletal 
Muscle Myopathy? 
The genes encoding embryonic, II a, llx/d, lib, perinatal and extraocular MyHCs 
are located in a cluster on chromosome 17 (Weiss et al., 1999). By linkage 
analysis and radiation hybrid mapping, Martinsson et al. (1999) localised an AD 
hereditary inclusion-body myopathy gene (Human Genome Map locus name: 
I 8M3) to chromosome region 17p13.1. An axon 17 G2116A mutation in the 
chromosome 17p13.1 MyHC-1/a gene, has been found to segregate with 
18M3 hereditary inclusion-body myopathy (Martinsson et al, 2000). Therefore, 
a mutation in this chromosome 17 MYH gene is associated with a human 
skeletal muscle myopathy. 
8.1.7 Sarcomeric Gene Mutations and Laing Myopathy: 
An Evaluation 
In the introduction to this analysis it was stated that, 'difficulties confronting the ~­
MyHC A 1663P Laing myopathy candidature and possible disease 
mechanisms will be identified and analysed' {p. 218). Three difficulties 
confronting the A 1663P Laing myopathy candidature were identified and 
discounted. 
First, although MYH7 mutations do cause CMH, none of these mutations lie in 
the LMM region of the ~-MyHC molecule. Furthermore, TMD shows no signs 
of CMH yet, like Laing myopathy, it also has a CMH gene, titin (CMH9), as its 
candidate gene. Although differential splicing may explain the absence of 
CMH from TMD, it does not do so for Laing myopathy. However, skeletal 
muscle myopathy and central core phenotype do segregate with MYH7 
mutations, without CMH1 phenotype. MYH7 mutations can cause skeletal 
muscle myopathy, restricted to specific muscles and without cardiac phenotype. 
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Second, mutation to a human MYH gene, MyHC-1/a, can cause myopathy 
(Martinsson et al, 2000). Third, mutations to the MyHC LMM rod region can 
have selective phenotypic expression. Mutations to the LMM rod region of 
the Drosophila melanogaster MYH gene causes a hypercontractile state in only 
one type of muscle, the indirect flight muscles. 
This analysis also gave two insights into disease mechanisms which may be of 
relevance to Laing myopathy. First, CMH1 mutations in the globular head of 
the ~-MyHC molecule cause hypocontractility (Redwood et al., 1999). 
Second, mutations in the LMM rod region of the Drosophila melanogaster 
MYH gene cause hypercontractility and this has been explained by the failure 
of flightin to attach to the MyHC LMM rod region (Kronert et al., 1995). In 
addition, a truncated mutant of MyBP-C without the domain for binding to 
MyHC LMM rod region, produced a clear dominant-negative disruption of 
myofibril assembly (Gilbert et al., 1996). Therefore, from this analysis of 
MYH7 mutations, two possible directions for future Laing myopathy have 
emerged. Research focussed on the contractility of myosin II containing both 
A 1663 and P1663 ~-MyHC monomers, and research focussed on the 
interaction of the ~-MyHC LMM rod region with other macromolecules, 
involving A 1663 and P1663 ~-MyHC monomers if appropriate. 
By resolving some difficulties confronting MYH7 G5073C as the Laing 
myopathy mutation, the candidature of MYH7 G5073C has been 
strengthened. But the reality remains. · ~-MyHC A 1663P is a novel 
substitution, of effect(s) unknown. After MYH7 mutation analysis, the answer to 
question, "Could the ~-MyHC A 1663P substitution cause Laing myopathy?" 
was only, "It could". Further analysis was necessary. 
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The next four sections continue considering the likelihood of the ~-MyHC 
A 1663P Laing myopathy candidature, and continue looking for possible 
disease causing mechanisms. However, these sections adopt a different 
approach: the examination of the possible effect(s) of the ~-MyHC A 1663P 
substitution at the primary, secondary, and quaternary structural levels of ~­
MyHC, and then at the superstructural level of the thick filament. 
8.2 A 1663P AND THE PRIMARY STRUCTURE OF 
THE ~-MyHC ROD 
The primary structure of proteins is defined as their sequence of amino acids. 
Peptide bonds, also called vectors, link amino acids together to form 
polypeptides. Carbon atoms in amino acids are conventionally labelled a for 
the centre carbon atom and~. y, o and E for the subsequent side chain carbon 
atoms. Since this nomenclature is employed throughout the remainder of this 
chapter, Figure 8.3 provides a reference point. 
carbonyl oxygen 
0 ' -Cu Vector OX-CO Vector 
LYSINE ALANINE ~ 
Figure 8.3 A dipeptide showing two peptide bonds, two cu-ca 
vectors and the conventional labelling of carbon atoms in amino acids. 
The role of the ~ and 1/J angles in determining secondary protein structure 
will be discussed in Sections 8.3.2-8.3.4 {pp. 241-251 ). 
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The primary structure of the MyHC rod region is dominated by two repeat 
patterns, the heptad-residue repeat pattern and the 28-residue repeat pattern. 
The heptad repeat pattern is a regular, ?-residue pattern, conventionally 
labelled a-b-o-d-e-f-g, in which hydrophobic residues are concentrated at 
intervals of 3 and 4 residues in positions a and d (Mclachlan and Karn 1982, 
p.227). Sellers (1999, p. 52) also notes that the outermost positions b, ~and f 
contain the greatest number of charged, hydrophilic polar residues. The heptad 
distribution of hydrophobic and hydrophilic residues determines the quaternary 
structure of the MyHCs. Heptad repeats are only found in a-helices that form 
quaternary coiled-coil structures. Discussion of heptad repeats continues 
throughout this chapter, but particularly in the section considering quaternary 
structure. 
Internal comparison of the amino acid sequence of the C. elegans myosin rod 
region of the nematode shows that the entire rod sequence could be mapped 
out as a cyclical 28-residue charge-repeat pattern. This charge-repeat pattern 
controls thick filament formation (McLachlan & Karn, 1982, p.227). Discussion of 
28-residue, also continues throughout this chapter, but particularly in the section 
considering thick filament formation. 
8.2.1 Derived Primary Structure of (:\-MyHC 
Table 8.2 (p. 234) shows the derived primary structure for (:\-MyHC rod of 
WAMPD Laing myopathy proband, 111.2. Four observations and one 
deduction could be made from the primary ~-MyHC structure presented in this 
table. First, proline was not part of the rod sequence after position 838. It has 
never been identified between the residues 838 and 1935 in human (:\-MyHC 
sequence. 
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Table 8.2 The Derived {3-MyHC Rod Region Amino Acid 
Sequence for WAMPD Laing Myopathy Proband, 111.2. 
The WAMPD 111.2 sequence for ~-MyHC was derived from the 
determined MYH7 eDNA sequence, using SeqEd, Version 1.0.3 
(Myers,1992). Only the amino acid sequence for the ~-MyHC rod 
region is shown. The heptad repeats of the human ~-MyHC rod 
commence with an invariant proline residue (Offer and Knight, 1996, p. 
408), located at position 838, and both the rod and the ~-MyHC 
molecule terminate at residue 1935. Since the myosin rod starts with a 
proline in position d, the MyHC 28-residue repeats start at heptad 
position d. The amino acid sequence is presented in heptad and 28-
residue repeats. In the human ~-MyHC rod, there are 38, full, 28-
residue repeats and 2 half 28-residue repeats. For the purpose of 
identification, these repeats were numbered - , . The 28-residue 
repeat pattern is broken by four skip residues (boxed) at positions 
1188, 1385, 1582, and 1807. In addition. there is a 2 residue tailpiece 
occupying the final two positions, 1934 and 1935. 
Residues are highlighted in red for. charged hydrophilic polar residues; 
black for uncharged hydrophilic polar residues; and blue for 
hydrophobic nonpolar residues. The heptad positions d, , f, , a. b, c 
are also highlighted with the same colour code to indicate the predicted, 
'most common type of residue' in each position (Sellers,1999, p. 52). 
Positions and do not have a 'most common type of residue'. The 
numbers at the bottom of the d, , r, a, b . c columns indicate the 
frequency of each type of residue in each column. The maximum 
number of residues in each of these columns was 39, with the exception 
of the d and column starting at positions 838 and 839. These columns 
had 40 residues because they each included one residue of the 
tailpiece. Heptads within each 28-repeat were labelled according to 
convention - heptads 1, 2, 3, and 4. LMM commences between 
residues 1203-1282. 
Two changes to the published ~-MyHC sequence were detected 
(Jaenicke et al., 1990). The first of these was the 81124 substitution. 
This was present in the WAMPD proband 111:2 and all eight tested, 
unrelated, unaffected individuals. It was a homozygous change. The 
second amino acid change to be detected was the A 1663 substitution. 
This segregated with Laing myopathy. It was a heterozygous change. 
Universal, single letter codes were used to designate amino acid residues 
(see also Appendix C). Charged hydrophilic, polar residues: D = aspartic 
acid; E =glutamic acid; H =histidine; K = lysine; A =arginine. Uncharged 
hydrophilic, polar residues: C =cysteine; N =asparagine; Q =glutamine; S = 
serine; T =threonine; Y =tyrosine. Hydrophobic, nonpolar residues: A = 
alanine; F = phenylalanine; G = glycine; I = isoleucine; L = leucine; M = 
methionine; P =proline; W =tryptophan. 
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Second, the distribution of hydrophobic and hydrophilic residues showed 
trends towards the predicted distributions, sometimes matching them quite 
closely, sometimes not so closely. For example, the figures at the bottom of 
position 1 d (column 1 in Table 8.2) show that this heptad position had 33 
hydrophobic and 6 uncharged hydrophilic non-polar residues. This was a close 
approximation to the predicted occupancy for ad heptad position. However, 
Table 8.2 also shows that the other hydrophobic position in heptad 1, 1 a, had 
an amino acid occupancy far closer to that predicted for the b, q and f heptad 
positions. 1 a had 21 charged hydrophilic polar residues, 13 hydrophobic 
residues and 5 uncharged hydrophilic non-polar residues.. Excluding the non-
helical tailpiece, 99 of the 312 a ahd d residues in the {3-MyHC rod are polar 
residues, and 50 of these are charged polar residues. The tendency for 
hydrophobic residues to occupy a and d positions is just that, a tendency. 
From this observation it was possible to make a deduction. The moderate 
stringency with which heptad positions a and d were occupied by hydrophobic 
residues, suggested that heptad positions a and d were subjected to further 
selection force(s), in addition to 'hydrophobic selection'. Lupas (1996, p. 377) 
argues that core polar residues could be partly solvated in dimers, more so than 
in trimers and tetramers, so the presence of higher numbers of core polar 
residues would favour dimerisation. Exactly what is observed in {3-MyHC. 
The third observation to be made from Table 8.2 is that, for each a, b, q d, e, t, 
or g heptad position, the residue occupancy displayed considerable variation. 
This can be observed by comparing the figures at the bottom of all the a 
columns, then all the b columns, and so on. 
The final observation to be made from Table 8.2, is that there are four skip 
residues disrupting both the heptad and 28-residue repeats. The role of skip 
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residues will be considered further when the thick filament assembly is 
discussed in Section 8.5.2 (pp. 268-273). These last two observations 
support the deduction presented above. The variable occupancy for each 
heptad position and the presence of skip residues, both indicate that selection 
forces other than hydrophobic and hydrophilic selection must also be operating 
on the ~-MyHC rod region. The ~-MyHC A 1663P substitution could, 
therefore, potentially affect ~-MyHC function in a variety of ways. 
These four observations and one deduction made from the published and 
derived primary structure of ~-MyHC, did not provide enough information to 
predict why proline was so rare or the effect(s) it might have on ~-MyHC 
dimerisation or thick filament formation. Limited sampling, a lack of proline 
phenotype or the lethality of proline substitution (with WAMPD A 1663P being 
a very rare exception), could all explain why proline had not been identified in 
this section of ~-MyHC. These possibilities could not be discriminated. 
8.2.2 Comparative Arlalysls of MyHC Rod Primary Structure 
Table 8.3 (p. 237) compares the published sequence for the thirtieth 28-
residue repeat in the human ~-MyHC rod sequence to the WAMPD 
sequence, and to the equivalent 28-residue repeat sequences for all MyHCs 
found by a BLAST search based on the complete ~-MyHC rod sequence 
(http://www.ncbi.nlm.nih.gov/BLASTI). The thirtieth 28-residue repeat in the 
human ~-MyHC rod contains the A 1663P segregating with Laing myopathy. 
Apart from the last two entries in Table 8.3, all of the MyHC molecules 
identified by BLAST were muscle MyHCs. This table shows that proline was 
not present in the 30.4g position, the ~-MyHC A 1663P substitution heptad 
position, and it was not present in any of the heptad presented in this table. 
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Table 8.3 Comparison of Number 30 Human {3-MyHC 28-Resldue 
Repeat to Equivalent Regions In other MyHCs. 
The A 1663P substitution segregating with Laing myopathy in the WAMPD 
pedigree lay in the p-MyHC 28-residue repeat number 30, the top 
sequence in the table. The last 20, complete 28-residue repeats of the 
published human p-MyHC sequence (Jaenicke et al., 1990), from 28-
residue repeat number 20 to 39, were entered into BLAST to identify 
homologous sequences and to determine their degree of homology. This 
totalled 563 residues as 3 skip residues were included. The degree of 
homology of each sequence, over these 563 residues, to human ~-MyHC 
was shown in the '%'column. The 'Source' column employed common 
names to identify those organisms whose MyHCs were compared to 
human p-MyHC. The exception was the 'WAMPD' label which identified 
the human p-MyHC 28-residue repeat number 30 segregating with Laing 
myopathy. 
The abbreviations used in the 'Tissue' column to identify the site of MyHC 
expression, were: C for cardiac; S for skeletal; St for striated; Emb tor 
embryonic muscle;St muscle;Sm for smooth; NM for non-muscle. Apart 
from human ~-MyHC, only the first reported site of expression was listed. 
As for Table 8.2 (p. 234), red is used in this table to identify charged 
hydrophilic polar residues, black to identify uncharged hydrophilic polar 
residues, and blue to identify hydrophobic nonpolar residues. Heptad 
repeat positions, d, , f, , a, b, c are coloured to indicate the predicted, 
'most common type of residue' in each position (Sellers,1999, p. 52). 
Positions and do not have an identifiable residue pattern. 
Bolding and a change of FONT identify where residues differ from the 
published human p-MyHC residues (Jaenicke et al., 1990). 
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28f7 Repeat No. 30.1 30.2 30.3 30.4 i 
d f a be d f a be d f a be d f a bc • 
I 
A Q K Q V K S L Q S L L K 0 T Q I Q L D D AV A A N D D• 
Heptad Position 
Human ~MyHC 
I 
COMPARED TO 
• Source I Tissue I% 
A Q K Q V K S L Q S L L K 0 T Q I Q L D 0 A V A A N 0 D Rat 
A Q K Q V K S L Q S L L K D T Q I Q L D 0 A V A A N D D Hamster 
A Q K Q V K S L Q S L L K 0 T Q I Q L D 0 A V ~ N 0 D WAMPD 
A Q K Q V K S L Q S L L K D T Q I Q L D D A V A A N 0 D Pig 
A Q K Q V K S L Q S L L K D T Q I Q L D D A V A A N D D Human 
c 100 
c 99 
C&S 99 
c 98 
C&S 97 
A Q K H L K N L Q S L L K 0 T Q l Q L D D A V A A N 0 D Rat C 94 
A Q K H l K N L Q S L L K 0 T Q L Q L D D A L H A N D 0 Hamster C 93 
A Q K H l K N L Q S L L K 0 T Q l Q L 0 0 A V H A N 0 D Mouse C 92 
A Q K N L R N T Q G V L K D T Q I H L D 0 A L A S Q E 0 Chicken 5 75 
A Q K N L R NT Q G T L K 0 T Q I H L D D A L R T Q E D Chicken 5 74 
S L R N Y R N T Q G I L K t.. T Q L H L 0 D A L A G Q E D Human 5 71 
A I K N L R N T Q G I L K D T Q L H L 0 D A V A G Q D D Rabbit 5 71 
T I K H l R S V Q G Q L K D T Q L H L D D A L A G Q E 0 Rat 5 70 
T L K H L R S V Q G Q L K D T Q L H L D D A L A G Q E D Human 5 70 
0 L R N Y Q N T Q A I L K 0 T Q L H L D D A L R S Q E D Human 5 70 
A T K S A R G L Q T Q I K E L Q V Q L D D l G H L N E D Chicken 
A Q K N I K R Y Q Q Q L K D I Q T A L E E E Q A A R 0 D Fruit Fly 
S Q K Q M K K L Q A Q I K E L Q S M I D D E S A G R D 0 Hydra 
c 67 
Emb 52 
5t 47 
A Q K T I K K Y M E T V Q E L Q F Q I E E E Q A Q K 0 E Nematode 5t 45 
M E K T V K R Y Q Q Q I R E M Q T S I E E E Q A Q R D E Scallop 5t 44 
A Q K N L K R Y Q E Q V R E L Q L Q V E E E Q A N G A D Nematode 5t 42 
A Q K N L K K L F 0 Q V K E L Q G Q V D D E Q A R R E E Nematode Sf 40 
A I K Q L R K L Q A Q M K D Y Q R 0 L D D A R A A R E E Chicken Sm 35 
A I K Q L l K l Q A Q M K D F Q R E L E D A R A S R 0 E Rabbit Sm 34 
A I K Q L R K L Q A Q M K 0 F Q R E L E 0 A R A S R 0 E Human 
R V K Q L R R L Q A Q M K 0 Y Q R E L E E A R G S R D E Rabbit 
V K Q L R K L Q A Q M K 0 Y Q R E L E E A R A S R 0 E Human 
d f 11 s bc d f ., s bc d t g a bc d t 11 s bc 
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Sm 34 
NM 33 
NM 30 
An examination of the entire rod sequences of all of these MyHC failed to 
identify a single proline residue within their rod region. All rods started with a 
capping proline, and proline was sometimes present at the end of the a.-helical 
region, marking the start of a non-helical tailpiece For example, nematode 
MyHC had a proline starting its tailpiece and another within this tailpiece 
(McLachlan & Karn, 1982, p. 228). 
The comparative analysis of MyHC rod regions strengthened the case against 
proline. .Its complete absence within these rod regions implies that its presence 
is not advantageous. High conservation of a region indicates selection rigour. 
From Table 8.3 it can be seen that position 30.3e was 100% conserved and 
therefore presumably under strong selection. With eight different residues 
occupying position 30.4g, the position containing the A 1663P substitution, 
30.4g is not as conserved as 30.3e. Position 30.4g was, however, conserved 
until chicken skeletal muscle MyHC, where serine is substituted for alanine. This 
chicken skeletal muscle MyHC had only 73% homology to human ~-MyHC 
over the 563 residues compared. 
The MyHC phase shifts caused by skip residues are also highly conserved. 
Skip residues distort the electrostatic charge pattern determined by the 28-
residue repeats. The nematode MyHC rod has skip residues in the same 
positions as the human skip residues. The only difference between nematode 
and human MyHC skip residues is in the first skip residue, which, in the 
nematode, is the uncharged polar residue glutamine (McLachlan & Karn, p. 
228). In humans, the uncharged polar residue threonine occupies the first skip 
residue position (Table 8.2, p. 234). 
From the data shown in Table 8.3, and from this discussion of that data, it follows 
that the ~-MyHC A 1663P substitution occurs in a highly conserved region of a 
highly conserved molecule. The absence of proline within the rod regions of all 
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MyHCs and the high degree of conservation of the MyHCs, particularly over 
the region containing the A 1663P substitution in human ~-MyHC, further 
indicates that proline within the rod region is not advantageous. In fact, the 
supposition that proline could be deleterious to the structure and functioning of 
the MyHC rod region, now appear tenable. 
8.3 SECONDARY STRUCTURE OF THE ~-MyHC ROD 
The secondary structure of a protein has been traditionally defined as the folding 
of amino acid chain into motifs such as a.-helices, ~-pleated sheets, loops, or 
random coils. The fundamental secondary structure of the MyHC rod region is 
the a.-helix, a structure first proposed by Pauling and Corey (1951) to explain 
the X-ray diffraction patterns obtained for a.-keratin (cited in Crick, 1953, p. 689). 
8.3.1 The a.-helix: Structure, Direction and Sense of Twist 
The a.-helix involves the formation of a rigid cylinder. The structure is dominated 
by hydrogen bonding between carbonyl oxygens and the hydrogen atoms of 
the amino nitrogen. Stabilising hydrogen bonds form between carbonyl 
oxygens and amino nitrogen hydrogens in peptide bonds separated by three 
amino acids. That is, hydrogen bonds form between every fourth peptide 
bond. Consecutive a.-carbons and peptide linkages follow a regular spiral path, 
producing an a.-helix with 3.6 residues per turn. Amino acid side chains extend 
outwards from the axis of the spiral. 
Figure 8.4 (p. 240) presents a short segment of a polypeptide a.-helix. 
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Figure 8.4 Section of a right-handed polypeptide a-helix. It has 
3.6 residues per a-helix turn. Dashed lines identify stabilising hydrogen 
bonds between carbonyl oxygens and hydrogen atoms of amino 
nitrogens. Scanned from Kleinsmith and Kish (1995, p. 24). 
Crick (1953) first noted that four types of a-helix were possible, each 
described by its sense of twist, right-handed or left-handed, and by its direction, 
up or down. The sense of twist or 'handedness' of an a-helix and its direction 
are integral, unchanging properties of each helix. Right-handed a -helices 
always turn in a clockwise direction along their axis. Visually, they appear to 
spiral in a clockwise manner when viewed, from either end, along the direction of 
the main chain carbon atom sequence. Left-handed a-helices always spiral in 
an anti-clockwise direction along their axis, irrespective of viewing 'end'. 
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8.3.2 Proline the a-helix Breaker: Rigid-Geometry Analysis 
Proline is unique among the 20 naturally occurring amino acids in mammalian 
systems in that its side chain cyclizes back to the backbone amide/amino 
nitrogen, leaving one of its dihedral angles (t/1) fixed at approximately -65° 
(MacArthur & Thornton, 1991, p. 398). Two dihedral angles, 4J and 1/J, are called 
the main chain torsion angles and they measure the angle that the Ca-C~ bond 
makes to adjacent Ca-Ca vectors (diagrammed in Figure 8.3, p. 232). 
Rigid-geometry analysis of proline within a-helices assumes that all bond 
lengths and bond angles have fixed, ideal values and that a-helices are always 
regular (Weiner et al., 1986). Rigid-geometry calculations show that proline is 
detrimental to the a-helical conformation for three reasons. First, proline lacks an 
amide proton to form an a-helix stabilising intramolecular hydrogen bond with 
the carbonyl oxygen of a peptide bond located three amino acids away 
(Williams & Deber, 1991 ). Figure 8.5 (p. 242) identifies this and another 'lost' 
hydrogen bond. 
Second, the bulkiness of its pyrrolidine ring. places steric constraints on the 
conformation of the preceding residue in the a-helix. Schimmel and Florey 
(1968) cited in MacArthur and Thornton (1991, p. 401) showed that the space 
available to the preceding residue was severely curtailed by steric conflicts 
between the C/3H2 attached to the pyrrolidine amino nitrogen and the C6H2 of 
the preceding residue, and between this sameC/JH2 and NH amide group in 
the peptide bond joining the two preceding residues. Figure 8.6 diagrams 
steric clashes caused by proline residues. 
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Proe/3 
Figure 8.5 Molecular model of proline in a polypeptide a.-helix. 
The bonds of proline's pyrrolidine ring are coloured blue, 'lost' hydrogen 
bonds are indicated by red lines, and existing hydrogen bonds by 
broken lines. The section of a.-helix illustrated, shows residues 83-89 in 
myoglobin. Oxygen atoms are shown as stippled ellipses, nitrogen 
atoms as filled ellipses and carbon atoms as unshaded ellipses. Scanned 
from Barlow and Thornton (1988, p. 613), then coloured. 
The lack of a hydrogen bond involving the amino nitrogen of P88 is, as 
discussed, due to a lack of a proton on this nitrogen. The lack of a hydrogen 
bond involving the amino hydrogen of L89, is due to a steric effect of P88 (see 
Figure 8.5, p. 243). The second hydrogen bond is 'lost' because P88 forces a 
4.1 A gap between the L89 amide hydrogen and the N-terminal carbonyl 
oxygen four peptide bonds away. 4.1 A is longer than hydrogen bond range. 
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Figure 8.6 Steric clashes between the proline CtJH2 group and 
preceding C 6H2 and NH groups. Clashes between the proline residue 
C 6 and both the Cf3 and amide nitrogen of the preceding residue are 
shown by red lines. i = ca of proline; (i-1) = ca of residue preceding 
proline; C a_c a vectors shown as == ; • ca ; C-carbonyl; N-
amide; pyrrolidine bonds are shown in blue. Note that part of the ca-C a 
vector is also part of the pyrrolidine ring. Black and white version scanned 
from MacArthur and Thornton (1991, p. 401 ), then coloured. 
Proline is also detrimental to the a-helical conformation because, as a secondary 
amide, proline is a 'relatively polar' non-polar residue (its classification). As such, 
it forms strong hydrogen bonds with neighbouring amino acid residues, causing 
structural instability of a-helix segments. A multiplicity of local conformations 
become possible (Debar at al., 1990, p. 155). 
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Because of their importance to the final conformation and functioning of proteins, 
steric interactions between amino acids in polypeptides have been examined 
extensively. One further rigid geometry analysis is considered here, the 
conformation adopted by amino acid side chains. Ramachandran and 
Lakshminarayanan (1966) established that amino acid side chains could adopt 
one of two minimum energy conformations, the a-conformation or the {3-
conformation. Zimmerman et al. (1977) employed the Empirical 
Conformational Energy Program for Peptides to refine amino acid conformation 
classification by including side chain bond angles, intramolecular hydrogen 
bonds, entropy states and intrinsic torsional potentials as conformation 
determinants. Thomasson and Applequist (1990) described the a- and {3-
conformations adopted by the pyrrolidine ring of proline as the puckered 'up' 
and the puckered 'down' conformations. 
Summers and Karplus (1990) calculated that the a-conformation of a residue 
preceding a proline was 7 kcallmol less favourable than the {3-conformation. 
Since the a- and {3-conformations are found equally among known protein 
sequences, this meant that, not only were two hydrogen bonds missing with 
proline substitutions in a-helices, but that in approximately half such events an 
extra 7 kcallmol a-helix destabilisation energy was involved. 
MacArthur and Thornton (1991, p. 401) summarised the prevailing 'rigid-
geometry' view of proline within a-helices, "These conformational constraints on 
residues preceding proline have a most important consequence. Location 
within an a-helix is in theory impossible, not just because of the lack of 
hydrogen bonds but also because of this steric constraint''. It was largely the 
calculations of Schimmel and Florey (1968) that established the, "widespread 
belief that proline residues act as a-helix 'breakers'." (Barlow & Thornton, 1988, 
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p. 612). Proline residues were seen to cause an unacceptable disruption to a-
helix hydrogen bonding and to the packing of side chains. 
Rigid-geometry calculations conveniently explained the apparent lack of proline 
in the centre of periodic secondary structures such as the a-helix or ~-pleated 
sheet. When proline did occur in a-helices, it was usually located in the first turn, 
acting as an N-capping residue, marking the start of the main chain hydrogen 
bonds that characterise the a-helix (Richardson et al., 1988, p. 1650). 
8.3.3 The Validity of Rigid-Geometry Calculations 
Observations have subsequently shown that proline does occur within a-
helices (Barlow & Thornton, 1988; Kumar & Bansal, 1996). The presence of 
proline in a-helices was sufficient for these and other workers to reappraise the 
doctrine of 'proline the a-helix breaker' as developed from rigid-geometry 
calculations. Two rigid-geometry tenets came under scrutiny: that all bond 
lengths and bond angles have fixed, ideal values; and that a-helices are always 
regular. 
Hurley et al. (1992) challenged the notion that all bond lengths and bond angles 
have fixed, ideal values. They reconsidered the energy calculations of 
Summers and Karplus (1990) using flexible-geometry, which differed from 
rigid-geometry only in that bond lengths and angles were allowed to relax to the 
nearest energy minimum. The main chain torsion angles, tfJ and 'f/J and the 
conformation of residues were not fixed or independent of adjacent residues. 
The flexible-geometry calculations of Hurley et al. (1992. p. 1444), found that 
the energy cost of a residue in a-conformation preceding a proline was only 1.1 
kcal/mol, not the 7 kcal/mol determined by Summers and Karplus (1990). 
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Barlow and Thornton (1988, pp. 606-612) challenged the second tenet of rigid-
geometry, that all a-helices were regular. These authors analysed 48 a-helices 
in globular proteins and calculated the axis of each helix using a purpose built 
computer program HBEND. Twenty-eight (58.3%) of these a-helices were 
curved, seven (14.6%) were linear, five (10.4%) were malformed throughout 
their length and eight (16.7%) were kinked. For curved helices, their radius of 
curvature was approximately 60 A, corresponding to a deviation of about 1 ° of 
arc per residue from the arc defined by a linear a-helix. Figure 8.7 (p. 247) 
shows the curvature of an a-helix. The energy penalty calculated for a curvature 
deviation of one arc degree. per residue was approximately 0.1 
kilocalories/mole/residue, equivalent to 0.4184 Joules/mole/residue This 
penalty was so small that Barlow and Thornton {p. 616) considered that it could: 
account for the predominance of curved helices ... 
Although the perturbation required to cause curvature of 
the helix are small at the level of the individual residues, 
they can be greatly amplified in a long helix. . . . Thus 
the relative positions of the side-chains in a curved a-
helix, are quite different from those in a linear helix. This 
may be of benefit during protein evolution, since 
mutations that lead to changes in side-chain volume can 
be accommodated by minor changes in the main chain 
conformation e.g. a linear helix may become curved (or 
a curved helix, more curved) in order to preserve an 
optimal packing of side-chains. 
I 
r 
MacArthur and Thornton (1991, pp. 398-399) identified three further 
mechanisms operating at the secondary level of protein structure, that could 
attenuate the 'a-helix-breaking' reputation of proline located within a-helices. 
Proline isomerization, a- and /}-conformation of residues, and the presence of 
proline-stabilising hydrogen bonds. 
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Figure 8.7 A curved helix involving residues 14 to 32 in avian 
pancreatic polypeptide. The axis generated b¥ HBEND program is 
represented by a series of broken lines joining consecutive axis points 
which are shown as pluses (+). Main-chain Ca atoms are shown as 
filled circles. Scanned from Barlow and Thornton (1988, p. 601 ). 
In proteins, isomerization is measured relative to precedingr~ amino acid 
conformation. With the exception ~f proline, the frequency of cis-amino acid 
isomers in globular proteins is <0.001 (Brandts et al., 1975). Descriptively, the 
cis-configuration means that the side chains of adjacent amino acids lie on the 
same side of the Ca-Ca vector joining them. Proline adopts the cis-isomer of 
the preceding peptide bond with a frequency of 0.057 (58/1021), 57 times 
more frequently than any other amino acid (MacArthur & Thornton, 1991, p. 
400). However, out of the 166 a-helices containing proline, only two pralines 
adopted the cis-configuration. Both of these pralines were the third residue in 
their respective a-helix, P89 in cytochrome P450 and P131 in malate 
dehydrogenase (MacArthur & Thornton, 1991, p.407). Within a-helices, 
therefore, proline almost always adopts the trans-configuration. 
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These authors also noted that the a- or p-conformation adopted by proline in an 
a-helix was influenced by the nature of the preceding residue. For example, 
when arginine was the preceding residue (as is the case for the A1663P 
substitution in (3-MyHC), the proline conformational ratio was 24 a-conformation: 
76 p-conformation. The p-conformation was three times more likely than the a-
conformation. Chothia (1984) had earlier suggested that the pressures on an a-
helix that arise from packing effects could be relieved by changes in side chain 
conformation of all residues. Selectively adopting the a- or p-conformation was 
\ a general phenomenon, but one which could help a-helices accommodate 
proline residues. 
Finally, MacArthur and Thornton (p. 401) pointed out that the steric conflicts 
between the c<>H2 attached to the pyrrolidine amide nitrogen and the Cf3H2 in 
the preceding residue and also between the NH of the peptide bond 
connecting the two preceding residues (Figure 8.6, p. 243), "may be stabilised 
by hydrogen bonding to either the amide of residue X(i-1) [the residue 
preceding proline] or the carbonyl of .residue (i-2)". 
The theoretical analyses of proline in a-helices by B~rlow and Thornton (1988), 
/ 
', 
MacArthur and Thornton (1991 ), Chothia (1984) and Hurley et al. (1992), 
i 
identified mechanisms by which proline within a-helices might not cause the 
level of distortion predicted by rigid-geometry analysis. An examination of the 
observed secondary structure of a-helices containing internal proline will now be 
used to test the accuracy of these analyses. 
8. 3. 4 Secondary Structure of a-helices with Internal Proline 
Fibrous proteins like myosin II are only a tiny fraction of all proteins. They do not 
function as monomers in vivo. Fibrous protein monomers are very long and 
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always aggregate to form dimers, trimers, tetramers or pentamers, (Lupas, 
1996, p. 375). Therefore, the conformation of each constituent a-helix is, in 
part, a function of aggregation/quaternary structure. This makes it impossible to 
determine the effect of proline substitutions on secondary structure. Proline 
does, however, exist in 'monomer' sections of a-helices within globular 
proteins. The effect of internal proline on the secondary structure of globular 
protein a-helices was examined, therefore, as 'the best available option'. The 
major differences between globular and fibrous proteins are the obvious 
\ difference in length and the decreased solubility of fibrous proteins. Protein 
solubility decreases with size. 
In a survey of 291 a-helices in 57 proteins, Barlow and Thornton (1988, p. 
612-614) discovered ten internal pralines. They found that proline only 
occurred in relatively long helical sections of mean length of greater than 5 turns. 
These authors concluded that proline had been selected to kink the helix. They 
based this conclusion on the fact that the a-helices were all kinked in the vicinity 
of the proline, that these proline were highly conserved, and that they lay within 
sequences which had no common pattern. Each of these a-helices was kinked 
because of the presence of the proline, and on)y because of the proline. 
Barlow and Thornton (1988, pp. 616-618) also noted that proline-induced kinks 
occurred near residues close to active sites, from which they developed a list of 
proposed functions for proline-induced kinks. All of the functions they identified 
caused only very local effects. Of interest to this project was the Barlow and 
Thornton proviso (p. 618) that, "The kinks that are caused by proline residues 
are tolerated only by long helices that are packed against several other 
secondary structures". The myosin rod is extremely long and fits the description 
of being 'packed against several other secondary structures' extremely well. 
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More proline residues have been uncovered in globular proteins since the work 
of Barlow and Thornton. Kumar and Bansal (1998) analysed 205 non-
homologous globular proteins whose three-dimensional structures had been 
solved by X-ray crystallography. These authors identified 1131 non-identical 
a-helical sequences of 9 or more amino acid residues, the minimum helix length 
required by their helix analysing program, HELANAL (Kumar & Bansal, 1996). 
HELANAL identified a total of 45 kinks in the 1131 a-helical regions. 
~ Significantly, 25 of these 45 kinks were caused by the presence of proline, 
which created an average kink angle of 32° ± 8°, with a range of 17°-58°. The 
kink angle was calculated as the angle between the least-squares lines, fitted to 
the local helix fragments before and after the region of kink. On average, two 
main-chain hydrogen bonds were 'lost' in proline-induced a-helical kinks (Kumar 
& Bansal, 1998, pp. 1937-1940). 'Lost' hydrogen bonds in proline-induced 
kinks were identified in Figure 8.5 (p. 242). The average proline kink angle of 
320±80 determined by Kumar and Bansal agreed with an earlier estimate of 
260±5o by Barlow and Thornton (f988, p. 612-613) who commented: 
I 
The conformational changes that take place to 
accommodate proline vary from one structure to 
another. In most cases the changes are relatively minor, 
so that all residues retain the t/J/lp angles appropriate for 
a right-handed helix. . . . All ten of the helices show 
surprisingly little disruption of the hydrogen bonding. 
The average len,gth of the ten proline-containing a-helices identified by Barlow 
and Thornton, was 19.9 residues with proline positioned, on average, 10.5 
residues from the start of the helical region. These were, therefore, relatively 
short a-helices with truly internal pralines. 
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In comparison, the ~-MyHC a.-helical rod contains 1096 residues. It is 
remarkable that even in the short a.-helical regions described by Barlow and 
Thornton and Kumar and Bansal, the degree of distortion caused by internal 
proline is relatively small. Distortion to an a.-helix caused by proline is illustrated 
in Figure 8.8. 
Figure 8.8 A schematic diagram showing how the a.-
helical kink angle ( fJ) is defined. The a.-helix is represented by a 
broken cylinder, and the axes, or 'least-squares lines' of the N-
and C-terminal 'halves' are shown as blue lines. The analysis of 
globular protein a.-helical regions containing internal proline, 
indicates that proline residues introduce only moderate kinks. 
Redrawn from Barlow and Thornton (1988, p. 613). 
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8.4 QUATERNARY STRUCTURE OF MYOSIN II 
The quaternary structure of myosin II is the complete three-dimensional folding 
pattern of the two MyHC polypeptides, the two essential light chains and the 
two regulatory polypeptides. The rod section of myosin II comprises two J3-
MyHC molecules wound together in a coiled-coil dimer superhelix. Figure 8.1 
(p. 219) is a two dimensional representation of the six polypeptides in a 
myosin II molecule. It shows the coiled-coil section of myosin II. 
\ The coiled-coil structure was first proposed by Crick (1952, p. 882; 1953, p. 
689) when he noticed that some characteristics of the a-keratin X-ray diffraction 
pattern did not agree with that calculated for a perfect a-helix. In particular, the 
presence of meridional arcs at spacings of about 5. 15 Angstroms (A) 
disagreed with a predicted a-helix intensity of zero. To explain the observed 
5.15 A meridional arcs of the a-keratin X-ray diffraction pattern, Crick (1952) 
suggested that the a-keratin might be deformed so that two identical keratin a-
- -~ I 
helices could wind round eacl) 6ther to form an a-keratin dimer in the form of a 
coiled-coil. 
8.4.1 Deformed a-helices and Coiled-Coils 
Deformation of a-helices was necessary because the coiled-coil structure 
proposed by Crick required the regular meshing of the amino acid side chains of 
each a-helix as they wound around each other. In the perfect a-helix, the 
position of amino acid side chains repeat only every 18 residues, or after 5 turns 
(5 X 3.6 = 18). Although two keratin a-helices start by meshing their side 
chains, this would not continue for long. To avoid separation of a-helices, side 
chains must occupy equivalent positions turn after turn after turn. This was an 
impossibility for perfect, undistorted, 3.6 residues per turn a-helices. 
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Crick (1953, pp.690-691) developed the basic coiled-coil packing scheme for 
two a-helices of the same sense and direction. Starting with an idealised a-
helix, with side chains of uniform size and shape: 
Let us pretend that we wrap around it at a radius of 
about 5 A, a cylinder of paper, and mark on the paper 
the point where each side chain comes. We then open 
the paper until it is flat again, and examine the pattern 
we have drawn. . . . Let us do the same thing for a 
second a-helix. Naturally we get the same pattern as 
before. If we now try to pack our two helices together, 
the two pieces of paper will come into contact, and the 
condition that the knobs of one helix fall between the 
knobs of the other is equivalent to saying that where 
the two pieces of paper are in contact - or nearly in 
contact - the marks on one must fall between the marks 
on the other. If we do this with the two bits of paper 
opened out flat, however, we must turn one of them 
over before we superimpose them, since the 'outside' 
of both sheets must come into contact. It is 
immediately 'found that we can only do this in one way 
if the chains are to be approximately parallel. 
' 
Figure 8.9 (p. 254) i.llustrates how the two pages have to be aligned 
(deformed) so that the knobs on one a-helix (marked as crosses) fall between 
the knobs on the second a-helix (marked as circles). Crick (1953) calculated 
that a left-handed twist to right handed a-helices, would reduce the number of 
residues per a-helical turn to 3.5, and allow the position of side chains to repeat 
after two turns (or seven residues). 
The deformation angle shown in Figure 8.9 represented (in two dimensions) the 
left-handed twist to right handed a-helices necessary for the formation of left-
handed coiled-coils. 
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0 l( 
0 
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Figure 8.9 The pattern formed by the side chains of two 
superimposed a-helices. Side chains are marked on two separate 
pieces of paper wrapped around each a-helix. In this 
representation, the side chains of the a-helix are marked with orange 
crosses on one piece of 'wrapping' paper, and with green circles on 
the other piece of 'wrapping' paper. The pages are arranged so that 
when helices come into contact, the side chains of one a-helix fall 
between those of the other. Redrawn from Crick (1953, p. 691 ). 
Residues are about 5A apart. Crick (1952, p. 882) calculated that the 
necessary deformation required little energy, approximately 0.1 
kilocalories/mole/residue (0.4184 J), and speculated that the driving force 
behind a-helical deformation and coiled-coil assembly might simply be the 
need to remove apolar residues from the aqueous medium. In support, Crick 
(1953, p. 696) cites an analysis of tropomyosin (Bailey, 1948) which showed 
that hydrophobic alanine, valine and leucine made up 0.29 (-2!1) of the total 
tropomyosin residues. This was consistent with, but did not prove, Crick's 
deduction that the apolar residues in coiled-coils occurred at intervals of 3.5 
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residues, always pointed inwards, and fitted like 'knobs-into-holes' between the 
'core' apolar residues on the other a-helical strand(s) of the coiled-coil (Crick, 
1952, p. 882). Fifty years later, it is known that all dimer coiled-coils like those 
found in the MyHCs are left-handed superhelices, winding around each other in 
the opposite direction to their constituent right handed helices (Lupas, 1996, p. 
379). Crick's coiled-coil analysis was correct. Figure 8.10 shows a 
representation of a coiled-coil dimer. 
Figure 8.10 Two right-handed a-helices forming a left-handed, 
coiled-coil superhelix. Note that each a-helix turns in a clockwise direction 
while winding around the other in an anti-clockwise direction. Crick (1953) 
proposed that the hydrophobic side chains, shown here in blue, were 
positioned such that they would form hydrophobic cores in the centre of 
coiled-coils as the two a-helices wrapped around each other. An orange 
and green hetero-dimer is shown (to match the colours used in Figure 
8.9). The MyHCs form homo-dimers, built from two identical monomer 
helices. Scanned and modified from Alberts et al. (1994, p. 125). 
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Coiled-coils can comprise two, three, four, or (rarely) five strands (Lupas, 1996, 
p.375). Coiled-coils have two geometries: the geometry of the constituent a-
helices and the geometry of the whole, called a superhelix. Figure 8.11 shows 
the global parameters of the two-stranded superhelix. The values of pitch, the 
pitch angle and crossing angle shown in this . figure, follow directly from the 
distortion necessary to achieve the critical coiled-coil 3.5 residue repeat. 
,.__ _____ Pitch _____ ___.. 
Pitch (or supercoil) angle Helix crossing angle 
I 
Figure 8.11 z The global parameters of a two stranded 
coiled-coil. Pitch, is the distance that the superhelix takes to 
complete a full turn; pitch angle the angle that each helix assumes 
·, \ 
relative to the superhelix axis; and crossing angle is the angle 
between two neighbouring helices. Scanned and modified from 
Lupas, 1996 ( p. 378). 
The a-helices of almost all natural proteins are right-handed (Wolfe, 1993, p. 
63). The two a-helices comprising the MyHC rod are right-handed and 
deformed in accordance with Crick's calculations, to form a dimer coiled-coil 
(Brown et al., 1996 p. 136). 
8.4.2 MyHC Dimerisation Geometry: Heptad Repeats 
The characteristic, 7-residue repeating pattern, a-b-o-d-e-f-g (see p. 233), in 
which hydrophobic residues are concentrated at intervals of 3 and 4 residues at 
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positions a and d was first clearly identified by Mclachlan and Karn (1982, 
p.227). Although Crick had articulated this possibility thirty years earlier, the 
structure of sufficient a-helical coiled-coil proteins had to be determined before a 
clear pattern was established. The structure of the coiled-coil domains in 
tropomyosin, fibrinogen, a -keratin and nematode MyHC provided proof that 
the heptad repeat was the basic unit of the a -helices that formed coiled-coil. In 
globular proteins a-helices do not have heptad repeats. Figure 8.12 presents 
a transverse view through two a-helical turns of a coiled-coil dimer. This is 
known as a heptad wheel representation. 
Figure 8.12 Two heptad wheels showing the sequence motif of an 
a-helical, coiled-coil dimer. This representation descends into the page 
from position a. Note the clockwise arrangement of the heptad letters 
characteristic of right-handed helices. The letters a to g mark positions 
along the a-helix. Positions a and d are typically occupied by 
hydrophobic residues and constitute the core of the coiled-coil dimer. 
Positions b , c and r constitute the 'outer' surface of the coiled-coil dimer 
and are typically occupied by polar hydrophilic residues, which are 
often charged. 
Figure 8.13 (p. 258) adds the essential features of the a-helical heptad repeat 
to Crick's model for two interacting deformed a-helices. 
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Figure 8.13 Crick's a-helical, coiled-coil dimer with heptad 
repeats. The conventional a to g letters of the a -helical heptad 
repeat replace the crosses and circles used in Figure 8.9 (p. 254). 
Twenty-eight residues in one helix are numbered to show 
handedness and direction. This figure reveals that Crick (1953, p. 
691) plotted the residues of a left-handed, descending a-helix. 
The advantage of replacing the crosses and circles used by Crick with heptad 
letters is that it shows which knobs fit into which holes. Clearly, knobs on one 
a-helix fit into dgda holes on the other a-helix (reading clockwise from the top), 
while a knobs on the other a-helix fit into « 7t.1 holes on the first helix (reading 
anti-clockwise from the top); similarly and d knobs fit into adae and d~r holes 
on their partner a-helix. Figure 8.14 also demonstrates this phenomenon, but 
on the now commonly used helix-net diagram. 
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a-helix direction 
« clockwise 
~ sense of twist 
Right-handed helix 
Figure 8.14 Helix-net representation of dimer coiled-coil interactions. 
The green circles in this helix-net diagram represent two 28-residues 
repeats. The orange circles identify its dimer partner and show where these 
two a-helices come into contact at core residues. Heptad repeat positions 
are indicated within these circles. Red letters identify 'hydrophilic' surface 
residues, blue letters identify 'hydrophobic' core residues while purple 
letters identify residues lying between the core and the surface. Numbers 
are included to indicate direction and handedness. In agreement with the 
modified Crick representation shown in Figure 8.13 (p. 258), a knobs fit into 
dgda holes and d knobs fit into adae holes in their partner helix. 
8.4.3 A1663P Distorts Perpendicular and Parallel Geometry 
The ~-MyHC A 1663P substitution distorts the a-helix in which it lies by altering 
the geometry of dimerisation. Table 8.2 (p. 233) shows that the ~-MyHC 
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A1663P substitution occurs in position gin heptad 30.4. This position was part 
of a dgda hole into which fitted an a knob from its dimer partner. Not only was 
the geometry of this hole altered, but the geometry of the a knob adjacent to 
position 30.4g was also altered by the ~-MyHC A 1663P substitution. 
Figure 8.15 presents an cross-sectional view of the geometry for the MyHC 
dimer coiled-coil. 
Parallel 
a-layer 
'top' a-knob azimuthal arc of -carbon 
atoms in the a -helix 
Perpendicular 
d-layer 
'top' d-knob 
l " 
'bottom' a-hole Ca-Ca. vector 'bottom' d-hole Ca -Ca vector 
Figure 8.15 Cross-sectional view of amino acid side chain 
interactions in the hydrophobic core of a coiled-coil dimer. The packing 
of dimer coiled coils is such that a-layers and d-layers alternate along 
their length. 
In two-stranded coiled-coils, the Ca-C~ bond of an a core residue is parallel to 
the Ca-Ca vector at the bottom of the facing hole, but at right angles to theCa-
C ~ bond of a d core. Residues and holes are described in relation to the 
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alignment of carbon atoms in amino acids, numbered a for the centre carbon 
atom and (3, y, 6 and e as shown in Figure 8.3 {p. 232). 
Selection will favour the most appropriate amino acids in positions d and a. 
Therefore the perpendicular geometry of the d position should favour leucine, 
but not isoleucine, while parallel geometry of the a position should favour 
isoleucine (Harbury et al., 1994). 
An inspection of the amino acid sequence determined for WAMPD Laing 
\ . 
myopathy proband, 111.2. in Table 8.2 {p. 234) reveals that the d-heptad 
position was occupied by 66 leucines and 4 isoleucines. Given the 
perpendicular side chain g99metry of leucine, and therefore its penchant for 
perpendicular holes, the pre~onderance of leucine in the d-heptad position of 
the (3-MyHC rod, agreed with that predicted by knobs-into-holes geometry. 
I 
On the other hand, the a-heptad position of the (3-MyHC rod was occupied by 
15 isoleucines and 45 leucines, only showing a trend towards the occupancy 
predicted by knobs-into-holes geometry. Since the (3-MyHC A 1663P 
substitution is in a g position, proline steric clash will disrupt the adjacent a knob 
'parallel geometry'. In addition, it will disrupt the geometry of the 'a accepting' 
dgda holes, which contain the altered g position. How serious this disruption is, 
depends on the importance of local knob and hole geometry to the functioning 
of the myosin II hexamer. There are 312 knobs-into-holes interactions in the 
myosin II rod. The low isoleucine occupancy of a-heptad positions in the (3-
MyHC rod, and the uncharged hydrophilic, polar residue R in hydrophobic 
30.4a position (residue 1664), suggest relaxed parallel-geometry selection at a 
positions, and specifically at 30.4a. Distortion caused by J3-MyHC P1663 may 
be better tolerated at 30.4a than in other positions. 
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8.4.4 Proline Effect on MyHC Dlmerisatlon: COILS Analysis 
The effect of proline on the ability of MyHC monomers to form multicoil-dimers 
was analysed using the COILS program, version 2.2 with MTK matrix (Russell 
& Lupas, 1999). The COILS program, takes into account the residue 
distribution in known coiled-coils to evaluate submitted sequences. It relies on 
determined sequence profiles. Table 8.4 (p.263) presents the results of 
COILS analysis for five peptide sequences. The legend for this table explains 
how to interpret COl LS results and the factors used to select peptides for 
comparison. 
There was one further consideration, relevant to the interpretation of COILS 
results. Window size 14 was the best window size for identifying local 
discontinuities, as the status of each residue contributed one fourteenth of the 
total to determination of probabilities. However, window size 14 was 
confounded by the fact that COILS prediction reliability decreases strongly with 
decreasing window size. The combined effects of lower statistical significance of 
smaller samples and the increasing number of packing options for shorter 
peptides, even for those with excellent coiled-coil forming potential, means that, 
"reliable coiled-coil predictions could only be made from 14-residue window if a 
coiled-coil was consistently predicted in a family of divergent sequences with 
less than 50% identity'' (Lupas, 1996, p. 377). Larger window size reduced 
this problem, but necessarily diminished the effect of individual residues and, 
therefore, of individual sequence alterations. 
Comparison of human ~-MyHC to fruit fly MyHC-A (with 52% homology) 
showed their quaternary structures both to be dominated by coiled-coil dimers 
over the entered sequences. The same pattern of coiled-coil dimer also 
characterised human SMMyHC, which had only 33.1% homology. 
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Table 8.4 COILS Analysis of Polypeptides with Varying 
Degrees of Homology to Human {3-MyHC. 
Results of the COILS program (Russell & Lupas, 1999) were compared 
from residue 1635M to 1691V for five proteins over the published human 
~-MyHC sequence (Jaenicke et al., 1990). This included 28 residues on 
either side of the ~-MyHC residue of interest, 1663. To avoid spurious 
low coiled-coil probabilities at either end of this sequence, the actual 
sequence entered into COILS ran from residue 1583 to 1750 in human p-
MyHC and over the equivalent 168 residues (6 X 28-residue repeats) in 
the other proteins. The degree of homology between each sequence and 
human ~-MyHC, was also determined from a comparison of these 168 
residue sequences. 
The sequences compared were: wild type ~-MyHC (P12883 - SwissProt 
Accession Number); WAMPD A1663P ~-MyHC; fruit fly (Drosophila 
melanogaster) embryonic muscle MyHC-A (P05661); human smooth 
muscle SMMyHC (P35749); and human centromeric protein-E. CENP-E 
(002224) . 
Row 2 presents the homology of each of these proteins to human p-
MyHC. They were selected for comparison to human p-MyHC because 
the first three of these proteins were all muscle MyHCs, with the third, 
SMMyHC, having the lowest homology to ~-MyHC of all the human 
MyHCs. CENP-E was selected as the 'highest homology to ~-MyHC' 
protein that contained a naturally selected proline, designated as . 
In its analyses, COILS used the 3 different window sizes of , 21 and 28 
adjacent residues. Limitations and advantages of window size are 
considered in the text. This table presents the probabilities of a residue 
forming a multicoil-dimer based on their status, the status of adjacent 
residues and as a function of window size. Probabilities were presented on 
a scale of 1 to 9. where 1 stood for a probability in the range, 0.1-0.2 and 9 
stood for a probability range, 0.9-1.0. 
Cardiac & Skeletal Muscle Embry. Muscle Oesophagus HelaCells 
HOMOLJY~ 98% 52% 33.1% 26% 
HUMA~ WAMPD FRUIT FLY HUMAN HUMAN 
~-MyH {3-MyHC rHG-A rMyHC CENP·E ~ WINDOWS ~ WINDOWS WINDOWS WINDOWS ~ WINDOWS 
14 2 1 28 14 2 1 28 14 21 28 1 21 28 21 28 
g M li. 9 9 M 'l 9 9 A 8 9 9 G 3 9 9 M 9 9 
a A t3 9 9 A " 9 9 N ~ 9 9 R 9 9 9 Q 8 9 9 
b A 8 9 9 A 8 9 9 A 9 9 9 E 9 9 9 v 0 9 9 
c E 8 9 9 E 8 9 9 E 9 9 9 E 9 9 9 D 8 9 9 
d A 8 9 9 A 8 9 9 A 9 9 9 A 9 9 9 L 8 9 9 
e Q 8 9 9 Q 8 9 9 Q 9 9 9 I 9 9 9 E 8 9 9 
f K 8 9 9 K 8 9 9 K 9 9 9 K 9 9 9 K 8 9 9 
g Q l 9 9 Q a 9 9 N 9 9 9 Q !j 9 9 E ,j 9 9 
a v 8 9 9 v 8 9 9 I 9 9 9 L 9 9 9 L 9 9 9 
b K u 9 9 K 0 9 9 K < 9 9 R ;} 9 9 Q :; 9 9 
c s 8 9 9 s 8 9 9 R q 9 9 K 9 9 9 s Q 9 9 
d L 8 9 9 L 8 9 9 y 9 9 9 L 9 9 9 L 9 9 9 
e Q , 9 9 Q 8 9 9 Q 9 9 9 Q 9 9 9 E 9 9 9 
f s 8 9 9 s 8 9 9 Q 9 9 9 A 9 9 9 G i 9 9 
g L .., 9 9 L 8 9 9 Q r 9 9 Q J 9 9 K J 9 9 
a L 9 9 L '1 9 9 L R 9 9 M 9 9 9 I l 9 9 
b K 9 9 K " 9 9 K 9 9 K ~ 9 9 T 1 9 9 
c D 9 9 D 3 9 9 D 8 9 9 D 9 9 9 D J 9 9 
d T 3 9 9 T 3 9 9 I '"' 9 9 F 9 9 9 L l 9 9 
e Q _, 9 9 Q 'l 9 9 Q e 9 9 Q & 9 9 Q :} 9 9 
f I 9 9 I 1 9 9 T J 9 9 R 9 9 9 K 9 9 9 
g Q 'l 9 9 Q ~ 9 9 A 9 9 E w' 9 9 E c.. 9 9 
a L ( 9 9 L 2 8 L 9 9 L f' 9 9 L 9 9 
b D 9 9 D 2 8 E ! 9 9 E ( 9 9 N I 9 9 
c D 9 g D 2 8 E l 9 9 D C) 9 9 K ~ 9 9 
d A 9 9 A 2 8 E 9 9 A 9 9 E 9 9 
e v 7 9 9 v 2 8 Q 9 9 9 R J 9 9 v 7 9 9 
f R I 9 9 R 2 8 R 9 9 9 A 9 9 9 E 7 9 9 
g A 7 9 9 p 2 8 A ) 9 9 s 9 9 9 E 7 9 9 
a N b 9 9 N , 9 9 R 9 9 9 R 6 9 N 5 9 9 
b D 8 9 9 D 8 9 9 D 9 9 9 D - 6 9 E 5 9 9 
c D tl 9 9 D 8 9 9 D q 9 9 E 6 9 A ') 9 9 
d L 8 9 9 L 8 9 9 A 9 9 9 I - 6 9 L !> 9 9 
e K 8 9 9 K 8 9 9 R 9 9 9 F 6 9 R 5 9 9 
f E 8 9 9 E 8 9 9 E 9 9 9 A 6 9 E 5 9 9 
g N 8 9 9 N 8 9 9 Q 9 9 9 T 6 9 E 5 9 9 
a I I 9 9 I 8 9 9 L .! 9 9 A l:i 9 9 v - . 9 
b A I 9 9 A J 9 9 G ;. 9 9 K ) 9 9 I - 9 
c I tl 9 9 I 8 9 9 I 9 9 E b 9 9 L - - 9 
d v 8 9 9 v b 9 9 s 2 9 9 N 6 9 9 L - 9 
e E 8 9 9 E 8 9 9 E ? 9 9 E 6 9 9 s - 9 
f R 8 9 9 R 8 9 9 R " 9 9 K 6 9 9 E - 9 
g R d 9 9 R 8 9 9 R .., 9 9 K 6 9 9 L 1 1 9 
a N 5 9 9 N 5 9 9 A 1 9 9 A 9 9 9 K 1 1 1 
b N 5 9 9 N b 9 9 N 4 9 9 K ~ 9 9 s 1 1 1 
c L !> 9 9 L b 9 9 A t 9 9 s 9 9 9 L 1 1 1 
d L b 9 9 L b 9 9 L 4 9 9 L !; 9 9 p 1 1 1 
e Q 5 9 9 Q t> 9 9 Q 4 9 9 E 9 9 9 s 1 1 1 
f A 9 9 A 9 9 N 4 9 9 A !:1 9 9 E 1 1 1 
g E ~ 9 9 E , 9 9 E ~ 9 9 D ~ 9 9 v 3 6 7 
a L 8 9 9 L 8 9 9 L 7 9 L 9 9 9 E 3 6 7 
b E r:l 9 9 E 8 9 9 E 4 7 9 M !; 9 9 R 3 6 7 
c E 8 9 9 E 8 9 9 E 1., 7 9 Q q 9 9 L 3 6 7 
d L 8 9 9 L 8 9 9 s 4 7 9 L 9 9 9 R 3 6 7 
e R ) 9 9 R 8 9 9 R 4 7 9 Q (" 9 9 K 1 6 7 
f A d 9 9 A 8 9 9 T ~ 7 9 E q 9 9 E 3 6 7 
g v 9 9 9 v 8 9 9 L 4 7 9 D 9 9 9 I 3 6 7 
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Since human SMMyHC was the human MyHC with the least homology to 
human ~-MyHC (33.1 %), it appeared that the coiled-coil dimer dominated the 
quaternary structure of the rod regions of all known human MyHCs. 
The COILS predicted effect of the ~-MyHC A1663P substitution on ~-MyHC 
rod region, can be seen in the WAMPD ~-MyHC column. Coiled-coil 
probabilities were reduced only in the heptad on the N-terminal side of P1663, 
by an amount that was a;lJ~ction of window size. Importantly, all window sizes 
I 
predicte~an effect overbne heptad only. COILS predicted a local effect. This 
limited effect agreed the findings of Barlow and Thornton (1988, p. 612; 
discussed on p. 250). The N-term·inal effect of P1663 was also in agreement 
with the arguments already presented in Section 8.3.2 (p. 241-243), that 
proline-induced steric clashes and 'lost' hydrogen bonds lay on the N-terminal 
side of proline within a-helices. 
Human centromeric protein-E (CENP-E) appears in Table 8.4 because it was 
the only coiled-coil dimer with an internal proline. CENP-E has only 26% 
homology to the ~-MyHC. This protein is located in the kinetocore complex, a 
macromolecular structure within the centromeric heterochromatin of mitotic 
chromosomes. Like myosin II, it is a 'molecular motor', but is involved in the 
movement of chromosomes not muscle. 
COILS predicted that the effect of the CENP-E proline and the ~-MyHC 
P1663 were similar. Both produced a mild-kink on N-terminal side, as predicted 
by Barlow and Thornton (1988) and Kumar and Bansal (1996). It was 
reassuring that the COILS program gave essentially the same result for the ~­
MyHC P1663 substitution and for CENP-E, with its naturally selected proline. 
The importance of this result is that it partly assuaged doubts that always linger 
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with program analyses. They analyse only according to their settings. In 1996 
Lupas (p.377), the original author of the COILS program, expressed this 
doubt, " ... never simply believe a computer output. Programs are a great help, 
but nothing replaces the informed opiniohc6tthe researcher." 
\ 
The opinion of Dr John Sparrow, Department of Biology, York University was 
sought regarding the likely effect of ~-MyHC A1663P. In a personal 
communication (2000) he commented that, "such a mutation in the rod may lead 
to disruption of rod formation and/or dimer-dimer interactions [necessary] to form 
a thick filamenf' and that, "mutant/+ or mutant/mutant dimers might additionally 
interfere with higher order processes in thick filament assembly e.g. dimer-dimer 
binding. It might be especially poter\t at the outset where the myosins 
assemble at what will be the centre of the thick filament in an anti-parallel 
manner." 
8.5 SUPERSTRUCTURE OF MYOSIN II 
The superstructure of myosin II is the thick filament. Thick filaments are bipolar 
spindle shaped structures, 1.6 f.tm in length and 15 nm in diameter, which 
dissolve when treated with high ionic solution (Huxley, 1963). EM revealed 
that myosin molecules treated in this way were myosin dimers and that each 
thick filament was a polymer of about 300 molecules. Negatively stained EM 
preparations of isolated filaments had a rough appearance along their length 
except for a centrally located 'bare zone'. Huxley (1963) proposed a simple 
thick filament assembly model to account for the appearance of the thick 
filaments preparations he observed under EM. Figure 8.16 (p. 266) shows 
Huxley's thick filament assembly model. 
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Figure 8.16 Model of assembly of myosin molecules to 
form the thick filament. Molecules initially associated in a head-to-
tail, antiparallel array with the 'tail-only' region accounting for the bare 
zone. The filaments then elongate by staggered, head to tail, 
parallel addition of molecules at each end. Scanned from A. Craig 
in Engel (1994, p. 141). 
8.5.1 Thick Filament Formation: Charged-Repeat Attraction 
Heptad repeats are not the only repeats found in coiled-coils. Internal 
comparison of the amino acid sequence of the C. elegans myosin rod region of 
the nematode showed that the entire helical sequence of each coil could be 
mapped out as a repeating pattern of 28 residues. A typical MyHC rod 28-
residue zone divides into eight hydrophobic zones and six alternating bands of 
positive and negative charge which are spaced so that the strongest position of 
the positive charge (position 1b) is exactly 14 residues (or one half zone) away 
from the strongest peak of negative charge (position 3b} (McLachlan & Karn, 
1982, p. 227). 
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The high density of charged groups and the regular bands of charge on the on 
the outer surface of the myosin rod, led McLachlan and Karn (1982, pp. 228-
230) to suggest that ionic attractions were most important in the assembly of 
thick filaments. They suggested that rod sections of myosin molecules had 
I 
\ 
staggered alignment so that positive and negative charges came together. 
Strong attractions were the organising force of thick filament formation. 
The distribution of charge on the MyHC rod indicated that the coils in the MyHC 
dimer coiled-coil would most strongly attract each other when they were 
staggered by odd multiples of half-repeats, or 14 residues. Particularly strong 
attractions were predicted for staggers of 7 'half-repeats' or 98 residues, and for 
21 'half repeats' or 294 residues (McLachlan & Karn, 1982, pp. 230-231). The 
"--
charge-repeat periodicity ratio of 3:1 (294:98) was the same as the periodicity 
ratio of axial spacings in muscle. X-ray diffraction patterns had shown the axial 
distance between adjacent actin-myosin cross-bridges was 143 A, and the 
repeat distance of the helix was 430 A (3 X 143 A = 429 A) (Poulsen & Lowy, 
1983). These periodicities are diagrammed in Figures 8.17 (p. 268). 
It was the coincidence of charge-repeat periodicity and helix : cross-bridge 
periodicity that suggested to McLachlan and Karn that the rod charge-repeat 
periodicities were responsible for the arrangements of cross-bridges on the 
surface of the thick filament. It elegantly explained the same periodicities in the 
rod sequence, X-ray diffraction patterns and myosin electron micrographs 
(Craig, 1994). Since the A 1663P substitution in 13-MyHC replaced one non-
polar amino acid with another non-polar amino acid, there was only one way in 
which this substitution could affect thick filament formation: by altering charge 
distribution through azimuthal distortion of the rod. 
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Figure 8.17 Schematic diagram of cross-bridge and helical 
periodicity in thick filaments as determined from X-ray diffraction 
patterns. The 'rod' is the myosin II thick filament backbone, the 
'pegs' are the cross-bridges to actin. Blue identifies the 143 A axial 
periodicity, while red identifies the 430 A axial periodicity. Scanned 
and retouched from R. Craig in Engel (1994, p. 142). 
8.5.2 Thick Filament Formation: Charge-Phase Distortion 
Skip residues distort the charge-phase of the MyHC rod. Only a few coiled-
coils are without skip residue, charge-phase distortions. An analysis of their 
effect may indicate if, and how, the ~-MyHC A 1663P substitution could do 
likewise. The four skip residues in human ~-MyHC rod all occur within four 28-
residue repeat. Conventionally they are placed at the end of that repeat. The 
first skip residue is the uncharged polar residue, threonine, at position 1188, the 
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next two skip residues are the charged polar residue, glutamic acid, at positions 
1385 and 1582, and the fourth skip residue is the uncl')arged non-polar residue, 
-' 
glycine at position 1807 (Table 8.2, p. 234). -r:he high degree of ~-MyHC 
skip-residue conservation from nematodes to , humans indicates that skip 
residues are likely to have global as well as lqcal consequences, possibly 
affecting thick filament formation (Brown et al., 1996, p. 143). 
As early as 1982, McLachlan and Karn (p. 228) suggested that skip residues 
might have important effects on the way myosin molecules packed in the cross-
sections of the thick filaments. Although two of the nematode MyHC rod region 
skip residues were charged polar residues, and therefore altered the charge on 
the MyHC rod, these authors focussed en the azimuthal effect of skip residues 
on charge-phase distortion, and reported that skip residues cause: the a-helix to 
have a wider turn because the twist of the supercoil was under -wound for a few 
turns; and the seam of hydrophobic residues to shift across the helix surface for 
14-21 residues. 
Brown et al. ( 1996, pp.135-136) reported that the movement, or azimuthal 
shift, caused by skip residues was about + 1 000, and the displacement caused 
by each skip residue was resolved within 2 to 3 heptads, at which point the 
regular coiled-coil pattern resumed. In each skip region, the supercoil 
accommodated the extra residue by yielding to local distortions without severe 
alteration to the structure (Lupas, 1996, p. 378-379). Figure 8.18 (p. 270) 
shows the effect of a skip residue in an a-helix net diagram. Brown et al. (p. 
144) noted that an important consequence of skip residues, "would be the 
alteration of the azimuthal position of the periodic patches of charged and/or 
polar residues along the coiled-coil that are known to play a primary role in the 
aggregation of some a-fibrous proteins". 
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Figure 8.18 A single skip residue causing a 1 ooo azimuthal shift of 
MyHC hydrophobic core residues. Core residues in this helix-net 
diagram were positioned more centrally than in Figure 8.14 (p. 259). 
This was a diagrammatic device to prevent the azimuthal shift moving 
core residues from one side of the figure to the other, obscuring the 
effect of the skip residue. Red letters identify 'hydrophilic' surface 
residues, blue letters identify 'hydrophobic' core residues while purple 
letters identify residues lying between the core and the surface. 
8.5.3 ~-MyHC A1663P and Azimuthal Charge Disruption 
Only one analysis has proposed a model for thick filament aggregation which 
suggests a mechanism whereby the apparently private WAMPD {3-MyHC 
A 1663P substitution could cause azimuthal charge-phase distortion. If correct, 
such charge-phase distortion could, theoretically, disrupt thick filament assembly. 
270 
Atkinson and Stewart (1992) considered the possibility that the driving force for 
myosin assembly was a favourable entropy change as myosin II moved from 
solvated state to assembled state. If this was so, the complementation of 
charged zones would not make a major contribution to the free energy 
difference between molecules in solution and aggregates. The essential role of 
the charged zones were to block 'inappropriate' and 'energetically less 
favourable' assembly geometries. 'Appropriate' sJ§ggefs had a lower free 
energy than any other arrangements. Atkinson. and Stewart (p. 11) developed 
a hypothesis linking small MyHC sequence changes to thick filament disruption: 
There are probably a large number of ways in which 
LMM molecules can interact that have nearly the same 
energy. In other words, there are probably a number 
of potential polymer states that differ only very slightly 
in their free energy from the "normal", polymer state 
usually observed. ~uch "cryptic" states would not be 
observed if their critical concentration for polymerisation 
was only marginally higher than that of the "normal", 
because the concentration of free monomers would 
never reach that required for their formation. Even small 
changes to the protein (by mutation for example) might 
raise the critical concentration for the "normal" form 
above that of the "cryptic", so that formation of the latter 
becomes possible. 
According to this hypothesis, an azimuthal charge-phase distortion caused by 
the ~-MyHC A 1663P substitution might raise the critical concentration of the 
dimer required for normal ~-MyHC thick filament formation, above that required 
for the cryptic aggregation of mutated dimers. The cryptic aggregation of ~­
MyHC coiled-coils would underlie Laing myopathy. In affected muscles, the~­
MyHC A1663P substitution would have made misalignment of ~-MyHC 
monomers energetically more favourable than the correct alignment. 
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8.5.4 ~-MyHC A1663P and the Assembly Conserved Domain 
Thick filament formation is critically dependent upon a small, highly conserved, 
negatively charged C-terminal residue sequence (Sohn et al., 1997). This 
region has been termed the ACD for assembly competence domain, and it 
runs from residue 1871 to residue 1899 in the human ~-MyHC. Cohen and 
Parry (1998, p. 324) identified an extended ACD running from 1860 to residue 
1922 and argued that, "the ACD would act as an additional f~ctor to insure the 
selection of the correct molecular stagger for assembly''. Were the ~-MyHC 
A 1663P substitution to interfere with the A9D it would have to have a long-
range effect, spanning a minimum of 227 residues. Of interest, was the Cohen 
and Parry observation (p. 324), "that the ACD is not sufficient for assembly if 
the rod fragment is below a certain length". The shortest human fast lid skeletal 
MyHC rod in which they observed ACD functioning normally, was a fragment 
running from residue 1661-1902. The ~-~HC A 1663P substitution falls within 
this region and so it may, or it may not, be close enough to the ACD to 
influence its function. Similar in vitro experiments with A 1663P ~-MyHC would 
be informative. Since neither Sohn or Cohen and Parry investigated the ACD 
effect in heterozygous combination, this would be a useful extension to their 
work, and of direct importance to dominant-negative diseases like Laing 
myopathy. 
8.6 CONCLUSION 
An analysis of sarcomeric gene mutations, particularly mutations of the MYH 
genes, revealed that mutations in these genes can have skeletal muscle 
phenotype alone, even when a gene is also expressed in the heart. CMH1 
mutations are variably expressed, leaving some patients with skeletal muscle 
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myopathy but no cardiac phenotype. This analysis also found that mutations to 
the Drosophila MYH gene, which altered conserved residues in the LMM rod 
region, only developed a phenotype in one type of muscle, the indirect flight 
muscles. In a general sense, the analysis of sarcomeric gene mutations pointed 
to changes in contractility and to the interaction of the ~-MyHC rod region with 
other macromolecules as promising areas of future research into Laing 
myopathy. 
The analysis of the effect of the ~-MyHC A 1663P substitutioh'at various levels 
of protein structure also strengthened the candidature of MYH7 G5073C as the 
Laing myopathy mutation. It demonstrated the extreme rarity of this type of 
substitution, it showed that the ~-MyHC A 1663P substitution did have a 
detrimental effect on coiled-coil formation, and it identified several ways in which 
~-MyHC A 1663P could disrupt myofibrillogenesis. However, predicting the 
precise effect the ~-MyHC A 1663P substitution might have on 
~ 
myofibrillogenesis, is not possible from this theoretical analysis. 
Future research on myofibrillogenesis involving both the A1663 and the P1663 
~-MyHC monomers would be worthwhile. Transfection of cultured-MYH 
mouse myoblasts with different CMH1 mutants, followed by the stable 
expression of ~-MyHC, is already being employed by a group investigating 
myofibrillogenesis in CMH1 patients (personal communication, Dr. Michelle 
Peckham, School of Biological Sciences, University of Leeds, UK). Such a 
system would be very suitable for the investigation of myofibrillogenesis in 
Laing myopathy patients. 
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CHAPTER 9 
DISCUSSION 
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9.0 DISCUSSION 
The rationale of this thesis was, 'Knowledge of the structure and function of the 
human genome will improve the nosology, diagnosis, prognosis, prevention, 
treatment and future research into the molecular pathology of MD' (p. 3). This 
rationale has been supported by the work reported here: 
The isolation of genomic clones for the slow skeletal 
muscle troponin gene ( TNN/1), the human skeletal 
muscle alpha actin gene (ACTA 1) and the ~­
tropomyosin gene (TPM2) for use in the in situ 
cytogenetic mapping of the TNN/1, ACTA 1 and 
TPM2 skeletal muscle contractile protein genes. 
The first localisation of an AD-distal myopathy, Laing 
myopathy, to the MPD1 candidate region. 
The first demonstration of AD-distal myopathy genetic 
heterogeneity with the exclusion of the MPD1 
candidate region for Silburn myopathy. 
Confirmation of the genetic heterogeneity of AD-distal 
myopathy by the exclusion of the MPD1 candidate 
region for Felice myopathy. 
The exclusion of the French Canadian 14q AD-OPMD 
candidate region for an AD putative-OPMD 
segregating in a Western Australian family. 
The discovery of neutral polymorphisms in MYH7. 
The discovery of a possible disease-causing mutation, 
MYH7 eDNA C5073/gDNA C23628, segregating 
with Laing myopathy. 
The publications emanating from this work (Eyre et al., 1993; Akkari et al., 1993; 
Hunt et al., 1994; Laing et al., 1995b; Felice et al., 1999), show that this project 
was a collaborative project. It was also part of a much larger collaborative 
project, the HGP, to which all of the above publications contributed. 
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An 'evolving concepts' approach has been adopted in this Chapter, to reflect 
the dynamic state of MD molecular pathology. 
9.1 EVOLVING CONCEPTS IN MUSCULAR DYSTROPHY 
During the rapid development of molecular genetics throughout this thesis, one 
discipline has been given substantial impetus; molecular pathology. "Molecular 
pathology seeks to explain why a given genetic change should result in a 
particular clinical phenotype." (Strachan and Read, 1996, p. 401 ). The definition 
of sickle cell anaemia as a molecular disease (Pauling et al., 1949), launched 
molecular pathology. Pauling et al. (1949) used aspects of the the clinical 
phenotype to determine the biochemical basis of sickle cell anaemia. It was the 
first example of functional cloning. Collins (1992, p. 3) makes the point that 
very few human genes are amenable to functional cloning: 
While these strategies, referred to here as 1unctional 
cloning', have been remarkably successful, they are 
limited to disorders for which biological information 
about the basic genetic defect exists. Unfortunately, 
for the vast majority of single gene disorders listed in 
McKusick's catalog, Mendelian Inheritance In Man 
(1991), no such functional detail exists. 
Molecular genetics' contribution to molecular pathology would have been 
considerably diminished had it remained dependent on functional cloning. It did 
not. The position-independent candidate approach, positional cloning and the 
positional candidate approach (reviewed pp. 56-64), have greatly increased 
the contribution of molecular genetics to molecular pathology. The founding 
pathological events for the majority of human diseases will be identified within 
five years (Collins et al., 1998, p. 682). Molecular genetics has become the 
foundation of the molecular pathology of inherited diseases. 
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9.1.1 Molecular Pathology has Refined MD Nosology 
Since, the identification of the mutated dystrophin gene as the disease gene 
causing DMD and BMD, a further 33 genes causing various forms of MD have 
been localised. Nineteen of these genes have been cloned (Tables 9.1 & 9.2, 
pp. 278 & 279), and the investigation of their molecular pathology commenced. 
Molecular pathology is a very incomplete discipline, but it has already made a 
significant change to one part of clinical genetics; nosology. In slightly more than 
a decade, MD nosology has moved from clinical presentation and pathology to 
a base which also includes molecular genetics. Evidence of this shift can be 
discerned from a comparison of Table 1.1 (p. 9) with Tables 9.1 and 9.2. 
Although Tables 9.1 and 9.2 are not intended to be complete, they do show 
that many new subdivisions within the MDs have appeared since this thesis 
started. Refinement has occurred with the genetic localisation of disease genes 
and with the identification of disease-causing mutations. The criteria used to 
define MD has expanded, improving both diagnostic accuracy and precision. 
Mastaglia and Laing (1996, pp. 263-265) considered that the application of 
molecular genetic methods permitted the classification of the MDs into: 
dystrophinopathies, LGMDs, sarcoglycanopathies, congenital MDs (CMD), 
facioscapulo-humeral MD (FSHD), OPMDs, Emery-Dreifuss MD and the distal 
myopathies. Tables 9.1 and 9.2 include these MD groups. 
The developing nosology of the LG MDs illustrates the impact of molecular 
genetics on MD nosology. By 1993, disease gene location could only confirm 
the diagnosis of one form of AD-LGMD and one form of AR-LGMD. Clinical 
phenotype and mode of inheritance remained the only way to distinguish 
between the other form of AD-LGMD and the three other forms of AR-LGMD 
identified at that time (Table 1.1, p.9). 
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Table 9.1 
Dystrophy type 
A!.!t~;uu,!mill Qgminsmt 
Myotonic dystrophy 
DM1 
DM2(PROMM) 
Facioscapulohumeral MD 
FSHD 
Limb-girdle MD 
LGMD1A 
LGMD1B 
FDC'rCDM 
LGMD1C 
LGMD1? 
Bethlem myopathy 
COL6A1 
COL6A2 
COL6A3 
Distal myopathy 
'- ~..-:1- -Welandet: 
-I/ Finnish Tibial 
Markesbery 
Laing (MPD1) 
Feit (VCPDM) (MPD2) 
Oculopharyngeal MD 
OPMD(PABP2) 
Oculopharangodistal MPD 
Molecular Genetics and Autosomal Dominant Muscular Dystrophy Nosology 
Identification Cytogenetic Location Gene 
Bell, 1947 
Bell, 1947 19q13.2-q13.3 Harley et al., 1991 Protein kinase (DMPK) Brook et al., 1992 
Dayet al., 1999 3q Ranum et al., 1998 
Tyler & Wintrobe, 1950 
4q35 Wijrnenga et al., 1992 non-transcribed Lemmers et al., 
p13E-11 del. 1998 
Gilchrist et al., 1988 5q31-q33 Speer et al., 1992 Myotilin Hauseretal.,2000 
van der Kooi et al., 1997 1q11-q21 van der Kooi et al., 1997 
Messina et al., 1997 6q23 Messina et al., 1997 
Minetti et al., 1998 3p25 Minetti et al., 1998 Gaveolin-3 ( CA V3) Minetti et al., 1998 
Speer et al., 1999 5q Speer et al., 1999 
Bethlem et al., 1976 
Jobsis et al., 1996a 21q22.3 Jobsis et al., 1996a Collagen6A 1 ( COL6A 1) Jobsis et al., 1996b 
Jobs is et al., 1996a 21q22.3 Jobsis et al., 1996a CoUagen6A2 ( COL6A2) Jobs is et al., 1996b 
Mohire et al., 1988 2q37 Speeretal., 1996 Colfagen6A3 ( COL6A3) Pan et al., 1998 
Welander, 1951 2p13 Ahlberg et al., 1998 &1999 
Udd et al., 1991 & 1993 2q31 Haravuori et al., 1998a 
Markesbery et al., 1974 2q Haravuori et al., 1998b 
Laing et al., 1995(b) 14q Laing et al., 1995(b) 
Feit et al., 1998 5q31 Feit et al., 1998 
Taylor, 1915 
(cited in Brais et al., 1995) 
Barbeau, 1965 14q11.2-q13 Brais et al., 1995 & 1997 Poly(A)Bind. Protein-2 Brais et al., 1998 
(cited in Brais et al., 1995) (PABP2) 
Satoyoshi & Kinoshita (1977) 
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Table 9.2 
Dystrophy type 
~-linluu:l B~~~~~iv~ 
Dystrophinopathies 
Duchenne 
Becker 
Quadriceps myopathy 
Myalgia and cramps 
Emery-Dreifuss MD (EDMD) 
AutQI!2mDI B~~~~siv~ 
Urrb girdle MD 
LGMD2A 
LGMD2B 
LGMD2C (y-00 SCARMD) 
LGMD2D (a-SG SCARMD) 
LGMD2E (~·SG SCARMD) 
LGMD2F (6-SG SCARMD) 
LGMD2G 
LGMD2H 
Congenital MD 
Merosin deficient 
Fukuyama 
Congenital MD (ITGAl) 
Walker-warburg syndrome 
Muscle, eye and brain 
disease (MEB) 
Distal myopathy 
Miyoshi (MM) 
']>_ Nonaka 
Oculopharyngeal MD 
OPMD (PABP2) 
Hered.lnc.BodyMP (h-IBM) 
Molecular Genetics and X-linked Recessive and Autosomal Recessive Muscular Dystrophy Nosology 
Identification Cytogenetic Location Gene 
Koenig et al., 1987 
Meryon, 1852 Xp21.2 Boyd & Buckle, 1986 Dystrophin (DM~ Koenig et al., 1987 
(c. Partridge, 1993, p. xiii) 
Becker, 1955 Xp21.2 Koenig et al., 1987 Dystrophin (DM~ Koenig et al., 1987 
(c. ClzaMi , et al., 1998, p. 421) 
Thage, 1965 Xp21.2 Sunohara et al., 1990 Dystrophin (OM~ Koenig et al., 1987 
Kuhn et al., 1979 Xp21.2 Gaspe et al., 1989 Dystrophin (OM~ Koenig et al., 1987 
Emery & Dreifuss, 1966 Xq28 Gonsalez et al., 1991 Emerin (EMCJ} Bione et al., 1994 
Beckmann et al., 1991 15q15.1-q21.1 Beckmann et al., 1991' O:l.lpain-3 ( CANP3) Richard et al., 1995 
Passos-Bueno et al., 1991a & b 2p13.3 Bashir et al, 1994 Dysferlin (DYSF) Uu et al., 1998 
Ben Othmane et al., 1995 13q12 Ben Othmane et al., 1995 y-sarcoglycan (y-SG) Noguchi et al., 1995 
Roberds et al., 1994 17q12-q21.33 Roberds et al., 1994 a-sarcoglycan (adhalin) Roberds et al., 1994 
Bonnemann et al., 1995 4q12 Bonnemann et al., 1995 ~-sarcoglycan (~-SG) Umetal., 1995 
Passos-Bueno et al., 1991a & b 5q33-q34 Passos-Bueno et al., 1996 6-sarcoglycan (6-SG) Nigro et al., 1996 
Passos-Bueno et al., 1991a & b 17q11-q12 Moreira et al., 1997 
Shokeir & Kobrinsky, 1976 9q31-q33 Weiler et al., 1996 
Tome et al., 1994 6q22-q24 Hillaire et al., 1994 a-2 Laminin (LAMA2) Helbling-leclerc, 1995 
Fukuyarna et al., 1981 9q31-q33 Toda et al., 1993 
Hayashi et al., 1998 12q13 Wang et al., 1995 lntegrin a7 (ITGAl) Hayashi, 1998 
warburg, 1976 
Santavuori & Leisti 1980 1p32-p34 Corrnand et al., 1999 
Miyoshi, et al., 1986 2p12-p14 Bejaoui et al., 1995 Dysferlin (DYSF) Liu et al., 1998 
Nonaka, et al., 1981 & 1985 9p1-q1 lkeuchi et al., 1997 
Brais et al., 1998 14q11.2-q13 Brais et al., 1998 PABP-2 Brais et al., 1998 
Argov & Yarom (1984) 9p1-q1 Mitrani-Rosenbaum, 1996 
Subsequently, increased knowledge of LG MD disease gene locations and the 
identification of disease-causing mutations has made it possible to distinguish 
five forms of AD-LGMD (Table 9.1) and eight forms of AR-LGMD (Table 9.2). 
Linkage analysis has excluded the eight AR-LGMD genes in two Brazilian 
families segregating a form of AR-LGMD, indicating that there is at least one 
more AR-LGMD gene (Passos-Bueno et al., 1999). 
At all levels, MD nosology now includes molecular pathology. Together, 
Tables 9.1 and 9.2 comprise an MD nosology based on clinical phenotype and 
founding molecular event. 
9.2 EVOLVING CONCEPTS IN DISTAL MYOPATHY 
During the course of this thesis, the genetic location of eight forms of distal 
myopathy were identified, some of which may be allelic. The first genetic 
location of the distal myopathies was reported from work conducted in this thesis 
by Laing et al. (1995b). By 1999, the genetic locations of four of the distal 
myopathies listed in Table 4.1 (p. 94) had been identified. These were those 
first described by: Welander (1951) (WDM)- localised by Ahlberg et al. (1998 
& 1999); Markesbery et al. (1974) - localised by Haravuori et al. (1998b); 
Nonaka et al. (1981 and 1985)- localised by lkeuchi et al. (1997); and Miyoshi 
et al. (1986) (MM) -localised by Bejaoui et al. (1995). 
In addition to these localisations, four more forms of distal myopathy were 
! 
identified and localised: tibial muscular dystrophy, Udd et al. (1993) - localised 
)ll 
by Haravuori et al. (1998a); Laing myopathy - described and localised 
simultaneously by Laing et al. (1995b); distal anterior compartment (tibial) 
myopathy (DMAT) - described and localised simultaneously by lila et al. 
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(1998); distal myopathy with vocal cord and pharyngeal weakness (AD-
VCPMD) (MPD2) - described and localised simultaneously by Feit et al. 
(1998). In addition to these localisations, a distal myopathy disease gene, 
dysferlin (DYSF), has been cloned from within the MM and DMAT overlapping 
candidate regions (Liu et al. 1998; Bashir et al., 1998). Yet despite these 
successes, the molecular pathology of the distal myopathies is still poorly 
understood. Currently, old concepts are being reviewed and new concepts 
developed from molecular genetic discoveries. Only those of relevance to the 
distal myopathies investigated in this thesis are reviewed. 
9.2.1 Molecular Genetics Confirms and Refines 
Traditional Distal Myopathy Nosology 
In 1994 Griggs and Markesbery published a revised nosology of the distal 
myopathies and this was followed by the publication of a similar classification 
from discussions at the 25th European Neuromuscular Centre (ENMC), 
'International Workshop: Distal Myopathies', held in February 1994 (Somer, 
1994). Subsequently, a refinement of distal myopathy nosology was 
proposed (Somer et al., 1998). It retained all the essential structure of Griggs 
and Markesbery (1994) and Somer (1994) nosologies, and continued to be 
built on traditional clinical and genetic grounds. 
Table 9.3 (p. 282) shows the distal myopathy nosology developed by these 
authors. It was remarkable in its similarity to that of Barohn e~ al. (1991 , p. 1369) 
(Table 4.1, p. 94). It had three changes to that suggestid by Barohn: minor 
name changes to the four forms of distal myopathy; the. ~xclusion of sporadic 
and familial reports of distal myopathy, including only forms displaying 
unequivocal AR or AD inheritance; and the inclusion of tibial muscular dystrophy 
(TMD) (Udd et al., 1993) in, 'Category II: Late Adult-Onset in Legs'. 
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Table 9.3 
Clinical phenotype 
Identification: 
Inheritance: 
Age of onset: 
First symptoms: 
--c>--~ 
-
Progression: 
cardiomyopathy: 
SerumCK: 
Electromyography: 
Muscle biopsy: 
Nosology of the Hereditary Distal Myopathies (after Griggs & Markesbery, 1994; Somer eta/., 1998) 
I II Ill IV 
Late Adult-Onset Late Adult-Onset in Legs. AD. Early Adult-Onset in Posterior Early Adult-Onset in Anterior 
in Hands. AD. Leg Compartment. AR. Leg Compartment. AR. 
Welander, 1951 Markesbery et al., 1974 Markesbery et al., 19n Nonaka et al., 1981 & 1985 
Dahlgaard, 1960 (cited in Udd et al., 1993 (tibial Miyoshi et al., 1986 
Somer etal., 1m3, p.183) muscular dystrophy-TMD) 
AD AD AR AR 
Overage40 Over age 40 (Markesbery) 15-30 years 2D-30 years 
Over age 35 (Udd) 
Hand muscles Distal leg muscles, Distal leg muscles, Distal leg muscles, 
anterior compartment posterior compartment anterior compartment 
Very slow to distal Markesbery: slow to upper Markesbery: Medium to proximal leg Rapid to proximal leg muscles, 
flexors and extensors extremities and proximal limb muscles. Forearm muscles become hands, neck then trunk. 
muscles. Udd: slow, does not mildly atrophic. Tendon reflexes diminished 
progress to upper extremities Miyoshi: progression towards a 
or to proximal limb muscles generalised atrophy 
No Markesbery: one patient No No 
Udd:none 
Normal or sHghtly Normal or slightly elevated 10 to 150X normal Increased, usually< 10X 
elevated normal, onen 2-5X normal 
Myopathic pattern Markesbery: not recorded Myopathic pattern Myopathic pattern 
Udd: myopathic pattern 
Variable, some Rimmed vacuoles Dystrophic changes, no vacuoles, Rimmed vacuoles 
rimmed vacuoles some gastrocnemius weakness 
The 'Category II: Late Adult-Onset in Legs' classification had been previously 
called, 'Late Adult-Onset, Type 2' in the nosology of Barohn et al. (1991 ). 
Table 9.3 also shows that TMD and the Markesbery distal myopathy (1974) 
have significant differences in disease progression. In grouping of TMD and the 
Markesbery distal myopathy (1974) together in, 'Category II: Late Adult-Onset 
in Legs', Somer et al. (1998, p. 186) expressed some concern, "Whether 
TMD patients have the same disease as those described by Markesbery et al. 
(1974) cannot be settled at the moment." 
It is evident from Table 9.3 that genetic location was not employed to classify 
the distal myopathies. Somer (1994, p. 4) did record the localisation of MPD1 
in the Workshop Report of the, '25th ENMC International Workshop: Distal 
Myopathies': 
Emery informed about a breakthrough achieved by 
Nigel Laing and collaborators in Australia in mapping 
one form of distal myopathy to chromosome 14. 
Patients with this myopathy have a phenotype 
resembling that described by Gowers already in 1902 
showing onset in childhood and early adulthood, and 
distal muscle weakness predominantly in the upper 
extremities. Linkage was obtained by analysis of one 
large family. This clinical entity was previously 
considered somewhat uncertain, and has not been 
included in recent classifications. This now appears to 
be the first distal myopathy with established genomic 
location. 
The fact that MPD1 was the only distal myoJ:)athy locus identified in 1994, is 
'-~--~__::;-~, 
possibly why Griggs and Markesbery (1994) and:Somer (1994) did not use 
genetic location of MPD1 in their classifications of distalfnyopathies. However, 
distal myopathy nosology based on traditional clinical and genetic grounds was 
continued by Somer et al. (1998), despite their recognition of the potential 
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usefulness for classification purposes of the four distal myopathy gene locations 
that were known at that time. These were: MPD1 to 14q (Laing et al., 1995b); 
MM to chromosome 2p12-p14 (Bejaoui et al., 1995); Nonaka myopathy to 
9p1-q1 (lkeuchi et al., 1997); TMD to 2q31-33 (Haravuori et al., 1998a). 
Laing myopathy reported in this thesis and by Laing et al. (1995b), continued 
to be excluded, seemingly due to its rarity and because insufficient clinical detail 
was available for its status as a distal myopathy to be firmly established. It was 
both rare and equivocal. Somer et al. (1998, p. 195) comment, 
"Histopathological characterisation of Gowers' phenotype in the Australian family 
(Laing et al., 1995) is still unknown". In more general terms Somer et al. (p. 
190) state that, "Laing et al. (1995) reported genetic linkage of a myopathy 
inherited in autosomal dominant fashion to chromosome 14 in an Australian 
family, where the phenotype is said to resemble that described by Gowers 
(1902). A more detailed clinical description is still lacking". 
Lately, a more detailed clinical ascertainment of the Laing myopathy family has 
been conducted (personal communication, Dr. Beverly Phillips, ANAl, Perth, 
Westem Australia, 1999). This review classifies Laing myopathy as 'early-
onset'. 
Two recent distal myopathy classifications were presented by Felice et al. 
(1999, p. 64) and Barohn and Amato et al., (1999, p. 47). They were the first 
attempts to develop a classification of the distal myopathies based on gene 
location. Predictably, they were very similar. They differed only in that the 
classification of Barohn and Amato, inqluded myofibrillar (desmin) myopathy. 
·.~·· 
Table 9.4 (p. 285) shows the Felice distal<,myopathy classification. 
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Table 9.4 Classification of Distal Myopathies based on 
Gene Location (modified from Felice eta/., 1999) 
Myopathy ARIAD Genetic Authors 
Location (localisation) 
AR distal myopathy AR 
(Miyoshi myopathy) (MM) 
2p12-14 Bejaoui et al. (1995) 
Distal anterior compartment AR 
(tibial) myopathy (DMAT) 
2p13 lila et al. (1998) 
Tibial MD (TMD) AD 2q31 Haravuori 
(Udd myopathy) et al. (1998a) 
Late-onset distal myopathy AD 2q31 Haravuori 
(Markesbery myopathy) et al. (1998b) 
Nonaka myopathy AR 9p1-q1 lkeuchi et al. (1997) 
Hereditary inclusion body AR 9p1-q1 Mitrani-Rosenbaum 
myopathy (h-IBM) et al. (1996) 
AD distal myopathy 
(Laing myopathy) (MPD1) 
AD 14q Laing et al. (1995b) 
Welander myopathy (WDM) AD ? 
A comparison of Table 9.4 with Table 4.1 (p. 94) and Table 9.3 (p. 282), 
shows that molecular genetics has confirmed the traditional clinical and genetic 
nosology of the distal myopathies as proposed by Somer et al. (1998). 
Notwithstanding its cautious approach, this traditional distal myopathy 
classification did successfully discriminate MM, Nohaka and TMD forms of distal 
' 
myopathy. 
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Compared to the Somer nosology (1998), the Felice nosology (1999) 
contained new categories and new groupings. Laing myopathy was included 
as a new category, DMAT was included and grouped with MM, and h-IBM was 
included and grouped with Nonaka myopathy. One advantage of developing 
nosology based on genetic location was its ability to diminish uncertainties 
based on clinical phenotype. In this context, the Felice nosology: confirmed a 
connection between distal myopathy and h-IBM as suggested by Askanas 
(1997, p. 422); it diminished the uncertainties expressed by Somer et al. 
(1998, p. 186) about grouping TMD and Markesbery distal myopathy 
together; it placed Laing myopathy in a class by itself; and it associated MM 
with DMAT. Distal myopathies with overlapping genetic locations may have 
the same starting point for their pathology, those with different genetic locations 
have different starting points for their pathology. 
Table 9.4 was the first genetic classification of distal myopathies and in 
appreciation of this fact Felice {p. 64) described their genetic classification of the 
distal myopathies as 'tentative'. There was an expectation that their proposed 
distal myopathy classification would continue to change, as distal myopathy 
disease gene locations and disease-causing mutations were discovered. In fact, 
between its acceptance and publication, the classification proposed by Felice et 
at. (1999) had already undergone refinement. Ahlberg et at. (1998, p. S6) 
announced the genetic localisation of WDM at the 'IX International Congress on 
Neuromuscular Diseases', Adelaide, Australia. Identification of a common 
shared haplotype in seven Swedish families segregating WDM located this 
distal myopathy disease gene to a 0.2-2A eM region on chromosome 2p 
f 
between the markers D2S303 and D2S2115. This is very close to the 
localisation of the Miyoshi myopathy and the dysferlin gene. Dysferlin has 
been excluded as the gene for WMD (B. Udd, personal communication, 2001 ). 
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9.2.2 Nonaka Distal Myopathy and a form of h·AR-IBM may 
have a Common Disease Gene 
Nonaka distal myopathy is an AR-RV form of distal myopathy, while the Laing, 
Silburn and Felice myopathies reported here were AD, non-vacuolar forms of 
distal myopathy. Nevertheless, the conclusions derived in this section, and the 
following section, are directly relevant to the Laing, Silburn and Felice 
myopathies. 
Askanas. and Engel (1993) introduced the term 'hereditary inclusion body 
myopathies' (h-IBMs) to describe hereditary progressive muscle diseases with 
muscle pathology strikingly similar to the pathology of 'classic' sporadic inclusion-
body myositis (s-IBM) (Yunis & Samaha, 1971; Fardeau & Tome, 1998, 
p.252), except that: h-IBM muscle biopsy specimens lacked signs of 
inflammation (hence 'myopathy' rather than 'myositis'); usually occurred in 
childhood or young adulthood; and frequently displayed an unusual distribution 
of atrophy, sparing quadriceps muscles (Argov & Yarom, 1984). Currently, h-
IBMs have been delineated as the h-AR-IBM and h-AD-IBM genetic 
myopathies (Fardeau & Tome, 1998, pp. 252-256), both of which have similar 
muscle pathology (Askanas & Engel, 1995; Griggs et al., 1995). 
A form of h-AR-IBM, first reported by Argov and Yarom (1984) in 30 
members of nine Iranian Jewish families, has been associated with the Nonaka 
form of distal myopathy (Nonaka et al., 1981). These two myopathies were 
found to be strikingly similar. Both displayed AR inheritance; both were 
quadriceps-sparing (although the quadriceps muscle was slightly affected in 
[<;, 
some Nonaka myopathy patients); both were RV myopathies with multiple or 
! 
single RVs that were more common in type I ~uscle fibres (Argov et al., 1997); 
both showed marked variation in muscle fibre size; both had myogenic and 
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neurogenic EMGs; both were associated with lower limb distal weakness 
causing foot-drop and steppage-gait; and both progressed slowly to proximal 
muscles (Sunohara et al., 1989; Serratrice, 1998). 
Muscle pathologies of these myopathies were also found to be strikingly 
similar, both possessing paired helical filaments and both possessing the same 
Alzheimer-characteristic protein accumulations within vacuolar muscle fibres: ~-
amyloid protein, two ~-amyloid precursor protein epitopes, apolipoprotein E, 
hyperphosphorylated 1:, a 1-antichymotrypsin, and ubiquitin (Murakami et al., 
1995; Askanas, 1997). As disease phenotype similarities between Nonaka 
myopathy and Iranian h-AR-IBM grew, Askanas and Engel (1995) proposed 
that the h-AR-IBM of Iranian Jews and Nonaka distal myopathy might be the 
same entity. Subsequently, Satoyoshi et al. (1998, p. 249) have indicated that 
the disease phenotypes of these two disease are so similar that misdiagnosis 
could occur: 
In Japan, however, IBM is reported much less 
frequently ... there were only 5 patients with IBM 
among 143 patients with inflammatory myopathies, 
whereas there were 18 patients with DMRV. One 
might raise the possibility that IBM was misdiagnosed 
as DMRV because RV formation is common to both 
diseases. 
The localisation to chromosome 9p1-q1 of the h-AR-IBM disease gene in: 
Iranian-Jews (Mitrani-Rosenbaum et al., 1996), Afghani-Jews, Egyptian-Jews, 
Iraqi-Jews, non-Jews from India (Argqv et al., 1997; Argov & Mitrani-
."' Rosenbaum, 1998), and non-Jews from Mexico (Askanas, 1997; Askanas & 
Engel, 1998) followed by the the localisation, of Nonaka myopathy to the same 
9p1-q1 (lkeuchi et al., 1997) region, led Argov and Mitrani-Rosenbaum (1998, 
p. 209) to conclude that: 
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A recent report suggests that a Japanese form of distal 
myopathy also maps to a region of chromosome 9p1-
q1 (lkeuchi et al., 1997). These findings suggest that in 
addition to the disease in Jewish communities related to 
Persia, a similar. (allelic?) disease exists in non-Jews, 
most probably resulting from defects in the same gene. 
Askanas (1997, p. 422) had already reached the same conclusion, "It is 
apparent that the Japanese 'distal myopathy with RVs' and the above 
examples of 'quadriceps-sparing h-IBM' are the same disorder or very closely 
related disorders." The eventual cloning of the disease gene responsible for 
either h-AR-1 BM or Nonaka myopathy will allow this conclusion to be tested. 
Askanas (1997, p. 422) argues for the establishment of an h-IBM dassWication 
and nomenclature to include some 'distal myopathies'. Others argue that distal 
myopathy classification and nomenclature should include some 'h-IBMs' (Felice 
et al., 1999, p. 64). 
9.2.3 Different Aetiologies Can Produce Similar 
Pathogenic Cascades 
Askanas and Engel (1995, pp. 490-494) suggested h-AR-IBM and h-AD-IBM 
were probably caused by different genetic defects because they had different 
genetic transmission. They must also have a different aetiology to s-IBM, which 
could be viral in origin (Askanas, 1997, p. 421 ). Yet in many clinical respects h-
AR-IBM, h-AD-IBM and s-IBM are quite similar (Askanas & Engel, 1995). This 
led these authors to ask whether various causes of IBM could lead to the same 
IBM pathological process, or as Askanas (1997, p. 422) suggests, "are the 
result of the same final pathogenic cascade." 
'·" 
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The AD inheritance of WDM and its localisation to 2p 13 (Ahlberg et al., 1998) 
means that it has a different mode of inheritance and a different disease gene to 
the 9p1-q1 Nonaka distal myopathy (lkeuchi et al., 1997) and to the 9p1-q1 
form of h-AR-IBM (Mitrani-Rosenbaum et al., 1996). The fact that WDM 
pathogenesis is similar to a very slowly progressive form of h-IBM and the fact 
that h-AR-IBM, h-AD-IBM and s-IBM can be hard to distinguish (Askanas & 
Engel, 1995, pp. 490-494; Serratrice, 1998, pp. 95-97), supports the concept 
that different aetiologies can produce the same final pathogenic cascade. 
At present, the IBM/distal myopathy pathogenic pathways are not well 
understood. As genetic loci for h-ISMs and distal myopathies are identified and 
disease genes cloned, their effect on the muscle fibre will be delineated and the 
pathogenic pathway of each disease will begin to emerge. If this concept is 
correct, it predicts that points of convergence in the molecular pathology of each 
disease will be revealed. Uncovering the factors that cause s-IBM may also 
start to uncover its pathogenic pathway. Further points of convergence 
between s-IBM, h-IBM and some of the distal myopathies may then be 
identified. 
The implication for the Laing, Silburn and Felice myopathies is clear. 
Pathognomic similarities may not reflect events precipitating disease onset, but 
rather reflect a final common pathogenic cascade. Clinical ascertainment cannot 
resolve this issue, highlighting the danger of combining families of similar clinical 
phenotype for the purposes of linkage analysis. Exclusion analysis was able to 
establish that Laing myopathy had a different disease gene location to both 
Silburn and Felice myopathies and to the putative-OPMD segregating in a 
Western Australian family. Unequivocally, therefore, Laing myopathy has a 
different starting point for its pathogenic pathway to these other forms of MD. 
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Its pathognomic similarities to these MDs must be due to convergence of 
pathological pathways. It does not belong to an allelic series that includes any 
of these other MDs, thus its phenotypic similarities to them cannot be explained 
by allelic heterogeneity. 
Molecular genetic investigations into the distal myopathies has started to reveal 
possible cases of allelism (Table 9.4, p. 285). The possibility of an allelic 
series containing any two or all three of the Silburn myopathy, Felice myopathy 
and the Western Australian putative-OPMD cannot be discounted. Only the 
discovery of disease-causing mutation(s) can resolve this question. 
9.2.4 Markesbery Distal Myopathy and TMD may have 
the Same Disease Gene 
TMD (Udd et al., 1993) and Markesbery distal myopathy (Markesbery et al., 
1974) are clinically similar AD diseases of late adult onset. Both show onset in 
the tibial anterior muscles, AD-TMD between the fourth to seventh decade and 
Markesbery between the ages of 43-51. In TMD, muscle weakness remains 
confined to tibial anterior muscles in most patients while in Markesbery distal 
myopathy muscle weakness manifests distally in tibial anterior muscles, but then 
progresses to the proximal muscles. 
A comparison of morphologic changes seen in muscle biopsy reveals: at the 
early stage of dystrophic change in both TMD and Markesbery, RVs in affected 
muscle fibres varied from very few to numerous; severe end-stage dystrophy, 
manifest in Markesbery by variability in fibre size, necrosis, central nuclei, an 
increase in connective tissue and fatty infiltration (Serratrice, 1998, p. 97), and 
manifest in TMD by variability in fibre size, fibre splitting, and internalised nuclei 
(Udd et al., 1998, p. 235). 
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AD-TMD and AD-Markesbery distal myopathy differ in their rate of dinical 
progression. In AD-TMD, weakness of lower leg muscles is slowly 
progressive, eventually causing a moderate foot drop. Walking ability is 
preserved throughout the patient's lifetime because muscle weakness remains 
confined to the tibial anterior muscles (Udd et al., 1998, p. 233). Muscle 
weakness is not so confined in AD-Markesbery distal myopathy and 
progresses to the intrinsic hand muscles and the wrist extensors then, finally, to 
proximal muscles (Markesbery et al., 197 4, p. 127 & 129). 
Haravuori et al. (1998b) tested the only AD-Markesbery distal myopathy 
family (LOOM) to verify or exclude the AD-TMD 2q31 locus. A maximum two-
point lad score of 2.57 (8 = 0.00) was obtained for the marker D282310 and a 
multipoint lad score analysis placed the AD-Markesbery distal myopathy locus 
between the markers D28385 and D28389 with a maximum lad score of 3.62. 
This showed that the AD-TMD and the AD-Markesbery distal myopathy 
candidate regions overlapped, leading Haravuori et al. (1998b, p. A 186) to the 
conclusion that AD-TMD and the AD-Markesbery distal myopathy, "may be 
caused by the same defective gene since these diseases appear to be allelic." 
There is little scope to refine the 1cM AD-TMD candidate region, so the cloning 
of the disease gene(s) will determine if AD-TMD and AD-Markesbery distal 
myopathy are allelic. This will most likely be by the positional candidate 
approach since, as discussed in Chapter 8, within this candidate region there is a 
strong candidate gene, the titin gene. 
9.2.5 The Same Mutation can produce different Pathogenesis 
Liu et al. (1998) found that the DYSF A4265G mutation, causing an 11299V 
substitution, gave rise to MM and DMAT in homozygous G4265 individuals 
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belonging to the same Italian family. DYSF has a 5' UTA of 368 bases. 
Moreover, in two Spanish families the deletion of G at 5966, resulted in MM in 
one of these families but DMAT in the other. A single mutation causing two 
phenotypically different MDs cannot be described as demonstrating allelic 
heterogeneity (Gelehrter & Collins, 1990, p. 299) or as belonging to an allelic 
series (McKusick, 1973, p. 446). The term 'mutation heterogeneity' is 
proposed here to describe these occurrences. 
The discovery of the role of the DYSF gene in MM by Liu et al. (1998), made it 
possible to test the hypothesis that the same mutation caused both MM and 
LGMD28 co-segregating in a large Canadian aboriginal kindred (Weiler et al., 
1996). Weiler et al. (1999) found that all LGMD28 and MM patients in this 
kindred were homozygous for DYSF G2745, a C->G mutation causing a 
P791 R dysferlin substitution. P791 R resulted in similar reductions of D YSF 
expression in the two types of patients, strengthening the conclusion that the 
homozygous DYSF G2745 genotype could cause two forms of MD in the 
same kindred. The concept of mutation heterogeneity had been confirmed. 
The DYSF investigations of Liu et al. (1998) and Weiler et al. (1999), have 
made it clear that disease classification retains some refractory aspects at the 
level of disease-causing mutation. Evidence of mutation heterogeneity 
confounded the connection between mutation and pathogenesis and 
immediately led to speculation that modifier gene(s) or additional factors must 
account for the differences in the clinical phenotype (Weiler et al., 1999, p. 871 
& 875). Bashir et al. (1998, p. 40) suggested that, "Some muscular dystrophy 
genes may allow for variability in the patterning observed, or the involvement of 
another gene may modify the phenotype." 
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In support of MD genes giving rise to 'variability in the patterning', Anderson et 
al. (1999, p. 855) have offered a hypothesis about how dysferlin might 
produce different patterns of affected muscles. lmmunolabelling with 
monoclonal antibody to the DYSF protein localised this protein to the muscle 
fibre membrane at both the light and electron microscopic level: 
Analysis of human fetal tissue showed that dysferlin 
was expressed at the earliest stages of development 
examined, at Carnegie stage 15 or 16 (embryonic age 
5-6 weeks). Dysferlin is present, therefore, at a time 
when the limbs start to show regional differentiation. 
Lack of dysferlin at this critical time may contribute to the 
pattern of muscle involvement that develops later, with 
the onset of a muscular dystrophy primarily affecting 
proximal or distal muscles. 
This is still an untested hypothesis. Other possibilities exist. Dysferlin is located 
in the membrane and both Anderson et al. (1999) and Weiler et al. (1999) 
found low levels of dysferlin in MMILGMD2B patients, reminiscent of 
dystrophin levels in many Duchenne patients. The dysferlinopathies may not 
be a separate type of MD as suggested by Liu et al. (1998), but instead be a 
'loss of muscle cell membrane integrity' type of MD, similar to the MDs with 
defects in dystrophin and dystrophin-associated proteins. 
This discussion leads to the conclusion that any two, or all of Silburn myopathy, 
Felice myopathy and the putative-OPMD segregating in a Western Australian 
family, could be caused by the same mutation. Only genetic localisation of 
these distal myopathies, started in this thesis, and the subsequent identification 
of disease-causing mutation(s), can confirm or exclude these possibilities. 
294 
9.2.6 Distal Myopathy May be Caused by Mutations In 
Genes Encoding Contractile Proteins 
Table 8.1 (p. 225) shows that all of the hypertrophic cardiomyopathy (CMH) 
genes encode contractile proteins. Could the same be true for the distal 
myopathies? Dysferlin has been identified as a distal myopathy disease gene 
(Liu et al., 1998; Bashir et al. 1998), Udd et al. (1998) have identified titin as a 
'superior candidate' for TMD, Martinsson (unpublished) has recently found a 
mutation in a chromosome 17 MYH gene segregating with a hereditary 
inclusion~body myopathy (18M3), and this thesis argues that MYHl, which lies 
within the MPD1 linkage region, is a strong candidate gene for Laing myopathy. 
The possibility that many of the distal myopathies are a new class of contractile 
protein disease cannot be excluded. 
9.2. 7 Childhood Onset Distal Myopathy 
One further distal myopathy concept emerged during this review. Surprisingly, 
it did not come from molecular genetic analysis, but from an examination of distal 
myopathies systematically excluded from nosologies during the past 35 years. 
The refinement of distal myopathy classification by Griggs and Markesbery 
(1994), Somer (1994) and Somer et al. (1998) were based on traditional clinical 
and genetic grounds. They excluded rare or genetically undetermined distal 
myopathies, and those where distal weakness was just one prominent feature 
of a disease. Somer et al. (1998 p. 190) identified five other, "myopathies with 
onset in distal muscles" that did not fit their classification, "Nevertheless, their 
clinical picture, histopathology and genomic location provide interesting 
similarities to the distal myopathies described above, and are reviewed briefly 
here." Table 9.5 (p. 296) lists these 'excluded' distal myopathies. 
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Table 9.5 Distal Myopathies Excluded from the Distal 
Myopathy Nosology (after Somer eta/., 1998). 
Distal Myopathy 
I. Early adult onset. 
II. Early adult onset. 
Ill. Late onset. 
IV. Infantile onset. 
V. Adult onset. 
Ascertainment 
Facial, sternomastoid 
atrophy. AD. 
Respiratory, bulbar, 
proximal muscles 
all affected. Desmin 
storage, autophago-
cytosis. AD. 
Thenar, hand flexors, 
proximal muscles all 
affected. Intermediate 
filaments, sarcoplasmic 
bodies. AD. 
Peroneal, facial and 
trunk musdes all 
affected. AD. 
Vacuolar myopathy 
sparing quadriceps. 
Persian Jews. AR. 
Authors 
Gowers (1902) 
Laing et al. (1995b) 
Milhorat and Wolff, 
(1943); Horowitz & 
Schmalbruch (1994) 
Edstrom et al. (1980) 
Scoppetta et al. 
(1995) 
Argov & Yarom 
(1984); 
Sadeh et al. (1993) 
Categories I to V are presented as suggested by Somer et al. (1998). 
They are not related to Categories I to IV in Table 9.3 (p. 282). 
Somer et al. (1998, p. 190-192) justified the exclusion of the myopathies in 
Table 9.5 because they: had only been detected in a single large pedigree 
(Milhorat and Wolff, 1943; Laing et al., 1995b); had distal muscle weakness as 
a predominant dinical finding only for a certain stage of their disease ( Edstrom et 
al., 1980); or were 'dated' studies, lacking sufficient data for classification 
purposes (Gowers, 1902). 
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Somer et al. (1998) also excluded the report by Scoppetta et al. (1995) of AD 
infantile-onset in four Italian families without explanation. It did not qualify for 
exclusion on any of the above grounds. The Somer nosology did not include 
an infant-onset/childhood-onset category. 
Laing myopathy was included in the distal myopathy classification of Felice et al. 
(1999, p. 64), on the strength of its genetic localisation, not its age of onset. 
Nosological inclusion or exclusion, therefore, clearly depends upon the 
classification criteria used. The Laing and Scoppetta distal myopathy families 
share clinical features with four other distal myopathy families reported by Voit et 
al. (1997), Bautista et al. (1978), Does de Willebois et al. (1968) and Magee & 
DeJong (1965). The Scoppetta and Voit distal myopathy families were 
discussed in Section 7.3.2.10 (pp. 211-212). Recently, the Voit family and 
one of the Scoppetta families have been reviewed (Voit et al., 2001). 
All of these families displayed: AD inheritance; onset in infancy or childhood; 
initial weakness in anterior calf muscles followed by weakness in finger 
extensors; a lac k of RVs. All of these families except the Voit family also 
displayed: EMG indications of a myopathic origin; an increase in connective and 
adipose tissue and central nuclei in affected muscle; a variation in muscle fibre 
size; normal or moderately elevated CK levels (maximum was 3X); and benign 
to mild progression. 
Voit et al. (1997, p. 251) claimed that the distal myopathy in their family was 
distinguished by its very early age of onset, "As far as the existing literature is 
concerned no such family with dominant transmission and infantile onset within 
the first year of life has been reported to date." This claim may not be correct. 
Magee and DeJong (1965, p. 390) report that in their distal myopathy family, 
/' . 
with 18 affected members, onset was evident: 
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no later than age 2 ... it is possible that the weakness is 
present from birth and that the disorder should properly 
be termed "hereditary distal myopathy with onset in 
infancy." Because evaluation of muscle function was 
impossible before affected children began to walk, the 
term "hereditary distal myopathy with onset in infancy," 
although less precise, seems to be the most 
appropriate name for the disorder we have described. 
The reports of distal myopathy by Bautista et al. (1978), Does de Willebois et 
al. (1968) and Magee and DeJong (1965) are seldom mentioned in the 
literature and, for the purposes of distal myopathy nosology, they had faded 
from view. A re-examination of the literature has identified traditional clinical and 
.genetic evidence to indicate that a form, or forms, of distal myopathy with 
infant/childhood onset might exist. One of these distal myopathies was studied 
in this thesis, Laing myopathy. 
9.3 EVOLVING CONCEPTS IN OPMD 
In contrast to distal myopathy nosology, OPMD classification has remained 
stable. The OPMD diagnostic criteria of AD segregation, late-onset dysphagia 
and progressive ptosis, generally after age 45, and 8.5 nm diameter skeletal 
muscle INI (Tome & Fardeau, 1980), have become firmly established as 
prerequisite for OPMD diagnosis. This is of relevance to the putative-OPMD 
reported in Chapter 6, which does not meet these strict diagnostic criteria. 
9.3.1 Locus Heterogeneity Unlikely for OPMD 
Since Brais et al. (1995) localised the OPMD segregating in French-Canadian 
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families, OPMO locus heterogeneity has not been reported. Bouchard et al., 
(1998) have listed 17 populations around the world that meet OPMO 
diagnostic criteria, and include: French-Canadians, Russian and Bukhara Jews, 
Armenians, English, Brazilians and Australians of German descent. An additional 
five ethnic groups have had their OPMO localised to 14q, overlapping the 
14q11.2-q13 French Canadian OPMO candidate region (Brais et al., 1995). 
These were: one multigenerational family of Scottish/English ancestry (Stajich et 
al., 1996); one large pedigree of northern German ancestry (Friesland) 
(Perschke et al., 1997; Kress et al., 1998); one large pedigree of Bavarian 
ancestry (Kress et al., 1998); an Australian kindred of German descent (Teh et 
al., 1997); and three American families of Hispanic descent (Grewal et al., 
1998). All of these ethnic groups had different risk haplotypes to each other 
and to the French-Canadian OPMO population, suggesting 6 independent 
mutations for this disorder. Four multi-generational American families of French-
Canadian ancestry in the investigation by Stajich et al. (1996), had the same risk 
haplotype as the French-Canadian population studied by Brais et al. (1995). 
Linkage analysis with seven chromosome 14q polymorphic markers in 11 large 
French Canadian OPMO families established 0148283 as the new centromeric 
flanking marker, reducing the previously reported ScM candidate interval (Brais 
et al., 1995) to 2cM (Brais et al., 1997). Multipoint analysis suggested that the 
OPMO disease gene lay within a 1.5cM region around 0148990. A candidate 
for OPMO, poly(A) binding protein 2 gene (PABP2) had been mapped by in 
situ hybridization to chromosome 14q11 (Nemeth et al., 1995). PABP2 was a 
good candidate because its mANA was highly expressed in skeletal muscle 
and PABP2 protein was exclusively localised to the nucleus (Krause et al., 
1994) where it acted as one factor in mANA polyadenylation (Bienroth et al., 
1993). PABP2 exon 1 contains the start codon and a (GCG)s repeat coding 
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for six alanine residues. Brais et al. (1998, p. 164) found that (GCG)s allele 
was present in 98.0% of French Canadian controls, while the (GCG)? allele was 
found in the remaining 2.0% of this control population (n=86). Screening 144 
OPMD families from 15 different countries for a 242 bp PABP2 axon 1 
fragment, revealed a PCR product in all affected individuals that exceeded 
those found in controls by 6 to 21 bp (Brais et al., 1998). The disease gene 
causing AD-OPMD had been identified. 
The length of time taken to swallow 80 ml of ice cold water was found to 
correlate with disease severity, the size of GCG-repeat expansion, and with 
mode of inheritance in the French Canadian OPMD population (Brais et al. 
1998, p. 165). In the (GCG)g+(GCG)s genotype the (GCG)g allele was 
inherited as a dominant disease allele, causing a progressive increase in 
swallowing difficulty from about age 40 compared to control genotype 
(GCG)s+(GCG)s. The (GCG)7+(GCG)7 genotype had a late-onset, 
biopsy-proven, form of OPMD which, from pedigree analysis, had AR 
inheritance. This accounts for the inclusion of a new AR form of OPMD in Table 
9.2 (p. 279). 
The identification of PABP2 as the OPMD disease gene and the proposed 
accumulation of INI as the central event in OPMD molecular pathology, make 
OPMD locus heterogeneity unlikely. The fact that OPMD can also be a rather 
generalised dystrophy has not, and will not, influence the stringency of 
diagnostic criteria. Reports continue to appear of OPMD with diffuse 
phenotypes including: signs of distal symmetrical neuropathy (Porschke et al., 
1997); paracrystaline mitochondrial inclusions (Wong et al., 1996); and genetic 
anticipation (Biumen et al., 1997). Wong et al. (1996) suggest that abnormal 
mitochondria are a non-specific epiphenomena in OPMD while Porschke et al. 
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(1997) continue to agree with Hardiman et al. (1993) that the association 
between neurogenic lesion and OPMD remains unclear. Notwithstanding this 
debate, all of these reports of OPMD with diffuse phenotype also displayed 
AD segregation, late-onset dysphagia, progressive ptosis after age 45, and 
8.5 nm diameter skeletal muscle INI. 
From this it follows that the exclusion of the 14q OPMD locus for the WAOPMD 
family (Figure 6.5, p. 172) cannot be taken as evidence for OPMD locus 
heterogeneity until it is shown that the affected members of this family possess 
skeletal muscle INI histological markers. Even before PABP2 cloning, Meola et 
al. (1997, p. 853) had presented a strident argument in favour of INI as 
diagnostic for OPMD, "The identification of nuclear inclusions is mandatory in 
order to confirm the diagnosis prior to linkage analysis." The cloning of the 
PABP2 as the OPMD disease gene and its emerging molecular pathology, 
have made an exhaustive search for INI in affected WAOPMD skeletal muscle, 
a top priority. 
9.4 CONCLUDING COMMENTS 
McKusick (1990, p. v) has defined clinical genetics as: 
The science and practice ('art') of the diagnosis, 
prevention, and treatment of genetic disease. Some 
years ago I heard the British biostatistician Bradford Hill 
suggest that the practice of medicine consists of seeking 
the answers to three questions: What is wrong? (The 
answer is diagnosis). What is going to happen? (The 
answer is prognosis). What can be done about it (The 
answer is treatment). I would add a fourth question, 
Why did it happen? On the answer to this question 
depend prevention and the advancement of science. 
301 
Human molecular genetics has provided many answers to this last question. 
During the past decade it has forged numerous links between genotype and 
clinical phenotype. In addition, human molecular genetics has largely overcome 
the traditional foes of clinical genetics; long human generation time and small 
family size. Clinical genetics has become clinical molecular genetics. The 
expectation is that clinical molecular genetics will continue to change the medical 
landscape by constantly refining clinical practice. 
AD-MDs were the subject of this thesis because AD-mutations have the 
greatest effect on disease onset, the greatest effect on disease progression, 
and they are the easiest to clone. ·This means that research into AD-diseases 
has the best prospect for success; to delay the onset of diseases, to slow 
progression and, ultimately, to neutralise the pathological effect of disease-
causing mutations. A 'candidate mutation' was identified for Laing myopathy and 
future research directions described in Section 8.17 (p. 231 ). Molecular genetic 
analysis indicated that investigations into the the contractility of myosin II 
containing both A 1663 and P1663 ~-MyHC monomers, and the interaction of 
the ~-MyHC LMM rod region with other macromolecules, could both be 
productive areas of research. Productive not only for understanding Laing 
myopathy but also for understanding the pathological links between different 
forms of distal myopathy. 
The very similar appearance of Laing myopathy and TMD in MAl and CT 
scanning (personal communication, N.G. Laing, 2000) highlight the possibility of 
a common final pathway for these forms of distal myopathy. In Section 8.1.5 
(p. 229) the failure of MyBP-C to bind to ~-MyHC in Laing myopathy and to 
titin in TMD was identified as possible connection between these 
phenotypically similar diseases. Although it is impossible to predict what 
302 
molecular connections future research might find between the distal myopathies, 
it will become successively easier to look in the right places, and it is almost 
certain that patho-physiology connections will be found. Research on one form 
of distal myopathy will increasingly point the way for others. As molecular 
pathologies of the distal myopathies emerge and converge, it will be possible 
to influence the progression of this type of MD. In small ways to start with, but 
with gradual improvement as research progresses. 
Ultimately, Nagel (1999, p. 3) has argued, that as molecular genetics 
progresses we will no longer treating diseases but diseased individuals, .. The 
more that we know about the genetics of each individual, the more it will 
become apparent that each pathological event is unique to that individual". For 
Nagel, the conclusion became inescapable: the traditional concepts of disease 
had outlived their usefulness. Each mutation acts in the 'genetic terrain' in which it 
finds itself. By adding genetic individuality to the disease process, molecular 
genetics had opened another conceptual framework for pathology. The genetic 
individualisation of disease; there are no diseases, only diseased individuals. 
Molecular genetics was leading to customised medicine. 
In practice, however, a range of logistical factors will combine to limit the 
development of customised medicine for diseased individuals, including: 
statistical impasses; ascertainment difficulties; non-genetic environmental factors; 
and the frequency and effect of mutations. In addition, contributory disease 
genes will be harder and harder to detect, therefore more and more expensive 
to identify, as their contribution to disease diminishes. So how can research into 
rare diseases like Laing myopathy be encouraged? How can the most 
expensive option of all, 'the genetic individualisation of disease' be pursued so 
that medicine really starts to become customised? We need not ask. The tried 
and tested traditional method is at hand. The doctoral candidate! 
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Abstract. The human gene for slow-twitch skeletal muscle 
troponin I (TNNII) has previously been mapped to lql2~qter 
using somatic cell hybrids. The TNNII locus has now been fur-
Each muscle-specific gene should be associated with an 
inherited muscle disease, unless mutations do not occur in that 
gene or all mutations of that gene are lethaL Precise mapping of 
muscle genes in the human genome therefore becomes impor-
tant in relation to mapping muscle diseases. 
Striated muscle contraction is regulated by Ca2+ through the 
troponin complex (Ebashi et aL, 1967; Zot et aL, 1987). The 
troponin complex is composed of three polypeptides: troponin 
C (TnC), troponin I (Tni), and troponin T (TnT). Each polypep-
tide of the troponin complex is a member of a multigene family 
that is muscle-fibre specific. Thus, the Tni family consists of 
three isotypes, Tni-fast, Tnl-slow, and Tni-cardiac, which are 
components of fast and slow skeletal muscle fibres and cardiac 
muscle fibres, respectively (Cummins and Perry, 1977). 
The isoform Tni-slow was previously mapped to 1 q 12~ qter 
by analysis of a somatic cell hybrid panel, using an isoform-
specific probe from the 3' untranslated region (3' UTR) of the 
slow troponin I mRNA (Wade et aL, 1990). The chromosome I 
locus was designated TNNII (Wade et aL, 1990). We describe 
the assignment of the TNN II locus to 1 q32 by utilising the 3' 
UTR probe to initially isolate genomic clones ofTNNII, which 
were then used for in situ hybridization. 
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ther localised to lq32 using fluorescence in situ hybridization. 
This result confirms the previous assignment of this locus and 
maps the gene to a single chromosome band. 
Materials and methods 
Isolation of genomic clones 
The genomic library was constructed in A.Gem II (Promega) following 
partial Sau3A digestion. The library was plated out at six-fold redundancy, 
and duplicate lifts were made using Hybond N' colony/plaque screening 
membranes (Amersham). The probe, LK 603, derived from the 3' UTR region 
ofTNNII, was radiolabeled with [u-l2P]dCTP (Amersham) using a random-
primer kit (Promega). The duplicate lifts were hybridised with the probe for 
16 hat 42 •c in a hybridisation solution of 50% formamide, 10% dextran 
sulphate, I M NaCI, 50 mM Tris-HCI (pH 7.5], and 0.1 mg/ml herring sperm 
DNA. LiftswerewashedinO.I %SDS, 0.1 xSSCfor 30 minat65 •c. Autora-
diography was performed overnight with Dupont Cronex 4 X-ray film and 
Quanta III autoradiography screens at -80 • C. Plaques that were duplicated 
in the autoradiographs were considered positive. The purity of the positive 
plaques was ensured by a second and third round of screening. 
Pure clones were then amplified by the plate lysate method (Sambrook et 
al., 1989). Phage were eluted overnight in SM buffer (5.8 g NaCI, 2 g 
MgS04 ·?H20, 50 ml of I M Tris (pH 7.5], 5 ml of 2% gelatin solution, and 
sufficient H20 to make up 1 liter) at -4 • C. Eluates were collected and centri-
fuged at 9,000 rpm in an SS34 Dupont rotor for 15 min to pellet any bacteria 
that might be present. The supernatant was collected, and the phage were 
precipitated with 10% polyethylene glycol, I M NaC1 on ice for I hand then 
centrifuged at 1,500 rpm in an SS34 Dupont rotor. Supernatant was poured 
off, and the pellet was resuspended in 0.5 ml of TE (pH 8.0). The phage 
suspension was digested with 0.24 mg/ml RNase A at 37 •c for 30 min, then 
digested with 0.4 mg/ml proteinase K, 20 mM EDTA, 0.5% SDS for 15 min at 
65 • C. The sample was extracted three times with a mixture of phenol and 
chloroform and once with chloroform alone. DNA integrity was checked by 
running 9 111 of each sample on a 0.8% agarose gel at 100 V for 30 min, 
followed by staining with ethidium bromide. Single, high-molecular-weight 
bands were seen on the gel. Whole clones were then used for in situ hybridisa-
tion. 
In situ hybridisation 
The probes were nick-translated with biotin-14-dATP and hybridised in 
situ at a total probe concentration of 15 ng/111 to meta phases from two normal 
males. The nuorescence in situ hybridisation (FISH) method was modified 
from that previously des9ribed (Callen et al., 1990) in that only two rounds of 
amplification with nuorescein-conjugated avidin and biotinylated goat anti-
avidin were required, and the chromosomes were stained before analysis with 
both propidium iodide (as a counterstain) and 4',6-diamidino-2-phenylindole 
(DAPI) (for chromosome identification). 
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Fig. 1. Whole and partial metaphases showing in situ hybridization with the biotinylated probe (TN Nil). (a, b, d) Normal male 
chromosomes stained with propidium iodide. Hybridisation sites on chromosome I are indicated by arrows. (c, e) DAPI staining 
of the same metaphases for chromosome identification. 
Results and discussion 
Twenty-five metaphases from the first normal male were 
examined for fluorescent signals. Twenty-three of these meta-
phases showed signal on one or both chromatids of chromosome 
I in the region of 1q31 ~q32. Ninety percent of this signal was 
at q32 (Fig. 1 ). A total of nine nonspecific background dots were 
observed in these 25 metaphases. 
A similar result was obtained by hybridization of the 3' UTR 
probe ofTni-slow to metaphases derived from the second nor-
mal male {data not shown). 
To localize TNNil to lq32, it was necessary to use a probe 
that distinguished this Tnl-slow isoform from the Tnl-fast and 
Tnl-cardiac isoforms. Although the 3' UTR probe ofTni-slow 
distinguishes it from the other two isoforms of the Tnl gene 
References 
family, the size of the probe (250 bp) was not large enough for 
the in situ hybridization method used. The 3' UTR probe was 
therefore used to isolate genomic clones whose insert size was 
large enough for in situ hybridization. 
The results of this study confirm the previous assignment of 
the human TNNillocus to lql2~qter(Wade eta!., 1990) and 
further localise the gene to lq32. The localisation ofTNNil to 
lq32 should be of interest to laboratories searching for linkage 
of inherited human muscle disorders, especially those that have 
already linked diseases to this region. 
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Abstract. The human skeletal muscle alpha actin gene 
(ACTA!) has previously been localized to lp2l~qter using 
somatic cell hybrids and a specific probe from the 3' untrans-
Alpha actin is one of the major components of the contrac-
tile unit in skeletal muscle. The human skeletal muscle alpha 
actin gene, ACTA! has previously been localized to 
1 p21 ~ qter by somatic cell hybrid analysis using an isoforrn 
specific probe derived from the 3' untranslated region of a full 
length cDNAclone of ACTA! (Gunninget a!., 1984}. 
We describe the mapping of the ACTA! gene to lq42 by 
initially using the ACT AI sequence tagged site (STS) (Freeman 
and States, 1991) to isolate pure genomic clones, followed by 
fluorescence in situ hybridization (FISH) (Callen et al., 1990) 
of these clones to metaphase chromosome spreads. 
Materials and methods 
Isolation of genomic clones 
The genomic library was constructed in 1.. Gem II (Pro mega) following a 
partial Sau 3A digestion. The library was plated at 6-fold redundancy and 
duplicate lifts were made using Hybond N+ colony-plaque screening mem-
branes (Amersham). The PCR amplified STS of the ACTA! gene (Freeman 
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lated region of the gene. Using fluorescence in situ hybridiza-
tion the localization has been confirmed and the ACTA! gene 
precisely mapped to Iq42. 
and States, 1991) used as a probe, was labeled witb [ a.llP]dCTP (Amersham) 
using a random-primer kit (Promega). The duplicate lifts were hybridised 
with probe at 42 o C for 16 hours in a hybridisation solution of 50% form-
amide, I O%dextran-sulphate, IM NaCI, 50 mM Tris-HCI pH 7.5, 0.1 mglml 
herring sperm DNA. Lifts were washed in 0.1% SDS and 0.1 x SSC at 65 oc 
for 30 min. Dupont Cronex 4 X-ray film with Quanta III autoradiography 
screens were used for autoradiography at- 80 o C overnight. Plaques showing 
up in duplicate on the autoradiographs were considered positive. STS-PCR 
assay confirmed the presenceoftbe ACTA I sequence in the genomic clones. 
Pure clones were !ben amplified by the plate lysate method (Sambrook et 
al., 1989). Phage were eluted in SM buffer (100 mM NaCI, 8 mM 
MgSO,- 7H20, 50 mM Tris pH 7.5, 0.01% gelatin solution) at 4 oc over-
night. Eluates were coUected, phage purified on caesium chloride gradient 
(Sambrook, et al., 1989) and DNA extracted. DNA integrity was checked by 
running each sample on a 0.8% agarose gel at 100 volts for 30 min then 
staining witb ethidium bromide. Confirmation that the extracted DNA con-
tained ACTA I gene was obtained by STS-PCR and also by PCR amplifica-
tion of the 5' and 3' ends of the gene (5' primer set: (TGA-
GACTTCTGCGCTGATGCA, ACTCACCGGTGGTCCTTCCGGA], 3' 
primer set: [GCACAGGCATCGTGCTGGACT, TATGTACACGTTA-
T AAACACTG]). Whole clones were then used as probes for in situ hybridi-
sation. 
In situ hybridisation 
The probes were nick-translated with biotin-14-dA TP and each was 
hybridized in situ at a final concentration of20 ng/[11 to metapbases from two 
normal males. The FISH method was modified from that previously 
described (Callen, et al., 1990) in that chromosomes were stained before 
analysis with both propidium iodide (as counterstain) and DAPI (for chro-
mosome identification). 
Cell lines 
The construction of the mouse-human hybrid cell lines was described by 
Callen et al. (1992). Table l shows the human chromosome I content of the 
cell lines. 
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Fig. 1. Whole and partial metaphases showing in situ hybridization 
with the biotinylated probe :I.HACT-1. (a) (b) (d) normal male chromo-
somes stained with propidium iodide. Hybridization sites on chromosome 
I are indicated by arrows. (c)( e) DAPI staining of the same metaphases for 
chromosome identification. 
Results and discussion 
In order to-map ACTA! to lq42 by FISH, probes greater 
than I kb in length are required. The isoform specific STS PCR 
product (l88bp) (Freeman and States, 1991) was initially used 
as a hybridization probe to the genomic library which has an 
average insert size of 15 kb. Six positive plaques were picked; 
and respread at lower density so that individual plaques could 
be isolated. The STS primer set was used to assay selected pure 
plaques. Two pure plaques which gave positive STS signals, 
A.HACT-1 and A.HACT-2, were then further propagated. 
A.HACT-1 gave positive results for both the 3' and 5' prim-
ers and is therefore likely to contain the whole ACTA! gene. 
A.HACT-2 gave a positive signal for the 3' primer set but not the 
5' primer set demonstrating that only part of the gene is present 
in this.clone. 
A.HACT-1 and A.HACT-2 were then used for FISH to meta-
phase spreads from two normal males. Twenty-five meta phases 
from the first normal male were examined for fluorescent sig-
nal with A.HACT-1. Twenty.one of these metaphases showed 
signal on one or both chromatids of chromosome I in the 
region q42~q43; 73% of this signal was at q42 (Fig. I}. Seven 
non-specific background dots were observed in the 25 meta-
phases. Similar results were obtained in 20 metaphases from 
the second normal male hybridized with this probe and from 
hybridizations using A.HACT-2 as the probe. These results 
assign the ACTA I locus to lq42. 
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Table I. Assignment of ACTA I by STS-PCR amplification of chromo-
some I hybrids 
Hybrid cell line 
CYI5 
CYI29 
CYI52 
CYI28 
CYI96 
CYIJ 
Human chromosome content 
der(l6)t( I ;16)(p34;pl2.2)b 
der(l6)t(l;l6)(pl3.1;pll.2)• 
der(l6)t(l;16)(pll;pl1.2)• 
der(l)t(l ;16)(q43;q22.1) 
der(l6)t( I ;16)(ql2;pl3.3) 
der( 16)1( I ;16)(q44;p 12.3)• 
PCR amplification of the ACTA I STS is indicated by(+). 
Hybridizationa 
+ 
+ 
b Although these cell lines contain other human chromosomes, the presence of 
chromosome I has been excluded. 
PCR analysis of the hybrid cell panel showed that the hybrid 
cell lines CY 128 and CY 196 contained the ACT A l sequence 
(Table I). The only region of chromosome I unique to these cell 
lines is ql2~q43, which is consistent with the in situ hybridi-
zation result placing ACT AI in q42. 
These results confirm the assignment of the ACT A l locus to 
I p21 ~ qter using a specific probe for the 3' untranslated region 
with somatic cell hybrids (Gunning et al., 1984) and further 
localise the gene to lq42. 
The skeletal muscle alpha-actin gene has been localized to 
chromosome 8 in the mouse (Actsk-1) (Alonso et al., 1993; 
Cytogenet Cell Genet, Vol. 65, 1994 
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Abonia et al., 1993) and chromosome 1 in human {ACfA1) 
{Gunning et al., 1984; this report). Alonso et al. {1993) and 
Abonia et al. (1993) show that angiotensinogen (Agt) is closely 
linked to Actsk-1 on chromosome 8 in the mouse while AGT 
has been localised to lq42--+q43 in human (Isa et al., 1990; 
Gaillard-Sanchez et a!., 1990). The present FISH localisation of 
ACfAI to lq42 is further evidence of a conserved region of 
homology between mouse chromosome 8 and human chromo-
some 1 and confirms the inference that ACfAI in human 
should map in the region of 1 q42--+ q43 (Alonso et al., 1993; 
Abonia eta!., 1993). 
The localization of ACf AI to 1 q42 should be of interest to 
laboratories searching for linkage of inherited neuromuscular 
disorders, especially those that have already linked such dis-
eases to this region. 
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Autosomal Dominant Distal Myopathy: Linkage to Chromosome 14 
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Summary 
We have studied a family segregating a form of autosomal 
dominant distal myopathy (MIM 160500) and containing 
riine living affected individuals. The myopathy in this fam-
ily is closest in clinical phenotype to that first described by 
Gowers in 1902. A search for linkage was conducted using 
microsatellite, VNTR, and RFLP markers. In total, 92 
markers on all 22 autosomes were run. Positive linkage 
was obtained with 14 of 15 markers tested on chromo-
some 14, with little indication of linkage elsewhere in the 
genome. Maximum two-point LOD scores of 2.60 at re-
combination fraction .00 were obtained for the markers 
MYH7 and D14S64-the family structure precludes a 
two-point LOD score ;;,3. Recombinations with D14S72 
and D14S49 indicate that this distal myopathy locus, 
MPD1, should lie between these markers. A multipoint 
analysis assuming 100% penetrance and using the markers 
D14S72, D14S50, MYH7, D14S64, D14S54, and D14S49 
gave a LOD score of exactly 3 at MYH7. Analysis at a 
penetrance of 80% gave a LOD score of2.8 at this marker. 
This probable localization of a gene for distal myopathy, 
MPD1 on chromosome 14 should allow other investiga-
tors sn:dying distal myopathy families to test this region 
for linkage in other types of the disease, to confirm linkage 
or to demonstrate the likely genetic heterogeneity. 
Introduction 
The distal myopathies are a heterogeneous group of disor-
ders showing both autosomal dominant and autosomal 
recessive inheritance, with diverse phenotypic features and 
pathological changes (Mastaglia 1991). Gowers (1902) de-
scribed a patient with weakness and wasting of the hand, 
forearm, and anterior tibial muscles, which had developed 
by the age of 10 years; and by the age of 18 years there 
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was also severe wasting of the sternomastoids, wasting of 
the tongue, and weakness of the facial muscles. lbis is 
accepted as the first description of the hereditary distal 
myopathies (MIM 160500; McKusick 1992), although it 
has been suggested that Gowers's patient may have had 
myotonic dystrophy, which shows a similar pattern of mus-
cle atrophy and weakness (see Walton and Gardner-Med-
win 1981). The better-known of the distal myopathies are 
the dominantly transmitted forms, occurring particularly 
in Scandinavia, which may have a late onset and either a 
relatively benign course (Welander 1951) or a more rapid 
progression (Edstrom et al. 1980). Recessive forms have 
also been described, particularly in Japan, where a distinc-
tive myopathy characterized histologically by the presence 
of rimmed vacuoles in muscle fibers occurs (Nonaka et al. 
1981). 
To date, genetic linkage has not been demonstrated in 
any of the forms of distal myopathy, nor have any candi-
date genes been identified (McKusick 1992). We report 
here positive linkage to the long arm of chromosome 14 
in a family with dominantly inherited distal myopathy with 
phenotypic features closely resembling those described in 
Gowers's original report (Gowers 1902). These results have 
previously been reported in brief (Meredith et al. 1994). 
Subjects and Methods 
Family 
The condition was dominantly transmitted with high 
penetrance in three generations of the family, which is of 
English/Welsh origin (fig. 1). Nine affected and three unaf-
fected members from three generations were examined. 
Oinica/ Features 
Age at onset was 4-25 years, with selective weakness 
of the toe and ankle extensors and the neck flexors, fol-
lowed, after several years, by progressive weakness of the 
finger extensors. The finger flexors and intrinsic hand mus-
cles were Telatively unaffected, but certain proximal muscle 
groups such as the hip abductors and external rotators and 
shoulder abductors were mildly affected. Although progres-
sion was gradual, there was eventually a moderate de~ee 
of incapacity, as in ll:2, the oldest living affected famtly 
member, who was initially investigated in 1969 and who 
360 
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1:2 1:3 1:4 
11:1 11:2 11:3 11:4 11:5 11:6 11:7. 11:8 
111:1 
"' 111:2 
111:3 111:6 111:7 
IV:I IV:2 IV:3 IV:4 IV:S IV:6 IV:7 IV:8 IV:9 IV:IO 
Figure I Pedigree of the family segregating distal myopathy. The proband (ill:2) is indicated by the arrow. Each individual marked with a 
cross was examined clinically, and an immortalized cell line was established for him or her. Blackened symbols denote affected individuals; an "N" 
in the center of the symbol denotes that the individual is clinically unaffected, and a question mark (?) in the center of the symbol denotes that the 
individual's status is unknown. 
was reexamined in 1992 when he was still walking but 
had difficulty maintaining an erect posture when standing. 
In all affected individuals the deep-tendon reflexes were 
preserved, and the plantar responses were flexor. There was 
no myotonia, sensory impairment, or other neurological 
abnormality. Serum creatine kinase levels were elevated 
(216-531 U!liter [normal <180 Ulliter]) in three affected 
individuals. 
Electrodiagnostic Studies 
Electromyography and nerve conduction studies were 
performed in the proband (ill:2; fig. 1) and in Il:2 and 
N:2. Muscle sampling with a concentric needle electrode 
showed striking myopathic motor-unit potential changes 
(i.e., low amplitude and brief duration units, with many 
polyphasic units) and a full, low-amplitude (<0.5 mV) 
interference pattern particularly in affected distal limb mus-
cles and, to a lesser extent, in some proximal muscles. 
Occasional spontaneous fibrillation potentials and positive 
waves were present in some affected muscles in III:2. Myo-
tonia was not found. Results of motor- and sensory-nerve 
conduction studies in the upper and lower limbs were 
normal. 
Histological Changes 
An open biopsy taken from the left vastus lateralis mus-
cle in III:2 showed occasional necrotic and regenerating 
fibers, excessive variation in fiber size, increased numbers 
of fibers with internal nuclei, occasional angulated atrophic 
fibers, and nuclear clumps (fig. 2). There were no rimmed 
vacuoles or sarcoplasmic inclusions. Histochemistry 
showed only nonspecific changes with moth-eaten fibers 
and increased enzyme activity in angulated fibers in the 
NADH-TR preparations (fig. 2). There was no pathological 
fiber-type grouping. There were no sarcoplasniic inclusion 
bodies as found in the family described by Edstrom et a!. 
(1980). Results of dystrophin and desmin immunohisto-
chemistry were normal. A biopsy of the left tibialis anterior 
muscle from II:2, taken in 1969, showed evidence of end-
stage disease with extreme muscle-fiber atrophy, many cen-
tral nuclei and nuclear clumps, and condensation of endo-
mysia! connective tissue. 
Blood Samples 
Blood samples were taken, and immortalized cell lines 
were established for the 15 family members who volun-
teered to participate in the study (fig. 1). Venous blood 
samples ( .;;40 ml) from adults were split 50:50 into lithium-
heparin and EDTA tubes for, respectively, lymphocyte iso-
lation and immortalization with Epstein-Barr virus (Neitzel 
1986) and immediate DNA isolation by either conventional 
phenol-chloroform or salt-precipitation (Miller eta!. 1988) 
techniques. 
Unkage Analysis 
Ninety-two polymorphic markers spread over all au-
tosomes were tested. These were D1S80, D1S185, D1S176, 
CRP, D1S104, AT3, and ACTN2; APOB, D2S44, HOX4, 
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Figure 2 Top, Vastus lateralis biopsy from III:2, showing excessive 
variation in myofibril size and nuclear clumps: hematoxylin and eosin 
(X 400). Bottom, Vastus lateralis biopsy from III:2, showing darkly 
stained angulated atrophic type II fibers and moth-eaten type I fibers: 
NADH·TR (X 400). 
and D25102; D351307, D351304, D351285, D351287, 
D351279, D351282, D351262, and D351311; HD, 
D45174, and D45171; D55268, D55112, D5539, APC, 
and D55210; OMDL; D75472, D75435, 075474, GCK, 
075440, and CF; D85166, D8584, 085198, and D85200; 
095104, 09515, and D9553; 010528; D115875, 
0115873, C03D, and D115836; D12543 and D12560; 
RB1; 014572, D14550, MYH7, D14564, D14554, 
014549, D14552, 014576, D14553, 014574, D14548, 
014581, 014545, 014551, and D14531; D15587; 
D165291, D165292, D165287, D165295, 0165298, 
0165300, D165308, 0165265, 0165186, 0165301, 
D165260, D165266, and D165305; D17530, D175122, 
GX-Alu, HOXB, and D17526; D18540 and D18551; 
D19575, APOC2, and DM; D20566; 0215210 and 
D215213; and D225258. 
VNTR Analysis 
Probes for genotyping the VNTR markers D2544, 
D10528, D14513, and D17526 were purchased from Pro-
mega. For each family member, 4 J1g of DNA isolated as 
above was digested overnight with Haeiii (Amersham). 
Fragments separated in a 0.8% agarose gel electrophoresis 
were alkali-transferred to Hybond N+ nylon membranes 
\ 
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(Amersham) and hybridized with inserts labeled by random 
priming (Amersham). Cronex 4 film (Ou Pont) was ex-
posed for 7-10 d at - 80°C with single intensifying screens. 
Microsatel/ite and PCR Polymorphisms 
A Cyclone Plus DNA 5ynthesiser (Milligen/Biosearch) 
was used to synthesize primers for microsatellite (Weber 
and May 1989) and PCR polymorphisms. Primer se-
quences were obtained from the Genome Data Base. Mi-
crosatellite PCR co-nditions for a reaction volume of 20 J!l 
were as follows: 4 J!l of 5 X buffer (335 mM Tris-HCI 
[pH 8.8] at 25°C, 83 mM (Nl-J4)2504, 100 J1M dNTP, 0.2 
J!l of 25 mM MgCiz, 50 ng of each primer, 0.1 J!l of 32P-
dCTP (3,000 Ci!mmol; Amersham), 50 ng of target DNA, 
and 0.5 unit of Tth polymerase (Biotech International). The 
reactions were overlaid with mineral oil, and the cycling 
conditions were as follows: 94°C for 5 min to denature, 
58°C for 6 min to anneal and elongate for one cycle, fol-
lowed by 35 cycles of 94°C for 1 min and 58°C for 6 min. 
Where necessary, annealing temperatures were raised to 
improve primer specificity. Products were then refrigerated 
at 4°C until gel electrophoresis. Aliquots of the reaction 
woduct were mixed with an equal volume of formamide-
loading buffer and, depending on expected allele size, were 
electrophoresed on standard 6% or 4% acrylamide dena-
turing sequencing gels (5ambrook et a!. 1989, chap. 13). 
PCR reaction conditions for four nonmicrosatellite poly-
morphisms (APOB, AT3, HD, and D17530) were similar, 
except that no radioactive nucleotide was included in the 
reaction mix and aliquots of the reaction products were 
electrophoresed in 2% agarose. 
Unkage Analysis 
Two-point linkage analysis was carried out using the 
method of maximum likelihood and LOD scores (Morton 
1955), by the computer program UPEO (Ott 1974). Analy-
sis of the combined data from all the markers was per-
formed using the EXCLUDE program (Edwards 1987; 
5arfarazi eta!. 1989). The chromosomal positions of loci 
were estimated from the NIH/CEPH Collaborative Map-
ping Group (1992) linkage maps, the second-generation 
linkage map of the human genome (Weissenbach et a!. 
1992), and data from the ·Cooperative Human Linkage 
Center. Multipoint linkage analysis was performed using 
the CRIMAP version 2.4 package, as described elsewhere 
(Mulley eta!. 1993), at 100% and 80% penetrance. 
Results 
Unkage 
In total, 92 marker loci spread over all 22 autosomes 
were typed in the distal myopathy pedigree. Two markers 
on chromosome 8 gave positive two-point LOD scores 
> 1.00. D8584 gave a LOD score of 1.11 at recombination 
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Table I 
Results of Two-Point Linkage Analyses, for Linkage between MPDI and Markers on Chromosome 14 
LOD SCORE AT 9 = 
Locus loCATION' 0 .001 .01 .05 .10 .20 .30 .40 
D14S72 ......... qll -3.13 -1.56 -.59 .03 .23 .31 .26 .15 
D14S50 ......... qll 2.31 2.31 2.27 2.12 1.93 1'.51 1.06 .57 
MYH7 .......... qll 2.60 2.59 2.55 2.36 2.12 1.61 1.08 .53 
D14S64 ......... qll-q32 2.60 2.59 2.55 2.36 2.12 1.61 1.08 .53 
D14554 ......... qll-q32 .41 .41 .40 .35 .29 .17 .09 .02 
D14549 ......... qll-q32 -2.49 -1.25 -.30 .30 .47 .49 .36 .19 
D14S52 ......... .qll-q32 -99 -3.41 -1.45 -.22 .17 .32 .23 .10 
D14S76 ......... qll-q32 -99 -6.39 -3.42 -1.46 -.72 -.17 .01 .05 
D14S53 ......... qll-q32 -99 -3.31 -1.38 -.14 .27 .49 .44 .27 
D14S74 ......... qll-q32 -99 -.99 -.02 .55 .69 .66 .52 .30 
D14S48 ......... qll-q32 -99 -.47 .49 1.00 1.06 .87 .56 .26 
D14S81 ......... qll-q32 .20 .20 .19 .15 .10 .04 .01 .00 
D14S45 ......... q32.1-qter -99 -2.20 -1.21 -.57 -.34 -.15 -.07 -.02 
D14S51 ......... q32.1-qter -99 -3.77 -1.80 -.53 -.10 .15 .15 .08 
D14S13 ......... q32.1-qter -99 -1.61 -.63 -.03 .15 .19 .13 .04 
• From NIH CEPH Collaborative Mapping Group (1992) and Weissenbach et al. (1992). 
fraction (9) .00, and D8S200 gave a LOD score of 1.09 at 
9 = .00. These two markers were, however, only informa-
tive in one branch of the family, and other markers on 
chromosome 8-i.e., D8S166 and D8S198-which gave 
information for the other branch of the family, showed 
multiple recombinants. Thus, significantly negative LOD 
scores were obtained for these markers, and chromosome 8 
is unlikely to be the site of the disease locus. More strongly 
positive two-point LOD scores were obtained with markers 
on chromosome 14. D14S50, MYH7, and D14S64 showed 
no recombinants (table 1) and two-point LOD scores of 
2.31, 2.60, and 2.60, respectively. A multipoint LOD score 
of 3.00 was obtained for MYH7, and 2.99 for D14S64, 
when the information for D14S72, D14S50, MYH7, 
D14S64, D14S54, and D14S49 was used (fig. 3), under 
the assumption of 100% penetrance. A multipoint LOD 
score of 2.80 was obtained for MYH7 at a penetrance of 
80%. Recombinants with D14S49 and D14S72 indicate 
that the disease locus, MPDl, should lie between these 
markers. 
EXCLUDE 
The EXCLUDE program (Edwards 1987) was used to 
estimate the likelihood that the distal myopathy gene in 
this family lies on chromosome 14 and to estimate the 
proportion of the genome excluded as the possible site for 
the disease gene. Running the EXCLUDE program for the 
entire data set gave a probability of 99.9% that the gene 
responsible for autosomal dominant distal myopathy in 
this family, MPDl, lies on chromosome 14. The same 
probability of 99.9% for the disease gene lying on chromo-
\ 
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Figure 3 Multipoint analysis for the markers D14S72, D14S50, 
MYH7, D14S64, D14S54, and D14S49, assuming 100% penetrance. The 
graph shows multipoint LOD scores for chromosome 14; the LOD score 
for a penetrance of 80% was 2.8 at MYH7. Shown beneath the graph 
is the background map used to localize the disease genes. 9 is sex-averaged 
and is calculared by using Haldane's mapping function. 
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some 14 was obtained from EXCLUDE in an affecteds-
only analysis. Running the EXCLUDE program for the 
data set minus the data for chromosome 14 showed that 
a considerable proportion, ;;.50%, of the genome had been 
excluded as the possible site of the disease gene in this 
family. 
Discussion 
The pedigree investigated displays a form of distal myop-
athy that is quite distinct from the better-known distal 
myopathies described in Scandinavia and Japan. Welander 
(1951) described a benign Scandinavian form with weak-
ness first occurring in the fingers and wrists and later pro-
gressing to involve the anterior tibial and calf muscl(!s. 
There was also early involvement of the thumb, wrist, and 
finger muscles in the severe Scandinavian form described 
by Edstrom et al. (1980), with weakness progressing to 
other muscles and leading to major disability within 15 
years of onset of the disease. In comparison, the distal 
myopathy described here is very similar to that reported 
by Gowers (1902), with early involvement of the distal 
lower limb muscles and the sternomastoids and with rela-
tive sparing of the hand and forearm muscles. 
The distal myopathy in this family shows obvious domi-
nant inheritance. A considerable portion of the genome has 
been scanned with the 92 markers tested. The best evidence 
of linkage is seen with chromosome 14. The EXCLUDE 
program (Edwards 1987) gives a 99.9% likelihood of link-
age to chromosome 14, both in an affecteds-only analysis 
and when data for all the family members are used, while 
multipoint analysis gives a LOD score of 3.00 at MYH7, 
under the assumption of 100% penetrance, and gives a 
LOD score of 2.8 at 80% penetrance. There is littl~ evi-
dence of linkage elsewhere. It is unlikely that a larger [OD 
score will be obtained from study of this family, since the 
Australian branch of the family has lost contact with any 
remaining relatives in England/Wales, and, despite attempts 
to identify such relatives, none have been found. It is also 
possible that there are no other affected relatives. 
Both the linkage to MYH7 and D14S64 and the recom-
binations with D14S49 and D14S72 indicate that the mu-
tated gene, MPD 1, should lie in the region of these markers. 
Both the distal myopathy in this family and the other distal 
myopathies affect restricted groups of muscles in defined 
locations of the body; other muscle diseases affect other 
restricted muscle groups. Exactly what type of genes that, 
when mutated, could cause muscle diseases restricted to 
certain muscle groups is uncertain. They could perhaps be 
genes coding for muscle structural proteins, though this 
might seem unlikely because such proteins should be ex-
pressed in aU muscle groups. The mutated genes might, 
on the other hand, be genes involved in delineating body 
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segments during development. Recently a repeated homeo-
domain has been implicated in another restricted form of 
muscle disease, facioscapulohumeral muscular dystrophy 
(Wijmenga et al. 1992), although the exact relationship 
between the homeodomain and the disease has been 
brought into question by the identification of recombina-
tions between the homeodomain marker and the disease 
(Weiffenbach et a!. 1993). 
Two muscle genes that are known to lie within the 
MPDl linkage region on chromosome 14 are the alpha 
and beta cardiac myosin genes MYH6 and MYH7 (Matsu-
oka et al. 1989). Although beta cardiac myosin is expressed 
in skeletal muscle ijandreski et al. 1987), it is unlikely that 
mutations in that gene are the basis of the distal myopathy 
in the family under investigation, since mutations in the 
beta cardiac myosin gene lead to hypertrophic cardiomyop-
athy, which is not present in this family. Markesbery et al. 
(1974) reported autopsy findings of cardiomyopathy in 
their late-onset hereditary distal myopathy patients, but the 
pattern of muscle weakness in their patients was different 
from that in the family described here. Nevertheless, the 
cardiac myosin genes must be considered as candidate 
genes for MPDl and should be investigated for mutations 
in affected family members. 
Despite the phenotypic differences between the Gowers 
and other forms of distal myopathy, it is possible that some 
are aUelic, with different mutations producing the different 
phenotypes. The suggested linkage to chromosome 14 
should now aU ow other investigators researching distal my-
opathy families to confirm linkage or demonstrate the het-
erogeneity that might be expected from the variable clinical 
phenotypes seen in the condition. 
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Assignment of the human beta tropomyosin 
gene (TPM2) to band 9p 13 by fluor~scence in 
situ hybridisation 
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Abstract. A sequence tagged site (STS) was developed for 
the human beta tropomyosin gene (TPM2). The STS was used 
to amplify DNA from somatic cell hybrids to localise TPM2 to 
human chromosome 9. Genomic clones isolated with the STS 
Each muscle-specific gene should be associated with an 
inherited muscle disease, unless mutations do not occur in that 
gene, or all mutations of that gene are lethal. Precise mapping 
of muscle genes therefore becomes important in relation to 
mapping muscle diseases (Eyre eta!., 1993; 1994; Wilton eta!., 
1994). 
Tropomyosin is one of the components of the thin filaments 
of muscle, binding to actin, and, together with troponin, regu-
lating contraction in a calcium-dependent manner (Clayton et 
a!., 1988). There are at least four distinct tropomyosin genes in 
humans (TPM1-4) and each may encode different protein iso-
forms by alternate splicing (Clayton eta!., 1988). The alpha tro-
pomyosin gene TPM1 has recently been localised to 15q22 
(Eyre eta!., 1994) and has been shown to be mutated in some 
cases of familial hypertrophic cardiomyopathy (Thierfelder et 
a!., 1994). The alpha tropomyosin gene TPM3 has been recent-
ly localised to lq22--tq23 (Wilton eta!., 1994) and has been 
shown to be mutated in a family with autosomal dominant 
nemaline myopathy (Laing et al., 1995). 
We describe the mapping of the human beta tropomyosin 
gene TPM2 (Widada et a!., 1988) to 9p 13 by development of a 
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product were in turn used in fluorescence in situ hybridisation 
to metaphase chromosome spreads to further localise TPM2 to 
9pl3. 
sequence tagged site (STS) (Olson et a!., 1989), testing of a 
somatic cell hybrid panel, and fluorescence in situ hybridiza-
tion (FISH). 
Materials and methods 
STS for the TPM2 gene 
The eDNA sequence of the skeletal muscle transcript of the TPM2 gene 
(Widada, et al., 1988) was used, along with the known conserved exon pat-
tern of the tropomyosin genes (Clayton et al., 1988), to design primers for 
amplification which would amplify across intronic sequences (Wilton et al., 
1994). The primers were chosen such that at least one was located in a skele-
tal muscle specific exon (Clayton, et al., 1988; Widada, et al., 1988) to help 
avoid amplifying pseudogene sequences. The primers eventually used were 
in the muscle specific exon Vlllsk (TPM2.8R: 5'-AGTTACTGTAGTG-
GAGGGAG-31 and the common exon VI (TPM2.6F: 5'-A TTCCACCAAA-
GAAGATAAA-3') (Widada, et al., 1988). These primers amplified an STS 
product approximately 1.5 kb long. The amplification conditions for a reac-
tion volume of 25 111 were: 5 111 of 5 x buffer (335 mM Tris HCI, pH 8.8 at 
25 •c; 83 mM (NH4),S04, I mM dNTPs, 10 mM MgCI2, I mg gelatin!ml, 
and 2.25% Triton X-100), SOng target DNA and 0.5 U ofTth polymerase 
(Biotech International). Thermal cycling conditions were: 35 cycles of 94 • C 
for 30s, 58"C for 6min, with an initial denaturing period at 94"C for 
4.5 min. The 1.5-kb product was partially sequenced using an ABI 373A 
DNA sequencer to confirm that the STS product did indeed contain parts of 
the TPM2 gene. 
Isolation of genomic clones 
The genomic library was constructed in AEMBL3 SP6ff7 (Clontech) fol-
lowing a partial BamH I digestion. The library was plated out at 6-fold redun-
dancy and duplicate lifts made using Hybond N+ colony/plaque screening 
membranes (Amersham). The probe used was the 1.5-kb PCR amplified STS 
of the TPM2 gene which was radiolabeUed with [a-32P]dCTP (Bresatec) 
using a random-prime kit (Promega). The duplicate lifts were hybridised 
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with probe at 42 • C for 16 h in a hybridisation solution of 50% formam ide, 
10% dextran sulphate, I M NaCI, 50mM Tris-HCI pH7.5, 0.1 mglml her-
ring sperm DNA. Lifts were washed in 0.1% SDS and 0.1 x SSC at 65 • C for 
30 min. Autoradiography was carried out with Dupont Cronex 4 X-ray film 
with Quanta III autoradiography screens at -80 • C overnight. Plaques show-
ing up in duplicate on the autoradiographs were considered positive. Confir-
mation of the TPM2 sequence in the genomic clones was ensured by STS 
PCR assay and partial sequencing. 
Pure clones were then amplified by the plate lysate method (Sam brook et 
al., 1989). Phage were eluted in lambda dilution buffer (I 00 mM NaCI, 
10 mM MgS04·7H20, 100 mM Tris pH 7.5, 0.01% gelatin solution) at 4 •c 
overnight. Eluates were collected and phage were purified on caesium chlo-
ride gradients (Sambrook, et al., 1989) and DNA extracted. DNA integrity 
was checked by running each sample on a 0.8% agarose gel at I 00 V for 
30 min and staining with ethidium bromide. Extracted DNA was confirmed 
to contain the TPM2 gene by STS PCR and sequencing. Whole clones were 
then used for in situ hybridisation. 
In situ hybridisation 
The probes were nicktranslated with biotin-14-dATP and hybridized in 
situ at a final concentration of 20 ngl11l to meta phases from a total of three 
normal males. The fluorescence in situ hybridization (FISH) method was as 
described previously (Eyre et al., 1993; 1994; Wilton et al., 1994) with chro-
mosomes stained before analysis with both propidium iodide (as counter-
stain) and DAPI (for chromosome identification). Images of metaphase prep-
arations were captured by a ceo camera and computer enhanced. 
Cell lines 
A panel of rodent-human somatic cell hybrids was obtained from the 
National Institute of General Medical Sciences Human Genetic Mutant Cell 
Repository [NIGMS/mapping panel # 2]. The construction of the mouse-
human hybrid cell lines was described by Dubois and Naylor ( 1992). PCR 
amplification of the STS was performed with 50 ng of hybrid DNA and the 
primers TPM2.6F and TPM2.8R as above. 
Results and discussion 
Somatic cell hybrid panel 
The TPM2 STS gave an amplification product from only 
the control human DNA and the somatic cell hybrid GM/ 
NA10611 (Dubois et al., 1992) (data not shown). Only chromo-
some 9 was unique to this cell line indicating that TPM2 is on 
human chromosome 9. 
FISH 
The STS PCR product was used as a hybridization probe to 
the genomic library which has an average insert size of 15 kb. 
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Abstract 
The distal myopathies are clinically, pathologically and genetically heterogenous. Thus far, seven types of distal myopathy have been 
linked to four chromosome loci. We recently examined four affected members from three generations of an autosomal dominant distal 
myopathy kindred. A muscle biopsy was performed on the index case. Muscle histopathology showed non-specific myopathic findings 
including increased variation in fiber size and increased internalized nuclei. No abnormal inclusions or vacuoles were present Micro-
satellite markers for the four distal myopathy loci on chromosomes 2, 9 and 14 were studied on affected and several unaffected family 
members. Affected patients developed distal weakness in anterior foreleg muscles followed by progressive distal upper and proximal lower 
extremity involvement. Chromosome 2, 9 and 14 regional markers were informative and demonstrated recombinations with affected 
individuals in the pedigree. The resulting LOD scores obtained rrom the multipoint analyses gave no evidence of positive linkage to 
any of the regions and positively excluded (LOD score less than -2) all, or virtually all, of the candidate regions examined. This autosomal 
dominant distal myopathy family does not show evidence of linkage to any of the known distal myopathy loci, suggesting the existence of 
at least one more distal myopathy locus. Furthermore, the clinical and pathological features appear distinct rrom other previously described 
but genetically-undetermined autosomal dominant distal myopathies. © 1999 Elsevier Science B. V. All rights reserved 
Keywords: Distal myopathy; Autosomal dominant; Chromosome 
1. Introduction 
The familial distal myopathies are a pathologically and 
genetically heterogenous group of disorders which share the 
clinical feature of myopathic weakness beginning in the 
distal muscles of the upper or lower extremities, or both 
[1,2]. Previously, these disorders were classified by specific 
clinical and pathological features into several distinct dis-
orders including Welander, Markesbery, Nonaka and 
Miyoshi myopathies. Recently, the genetic loci for seven 
• Corresponding author. Tel.: +1-860-679-3186; fax: +I-860-679-4446; 
e-mail: fclice@nso.ucbc.cdu 
types of distal myopathy have been elucidated and, there-
fore, a revised genetic classification of these disorders is 
now emerging. In this report, we describe a new autosomal 
dominant distal myopathy family which does not show evi-
dence of linkage to any of the known distal myopathy loci. 
Furthermore, the clinical and pathological features appear 
distinct from other previously described but genetically-
undetermined autosomal dominant distal myopathies. 
2. Case reports 
The pedigree for this family is shown in Fig. I. Cases 1-4 
0960-8966/99/$ · see front maner © 1999 Elsevier Science B.V. All righiS reserved 
Pll: S0960-8966(98)00099-6 
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Fig. I. Pedigree for family. The index case is IU-2. Symbols represent the 
following: squares, males; circles, females; filled, definitely affected; half-
filled, probably affected based on hislory; slashes, deceased; and arrow 
beads, patients examined. 
were examined by one ofthe authors (KJF). Cases 5-7 were 
not examined but were probably affected based on the his-
tory. 
2.1. Case 1 (ll/-2) 
This 57-year-old man first became aware of weakness 
while working on a volunteer fire rescue and ambulance 
service at age 35 years. Prior to this, he described himself 
as strong and athletic. The initial problems included fre-
quent tripping due to foot drop and difficulty with stair 
climbing. The leg weakness progressed slowly since that 
time. For the past 2 years, he has had occasional falls due 
to gait imbalance. Recently, he started using a cane and 
bilateral ankle-foot orthoses. Other problems included pro-
gressive exertional dyspnea, bilateral cataract surgery (cap-
sular cataracts) at age 44 years, gouty arthritis, and 
hypertension. He denied double vision, swallowing pro-
blems, weight loss, upper extremity weakness, muscle 
cramps, sensory loss or paresthesias, passage of dark-
colored urine, exercise- or cold-induced weakness, or void-
ing difficulties. On examination, his height and weight were 
73 inches and 254 lbs. The heart and lung sounds were 
normal. The forced vital capacity (FVC) was I. 7 I (30% 
of predicted). There were no dysmorphic features, scapular 
winging, scoliosis, or foot deformities. The cranial nerve 
examination was normal with no weakness of eyelid, ocular, 
facial, pharyngeal, lingual or neck muscles. There was no 
sternocleidomastoid (SCM) muscle atrophy. Muscle bulk, 
tone and strength were normal in the upper extremities 
except for weakness (Medical Council Research grade; 
MRC) of the arm extensors (3), finger extensors (4), and 
the flexor digitorum profundus of digits 5 (2). There was 
marked foreleg and foot muscle atrophy (Fig. 2). He needed 
to push-off with both hands to stand from a chair. The gait 
was unsteady with a combined waddle and steppage quality. 
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The MRC-graded lower limb muscle strength was as fol-
lows: hip flexors (3), knee flexors (4), knee extensors (4), 
foot dorsiflexors {I), planter flexors (2), toe flexors(!), and 
toe extensors(!). There was no myotonia. Myotatic reflexes 
were hypoactive or absent. No pathological reflexes were 
present. The sensory examination was normal. The creatine 
kinase (CK) was 534 U/1 (n < 269). Other laboratory stu-
dies including thyroid stimulating hormone, thyroxine, car-
nitine, anti-nuclear antibody titer, lactate and aldolase were 
normal. Leukocyte DNA studies for the myotonic dystrophy 
CTG trinucleotide repeat expansion on 19ql3 were negative 
(Athena Laboratories, Worcester, MA). The electrocardio-
gram (ECG) and chest X-ray were normal. Sensory and 
motor nerve conduction, and repetitive motor nerve stimu-
lation studies were normal. Concentric needle electromyo-
graphy (CNE) revealed slightly increased insertional 
activity (complex repetitive discharges), rare fibrillations 
and positive waves, and increased recruitment of short dura-
tion, low amplitude, polyphasic motor unit action potentials 
(i.e. myopathic recruitment). A left vastus lateralis muscle 
biopsy revealed non-specific myopathic abnormalities 
including increased fiber size variation, increased interna-
lized nuclei, and mildly increased endomysia! fat and con-
nective tissue (Fig. 3). No rimmed vacuoles, inclusions, 
cores or rods were present. There was no abnormal storage 
of lipid or glycogen. Electron microscopy revealed normal-
appearing mitochondria with no abnormal inclusions or fila-
ments. These results were similar to a first muscle biopsy 
done on this patient at another Center several years prior. 
2.2. Case 2 (IV-1) 
This 35-year-old son of case I began to notice weakness 
while in the army at age 20 years. He recalled having pro-
blems walking on his heels, performing sit-ups and push-
ups, and running. The leg weakness slowly progressed. 
More recently, he began to suffer occasional falls due to 
leg and foot weakness. He denied double vision, swallowing 
problems, breathing problems, arm weakness, sensory loss 
or cramps. He also has small bilateral capsular cataracts. On 
examination, the height and weight were 63 inches and 287 
lbs. The FVC was 4.5 I (82% of predicted). There were no 
dysmorphic features or scapular winging. The abdomen was 
protuberant and the lumbar lordosis was exaggerated. There 
was no ocular, facial, lingual, pharyngeal or neck muscle 
weakness. The gait had both a waddling and steppage qual-
ity. There was moderate foreleg and foot muscle atrophy. 
Upper extremity muscle strength was normal except for 
mild finger extensor weakness. The MRC-graded lower 
limb muscle strength was as follows: hip flexors (3), knee 
flexors (5), knee extensors (5), foot dorsiflexors (3), planter 
flexors (4), toe flexors (2), and toe extensors (2). He was 
able to stand on his toes but not his heels. There was no 
myotonia. The myotatic reflexes and sensory examinations 
were normal. Myotonic dystrophy DNA studies were nega-
tive. The CK was 1701 U/1 (n < 269). The ECG was nor-
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Fig. 2. Photograph of patient I showing marked atrophy of anterior (a) and posterior (b) foreleg muscles. 
mal. Nerve conduction studies revealed absent peroneal 
compound muscle action potentials with otherwise normal 
sensory and motor studies. CNE revealed rare fibrillations, 
positive waves, and myopathic-type recruitment in proximal 
and distal limb muscles. 
2. 3. Case 3 (IV-2) 
This 32-year-old daughter of case I denied any weakness 
or myalgias. Her past medical history was remarkable for 
mild hypothyroidism which was treated with Synthroid. A 
recent ophthalmologic examination was negative for catar-
acts. On examination, her weight and height were 151 lbs 
and 67 inches. The cranial nerve examination was normal. 
There was no SCM atrophy. The gait was essentially normal 
except that she could not walk on her heels. Her foreleg and 
foot muscles were thin. She had minimal difficulty standing 
from a full squat. Upper extremity muscle strength was 
normal. There was no scapular winging. There was no myo-
tonia. In the lower extremities, there was mild weakness of 
the hip flexors, and foot and toe extensors. The sensory and 
reflex examinations were normal. Nerve conduction studies 
and CNE were normal. The CK was 406 U/1 (n < 230). 
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2.4. Case 4 (/l-7) 
This 83-year-old mother of case 1 admitted to mild diffi-
culty climbing stairs for the past 2-3 years. The past med-
ical history was remarkable for rheumatoid arthritis and 
mild late-onset cataracts. The examination was remarkable 
for moderate difficulty standing from a chair, inability to 
heel-walk, and mild to moderate weakness of the hip flexors 
and foot dorsifiexors. 
2.5. Case 5 (l-1} 
This is the maternal grandfather of case 1. He and his wife 
were born in Poland. There is no family history of consan-
guinity. He suffered from coronary artery disease and died 
at age 83 years. The family recalls that he walked with a 
cane and had difficulty climbing stairs, both disabilities 
were believed to be due to leg weakness. Specific details 
of his medical history were unknown. 
2.6. Case 6 (ll-3) 
This is a maternal aunt of case I. She died at age 93 years. 
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Fig. 3. Left vastus lateralis muscle biopsy from patient I showing non-specific myopathic changes including increased fiber size variation and increased 
internalized nuclei {hematoxylin and eosin, xiOO). 
From her mid-adult life on, she had problems walking up 
and down stairs, leg weakness, and difficulty rising from the 
floor. Specific details of her medical history are unknown. 
2. 7. Case 7 (IJ-5) 
This is a maternal uncle of case I. He died at age 72 years. 
He was diagnosed with a progressive form of 'muscular 
dystrophy' which began in his early 40's and primarily 
affected his legs. He required a wheelchair in his 50's. Spe-
cific details of his medical history are unknown. 
The following family members were found to have normal 
clinical examinations by one of the authors (KJF): III-I, III-
3, lV-3, IV-4, and IV-7. The following family members were 
not examined but, by history, appear to have not been affec-
ted or show no signs of weakness at this time: I-2, Il-l, ll-2, 
II-4, II-6, II-8, II-9, IV-6, IV-8, IV-9, V-1, V-2, V-3, V-4. 
3. DNA analyses 
3. I. Methods 
3.1.1. Microsatellite analysis 
The following microsatellite markers for the four known 
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distal myopathy loci were analyzed: (I) Miyoshi recessive 
distal myopathy locus on chromosome 2: 02S303, 02S291, 
02S292, 02S2111, 02S21 09, 02S 145, 02S286; (2) auto-
somal dominant tibial muscular dystrophy locus on chromo-
some 2: D2S300, 02SI48, 02S364, 02S2273, 02S350. 
02Sl52, 02S389; (3) Nonaka recessive distal myopathy 
locus on chromosome 9: 09S319, 09S43, 09S248 and 
09S276; and (4) autosomal dominant distal myopathy 
MPOI locus on chromosome 14: 014S72, 014S283, 
MYH7.1, DI4S264, 014S80, 014S275, 014S262, 014 
S252, 014S257, 014S49. The microsatellites were ampli-
fied and analyzed using standard conditions [3]. The anneal-
ing temperature was 55°C for all markers except OI4S257 
at 52°C; 02S2281, 02S2273, 02S2366, D2S389 at 57°C; 
D14S49, 014S80, 014S252, 0!4S253, 014S262, 014 
S275, 014S283 at 58°C; 014S264 at 60°C; 014S72 at 
6!°C and MYH7.1 at 64°C; extension temperature was 
72°C for all markers. The PCR reactions were performed 
using Tth Plus enzyme (Biotech International) in a reaction 
volume of 20 JLI with 50 ng genomic DNA and final con-
centrations of I mM MgCI2, 20 JLM dNTPs and I JLCi dCTP 
(Amersham), for 35 cycles. The amplified samples were 
electrophoresed on 6% 19: I acrylamide/bisacrylamide 
gels at 1300 V for 3 h. Gels were exposed to Dupont Cronex 
X-ray film at room temperature overnight. 
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Fig. 4. Multipoint linkage analysis of distal myopathy in a single family from Connecticut against fixed maps of markers for the Miyoshi distal myopathy (a) 
and tibial muscular dystrophy (b) regions on cluomosome 2, the Nooaka distal myopathy region on chromosome 9 (c), and the autosomal dominant MPDI 
region on chromosome 14 (d) obtained as described in Section 3.1. For all regions, distal myopathy was treated as a dominant disease with a penetrance of 
70"/o and a gene frequency of 0.001. Two sets of calculations were performed for aU regions: either the phenotypic status of uoaffected individuals was 
considered to be unknown (thin line), or phenotypic information ofuoaffected individuals was included (thick line). AI each locus, one marker was arbitrarily 
set at 10 eM and the other markers were then set according to the chromosome maps. 
3.1.2. Multipoint linkage analysis 
Multipoint LOD scores were calculated between a puta-
tive disease locus and a marker locus using the program 
GENEHUNTER [4]. Distances between markers on chro-
mosome 2 were fixed according to the maps given by Gya-
pay et al. [5], the maps at the Genethon web site (http:// 
www.genethon.fr/), and those ofBashir et al. [6]. Distances 
on chromosomes 9 and 14 were obtained fium the maps in 
Gyapay et al. [5), and the maps at the Genethon (http:// 
www.genethon.fr/) and Co-operative Human Linkage Cen-
tre (http://www.chlc.oorg/) web sites. In the linkage calcu-
lations the gene frequency was assumed to be 0.001. The 
number of affected family members is not large enough to 
draw any firm conclusions in regard to the penetrance. The 
penetrance was therefore set to the conservative value 70%. 
In addition, calculations were carried out ignoring the phe-
notypic status of the unaffected individuals ('penetrance 
free model'). 
3.2. Results 
Markers at all four distal myopathy loci were informative 
and demonstrated recombinations with affected individuals 
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in the pedigree. The resulting LOD scores obtained from the 
multipoint analyses were less than -2 for virtually the entire 
regions tested under either model (Fig. 4). All four distal 
myopathy regions can therefore be excluded for linkage and 
the disease is therefore not linked to any of the known distal 
myopathy loci. 
4. Discussion 
The clinicopathological features of the above described 
family included: (l) slowly progressive autosomal dominant 
distal myopathy with known affected members spanning 
four generations, (2) onset of anterior foreleg muscle weak-
ness in the second to third decades with progression to other 
distal and proximal muscles over time, (3) no cranial or neck 
muscle involvement, (4) respiratory muscle involvement in 
the index case, (5) early-onset cortical cataracts in patients l 
and 2, (6) no clinical or EMG evidence of myotonia, (7) mild 
to moderate elevations (1.8-6.3 times the upper limit of 
normal) in CK values, (8) non-specific muscle histopathol-
ogy with no evidence of vacuoles or inclusions, and (9) no 
genetic linkage to any of the known distal myopathy loci. 
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The distal myopathies have been classified into autoso-
mal dominant and recessive fonns [1,2]. The dominant con-
ditions include Welander [7-9] and Markesbery [10,11] 
myopathies, a Finnish fonn of tibial muscular dystrophy 
[11-14] and autosomal dominant distal myopathy 
(MPDl) [3]. The recessive fonns include Miyoshi [15-
19] and Nonaka [20,21] myopathies. In addition, less com-
mon fonns of hereditary distal myopathy have been 
described including severn) fonns of infantile- and child-
hood-onset distal myopathies [1,2,22] distal myopathy 
with abnonnal accumulation ofdesmin [23], and hereditary 
inclusion body myositis [24]. 
Recently, the genetic loci for seven types of distal myo-
pathy have been assigned to four distinct loci and, there-
fore, a revised genetic classification of these disorders is 
now emerging (fable 1). In 1995, Laing et al. localized 
an autosomal dominant distal myopathy kindred to chro-
mosome 14 (MPDl) [3]. In the same year, Bejaoui et al. 
found linkage of Miyoshi myopathy, an autosomal reces-
sive disorder, to chromosome 2pl2-14 [15]. Miyoshi 
myopathy appears to be allelic to two other autosomal 
recessive disorders, limb girdle muscular dystrophy 2B 
(LGMD2B) and a newly-described distal anterior com-
partment myopathy [6,25,26]. Moreover, the two disease 
phenotypes, Miyoshi myopathy and LGMD2B, have both 
been seen in one Canadian aboriginal kindred and in a 
family from Russia [16,17,19]. In a recent study by Liu et 
al., the gene product for Miyoshi myopathy, LGMD2B, 
and anterior compartment myopathy has been discovered 
and named dysferlin [18]. Tibial muscular dystrophy was 
recently localized to chromosome 2q31-33 and the late-
onset distal myopathy of Markesbery links to the same 
region [li,I3]. Interestingly, a proximal limb-girdle myo-
pathy rather than a distal myopathy may develop in 
patients who are homozygous for the tibial muscular dys-
trophy gene defect on 2q3l-33 [14]. In 1996, Mitrani-
Rosenbaum et al. found linkage of hereditary inclusion 
Table I 
Tentative classification of distal myopathies based gene location• 
body myopathy, a disorder with quadriceps-sparing and 
prominent distal weakness, to chromosome 9pl-ql [24]. 
Recently, lkeuchi et al. have found similar linkage to 
chromosome 9 for Japanese families with autosomal 
recessive distal myopathy (Nonaka myopathy) suggesting 
that this disorder and hereditary inclusion body myopathy 
are allelic disorders [21]. Genetic localization of Welan-
der myopathy is not yet published but recent work by 
Ahlberg et al. has excluded linkage to the Miyoshi or 
MPDI distal myopathy loci [9]. 
In reference to the present family, five of the six major 
fonns of distal myopathy are excluded based on DNA ana-
lyses (Markesbery, Miyoshi, MPDI, Nonaka, tibial muscu-
lar dystrophy). Moreover, several clinicopathological 
features seem to distinguish the present family from the 
dominantly-inherited distal myopathies. First, vacuolar 
changes on muscle histopathology are often observed in 
Welander, Markesbery and the Finnish tibial muscular dys-
trophies. Vacuoles were not found in two muscle specimens 
on patient I from this family. Second, weakness is usually 
begins after the age of 35 years in Welander, Markesbery 
and Finnish tibial muscular dystrophies. In the current 
family, the symptoms began in the second to third decade. 
Third, the pattern of weakness is also a distinguishing fea-
ture in at least two of the autosomal dominant distal myo-
pathies. In Welander distal myopathy, weakness begins in 
the hand muscles and progresses over many years to involve 
the distal lower extremity muscles. Proximal weakness is 
uncommon in this condition. Finnish tibial muscular dystro-
phy patients usually present with weakness of the anterior 
tibial muscles and, later, the long toe extensors. Upper 
extremity and proximal lower extremity involvement is 
quite rare. The pattern of weakness in Markesbery myopa-
thy, which includes onset in the anterior tibial muscles fol-
lowed by progressive weakness of intrinsic hand and 
proximal limb muscles, more closely follows that of the 
current family. Some differences are noteworthy, however. 
Myopathy Mode of inheritance Gene location References 
Autosomal recessive distal myopathy (Miyoshi myopathy)' 
Distal anterior compartment myopathy 
Tibial muscular dystrophy (Udd myopathy) 
Late-onset distal myopathy (Markesbecy myopathy) 
Nonaka myopathy 
Hereditary inclusion body myopathy 
Autosomal dominant distal myopathy 
Welaoder myopathy 
AR 
AR 
AD 
AD 
AR 
AR 
AD 
AD 
2p12-14 
2p12-14 
2q31-33 
2q31-33 
9pl-<jl 
9pl-<jl 
14 
[4,8] 
[7] 
[11-13,22] 
[13,21] 
[15,23] 
[14] 
[3] 
[16,19,20] 
'Classification excludes rare and genetically-undetennined disorders including the kindred in this report (see text), and other myopathies (e.g. myotonic 
dystrophy) in which distal weakness may be a prominent feature (see Ref. [2]). 
"Limb girdle muscular dystrophy type 2B also localizes to 2pl2-14. 
373 
K.J. Felice eta/. I Neuromuscular Disorders 9 (/999) 59-65 65 
Cases I and 2 in this series had mild weakness of finger 
extensors, finger flexors, or both but neither had involve-
ment of intrinsic hand muscles which is in contrast to most 
of the patients described by Marksbery et al. [10]. More-
over, cardiomyopathy was not present in this family but was 
noted in one of the seven cases reported by Markesbery et al. 
[10]. Fourth, other inconsistent features in this family 
including respiratory muscle involvement and early catar-
acts may be unique to this form of distal myopathy. Finally, 
of the dominantly-inherited distal myopathies, Welander 
myopathy could not be excluded based on DNA studies as 
the locus for this myopathy has not been elucidated [9]. 
However, in addition to the distinctive clinical features as 
noted above, Welander myopathy is usually restricted geo-
graphically to Sweden and parts of Finland, thereby, further 
distinguishing this myopathy from the family described in 
this report. 
Other dominantly-inherited muscular dystrophies in 
which distal limb muscle weakness may be prominent 
including myotonic dystrophy and fucioscapulohumeral 
muscular dystrophy warrant further mention. Despite the 
findings of distal weakness and early cataracts in this family, 
myotonic dystrophy was excluded based on the absence of 
clinical and EMG myotonia, and the negative DNA studies. 
Facioscapulohumeral muscular dystrophy was excluded 
based on the absence of characteristic clinical features 
including facial weakness and scapular winging. 
In conclusion, this autosomal dominant distal myopathy 
family does not show evidence of linkage to any of the 
known distal myopathy loci, suggesting the existence of at 
least one more distal myopathy locus. Furthermore, the clin-
ical and pathological features appear distinct from other 
previously described but genetically-undetermined autoso-
mal dominant distal myopathies. The identification of larger 
families with this phenotype will be needed in order to 
provide further genetic elucidation of this seemingly distinct 
distal myopathy. 
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APPENDIX B 
Lod Scores for the Segregation of the WAMPD 
and OMPD Disease Loci with Marker Loci 
Table 84.1 Lod Scores for Linkage between the MPD1 
Locus and Marker Loci. 
Table 85.1 Lod Scores for Linkage between the QMPD 
Locus and Marker Loci. 
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Table 84.1 Lod Scores for Linkage between the MPD1 Locus and Marker Loci. 
Analysis includes data from all family members. Chromosome position originally determined as% of pter-qter from 
NIH/CEPH Collaborative Mapping Group (1992), then progressively updated from CHLC Report (Murray et a/., 
1993 and 1994), Cox eta/. (1994) and ''The National Centre For Biotechnology Information" GB4 GeneMap'98 
(http://www.ncbi.nlm. nih.govl). 
D-numbers indicate anonymous DNAfragments (0-segments), other markers are associated with the genes: CAP-
C-reactive protein; AT3 -antithrombin II; ACTN2- alpha-2 actinin; APOB- apolipoprotein B; HOXD4- homeobox 
04; APC - adenomatosis polyposis ·coli; SCA 1 ~ spina cerebellar ataxia; DMDUDuchenne muscular dystrophy like 
(utrophin); GCK - Glucokinase; CFTR/cystic fibrosis transmembrane conductance regulator; CD3D - delta polypeptide 
antigen in TYT3 complex; RB1 - retinoblastoma 1; MYH7 - myosin beta chain (heavy polypeptide); TPM1 -
tropomyosin 1 (alpha); GX-Aiu - Alu polymorphism intragenic in NF1 gene; HOXB6- homeobox 86; APOC2-
apolipoprotein C-11; OM - dystrophia myotonica protein kinase. 
Two of the markers associated with genes, APOB and AT3, are non-microsatellite polymorphisms. The remainder are 
microsatellites. 
Table 84.1 Lod Scores for Linkage between the MPD1 Locus and Marker Loci on Chromosomes 1, 2, 3, 4 and 5. 
Chromosome Recombination Fraction ((}) Equivalent No. Equivalent No. 
%pter-qter Locus 0.00 0.05 0.10 0.20 0.30 0.40 Recombinations Informative Meioses 
1.05 D1S80 -99.99 -2.75 -1.59 -o. 59 -0. 15 -0.02 3.3 6.5 
1.19 D1S164 -99.99 -2.88 -1.52 -0.59 -o. 35 0.14 1.7 5.8 
1.44 D1S223 -99.99 -1.27 -o.49 0.08 0.22 0.23 2.1 6.5 
1.55 D1S185 -99. 99 -4.20 -2.79 -1.48 -0.78 -o.32 6.3 12.6 
1.57 D1S176 -99.99 -0.09 0.09 0.14 0.09 0.02 0.3 1. 7 
1.59 CRP -99.99 -1. 31 -0.81 -0.41 -o. 24 -o. 14 1.8 3.6 
1.62 D1S104 -99.99 -4.34 -2.91 -1.54 -0.80 -o. 32 6.6 13. 1 
1.67 AT3 0.13 0.10 0.08 0.05 0.02 0.01 0.0 0.4 
1.89 ACTN2 -99.99 -1.67 -0.90 -o. 26 -o. 03 0.03 1.5 3.8 
2.07 APOB -99.99 -2.99 -1.89 -o. 89 -0.41 -0. 14 4.3 8.5 
2.55 D2S44 -99.99 -3.73 -2.35 -1. 10 -0.49 -o. 16 5.3 10.6 
2.66 HOXD4 -99.99 -3.04 -1.92 -0. 91 -0.41 -o. 14 4.0 9.0 
2.94 D2S102 -99.99 -2.80 -1.74 -0.81 -o. 38 -0. 13 3.9 7.8 
3.00 D3S1307 -99. 99 -2.64 -1.79 -0.98 -o. 52 -o. 22 4.0 8.1 
3.07 D3S1304 -99.99 -3.61 -2.22 -o. 97 -0.38 -0.09 5.0 10.0 
3.38 D3S1285 -99.99 -0.77 -o. 22 0. 19 0.28 0.20 2.4 7.9 
3.52 D3S1278 -99.99 -3.22 -2.04 -o. 96 -0.42 -0. 13 4.6 9.2 
3.73 D3S1279 -99.99 -2.24 -1.20 -o. 37 -0.05 0.04 1.6 4.1 
3.81 D3S1282 -99.99 -1.96 -1. 14 -0.41 -o. 10 0.02 1.1 2.6 
3.89 D3S1262 -99.99 -2.52 -1.65 -0.82 -0.39 -o. 14 3.7 7.4 
3.99 D3S1311 -99.99 -2.54 -1.62 -o. 78 -0.37 -0. 13 3.6 7.3 
4.01 D4S45 -99.99 -3.75 -2.39 -1. 19 -o. 62 -o. 27 5.4 10.8 
4.28 048174 -99. 99 -0.43 0.02 0.31 0.37 0.12 1.7 6.6 
4.98 048171 -99.99 -3.61 -2.22 -0.97 -0.38 -0.09 5.0 10.0 
5.18 D5S268 0.82 0. 73 0.64 0.42 0.27 0. 14 0.0 2.6 
5.38 D5S112 -99.99 -0.34 0. 11 0.38 0.37 0.23 0.9 4.6 
5.39 D5S39 -99.99 -1.20 -0.46 0.10 0.25 0.20 2.1 7.0 
Table 84.1 Lod Scores for Linkage between the MPD1 Locus and Marker Loci on Chromosomes 5 (cont), 6, 7, 8, 9, 10, 11 and 12. 
Chromosome Recombination Fraction (9) Equivalent No. Equivalent No. 
Position Locus 0.00 0.05 0.10 0.20 0.30 0.40 Recombinations Informative Meioses 
5.60 APC -99. 99 -3.62 -2.24 -1.02 -o. 44 -o. 14 5.1 10. 1 
5.80 058210 -99.99 -3.24 -2.09 -1.01 -o. 46 -o. 15 4.7 9.4 
6. 13 8CA1 -99.99 -0.73 -0.21 0.15 0.24 0.19 0.7 2.0 
6.85 DMDL -99.99 -0.09 0.09 0.14 0.09 0.02 0.3 1. 7 
7.05 078472 -99.99 -4.29 -2.86 -1. 51 -o. 78 -o. 32 6.4 12.9 
7. 18 078435 -99.99 -1.45 -0.69 -o.09 0.10 0.12 5.3 13.2 
7.20 078474 -99.99 -0.71 -0.24 0.11 0. 18 0.13 1.5 5. 1 
7.26 GCK -99.99 -1.99 -1. 19 -0.50 -o. 19 -o. 04 2.7 5.4 
7.47 078440 -99. 99 -3.88 -2.47 -1. 17 -0.53 -0.17 5.6 11. 1 
7. 74 CFTR -99.99 -1.56 -o. 97 -o. 43 -o.17 -0.04 2.2 4.4 
8.41 088166 -99.99 -4.97 -3.27 -1.68 -o. 85 -0.33 7.4 14.6 
8.53 08884 1. 11 0.99 0.86 0.61 0.38 0. 18 0.0 3. 7 
8.65 088200 1.09 0.97 0.85 0.61 0.38 0.18 0.0 3.6 
8. 70 D8S198 -99.99 -3.73 -2.35 -1. 10 -o. 49 -0. 16 5.3 10.6 
9.20 098104 -99.99 -0.41 0.04 0.32 0.33 0.21 2.8 9.3 
9.29 09815 -99.99 -0.25 0.05 0.28 0.31 0.21 2.6 8.5 
9.55 09853 -99.99 -2.88 -1. n -o. 78 -0.30 -0.07 4.0 8.0 
10. 18 010828 -99.99 -3.81 -2.46 -1.25 -o. 66 -o. 29 5.5 11. 1 
11.09 0118875 -99.99 -2.46 -1. 61 -o. 83 -0.44 -0. 19 2.6 5.2 
11.52 0118873 -99.99 -3.69 -2.31 -1.08 -0.48 -0. 16 5.2 10.4 
11.70 GOOD 1.39 1. 25 1. 10 0.80 0.49 0.22 0.0 4.6 
11.76 0118836 -99.99 -2. n -1.70 -0.76 -0.34 -0. 12 3.8 7.6 
12.47 012843 -99.99 -2.53 -1.58 -o. 71 -0.27 -0.06 3.9 7.8 
12.95 012860 -99.99 -2.75 -1. 75 -o. 94 -o. 46 -o.06 4.1 8.3 
Table 84.1 Lod Scores for Linkage between the MPD1 Locus and Marker Loci on Chromosomes 13, 14, 15 and 16. 
Chromosome Recombination Fraction (fJ) Equivalent No. Equivalent No. 
Position Locus 0.00 0.05 0.10 0.20 0.30 0.40 Recombinations Informative Meioses 
13.41 RB1 0.13 0.10 0.08 0.05 0.02 0.01 0.0 0.4 
13.74 D13S71 -99.99 -1.47 -0.75 -0.19 0.03 0.10 1.4 3.4 
14.08 D14S72 -3.13 0.03 0.23 0.31 0.26 0.15 0.9 4.1 
14.10 D14S283 -1 93 1.14 1.24 1.11 0.81 0.43 1.1 8.8 
14.10 D14S50 2.31 2.12 1.93 1.51 1.06 0.57 0.0 7.7 
14.11 MYH7 2.00 2.36 2.12 1.61 1.08 0.53 0.0 8.6 
14.15 D14S64 2.00 2.36 2.12 1.61 1.08 0.53 0.0 8.6 
14.15 D14S264 2.00 2.36 2.12 1.61 1.08 0.53 0.0 8.6 
14.17 D14S80 1. 71 1.57 1.42 1.11 0.77 0.41 0.0 5.7 
14.18 D14S275 2.31 2.12 1.93 1.51 1.06 0.57 0.0 7.7 
14.18 D14S262 2.90 2.64 2.38 1.82 1.22 0.61 0.0 9.6 
14.18 D14S252 1. 05 0.95 0.86 0.65 0.45 0.23 0.0 3.5 
14.20 D14S54 0.49 0.41 0.34 0.21 0.10 0.03 0.0 1.6 
14.20 D14S257 1. 99 1.81 1.61 1.21 0.79 0.37 0.0 6.6 
14.22 D14S49 -2.50 0.30 0.47 0.49 0.36 0.19 0.8 4.6 
14.37 D14S52 -99.99 -D.22 0.17 0.32 0.23 0.10 0.9 4.2 
14.50 D14S76 -99.99 -1.46 -0.72 -0.17 0.01 0.05 2.1 5.1 
14.52 D14S53 -99.99 -D.14 0.27 0.49 0.44 0.27 1.8 7.6 
14.54 D14S74 -99.99 0.55 0.69 0.66 0.52 0.30 0.9 6.0 
14.58 D14S48 -99.99 1.00 1.06 0.87 0.56 0.26 0.7 6.8 
14.63 D14S81 0.20 0.15 0.11 0.04 0.01 0.00 0.0 0.7 
14.69 D14S45 -99.99 -o.57 -0.34 -o.15 -o.o7 -0.02 0.8 1.5 
14.70 D14S51 -99.99 -o.54 -0.10 0.15 0.16 0.08 0.8 3.0 
14.78 D14S13 -99.99 -o.o3 0.15 0.20 0.13 0.04 0.4 2.2 
15.49 TPM1 -99.99 -1.30 -o.78 -0.32 -0.10 -0.03 1.5 3.0 
15.98 D15S87 -99.99 -1.63 -Q.86 -0.24 -o.02 0.04 2.0 4.9 
16.04 D16S291 -99.99 -1.20 -0.46 0.10 0.25 0.20 3.1 9.4 
I MPD1 Unkage Region I 
Table 84.1 Lod Scores for Linkage between the MPD1 Locus and Marker Loci on Chromosomes 16(cont), 17, 18, 19, 20, 21 & 22. 
Olromosome Recombination Fraction (8) Equivalent No. Equivalent No. 
Position Locus 0.00 0.05 0.10 0.20 0.30 0.40 Recombinations Informative Meioses 
16.13 0168292 -99.99 -0.80 -0.50 -0.23 -0.09 -0.02 1.1 2.3 
16.17 D16S287 -99.99 -0.94 -0.36 0.08 0.19 0.14 2.1 6. 7 
16.20 D16S295 -3.40 -0.59 -0.34 -0.12 -0.04 -o. 01 0.7 1. 5 
16.28 D16S298 -99.99 0.18 0.34 0.37 0.27 0.14 0.6 3.6 
16.58 D16S308 -99.99 -0.83 -0.31 0.10 0.20 0.16 0.7 1. 4 
16.68 D16S265 -99.99 -3.99 -2.53 -1.18 -0.52 -0.16 5.7 11.4 
16.74 D16S186 -99.99 -3.57 -2.43 -1.35 -0.73 -0.31 5.5 11. 0 
16.74 D16S301 0.51 0.45 0.40 0.29 0.19 0.09 0.0 1. 7 
16.80 D16S260 -3.43 -0.25 -0.04 0.09 0.08 0.03 0.4 1. 7 
16.87 D16S266 -99.99 -1.27 -0.75 -0.30 -0.11 -0.03 1.7 3.4 
16.99 0168305 -99.99 -5.55 -3.80 -2.10 -1.15 -0.49 8.6 17.1 
17.04 D17S30 -2.19 0.63 0.75 0.67 0.44 0.18 0.5 4. 7 
17.29 D17S122 -99. 99 -1.36 -0.63 -0.07 0.11 0.11 5.2 12.9 
17.37 GX-Aiu -99.99 -3.62 -2.25 -1.02 -0.44 -0.14 5.1 10. 1 
17.54 HOXB6 -99.99 -1.19 -0.61 -0.13 0.04 0.06 2.2 5.5 
17.85 D17S26 -99.99 -1.24 -0.49 0.08 0.24 0.19 2.0 6.6 
18.11 D18S40 -99. 99 -2.45 -1.39 -0.49 -0.12 0.02 3.1 6.3 
18.61 D18S51 -99.99 -2.35 -1.30 -0.44 -0.09 0.03 2.9 5.9 
19.50 D19S75 -99.99 -3.55 -2.40 -1.30 -0.70 -0.30 5.4 10.8 
19.76 APOC2 0.20 0.17 0.13 0.07 0.03 0.01 0.0 0. 7 
19.77 DM -99.99 -5.44 -3.68 -1.98 -1.04 -0.42 8.3 16.6 
20.25 D20S66 -99. 99 -2.52 -1.47 -0.56 -0.16 0.01 3.9 9.0 
21.32 D21S210 -99. 99 -2.48 -1.41 -0.50 -0.12 0.02 0.9 2.3 
21.45 D21S213 -99.99 -3.04 -1.92 -0.91 -0.41 -0.14 4.3 8.7 
22.35 D22S258 -99.99 -2.78 -1.71 -0.77 -0.35 -0.12 3.8 7. 7 
Table 85.1 Lod Scores for Linkage between the QMPD Locus and Marker Loci. 
Analysis includes data from all family members. Chromosome position originally determined as% of pter-qter from 
NIH/CEPH Collaborative Mapping Group (1992), then progressively updated from CHLC Report (Murray eta/., 
1993 and 1994), Cox et a/. (1994) and "The National Centre For Biotechnology Information" GB4 GeneMap'98 
(http://www.ncbi.nlm. nih.gov/). 
0-numbers indicate anonymous DNA fragments (0-segments), other markers are associated with the genes: ACTN2 -
alpha-2 actinin; APOB- apolipoprotein B; SCA1 -spinocerebellar ataxia; DMDL!Duchenne muscular dystrophy like 
(utrophin); MYH7 • myosin beta chain (heavy polypeptide); TPM1 - tropomyosin 1 (alpha); GX-Aiu - Alu 
polymorphism intragenic in NF1 gene;DM - dystrophia myotonica protein kinase. 
One of the markers associated with genes, APOB is a non-microsatellite polymorphisms. The remainder are 
microsatellites. 
U> 
00 
0 
Table 85.1 Lod Scores for Linkage between the QMPD Locus and Marker Loci on Chromosomes 1, 2, 4, 6, 7, 8 & 13. 
Chroroosome Recombination Fraction (8) Equivalent No. Equivalent No. 
%pter-qter Locus 0.00 0.05 0.10 0.20 0.30 0.40 Recombinations Informative Meioses 
1.19 018164 -3.89 -o.72 -0.46 -0.23 -o.13 -0.06 1.0 2.1 
1.44 018223 -99.99 -1.13 -0.63 -0.27 -o.03 0.04 2.4 4.7 
1.45 D1S187 1.35 1.21 1.05 0.74 0.43 0.16 0.0 4.5 
1.55 D1S185 0.13 0.11 0.09 0.05 0.02 0.01 0.0 0.4 
1.64 D1S242 -99.99 -3.44 -2.29 -1.18 -o.56 .0.23 5.1 10.3 
1.89 AGfN2 -99.99 -1.49 -o.94 -0.46 -o.22 -o.09 2.1 4.3 
2.07 APOB -99.99 -1.08 -Q.54 -0.06 0.07 0.11 2.3 4.6 
2.88 D2S102 -99.99 -2.44 -1.59 .0.76 -o.37 -0.13 3.6 7.1 
4.28 D4S174 -99.99 -2.17 -1.65 -o.73 .0.42 .0.16 3.0 6.0 
4.98 D4S171 -99.99 -o.o8 0.13 0.25 0.23 0.15 1.0 4.1 
5.18 D5S268 -99.99 -2.44 -1.59 -0.76 -Q.37 -Q.13 3.6 7.1 
5.38 058112 -2.50 0.12 0.32 0.42 0.36 0.22 1.2 5.5 
5.39 D5S127 -99.99 -o.88 -0.38 0.02 0.14 0.12 2.2 6.4 
5.65 D5S399 -3.40 -0.72 .0.44 -o.19 -o.o8 0.02 1.0 2.0 
6.13 SCAr* -99.99 -2.47 -1.63 -o.88 -0.50 -o.24 3.7 7.4 
6.85 OMDL* -2.80 -0.18 0.27 0.14 0.14 0.08 0.6 2.6 
7.00 D7S531 -99.99 -4.72 -3.24 -1.79 -0.96 -o.41 7.3 14.6 
7.05 D7S472 0.90 0.79 0.68 0.43 0.21 0.05 0.0 3.0 
7.06 D7S517 -99.99 -4.72 -3.24 -1.79 -o.96 -o.41 7.3 14.6 
7.95 D7S483 -3.59 -o.33 -o.12 O.D1 0.02 0.01 0.8 1.9 
8.70 D8S198 -99.99 -2.44 -1.59 -o.76 -0.37 -o.13 3.6 7.1 
13.74 D13S71 -99.99 -0.94 -o.32 0.05 0.12 0.13 1.7 4.6 
U) 
CD 
...... 
Table 85.1 Lod Scores for Linkage between the QMPD Locus and Marker Loci on Chromosomes 14, 15, 17, 19, 20 & 21. 
Olrorrnsome Recombination Fraction (8) Equivalent No. Equivalent No. 
%pter-qter Locus 0.00 0.05 0.10 0.20 0.30 0.40 Recombinations Informative Meioses 
14.08 D14S72 -99.99 -2.44 -1.6 -0.79 -Q.37 -Q.13 3.6 7.1 
14.11 MYH7 -99.99 -Q.36 -0.12 0.05 0.09 0.07 0.9 2.9 
14.15 D14S64 -99.99 -2.64 -1.78 -Q.95 -0.50 -0.21 4.0 8.0 
14.17 D14S80 -3.50 -0.83 -Q.56 -Q.29 -Q.14 -0.04 1.3 2.5 
14.20 D14S54 0.13 0.09 0.05 0.01 -Q.01 -0.01 0.0 0.4 
14.22 D14S49 -99.99 -0.08 0.13 0.25 0.23 0.15 1.0 4.1 
14.50 D14S76 0.13 0.10 0.08 0.05 0.02 O.D1 0.0 0.4 
14.52 D14S53 -99.99 -1.64 -1.08 -o.55 -0.28 -Q.11 2.4 4.9 
14.58 D14S48 -99.99 -2.47 -1.63 -0.88 -o.5o -0.24 3.7 7.4 
14.69 D14S45 -99.99 -3.50 -1.23 -1.23 -Q.63 -0.25 5.3 10.5 
14.70 D14S51 -2.80 -0.18 0.27 0.14 0.14 0.08 0.6 2.6 
15.49 TPM1 0.31 0.29 0.20 0.11 0.05 -0.02 0.0 1.0 
15.98 015887 -99.99 -2.17 -1.65 -Q.73 -0.42 -0.16 3.0 6.0 
17.37 GX-Aiu* -99.99 -o.s8 -Q.38 0.02 0.14 0.12 2.2 6.4 
19.77 DM -99.99 -3.44 --2.29 -1.18 -Q.56 -0.23 5.1 10.3 
20.28 020866 -99.99 -0.08 ··o.13 0.25 0.23 0.15 1.0 4.0 
21.45 0218213 -3.40 -o.72 -0.44 -0.19 -o.os 0.02 1.0 2.0 
21.94 0218171 -99.99 -1.87 -1.47 -0.49 -Q.21 -0.11 2.0 4.0 
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Table C7.1 Sequence Comparisons of MYH6 and MYH7 eDNA, and of a-MyHC and {3-MyHC Amino Acids. 
The application program used to make these comparisons was SeqEd, Version 1.0.3 (Myers, 1992: ABI). The sense-strand 
exonic sequences for both genes were imported from a BLAST search (http://www.ncbi.nlm.nih.gov/BLASTI) which 
identified the full published genomic sequences, MYH6 (Epp et al., 1993) and MYH7 (Jaenicke et al., 1990). 
Row one shows the approximate base number of each gene. 'Misnumbering' bases is an unavoidable consequence of 
aligning these two sequences, because their s• untranslated regions are of different lengths, so MYH6 and MYH7 have 
different starting points. In addition, MYH7 has four deleted codons compared to MYH6. 
Row two and three show the sense-strand exonic sequences of MYH6 and MYH7. Row four compares these MYH6 and 
MYH7 exonic sequences. Dashes indicate identical bases, asterisks indicate non-identical bases. 
Row five and six show the derived amino acid sequences for the polypeptide encoded by MYH6, which is a-MyHC, and 
by MYH7, which is 13-MyHC. Epp et al., (1993) and Jaenicke et al. (1990) derived the a-MyHC and 13-MyHC amino acid 
sequences from the genomic sequences for these genes. Row seven compares these amino acid sequences. In this row, 
dashes indicate identical amino acids, asterisks indicate non-identical amino acids. 
Table C7.2 in this Appendix aligns genetic and amino acid codes. 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
a1pha-MyBC 
beta-MyBC 
al.pha VB beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
al.pha-MyBC 
beta-MyBC 
al.pha VB beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
al.pha-MyBC 
beta-MyBC 
a1pha VB beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
al.pha-MyBC 
beta-MyBC 
a1pha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
a1pha-MyBC 
beta-MyBC 
a1pha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
al.pha-MyBC 
beta-MyBC 
a1pha VB beta 
-------------------atagagagactctgcggcccagattcttcaggattctccgtgaagggataaccaggggaagoaccaagATGACCG~CCAG~TGACTTTGGGG 
-tgtctttccctgctgctctcaggtcccctgcaggocttggccoctttcctcatctgtagaoacaottgaqtagcooaggoacagocATGGGAGATTCGGA~A.~~~DGGG~ 
-------------------**--*****--**•*-*-***-***---******---******-****-*-**--***-*----****---···---·-··-------•-•--------
--------------------------------------------------------------------------------------M T D A Q M A D F G 
--------------------------------------------------------------------------------------M G D S E M A V F G 
---------------------------------------------------------~-------------------------------•-----•--•--------•--------
CAGCGGCCCAGTACCTCCGCAAGTCAGAGAAGGAGCGTCTAG.AGGCCCAGACCCGGCCCTTTGAC.Pd'TCGCACTGAGTGCTTCGTGCCCGATGACAAGGAAGAGTTTGTCAAAGCCAA 
CTGCCGCCCCCTACCTGCGCAAGTCAGAGAAGGAGCGGCTAGAAGCGCAGACCAGGCCTTTTGACCTCAAGAAGGATGTCTTCGTGCCTGATGACAAACAGGAGTTTGTCAAGGCCAA 
-*--*----**-----•--------------------*-----•--•------•----·------·-····-··--···---------•--------••-•-----------·-----
A A A Q Y L R K S B K E R L E A Q T R P F D I R T E C F V P D D K E B F V K A E 
A A A P Y L R K S E K B R L E A Q T R P F D L K K D V F V P D D K Q E P V K A E 
---------•--------------------------------------------------------·--·--·--·--·--------------------•------------------
GA!l'TTTGTCCCGGGAGGGAGGCAAGGTCATTGCTGAAACCGAGAATGGGAAGACGGTGACTGTGAAGGAGGACCAGGTG'I'TGCAGCAGAACCCACCCAAGTTCGACAAGATTCAGGAC 
'GATCGTGTCTCGAGAGGGTGGCAAAG'IACTGCCGAGACTGAGTATGGCAAGACAGTGACCGTGAAGGAGGACCAGG'l'GATGCAGCAGAACCCACCCAAGTTCGACAAAATCGAGGAC 
---**----*--*-----*-----*----•---•--•--*---•----*-----*-----*------------------•----------------------------~--**-----
I L S 
I V S 
R B 
R B 
G G K V I A B 
G G K V T A E 
T E 
T E 
N G K T V T V X B 
Y G K T V T V K B 
D Q 
D Q 
V L Q 0 
V M Q Q 
N 
N 
p 
p 
P K F D K 
P K F D K 
I 
I 
Q 
B 
D 
D 
-----•-----------------------•--------------•-----------------------------------·--------------------------------•----
ATGGCCATGCTGACCTTCCTGCACGAGCCCGCGGTGCTTTTCAACCTCAAGGAGCGCTACGCGGCCTGGATGATATATACCTACTCGGGCCTCTTCTGTGTCACTGTCAACCCCTACA 
ATGGCCATGCTGACCTTCCTGCATGAGCCCGCGGTGCTCTACAACCTCAAGGATCGCTACGGCTCCTGGATGATCTACACCTACTCGGGCCTCTTCTGTGTCACCGTCAACCCTTACJ! 
-----------------------•--------------•-•------------•-------***----------•--•--------------------------*--------•----
M A M L T F L B B P A V L F N L K B R Y A A W M I Y T Y S G L F C V T V N P Y 
M A M L T F L B B P A V L Y N L K D R Y G S W M I Y T Y S G L F C V T V N P Y 
----------------------------------------•-----------•--------•--•-----------------------------------------------------
AGTGGCTGCCGGTGTACAATGCCGAGGTGGTGGCCGCCTACCGGGGCAAGAAGAGGAGTGAGGCCCCGCCCCACATCTTCTCCATCTCCGACAACGCCTATCAGTACATGCTGACAGA 
AGTGGCTGCCGGTGTACACTCCTGAGGTGGTGGCTGCC'I'ACCGGGGCAAGAAGAGGAGCGAGGCCCCGCCCCACATCTTCTCCATCTCCGACAACGCCTATCAGTACATGCTGACAGA 
------------------•-•-•-----------•-----------------------*-----------------------------------------------------------
K W L P V Y N A E V V A A Y R G E K R S E A P P B I F S I S D N A Y Q Y M L T D 
K W L P V Y T P B V V A A Y R G K K R S B A P P B I P S I S D N A Y Q Y M L T D 
------------------•--•------------------------------------------------------------------------------------------------
TCGGGAGAACCAGTCCATCCTCATCACGGGAGAATCCGGGGCGGGGAAG.ACTGTGAACACCAAGCGTGTCATCCAGTACTTTGCCAGCATTGCAGCCATAGGTGACCGTGGCAAGAAG 
CAGAGAAAACCAGTCCATCCTGATCACCGGAGAATCCGGAGCAGGGAAGACAGTCAACACCAAGAGGGTCATCCAGTAC'r.I'TGCTATTGCAGCCATTGGGGACCGCA,..--'"'"""'"""' 
**-*--*--------------*-----*-----------•--•--------•--•---------*-*-----------------····-----------•--•-----••--------
R B N Q S 
R E N Q S 
I L I T G E 
I L I T G B 
S G A G K T V N T K R V I Q Y 
S G A G K T V N T X R V I Q Y 
F A S I A A I 
F A V I A A I 
G D R G 
G D R S 
K K 
K K 
--------------------------------------------------------------------------------------•-----------------------•-------
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7VBMYB6 
al.pha-MyBC. 
beta-MyBC 
alpha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
al.pha-MyBC 
beta-MyBC 
al.pha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
al.pha-MyBC 
beta-MyBC 
al.pha VB beta 
MYB6 eDNA 
MYB7 eDNA 
cDNA:MYB7VBMYB6 
al.pha-MyBC 
beta-MyBC 
al.pha vs beta 
MYB6 eDNA 
MYB7 eDNA 
cDNA:MYB7vsMYB6 
alpha-MyBC 
beta-MyBC 
al.pha va beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
alpha-MyBC 
beta-MyBC 
alpha VB beta 
GACAATGCCAA!t'GCGAACAAGGGCACCCTGGAGGACCAGATCATCCAGGCCAACCCCGCTCTGGAGGCC'1"1'CGGCAATGCCAAGACTGTCCGGAACGACAACTCCTCCCGC 
GACCAGAGCCCGGGC-f++AAGGGCACCCTGGAGGACCAGATCATCCAGGCCAACCCTGCTCTGGAGGCC~CAAGACCGTCCGGAACGACAACTCCTCCCGCTI'C€K*;Aj 
---•-•••-•••-*••••--------------------------------------•--------------*--------------•--------------------------·~---
D B A B A N ~ G T L E D Q I I Q A N P A L E A P G B A ~ T V R N D B S S R P ·G 
D Q S P G ? K G T L B D Q I I Q A B P A L B A P G H A ~ T V R B D H S S R P G 
----·--·--·--·--·-----------------------------------------------------------------------------------------------------
AATTCATTAGG~CACTTTGGGGCCACTGGAAAGCTGGCTTCTGCAGACATAGAGACCTACCTGCTGGAGAAGTCCCGGGTGATCTTCCAGCTGAAAGCTGAGAGAAACTACCACAT 
AATTCATTCGAATTCATTTTGGGGCAACAGGAAAGTTGGCATCTGCAGACATAGAGACCT~TTCTGGAAAAATCCAGAGTTATTTTCCAGCTGAAAGCAGAGAGAGATTATCACA'I 
--------*-*--*--*--------·--·------•----•--------------------•--•-----•--•---•-•--•--•--------------•------*-*--*-----~ P I R I B P G A T G K L A S A D I B T Y L L E K S R V I P Q L X A B R N Y B X 
~ P I R I B P G A T G X L A S A D I E T Y L L B X S R V I P Q L K A B R D Y B I 
------------------------------------------------------------------------------------------------------------*---------
CTTCTACCAGATTCTGTCCAACAAGAAGCCGGAGTTGCTGGACATGCTGCTGGTCACCAACAATCCCTACGAC'EACGCCTTCGTGTCTCAGGGAGAGGTGTCCGTGGCCTCCATTGA'l: 
TTTCTAC~CTGTCTAACAAAAAGCC'l'GAGCTGCTGGACA'I'GCTGCTGATCACCAACAACCCCTACGATTATGCATTCATCTCCCAAGGAGAGACCACCGTGGCCTCCATTGA'l: 
*--------*--*-----•-----*-----•---•-----------------·----------*--------*--*--*---*-*--*--*------****-----------------
P Y Q I L S H ~ ~ P B L L D M L L V T N N P Y D Y A P V S Q G B V S V A S X D 
F Y Q X L S H X X P E L L D M L L I T R N P Y ·D Y A P X S Q G B T T V A S X D 
-----------------------------------------------------*-----------------------------•--------------*--*----------------
GACTCCGAGGAGCTCATGGCCACCGATAGTGCC'.l"'r1'GACG - GC'l'GGCGTC'I7oCAAGCTGACGGGAGCCATCATGCACTACGGGAAC~ 
GACGCTGAGGAGCTCA'l'GGCCACTGATAACGC'IT1'TGATGTGCTGGGCTTCACTTCAGAGGAGAAAAACTCCATGTATAAGC'l'GACAGGCGCCATCATGCACTTTGGAAACA~••,.._.. 
---•-•-----------------*----**--*-----•---------------------------·····-·-·--·--------•--•-------------••--•----------
D S E B L H A T D S A F D V L G P T S B B ~ A G V Y X L T G A I M B Y G R M ~ 
D A B B L M A T D R A P D V L G F T S B B K H S H Y ~ L T G A I M B P G N H ~ 
----*-----------------------•--------------------------------------•--•--•-----------------------------•--------------
TCAAGCAGAAGCAGCGGGAGGAGCAGGCGGAGCCAGACGGCACCGAAGATGCTGACAAGTCGGCCTACCTCATGGGGCTGAACTCAGCTGACCTGCTCAAGGGGCTGTGCCACCCTCG 
TCAAGCTGAAGCAGCGGGAGGAGCAGGCGGAGCCAGACGGCACTGAAGAGGCTGACAAGTCTGCCTACCTCA!l'GGGGCTGATCAGCCGACCTGCTCAAGGGGCTGTGCCACCCTCG 
------•------------------------------------•-----*-----------•--------------------------•-----------------------------
p X Q X Q R E B Q A B P D G T B D A D K S A Y L M G L H S A D L L K G L C B P R 
F X L K Q R E B Q A B P D G T B B A D X S A Y L M G L H S A D L L K G L C B P R 
------•-----------------------------------------•---------------------------------------------------------------------
GGTGAAAGTGGGCAACGAG'l!ATGTCACCAAGGGGCAGAGCGTGCAGCA~TACTCCATCGGGGCTCTGGCCAAGGCAGTGTATGAGAAGATGTTCAACTGGATGGTGACGCGC 
GGTGAAAGTGGGCAATGAGTACGTCACCAAGGGGCAGAATGTCCAGCAGGTGATATATGCCACTGGGGCACTGGCCAAGGCAGTGTATGAGAGGATGTTCAACTGGATGGTGACGCGC 
---------------*-----•----------------**--*---------***--**---••-----•----------------------•-------------------------
V X V G B E Y V T X G Q S V Q Q V Y Y S I G A L A K A V Y B ~ M P H W M V T R 
V K V G H E Y V T ~ G Q H V Q Q V X Y A T G A L A ~ A V Y B R M P H W M V T R 
--------------------------------------*--------------•-----*--*-----------------------------·-------------------------
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
al.pha-Myac 
beta-MyBC 
al.pha vs beta 
MYB6 eDNA 
MYB7 eDNA 
dDNA:MYB7,vsMYB6 
al.pha-MyBC 
beta-MyBC 
al.pha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
al.pha-MyBC 
beta-MyBC 
al.pha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eONA:MYB7vsMYB6 
al.pha-MyBC 
beta-MyBC 
al.pha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eONA:MYB7vsMYB6 
a~pha-MyBC 
beta-MyBC 
al.pha va beta 
MYB6 eDNA 
MYB7 eDNA 
eONA:MYB7vsMYB6 
a~pha-MyBC 
beta-MyBC 
al.pha vs beta 
ATCAACGCCACCCTGGAGACCAAGCAGCCACGCCAGTACTTCArAGGAGTCCTGGACATCGCTGGCTTCGAGATCTTCGACTTCAACAGCTTTGAGCAGCTCTGCATCAACTTCACCA 
ATCAATGCCACCCTGGAGACCAAGCAGCCACGCCAGTACTTCATAGGAGTCCTGGACATCGCTGGCTTCGAGATCTTCGATrrCAACAGCTTTGAGCAGCTCTGCATCAACTTCACCA 
-----•--------------------------------------------------------------------------*-------------------------------------
r 
r 
H A T L B 
H A T L B 
T I( Q p 
T It 0 P 
R Q 
R Q 
y p 
y p 
X G V L 
X G V L 
D 
D 
r A G 
r A G 
p B 
p B 
r 
r 
p .D p 
p D p 
N 
H 
s 
s 
p E 
p B 
Q L 
Q L 
c 
c 
r 
r 
N P T 
N P T 
ACGAGAAGCTGCAGCAGTTCTTCAACCACCACATGTTCGTGCTGGAGCAGGAGGAGTACAAGAAGGAGGGCATTGAGTGGACATTCATTGACTTTGGCATGGACCTGCAGGCCTGCAT 
ACGAGAAGCTGCAGCAGTTCTTCAACCACCACATGTTTGTGCTGGAGCAGGAGGAGTACAAGAAGGAGGGCATCGAGTGGACArTCATTGACTTTGGCATGGACCTGCAGGCCTGCAT 
-------------------------------------*-----------------------------------•--------------------------------------------
H E K L Q Q P P N B B M P V L E 
H B K L Q Q P F N B B M P V L B 
Q B B Y K K B G r 
Q B B Y K K E G X 
E W T P 
B W T P' 
X D P G M D L 
r D P G M D L 
Q A C 
Q A C 
r 
r 
TGACCTCATCGAGAAGCCCATGGGCATCATGTCCATCCTGGAGGAGGAGTGCATGTTCCCCAAGGCCACTGACATGACCTTCAAGGCCAAGCTGTACGACAACCACCTGGGCAAGTCC 
TGACCTCATCGAGAAGCCCATGGGCA!l'CATGTCCATCCTGGAAGAGGAGTGCATGTTCCCCAAGGCCACCGACATGACCTTCAAGGCCAAGCTGTTTGACAACCACCTGGGCAAATCC 
------------------------------------------•--------------------------•-------------------------••-----------------*---
D L r B K P M G r M S r L E E B C M P P K A T D M T P It A K L Y D N B L G K S 
D L I B K P M G I M S r L B E E C K P P K A T, D M T P K A K L P D N B L G K S 
-----------------------------------------------------------------------------------------------•----------------------
AACAATTTCCAGAAGCCACGCAACATCAAGGGGAAGCAGGAAGCCCACTTCTCCCTGATCCACTACGCCGGCACTGTGGACTACAACATCCTGGGCTGGCTGGAAAAAAACGGA!l'C 
GCCAACTTCCAGAAGCCACGAAATATCAAGGGGAAGCCTGAAGCCCACTTCTCCCTGATCCACTATGCCGGCATCGTGGACTACAACATCATTGGCTGGCTGCAGAAGAACGGATC 
••---•--------------·--·-------------••--------------------------·-------••---------------•-•---------*-*--*----------
N H P Q X P R N r K G K Q E A B P S L 
A N P Q K P R N I K G K P B A B P S L 
I B Y A G T V D Y N r L G W L B K N K D 
r B Y A G r V D Y N r r G W L Q K N K D 
-*-----------------------------------•-----------------------------------*-----------------•-----------*-------------
CTCTCAACGAGACTGTTGTGGCCCTGTACCAGAAGTCCTCCCTCAAGCTCATGGCCACTCTCTTCTCCTCCTACGCAACTGCCGATACTGGGGACAGTGGTAAAAGCAAAGGAGGCAA 
CTCTCAATGAGACTGTCGTGGGCTTGTATCAGAAGTCTTCCCTCAAGTTGCTCAGCACCCTGTTTGCCAACTATGCTGGGGCTGATGCGCCT+++ATTGAGAAGGGCAAAGGCAAGGC 
-------•--------*----•-•----•--------•---------*-**-***---*--*--**--**---*--****--*---*-*******-*--**--**-------****** 
P L N B T V V A L Y Q X S 
P L N E T V V G L Y Q K S 
S L K L M A T L P S S Y A T A D T G D S G K S K G G K 
S L K L L S T L P A N Y A G A D A P ? r B K G K G K A 
---------------------*-----------------------------*--*--------------·--------•--------*--*--*--*--•-----*--------*--* 
GAAAAAGGGCTCATCCTTCCAGACGGTGTCGGCTCTCCACCGGGAAAATCTCAACAAGCTAATGACCAACCTGAGGACCACCCATCCTCACTTTGTGCGTTGCA!l'CATCCCCAATGAG 
CAAGAAAGGCTCGTCCTrrCAGACTGTGTCAGCTCTGCACAGGGAAAATCTGAACAAGCTGATGACCAACTTGCGCTCCACCCATCCCCACTTTGTACGTTGTATCATCCCTAAXGAG 
*--*--*-----*-----*-----•-----*-----*---·----------•--------•---------*--*-**----------*--------•-----*--------•------
K K G S S P Q T V S A L B R B N L N K L M T N L R T T B P B P V R C X r P N E 
K K G S S P Q T V S A L B R B H L N K L H T H L R S T B P B F V R C r r P N B 
-----------------------------------------------------------------------------•----------------------------------------
MYH6 eDNA 
MYH7 eDNA 
eDNA:MYH7vsMYH6 
al.pha-MyHC 
beta-MyHC 
al.pha VB beta 
MYH6 eDNA 
MYH7 eDNA 
eDNA:MYH7vBMYH6 
al.pha-MyBC 
beta-MyHC 
al.pha VB beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
al.pha-MyBC 
beta-MyBC 
a~pha VB beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYH7vsMYH6 
alpha-MyBC 
beta-MyHC 
a~pha vs beta 
MYB6 eDNA 
MYH7 eDNA 
eDNA:MYH7vsMYH6 
al.pha-MyBC 
beta-MyBC 
al.pha vs beta 
CGGAAGGCTCCAGGGGTGATGGACAACCCCCTGGTCATGCACCAGCTGCGCTGCAATGGCGTGCTGGAGGGCATCCGCATCTGCAGGAAGGGCTrCCCCAACCGCATCCTCTACGGGG 
ACAAAGTCTCCAGGCGTGATGGACAACCCCCTGGTCATGCACCAGCTGCGCTGCAATGGTGTGCTGGAGGGCATCCGCATCTGCAGGAAAGGCTrCCCCAACCGCATCCTCTACGGGG 
···---•-------•--------------------------------------------*-----------------------------*----------------------------
R K A P G V M D N P L V M B Q L R C N G V L E G I R I C R K G F P N R I L Y G 
T K 5 P G V M D N P L V M B Q L R C N G V L E G I R I C R K G F P N R I L Y G 
-·-----•--------------------------------------------------------------------------------------------------------------
ACTrCCGGCAGAGGTATCGCATCCTGAACCCAGTGGCCATCCCTGAGGGACAGTrCATTGATAGCAGGAAGGGGACAGAGAAGCTGCTCAGCTCTCTGGACATTGATCACAACCAGTA 
ACTrCCGGCAGAGGTATCGCATCCTGAACCCAGCGGCCATCCCTGAGGGACAGTrCATTGATAGCAGGAAGGGGGCAGAGAAGCTGCTCAGCTCCCTGGACATTGATCACAACCAGTA 
---------------------------------•----------------------------------------•-------------------•-----------------------
D F R Q R Y R I L N P V A I P E G Q P I D 5 R K G T E K L L S 5 L D I D B N Q Y 
D F R Q R Y R I L N P A A I P E G Q P I D 5 R K G A E K L L S S L D I D B N Q Y 
---------------------------------•-----------------------------------------•------------------------------------------
CAAGTTTGGCCACACCAAGGTGTrCTrCAAGGCAGGGCTGCTTGGGCTGCTGGAGGAGATGCGGGATGAGAGGCTGAGCCGCATCATCACGCGCATGCAGGCCCAAGCCCGGGGCCAG 
CAAGTTTGGCCACACCAAGGTGTTCTTCAAGGCCGGGCTGCTGGGGCTGCTGGAGGAAATGAGGGACGAGAGGCTGAGCCGCATCATCACGCGTATCCAGGCCCAGTCCCGAGGTGTG 
---------------------------------•--------*--------------•---~----•--------------------------•--•--------••----*--***-
K P G B T K V P F K A G L L G L L E E H R D E R L 5 R I I T R M Q A Q A R G Q 
K P G B T K V P P K A G L L G L L E E M R D E- R L 5 R I I T R I Q A Q 5 R G V 
-----------------------------------------------------------------------------------------------·-----------*--------·-
CTCATGCGCATTGAGTrCAAGAAGATAGTGGAACGCAGGGATGCCCTGCTGGTAATCCAGTGGAACATTCGGGCCTTCATGGGGGTCAAGAATTGGCCCTGGATGAAGCTCTACTTCA 
CTCGCCAGAATGGAGTACAAAAAGCTGCTGGAACGTAGAGACTCCCTGCTGGTAATCCAGTGGAACATrCGGGCCTTCATGGGGGTCAAGAATTGGCCCTGGATGAAGCTCTACTTCA 
---****-•--•----·---•---*-**-------*--*--**---------------------------------------------------------------------------
L H R I E P K K I V E R R D A L L V I Q W N I R A F M G V K N W P W M K L Y F 
L A R M E Y K K L L E R R D S L L V I 0 W N I R A F M G V K N W P W M K L Y P 
----•-----•-----*--------·--·--------------•--------------------------------------------------------------------------
AGATCAAGCCGCTGCTGAAGAGCGCAGAGACGGAGAAGGAGATGGCCACCA!l'GAAGGAAGAGTTCGGGCGCATCAAAGAGACGCTGGAGAAGTCCGAGGCTCGCCGCAAGGA 
AGATCAAGCCGCTGCTGAAGAGTGCAGAAAGAGAGAAGGAGATGGCCTCCATGAAGGAGGAGTTCACACGCCTCAAAGAGGCGCTAGAGAAGTCCGAGGCTCGCCGCAA.GGOA<;K:'JL'G<iAI 
----------------------•-----·-··---------------*----------*------***---*--------•----•--------------------------------
K I K P L L K 5 A E T E K E M A T M K B E P G R I K E T L B K S E A R R K E L E 
K I K P L L K 5 A E R E K E M A S M K E E F T R L K E A L E K S E A R R K E L E 
------------------------------*-----------------*-----------------•-----*--------*------------------------------------
~5 2)30 2~5 2~0 2?5 2~0 2~05 2?0 
~~~~~~------~ MYB6 eDNA GGAGAAGATGGTGTCCCTGCTGCAGGAGAAGAATGACCTGCAGCTCCAAGTGCAGGCGGAACAAGACAACCTCAATGATGCTGAGGAGCGCTGCGACCAGCTGATCAAAAACAAGATT 
MYB7 eDNA GGAGAAGATGGTGTCCCTGCTGCAGGAGAAGAATGACCTGCAGCTCCAAGTGCAGGCGGAACAAGACAACCTGGCAGATGCTGAGGAGCGCTGTGATCAGCTGATCAAAAACAAGATT 
eDNA:MYB7vsMYB6 ------------------------------------------------------------------------****-----------------•--•---------------------
al.pha-MyBC 
beta-MyBC 
a~pha VB beta 
E K M V S L L Q E K R D L Q L Q V Q A E Q D R L N D A E E R C D Q L I K R K I 
E K M V S L L Q E K N D L Q L Q V Q A E Q D R L A D A E E R C D Q L I K N K I 
--------------------------------------------------------------------------*-------------------------------------------
MYE6 eDNA 
MYE7 eDNA 
cDNA:MYE7vsMYB6 
a1pha-MyBC 
beta-MyEC 
a1pha vs beta 
CAGCTGGAGGCCAAAGTAAAGGAGA!L'GAATGAGAGGCTGGAGGATGAGGAGGAGATGAACGCGGAGCTCACTGCCAAGAAGCGCAAGTTGGAAGACGAGTGCTCAGAGCTCAAGAAGG 
CAGCTGGAGGCTAAGGTGAAGGAGA'1'GAACGAGAGGCTGGAGGA'1'GAGGAGGAGA'1'GAATGCTGAGCTCACTGCC~AAGCGCAAGTTGGAAGATGAGTGCTCAGAGCTCAAAAGGG 
-----------•--•--•-----------•-----------------------------•--•--------------------------------*-----------------*-*--Q L B A X V K E M N B R L E D B E E H N A B L T A X X R X L B D E C S E L 11: X 
Q L B A X V K E H N B R L E D E E E M N A B L T A X X R X L E 0 E C S E L 11: R 
-------------------------------------------------------------------------------------------------------------------*--
MYB6 eDNA ACATTGATGACCTGGAGC'1'GACACTGGCCAAGGTGGAGAAGGAGAAGCA'1'GCAACAGAGAACAAGG'1'GAAGAACCTAACAGAGGAGATGGC'1'GGGCTGGA'1'GAAATCATCGCTAAGCT 
MYB7 eDNA ACATCGATGATCTGGAGC'1'GACACTGGCCAAAGTGGAGAAGGA~CACGCAACAGAGAACAAGG'1'GAAAAACCTGACAGAGGAGATGGCTGGGCTGGA'1'GAGATCAT'1'GCCAAGCT 
cDNA:MYB7vsMYB6 ----•-----•--------------------*--------------*--*--------------------*-----•--------------------------•-----•--•-----
a1pha-MyEC D J: D 0 L E L T L A X V E 11: E X H A T E H 11: V X H L T B B H A G L D B J: J: A K L 
beta-MyBC D J: D 0 L B L T L A K V B K B K H A T B H K V X N L T B B H A G L D B I I A X L 
a1pha vs beta ----------------------------------------------------------------------------------------------------------------------
MYB6 eDNA 
MYB7 eDNA 
cDNA:MYB7.vsMYE6 
a1pha-MyBC 
beta-MyBC 
a1pha vs beta 
MYE6 eDNA 
MYE7 eDNA 
cDNA:MYB7vsMYB6 
a1pha-MyEC 
beta-Myac 
a1pha vs beta 
MYB6 eDNA 
MYB7 eDNA 
cDNA:MYB7vsMYB6 
a1pha-MyBC 
beta-MyBC 
a1pha vs beta 
MYE6 eDNA 
MYB7 eDNA 
cDNA:MYE7vsMYB6 
a1pha-MyBC 
beta-MyBC 
a1pha vs beta 
GACCAAGGAGAAGAAAGCTCTACAAGAGGCCCATCAGCAGGCCCTGGATGACCTTCAGGTTGAGGAAGACAAGGTCAACAGCCTGTCCAAGTCTAAGGTCAAGCTGGAGCAGCAGGTG 
GACCAAGGAGAAGAAAGCTCTGCAAGAGGCCCACCAACAGGCTCTGGATGACCTTCAGGCCGAGGAGGACAAGGTCAACACCC'1'GACTAAGGCCAAAGTCAAGC'1'GGAGCAGCAAG'1'G 
---------------------•-----------•--•-----•----------------··-----*-------------*----*-*---*-*--*-----------------•---
T X E X X A L Q E A H Q Q A L 0 D L Q V E B D K V H S L S K S K V X L E 0 Q V 
T K E X 11: A L Q E A H Q Q A L 0 D L Q A E E D K V N T L T X A K V K L E Q 0 V 
-----------------------------------------------------------*---------~----------•-----·-----·-------------------------
GATGATCTGGAGGGAXCCCTAGAGCAAGAGAAGAAGGTGCGCATGGACCTGGAGCGAGCAAAGCGGAAACTGGAGGGCGACCTGAAGCTGACCCAGGAGAGCATCATGGACCTGGAAA 
GATGATCTGGAAGGATCCCTGGAGCAAGAGAAGAAGGTGCGCATGGACCTGGAGCGAGCGAAGCGGAAGC'1'GGAGGGCGACC'1'GAAGC'1'GACCCAGGAGAGCATCATGGACCTGGAGA 
-----------•--------•--------------------------------------•--------*-----------------------------------------------*-
D D L E G S L B 0 E K K V R M 0 L E R A K R K L B G 0 L X L T Q E S J: M D L E 
0 D L E G S L E Q E X X V R H 0 L B R A X R K L B G D L X L T Q B S Z M D L E 
ATGATAAACTGCAGCTGGAAGAAAAGCTTAAGAAGAAGGAGTTTGACATTAATCAGCA.GAACAGTAAGATTGAGGATGAGCAGGCGCTGGCCCTTCAACTACAGAAGAAACTGAAGGII 
ATGACAAGCAGCAGCTGGATGAGcGGC'.l'GAAAAAAACTTTGAGCTGAATGCTCTCAACGCAAGGATTGAGGATGAACAGGCCCTCGGCAGCCAGCTGCAGAAGAAGCTCAAGGII 
----*--*-*---------*--***---*--*--*--*--*-----••-•---***-**---***-*------------•-----·--·-·-~··--·--·--------•--•-----
N D K L Q L E E K L K X K E F 0 I N 0 Q N S K J: B D E 0 A L A L 0 L Q K X L X E 
N D K Q Q L 0 E R L K X X D F E L H A L N A R J: E 0 E Q A L G S Q L Q K K L K E 
---------~--------·-----•--------------•-----•--•-----*--*-----*--*-----------------------•--•------------------------
AAACCAGGCACGCATCGAGGAGCTGGAGGAGGAGCTGGAGGCCGAGCGCACCGCCAGGGCTAAGGTGGAGAAGCTGCGCTCAGACCTGTCTCGGGAGCTGGAGGAGATCAGCGJIGCGG 
GCTTCAGGCACGCATCGAGGAGCTGGAGGAGGAGCTGGAGTCCGAGCGCACCGCCAGGGCTAAGGTGGAGAAGCTGCGCTCAGACCTGTCTCGGGAGCTGGAGGAGATCAGCGAGCGG 
****------------------------------------*-----------------------------------------------------------------------------
H Q A R I E E L E E E L E A E R T A R A X V E X L R S 0 L S R E L E E J: S B R 
L 0 A R I E E L E E E L E S E R T A R A K V B K L R S D L S R E L E E Z S E R 
-----------------------------------------•----------------------------------------------------------------------------
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
alpha-MyBC 
beta-MyBC 
alpha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
alpha-MyBC 
beta-MyBC 
alpha vs beta 
MYB6 eDNA 
MYB7 eDNA 
cDNA:MYB7vsMYB6 
alpha-MyBC 
beta-MyBC 
alpha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
alpha-MyBC 
beta-MyBC 
alpha vs beta 
MYB6 eDNA 
MYB7 eDNA 
cDNA:MYB7vsMYB6 
al.pha-MyBC 
beta-MyBC 
al.pha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
alpha-MyBC 
beta-MyBC 
alpha vs beta 
CTGGAAGAGGCCGGCGGGGCCACGTCCGTGCAGATCGAGATGAACAAGAAGCGCGAGGCCGAGT:I'CCAGAAGATGCGGCGGGACCTGGAGGAGGCCACGCTGCAGCACGAGGCCACTG 
CTGGAAGAGGCCGGCGGGGCCACGTCCGTGCAGATCGAGATGAACAAGAAGCGCGAGGCCGAGT:I'CCAGAAGA'l:'GCGGCGGGACCTGGAGGAGGCCACGCTGCAGCACGAGGCCllt.CTG 
----------------------------------------------------------------------------------------------------------------------
L B B A G G A T S V Q I E M N K K R E A B F Q K M R R D L E E A T L Q B E A T 
L B B A G G A T S V Q I E M N K K R E A B F Q K M R R D L E B A T L Q B E A T 
CCGCGGCCC'l:'GCGCAAGAAGCACGCCGACAGCGTGGCCGAGCTGGGCGAGCAGATCGACAACCTGCAGCGGGTGAAGCAGAAGCTGGAGAAGGAGAAGAGCGAGTTCAAGCTGGAGC'J: 
CCGCGGCCCTGCGCAAGAAGCACGCCGACAGCGTGGCCGAGCTGGGCGAGCAGATCGACAACCTGCAGCGGGTGAAGCAGAAGCTGGAGAAGGAGAAGAGCGAGT:I'CAAGCTGGAGC'J: 
A A A L R K K B A D S V A E L G E Q I D N L Q R V K Q K L E X B K S E F X L B L 
A A A L R K X B A D S V A B L G B Q I D N L Q R V K Q K L E K B K S E F K L E L 
GGATGACGTCACCTCCAACATGGAGCAGATCATCAAGGCCAAGGCAAACCTGGAGAAAGTGTCTCGGACGCTGGAGGACCAGGCCAATGAGTACCGCGTGAAGCTAGAAGAGGCCCAA 
GGATGACGTCACCTCCAACATGGAGCAGATCATCAAGGCCAAGGCTAACCTGGAGAAGATGTGCCGGACCTTGGAAGACCAGATGAATGAGCACCGGAGCAAGGCGGAGGAGACCCAG 
---------------------------------------------•-----------••---••-----••----·------···------*----****---***--*---*----* 
D D V T S N M E Q I I K A K A N L E K V S R T L E D Q A R E Y R V K L E B A Q 
D D V T S N M E Q I I K A K A N L B K M C R T· L B D Q M N E B R S K A B B T Q 
-----------------------------------------------------------*--*--------------------*--------*-----*-----*--------•----
CGCTCCCTCAATGATT:I'CACCACCCAGCGAGCCAAGC'l:'GCAGACCGAGAATGGAGAGTTGGCCCGGCAGCTAGAGGAAAAGGAGGCGCTAA'J:CTCGCAGCTGACCCGGGGGAAGCTCT 
CGTTCTGTCAACGACC'J:CACCAGCCAGCGGGCCAAGTTGCAAACCGAGAATGGTGAGCTGTCCCGGCAGCTGGATGAGAAGGAGGCACTGA'J:CTCCCAGCTGACCCGAGGCAAGCTCJ! 
--·--··----•--••------•------*------·----·-----------•---•--•----------•--•--•--------*--*-----*-----------*--*------* 
R S L N D F T T Q R A K L Q T E N G B L A R Q L E B K E A L I S Q L T R G K L 
R S V N D L T S Q R A K L Q T B N G B L S R Q L D B K B A L I S Q L T R G K L 
-------•--------•-----•--------------------------------------*-----------•--------------------------------------------
CTTATACCCAGCAAATGGAGGACCTCAAAAGGCAGCTGGAGGAGGAGGGCAAGGCGAAGAACGCCCTGGCCCATGCACTGCAGTCAGCCCGGCATGACTGCGACC'l:'GCTGCGGGAGCA 
CCTACACCCAGCAGCTGGAGGACCTCAAGAGGCAGCTGGAGGAGGAGGTTAAGGCGAAGAACGCCCTGGCCCACGCACTGCAGTCGGCCCGGCATGACTGCGACCTGCTGCGGGAGCA 
-•--•--------••-------------•-------------------••-----------------------•-----------•--------------------------------
S Y T Q Q M B D L K R Q L B E E G K A K N A L A B A L Q S A R B D C D L L R E Q 
T Y T Q Q L B D L K R Q L B E E V K A K N A L A B A L Q S A R B D C D L L R E Q 
•--------------•--------------------------------•---------------------------------------------------------------------
GTACGAGGAGGAGACAGAGGCCAAGGCCGAGCTGCAGCGCG'J:CCTGTCCAAGGCCAACTCGGAGGTGGCCCAGTGGAGGAC,CAAGTATGAGACGGACGCCAT'J:CAGCGGACTGAGG.AG 
GTACGAGGAGGAGACGGAGGCCAAGGCCGAGC'l:'GCAGCGCGTCCTT'J:CCAAGGCCAACTCGGAGGTGGCCCAGTGGAGGACCAAGTATGAGACGGACGCCA!I.'TCAGCGGACTGAGGAG 
---------------*-----------------------------•------------------------------------------------------------------------
y B E B T E A K A B L Q R V L S K A N S E V A Q W R T K Y E T D A I Q R T E B 
Y B E E 'J: E A K A E L Q R V L S K A N S E V A Q W R T K Y E T D A I Q R T E E 
----------------------------------------------------------------------------------------------------------------------
MYH6 eDNA 
MYH7 eDNA 
eDNA:MYS7vsMYH6 
al.pha-MyHC 
beta-MySC 
a1pha vs beta 
MYS6 eDNA 
MYS7 eDNA 
eDNA:MYS7vsMYS6 
alpha-MySC 
beta-MySC 
a1pha VB beta 
MYS6 eDNA 
MYS7 eDNA 
eDNA:MYH7vsMYB6 
alpha-Mya:c 
beta-MyHC 
a1pha vs beta 
MYH6 eDNA 
MYH7 eDNA 
eDNA:MYB7vsMYB6 
a1pba-MyBC 
beta-MyBC 
al.pha VB beta 
MYH6 eDNA 
MYB7 eDNA 
cDNA:MYH7vBMYB6 
a1pha-MyBC · 
beta-MySC 
al.pha VB beta 
MYB6 eDNA 
MYS7 eDNA 
cDNA:MYB7VBMYH6 
a1pha-MyBC 
beta-MyBC 
al.pha VB beta 
CTCGAAGAGGCCAAAAAGAAGCTGGCCCAGCGGCTGCAGGATGCCGAGGAGGCCGTGGAGGCTGTI'AATGCCAAGTGCTCCTCACTGGAGAAGACCAAGCACCGGCTACA~AG.II 
CTCGAGGAGGCCAAGAAGAAGCTGGCCCAGCGGCTGCAGGAAGCTGAGGAGGCCGTGGAGGCTGTTAATGCCAAGTGCTCCTCGCTGGAGAAGACCAAGCACCGGCTACAGAA'rGAGA 
-----•--------*--------------------------*--*--------------------------------------*----------------------------------
L E E A K K K L A Q R L Q D A E E A V E A V N A K C S S L E K T K B R L Q N E 
L E B A K K X L A Q R L Q B A E B A V B A V N A K C S S L E K T K B R L Q N E 
----------------------------------------•------------------------------------~----------------------------------------
TAGAGGACTrGATGGTGGACGTAGAGCGCTCCAACGCCGCTGCTGCAGCCCTGGACAAGAAGCAGAGAAACTTTGACAAGATCCTGGCCGAGTGGAAGCAGAAGTATGAGGAGTCGCA 
TCGAGGACTTGATGGTGGACGTAGAGCGCTCCAATGCTGCTGCTGCAGCCCTGGACAAGAAGCAGAGGAACTTCGACAAGATCCTGGCCGAGTGGAAGCAGAAGTATGAGGAGTCGCA 
-*--------------------------------*--*-----------------------------*-----*--------------------------------------------
I B D L M V 0 V E R S N A A A A A L D K X Q R N F D K I L A E W K Q K Y B B S Q 
I B 0 L M V 0 V E R S N A A A A A L D K X 0 R N F D K I L A B W K Q K Y E E S 0 
~TGGAGTCCTCACAGAAGGAGGCTCGCTCCCTCAGCACAGAGCTCTTCAAGCTCAAGAACGCCTACGAGGAGTCCCTGGAGCACCTAGAGACCTTCAAGCGGGAGAACAAG 
GTCGGAGCTGGAGTCCTCGCAGAAGGAGGCTCGCTCCCTCAGCACAGAGCTCTTCAAACTCAAGAACGCCTATGAGGAGTCCCTGGAACATCTGGAGACCTTCAAGCGGGAGAACAAA 
---*--------------•--------------------------------------•--------------•--------------*--*--*-----------------------* 
S E L E S S 0 K E A R S L S T E L F K L K N A Y E E S L B R L B T F K R E N K 
S E L B S S Q K E A R S L S T E L F K L K N A·Y E E S L B B L E T F K R E N K 
----------------------------------------------------------------------------------------------------------------------
4~5 4?0 4?5 4?o 4~5 4?o 4~e 4yo 
AACCTTCAGGAGGAAATCTCGGACC'l'TACTGAGCAGCTAGGAGAAGGAGGAAAGAATGTGCATGAGCTGGAGAAGGTCCGCAAACAGCTGGAGGTGGAGAAGCTGGAGCTGCAGTCAG 
AACCTGCAGGAGGAG.A!t'CTCCGACTTGACTGAGCAGTTGGGTTCCAGCGGAAAGACTATCCATGAGCTGGAGAAGGTCCGAAAGCAGCTGGAGGCCGAGAAGATGGAGCTGCAGTCAG 
-----•--------•-----•---•-•---------·-·--·····-·-------•-•-•--------------------•--•----------••------•---------------
N L 0 E B I S D L T E Q L G E G G K N V B E L E K V R K 0 L E V E K L B L Q S 
N L 0 E E I S D L T B Q L G S S G K T I H E L E K V R K 0 L E A E K M E L Q S 
-------------------------------------------•--•--------•--•-----------------------------------•--------*--------------
CCCTGGAGGAGGCAGAGGCCTCCCTGGAGCACGAGGAGGGCAAGATCCTCCGGGCCCAGCTAGAGTTCAACCAGATCAAGGCAGAGATCGAGCGGAAGCTGGCAGAGAAGGACGAGG.II 
CCCTGGAGGAGGCCGAGGCCTCCCTGGAGCACGAGGAGGGCAAGATCCTCCGGGCCCAGCTGGAGTTCAACCAGATCAAGGCAGAGATCGAGCGGAAGCTGGCAGAGAAGGACGAGGA 
-------------*-----------------------------------------------•--------------------------------------------------------
A L B B A E A S L E B B B G K I L R A 0 L E P N Q I K A E I B R K L A B K D B B 
A L B E A E A S L E R E B G X I L R A Q L E F N Q I X A E I B R X L A B K D E B 
GATGGAACAGGCCAAGCGCAACCACCAGCGGGTGGTGGACTCGCTGCAGACCTCCCTGGATGCAGAGACACGCAGCCGCAACGAGGTCCTGAGGGTGAAGAAGAAGATGGAAGGAGAC 
GAXGGAACAGGCCAAGCGCAACCACCTGCGGGTGGTGGACTCGCTGCAGACCTCCCTGGACGCAGAGACACGCAGCCGCAACGAGGCCCTGAGGGTGAAGAAGAAGATGGAAGGAGAC 
--------------------------•---------------------------------•-------------------------•-------------------------------M E 0 A X R N B 0 R V V D S L 0 T S L D A E T R S R N B V L R V K K K M E G D 
M E 0 A K R N B L R V V D S L Q T S L D A E T R S R N E A L R V X K K M E G 0 
--------------------------•-----------------------------------------------------------•-------------------------------
(1.) 
co 
0 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
alpha-MyBC 
beta-MyBC 
alpha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
alpha-MyBC 
beta-MyBC 
alpha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7VsMYB6 
a1pha-MyBC 
beta-MyBC 
alpha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
a1pha-MyBC 
beta-MyBC 
alpha vs beta 
CTCAATGAGATGGAGA'rCCAGCTCAGCCACGCCAACCGCATGGCCGCCGAGGCCCAGAAGCAAGTCAAGAGCCTCCAGAGCTTGCTGAAGGACACCCAGATCCAGCTGGATGATGCGG 
CTCAATGAGATGGAGATCCAGCTCAGCCACGCCAACCGCATGGCCGCCGAGGCCCAGAAGCAAGTCAAGAGCCTCCAGAGCTI'GTTGAAGGACACCCAGAT:l'CAGCTGGACGATGCAG 
------------------------------------------------------------------------------------•----------------•--------•-----•-
L N E M E I Q L S H A N R M A A B A Q ~ Q V K S L Q S L L K D T Q I Q L D D A 
L N B M E I Q L S B A N R M A A B A Q ~ Q V K S L Q S L L K D T Q I Q L D D A 
TCCGTGCCAACGACGACCTGAAGGAGAACA!rCGCCATCGTGGAGCGGCGCAACAACCTGCTGCAGGCTGAGC'.I'GGAGGAGCTGCGTGCCGTGGTGGAGCAGACAGAGCGGTCCCGGAA 
TCCGTGCCAACGACGACCTGAAGGAGAACATCGCCATCGTGGAGCGGCGCAACAACCTGCTGCAGGCTGAGCTGGAGGAGTTGCGTGCCGTGGTGGAGCAGACAGAGCGGTCCCGGAA 
--------------------------------------------------------------------------------•-------------------------------------
¥ R A N D D L K E N I A I V B R R N N L L 0 A E L E E L R A V V E Q T E R S R K 
V R A N D D L K E N I A I V E R R N N L L 0 A E L E E L R A V V E Q T E R S R K 
GCTGGCGGAGCAGGAGCTGATTGAGACCAGCGAGCGGGTGCAGCTGCTGCAT:l'CCCAGAACACCAGCCTCATCAACCAGAAGAAGAAGATGGAGTCGGATCTGACCCAGCTCCAGTCG 
GCTGGCGGAGCAGGAGCTGATTGAGACTAGTGAGCGGGTGCAGCTGCTGCATTCCCAGAACACCAGCCTCATCAACCAGAAGAAGAAGATGGATGCTGACCTGTCCCAGCTCCAGACT 
---------------------------*--*--------------------------------------------------------------**-•--•---•-----------·-· 
L A E Q 
L A E Q 
E L 
B L 
I 
I 
E 
E 
T S 
T S 
E R V Q L L 
B R V Q L L 
B 
B 
s 
s 
Q N T S 
Q N T S 
L I 
L- I 
N Q K K K M E S D L T Q L 
N 0 K K K M D A D L S 0 L 
Q s 
0 T 
--------------------------------------------------------------------------------------------•--•--------•-----------·-
GAAGTGGAGGAGGCAGTGCAGGAGTGCAGAAACGCCGAGGAGAAGGCCAAGAAGGCCATCACGGATGCCGCCATGATGGCAGAGGAGCTGAAGAAGGAGCAGGACACCAGCGCCCACC 
GAAGTGGAGGAGGCAGTGCAGGAGTGCAGGAATGCTGAGGAGAAGGCCAAGAAGGCCATCACGGATGCCGCCATGATGGCAGAGGAGCTGAAGAAGGAGCAGGACACCAGCGCCCACC 
-----------------------------*--*--*----------------------------------------------------------------------------------
E V E E A V 0 E C R N A E E K A K K A I T D A A M M A E E L K K E Q D T S A H 
E V E E A V Q E C R N A E E K A K K A I T D A A M M A E E L K K E Q D T S A H 
~vo 
~M~Y~B~6--e~D~N~A~----~ 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
alpha-MyBC 
beta-MyBC 
alpha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
a1pha-MyHC 
beta-MyBC 
alpha vs beta 
TGGAGCGCATGAAGAAGAACATGGAGCAGACCATTAAGGACCTGCAGCACCGGCTGGACGAGGCCGAGCAGA!I'CGCCCTCAAGGGAGGCAAGAAGCAGCTGCAGAAGCTGGAAGCGCG 
TGGAGCGCATGAAGAAGAACATGGAACAGACCATTAAGGACCTGCAGCACCGGCTGGACGAAGCCGAGCAGATCGCCCTCAAGGGCGGCAAGAAGCAGCTGCAGAAGCTGGAAGCGCG 
-------------------------*-----------------------------------•-----------------------•--------------------------------
L E R M K K N M E Q T I K D L Q B R L D E A B Q I A L K G G K K Q L 0 K L E A R 
L E R M K K N K B Q T I K D L Q B R L D E A E Q I A L K G G K K Q L Q K L E A R 
GGTGCGGGAGCTGGAGGGTGAGCTGGAGGCCGAGCAGAAGCGCAACGCAGAGTCGGTGAAGGGCATGAGGAAGAGCGAGCGGCGCATCAAGGAGCTCACCTACCAGACAGAGGAAGAC 
GGTGCGGGAGCTGGAGAATGAGCTGGAGGCCGAGCAGAAGCGCAACGCAGAGTCGGTGAAGGGCATGAGGAAGAGCGAGCGGCGCATCAAGGAGCTCACCTACCAGACGGAGGAGGAC 
----------------••------------------------------------------------------------------------------------------·-----•---
V R E L E G E L B A E Q K R N A B S V K G M R K S B R R I K B L T Y Q T E B D 
V R E L B N E L B A B Q K R N A E S V K G M R K S B R R I K E L T Y Q T E E D 
-----------------*----------------------------------------------------------------------------------------------------
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYH7vsMYB6 
a~pha-MyBC 
beta-MyBC 
a~pha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
a~pha-MyBC 
beta-MyHC 
a~pha vs beta 
MYB6 eDNA 
MYB7 eDNA 
eDNA:MYB7vsMYB6 
a~pha-MyBC 
beta-MyBC 
al.pha vs beta 
AAAAAGAACC'l'GC'l'GCGGCTACAGGACCTGGTGGACAAGC'l'GCAACTGAAGGTCAAGGCCTACAAGCGCCAGGCCGAGGAGGCGGAGGAGCAAGCCAACACCAACCTGTCCAAGTTCC 
AGGAAAAACC'l'GCTGCGGCTGCAGGACCTGGTAGACAAGCTGCAGCTAAAGGTCAAGGCCTACAAGCGcCAGGCCGAGGAGGCGGAGGAGCAAGCCAACACCAACCTGTCCAAGTTCC 
-••--•--------------•-----------•-----------•--•----------------------------------------------------------------------
X X N L L R L Q D L V D X L Q L X V X A Y X R Q A E E A E E Q A N T N L S X P 
R X N L L R L Q D L V D X L Q L X V X A Y X R Q A E E A E E Q A N T N L S X F 
-•-----------------------------------------~-------~------------------------------------------------------------------
GCAAGGTGCAGCATGAGCTGGATGAGGCAGAGGAGCGGGCGGACATCGCTGAGTCCCAGGTCAACAAGCTTCGAGCCAAGAGCCGTGACATTGGTGCCAAGCAAAAAA'l'GCACGATGA 
GCAAGGTGCAGCACGAGCTGGATGAGGCAGAGGAGCGGGCGGACATCGCCGAGTCCCAGGTCAACAAGCTGCGGGCCAAGAGCCGTGACATTGGCACGAAG++++++GGC'I:'TAATGA 
-------------*-----------------------------------•--------------------•--•--------------------··-·---·········•*••----
R X V Q H E L D E A E E R A D I A E S Q V R X L R A X S R D I G A K Q K M H D E 
R X V Q B E L D E A E E R A D I A E S Q V N X L R A X S R D I G T K ? ? G L N E 
------------------------------------------------------------------------------------------------•-----•--•--•--•--•---
GGAGTGAcactgcctogggaacctcactcttgocaacctgtaataaatatgagtgcea 
GGAGTAGctttgceaeatettgatctgctcagecetggaggtgccagcaaagceceatgctggagcctgtgtaacagctccttgggaggaagcagaataaagcaatttteettqaagc 
-----**-**----*-*******--******---·····-·····-**-******-** 
E 
E 
MYB6 eDNA <~ 
MYB7 eDNA ega 
eDNA:MYB7vsMYB6 <-= 
a~pha-MyBC <--
beta-MyBC <=-
a~pha vs beta <= 
(1.) 
<0 
1\) 
Table C7.2 Genetic and Amino Acids Codes. 
AGA UUA 
AGG UUG 
GCA CGA GGA CUA CXA 
GCC CGC GGC AUA cue CCC 
GCG CGG GAC AAC UGC GAA CAA GGG CAC AUC CUG AAA uuc CCG 
GCU CGU GAU AAU UGU GAG CAG GGU CAU AUU cuu AAG AUG uuu ccu 
Ala Arg Asp Asn Cys Glu Gin Gly His lie Leu Lys Met Phe- Pro 
A R D N c E Q G H I L K M F p 
GCf CGT GAT AAT TGT GAG CAG GGT CAT AlT CIT AAG ATG TIT CCT 
GCG CGG GAC AAC TGC GAA CAA GGG CA.C ATC CrG AAA TIC CCG 
GCC CGC GGC ATA CTC CCC 
GCA CGA GGA CTA CCA. 
AGG lTG 
AGA lTA 
RNA codons above, amino acid codes in the middle, and DNA 'codons' below. 
AGC 
AGU 
UCA ACA GUA 
ucc ACC GUC UAA 
uoo ACG UAC GUG UAG 
ucu ACU UGG UAU GUU UGA 
Ser Thr Trp Tyr Val Stop 
s u w y v 
TCT ACT TGG TAT GlT TGA 
TOO ACG TAC GTG TAG 
TCC ACC GTC TAA 
TCA. ACA GTA 
AGT 
AGC 
Table C7.3 Sequence of MYH7 and Its Primers 
Seq Ed, Version 1.0.3 (Myers, 1992: ABI) was used to convert the published single stranded 'sense strand' MYH7 
eDNA sequence (Jaenicke et al., 1990). 
The reading frame can be deduced at any point in the M YH7 sequence as the numbers on the top ruler identify the 
last base of every fifth codon. Table C7.2 in this Appendix is the genetic code. Primers were designed as 
described in Section 7.3.1.3 (pp. 183-187). 
115 310 45 610 75 90 105 1f0 1r I I I I 
42Ff------------------->l 
tqtctttocctgctgctctcagqtcccctgeaggccttggcccctttcctcatctqtagacacacttgagtagcccaggcacag~TTCGGAGATGGCAGTCTTTGGGGCTGCCGCCCCCTACCTGC 
acagaaagggacgacgagaqtccaggggacqtccggaaccggggaaaggagtagacatctgtgtgaactcatcgggtccqtgtcggTACCCTCTAAGCCTCTACCGTCAGAAACCCCGACGGCGGGGGATGGACG 
I-
1~0 1f5 1!0 1r5 210 215 210 2~5 27 
GCAAGTCAGAGAAGGAGCGGCTAGAAGCGCAGACCAGGCCTTTTGACCTCAAGAAGG~GTGCCTGA!l'GACAAACAGGAGTTTGTCAAGGCCAAGATCGTGTCTCGAGAGGGTGGCAAAGTCACTGCCG 
CGTTCAGTCTCTTCCTCGCCGATCTTCGCGTCTGGTCCGGAAAACTGGAGTTCTTCCTACAGAAGCACGGACTACTGTTTGTCCTCAAACAGTTCCGGTTCTAGCACAGAGCTCTCCCACCGTT1'CAGTGACGGC 
I-
2!5 3~0 3l5 3i0 315 3!0 3Is 3ro 4y 
396Ff---------
AGACTGAGTATGGCAAGACAGTGACCGTGAAGGAGGACCAGGTGATGCAGCAGAACCCACCCAAGTTCGACAAJU>d'CGAGGACATGGCCATGCTGACCTTCCTGCATGAGCCCGCGGTGCTCTACAACCTCAAGG 
TCTGACTCATACCGTTCTGTCACTGGCACTTCCTCCTGGTCCACTACGTCGTCTTGGGTGGGTTCAAGCTGTTT1'AGCTCCTGTACCGGTACGACTGGAAGGACGTACTCGGGCGCCACGAGATGT':I'GGAGTTCC 
I<--------------------I365R 
4f0 4f5 410 4!5 4r 415 5l0 5f5 51 
--------->1 
ATCGCTACGGCTCCTGGATGATCTACACCTACTCGGGCCTCTTCTGTGTCACCGTCAACCCTTACAAGTGGCTGCCGGTGTACACTCCTGAGGTGGTGGCTGCCTACCGGGGCAAGAAGAGGAGCGAGGCCCCGC 
TAGCGATGCCGAGGACCTACTAGATGTGGATGAGCCCGGAGAAGACACAGTGGCAGTTGGGAATGTTCACCGACGGCCACATGTGAGGACTCCACCACCGACGGATGGCCCCGTTCTTCTCCTCGCTCCGGGGCG 
555 syo sy5 600 6t5 630 615 660 67 
I- I I t I I 
CCCACATCTTCTCCATCTCCGACAACGCCTATCAGTACATGCTGACAGACAGAGAAAACCAGTCCATCCTGATCACCGGAGAATCCGGAGCAGGGAAGACAGTCAACACCAAGAGGGTCATCCAGTACTT1'GCTG 
GGGTGTAGAAGAGGTAGAGGCTGTTGCGGATAGTCA!I'G'I!ACGACTGTCTGTCTCTT1'TGGTCAGGTAGGACTAGTGGCCTCTTAGGCCTCGTCCCTTCTGTCAGTTGTGGTTCTCCCAGTAGGTCATGAAACGAC 
[<-------------------I611R 
690 705 720 7f5 7t0 7f5 7yo 795 at r I r r 
TTATTGCAGCCATTGGGGACCGCAGCAAGAAGGACCAGAGCCCGGGCAAGGGCACCCTGGAGGACCAGATCATCCAGGCCAACCCTGCTCTGGAGGCCTT1'GGCAATGCCAAGACCGTCCGGAACGACAACTCCT 
AATAACGTCGGTAACCCCTGGCGTCGTTCTTCCTGGTCTCGGGCCCGTTCCCGTGGGACCTCCTGGTCTAGTAGGTCCGGTTGGGACGAGACCTCCGGAAACCGTTACGGTTCTGGCAGGCCTTGCTGTTGAGGA 
8i5 a to 855 sro 885 9~0 915 9t0 91 
I- I I I 887FI------------------->l 
CCCGCTTCGGGAAATTCATTCGAATTCATTTTGGGGCAACAGGAAAGTTGGCATCTGCAGACATAGAGACCTATCTTCTGGAAAAATCCAGAGTT~CAGCTGAAAGCAGAGAGAGATTATCACATTTTCT 
GGGCGAAGCCCTT1'AAGTAAGCTTAAGTAAAACCCCGTTGTCCTTTCAACCGTAGACGTCTGTATCTCTGGATAGAAGACCTTTTTAGGTCTCAATAAAAGGTCGACTTTCGTCTCTCTCTAATAGTGTAAAAGA 
910 9J5 990 10,05 10(0 10,35 1050 10,65 1018 
r-- I r 
ACCAAATCCTGTCTAACAAAAAGCCTGAGCTGCTGGACATGCTGCTGATCACCAACAACCCCTACGATTATGCATTCATCTCCCAAGGAGAGACCACCGTGGCCTCCATTGATGACGCTGAGGAGCTCATGGCCA 
TGGTT1'AGGACAGATTGTTT'rl'CGGACTCGACGACCTGTACGACGACTAGTGGTTGTTGGGGATGCTAATACGTAAGTAGAGGGTTCCTCTCTGGTGGCACCGGAGGTAACTACTGCGACTCCTCGAGTACCGGT 
f<--------------------f1041R 
1--
10,95 1vo 11,25 1]40 11(5 1yo 11185 12,00 1211 
1145F(------------------->I 
CTGATAACGCT:L'TTGATGTGCTGGGCTTCACTTCAGAGGAGAAAAACTCCATGTATAAGCTGACAGGCGCCATCATGCACTTTGGAAACATGAAGTTCAAGCTGAAGCAGCGGGAGGAGCAGGCGGAGCCAGACG 
GACTATTGCGAAAACTACACGACCCGAAGTGAAGTCTCCTC'l"I'TTTGAGGT.ACATATTCGACTGTCCGCGGTAGTACGTGAAACCTTTGTACTTCAAGTTCGACTTCGTCGCCCTCCTCGTCCGCCTCGGTC'l'GC 
12?0 12,45 12,60 12?5 12,90 13,05 13?0 13,35 1315 
GC.ACTGAAGAGGCTGACAAGTCTGCCTJI>.CCTCATGGGGCTGAACTCAGCCGACCTGCTCAAGGGGCTGTGCCACCCTCGGGTGAAAGTGGGCAATGAG'l!ACGTCACCAAGGGGCAGAATGTCCAGCAGGTGATAT 
CGTGACTTCTCCGACTGTTCAGACGGATGGAGTACCCCGACTTGAGTCGGCTGGACGAGT'l'CCCCGACACGGTGGGAGCCCACTTTCACCCGTTACTCATGCAGTGGTTCCCCGTCTTACAGGTCGTCCACTATA 
13,65 13,80 13,95 14(0 14r5 14,40 14,55 14,70 148 I 
1472Ff-------------
ATGCCACTGGGGCACTGGCCAAGGCAG'1'GTATGAGAGGATGTTCAACTGGATGGTGACGCGCATCAATGCCACCCTGGAGACCAAGCAGCCACGCCAGTACTTCATAGGAGTCCTGGACATCGCTGGCTTCGAGA 
T.ACGGTGACCCCGTGACCGGTrCCGTCACATACTCTCCTACAAGTTGACCT.ACCACTGCGCGTAGTTACGGTGGGACCTCTGGTTCGTCGGTGCGGTCATGAAGTATCCTCAGGACC'1'GTAGCGACCGAAGCTCT 
15100 15(5 15,30 15145 15160 15175 15,90 16105 16( 
------>1 
TCTTCGATTTCAACAGCTT'l'GAGCAGCTCTGCATCAACTTCACCAACGAGAAGCTGCAGCAGTTCTTCAACCACCACATGTTTGTGCTGGAGCAGGAGGAGTACAAGAAGGAGGGCATCGAGTGGACATTCATTG 
AGAAGCTAAAGTTGTCGAAACTCGTCGAGACGTAGTTGAAGTGGTTGCTTCGACGTCGTCAAGAAGTTGGTGCAAACACGACCTCGTCCTCCTCATGTTCTTCCTCCCGTAGCTCACCTGTAAGTAAC 
I<-------------------I1589R 
16135 16t0 1665 1680 16195 1710 17(5 1740 175 I I I I I 
ACTTTGGCATGGACCTGCAGGCCTGCATTGACC~GAGAAGCCCATGGGCATCATGTCCATCCTGGAAGAGGAGTGCATGTTCCCCAAGGCCACCGACATGACCTTCAAGGCCAAGC'1'GTTTG.ACAACCACC 
TGAAACCGTACCTGGACGTCCGGACGTAACTGGAGTAGCTCTTCGGGT.ACCCGTAGTACAGGTAGGACCTTCTCCTCACGTACAAGGGGTTCCGGTGGCTGTACTGGAAGTTCCGGTTCGACAAACTGTTGGTGG 
~ 
17,70 17,85 18
1
oo 18,15 18,30 18,45 18,60 18,75 1819 
TGGGCAAATCCGCCAACTTCCAGAAGCCACGAAATATCAAGGGGAAGCCTGAAGCCCACTTCTCCCTGATCCACTATGCCGGCATCGTGGACT.ACAACATCATTGGCTGGCTGCAGAAGAACAAGGATCCTCTCA 
ACCCGTTTAGGCGGTTGAAGGTCTTCGGTGCTTTATAGTTCCCCTTCGGACTTCGGGTGAAGAGGGACTAGGTGATACGGCCGTAGCACCTGATGTTGTAGTAACCGACCGACGTCTTCTTGTTCCTAGGAGAGT 
1905 19r0 19,35 1950 19165 19t0 19t5 2010 20( I I I 
1943FI------------------->I 
ATGAGACTGTCGTGGGC'r'rGTATCAGAAGTCTTCCCTCAAGTTGCTCAGCACCCTGTTTGCCAACTA'l'GCTGGGGCTGATGCGCCTATTGAGAAGGGCAAAGGCAAGGCCAAGAAAGGCTCGTCCTTTCAGACTG 
TACTCTGACAGCACCCGAACATAGTCTTCAGAAGGGAGTTCAACGAGTCGTGGGACAAACGGTTGATACGACCCCGACTACGCGGATAACTCTTCCCGTTTCCGTTCCGGTTCTTTCCGAGCAGGAAAGTCTGAC 
j<-------------------(2015R 
f--
20il0 20,55 20?0 20,85 21,00 21,15 21?0 21,45 2116 
TGTCAGCTCTGCACAGGGAAAATCTGAACAAGCTGATGACCAACTTGCGCTCCACCCATCCCCACTTTGTACGTTGTATCATCCCTAATGAGACAAAGTCTCCAGGCGTGATGGACAACCCCCTGGTCATGCACC 
ACAGTCGAGACGTGTCCCTTTTAGACTTGTTCGACTACTGGTTGAACGCGAGGTGGGTAGGGGTGAAACATGCAACATAGTAGGGATTACTC'l<i'L'I'I'CAGAGGTCCGCACTACC'1'GTTGGGGGACCAGTACGTGG 
f<-------------------j2091R 
(A) 
co (J1 
r-
r-
21,75 21(_0 22,05 22(0 22,35 22,50 2365 22,80 2219 
2248P(------------------->I 
AGC~GCTGCAA!l.'GGTGTGC'Z'GGAGGGCATCCGCA'l'C'l'GCAGGAAAGGCTTCCCCAACCGCA'l'CCTCTACGGGGACTTCCGGCAGAGGTATCGCA'l'CCTGAACCCAGCGGCCATCCCTGAGGGACAGTTCA'l'TG 
TCGACGCGACGTTACCACACGACCTCCCGTAGGCGTAGACGTCCTT'l'CCGAAGGGGTTGGCGTAGGAGATGCCCCTGAAGGCCGTCTCCATAGCGTAGGACTTGGGTCGCCGGTAGGGACTCCCTGTCAAGTAAC 
23,10 2y5 23,40 23r· 23,70 23,85 2~00 24,15 2413 
ATAGCAGGAAGGGGGCAGAGAAGC'l'GCTCAGCTCCCTGGACATTGATCACAACCAGTACAAGTTTGGCCACACCAAGGTGTTCTTCAAGGCC~TGGGGCTGCTGGAGGAAATGAGGGACGAGAGGCTGA 
TATCGTCCTTCCCCCGTCTCTTCGACGAGTCGAGGGACCTGTAACTAGTGTTGGTCATGTTCAAACCGGTGTGGT'l'CCACAAGAAGTTCCGGCCCGACGACCCCGACGACCTCCTTTACTCCCTGCTCTCCGACT 
24,45 24,60 24(5 24,90 25,05 2120 25,35 25,50 2516 
2492P(-------------------->I 
GCCGCATCATCACGCGTA'l'CCAGGCCCAGTCCCGAGG~TCGCCAGAATGGAGTACAAAAAGCTGCTGGAACGTAGAGACTCCCTGCTGGTAA'l'CCAGTGGAACATTCGGGCCTTCATGGGGGTCAAGAATT 
CGGCGTAGTAGTGCGCATAGGTCCGGGTCAGGGCTCCACACGAGCGGTCTTACCTCA'l'GTTTT'l'CGACGACC~ATCTCTGAGGGACGACCATTAGGTCACCTTGTAAGCCCGGAAGTACCCCCAGTTCTTAA 
25,80 25,95 26(0 26,25 26,40 26,55 26,70 26,85 2710 
GGCCCTGGATGAAGCTCTACTTCAAGA'l'CAAGCCGC~TGAAGAG~AGAAAGAGAGAAGGAGATGGCCTCCATGAAGGAGGAGTTCACACGCCTCAAAGAGGCGCTAGAGAAGTCCGAGGCTCGCCGCAAGG 
CCGGGACC~CTTCGAGATGAAGTTCTAGTTCGGCGACGACTTCTCACGTCTTTCTCTCTTCCTCTACCGGAGGTACTTCCTCCTCAAGTGTGCGGAGTT'l'CTCCGCGATCTCTTCAGGCTCCGAGCGGCGTTCC 
I<-------------------(2639R 
27(5 27?0 27,45 27,60 27,75 2y1o 28,05 28,20 2813 
2782P(------------------->f 
AGCTGGAGGAGAAGATGGTGTCCCTGCTGCAGGAGAAGAATGACCTGCAGCTCCAAG'l'GCAGGCGGAACAAGACAACCTGGCAGATGCTGAGGAGCGCTGTGATCAGCTGATCAAAAACAAGATTCAGCTGGAGG 
TCGACCTCCTCTTCTACCACAGGGACGACGTCCTCTTCTTACTGGACGTCGAGGTTCACGTCCGCCTTGTTCTGT'l'GGACCGTCTACGACTCCTCGCGACACTAGTCGACTAG'l"rl"r:l'GTTTAAGTCGACCTCC 
28,50 28,65 28,80 28,95 29,10 29,25 29,40 29.55 29? 
CTAAGGTGAAGGAGATGAACGAGAGGCTGGAGGATGAGGAGGAG.AXGAATGCTGAGCTCAC~CAAGAAGCGCAAGTTGGAAGATGAGTGCTCAGAGCTCAAAAGGGACATCGATGATCTGGAGCTGACACTGG 
GATTCCACTTCCTCTAC~TCTCCGACCTCCTACTCCTCCTCTACTTACGACTCGAGTGACGG'11'CT':L'CGCGTTCAACCTTCTACTCACGAGTCTCGAGTTTTCCCTGTAGCTACTAGACCTCGAC'l'GTGACC 
I<-------------------]2906R 
29,85 3o
1
oo 30,15 30,30 30,45 30.60 30?5 30,90 3110 
CCAAAGTGGAGAAGGAGAAACACGCAACAGAGAACAAGGTGAAAAACCTGACAGAGGAGATGGCTGGGCTGGATGAGATCA~CAAGCTGACCAAGGAGAAGAAAGCTCTGCAAGAGGCCCACCAACAGGCTC 
GGTT'l'CACCTCTTCCTCTT'l'G.TGCGTTGTCTCTTGTTCCACTTTTTGGACTGTCTCCTCTACCGACCCGACCTACTCTAGTAACGGTTCGACTGGTTCCTCTrCX:ti!CGAGACGTTCTCCGGGTGGTTGTCCGAG 
31,20 31l5 31,50 31,65 31,80 31£5 3~(0 3)25 3214 
3137P(------------------->J 
TGGATGACCTTCAGGCCGAGGAGGACAAGGTCAACACCCTGACTAAGGCCAAAGTCAAGCTGGAGCAGCAAGTGGA!I'GATCTGGAAGGATCCCTGGAGCAAGAGAAGAAGGTGCGCATGGACCTGGAGCGAGCGA 
ACCTACTGGAAGTCCGGCTCCTCCTGTTCCAGTTG'l'GGGACTGATTCCGGTTTCAGTTCGACCTCGTCGTTCACCTACTAGACCTTCCTAGGGACCTCGTTCTCTTCTTCCACGCGTACCTGGACCTCGCTCGCT 
(<--------------------(3143R 
32155 32170 32185 33100 33~5 3330 33145 33160 3y 
r- I 3335Pf------------------->f 
AGCGGAAGCTGGAGGGCGACCTGAAGCTGACCCAGGAGAGCATCATGGACCTGGAGAATGACAAGCAGCAGCTGGATGAGCGGCTGA"aaaaaaaGAC'I"r..'GAGCTGATGCTCTCAACGCAAGGAT'rGAGGATG 
TCGCc=GACCTCCCGCTGGAC'rrCGACTGGG'X"CCTCTCGTAG'l'ACCTGGACCTCT'rACTGTTCGTCGTCGACCTACTCGCCGAC•:t XX t t t t ti'CTGAAACTCGACTTACGAGAGTTGCGTTCCTAACTCCTAC 
33[_0 34t5 34120 34135 34150 34165 34180 3~95 3511 
AACAGGCCCTCGGCAGCCAGCTGCAGAAGAAGCTCAAGGAGC'rrCAGGCACGCATCGAGGAGCTGGAGGAGGAGCTGGAGTCCGAGCGCACCGCCAGGGCTAAGGTGGAGAAGCTGCGCTCAGACCTGTCTCGGG 
TTGTCCGGGAGCCGTCGGTCGACGTCTl'CTTCGAGTTCCTCGAAGTCCGTGCG'l:AGCTCCTCGACCTCCTCCTCGACCTCAGGCTCGCGTGGCGGTCCCGATTCCACCTC'rrCGACGCGAGTCTGGACAGAGCCC 
l<-------------------f3404R 
35,25 35,40 35,55 35,70 35,85 36,00 36,15 36,30 3614 
AGCTGGAGGAGATCAGCGAGCGGCTGGAAGAGGCCGGCGGGGCCACGTCCGTGCAGATCGAGATGAACAAGAAGCGCGAGGCCGAGTTCCAGAAGATGCGGCGGGACCTGGAGGAGGCCACGCTGCAGCACGAGG 
TCGACCTCCTCTAGTCGCTCGCCGACC'rrCTCCGGCCGCCCCGGTGCAGGCACGTCT.AGCTCTAC'ITG'rrC'rrCGCGCTCCGGCTCAAGGTCTTCTACGCCGCCCTGGACCTCCTCCGGTGCGACGTCGTGCTCC 
r-
36160 36175 36190 37105 37c_o 37135 37150 37165 3718 
CCACTGCCGCGGCCCTGCGCAAGAAGCACGCCGACAGCGTGGCCG.AGCTGGGCGAGCJI.GA!I'CGACAACCTGCAGCGGGTGAAGCAGAJIGCTGGAGAAGGAGAAGAGCGAGTTCAAGCTGGAGCTGGATGACGTCA 
GGTGACGGCGCCGGGACGCGTTCTTCGTGCGGCTGTCGCACCGGCTCGACCCGCTCGTCTAGCTG'.l'TGGACGTCGCCCACTTCGTCTTCGACCTCTTCCTCTTCTCGCTCAAGTTCGACCTCGACCTACTGCAGT 
37195 38(-0 38125 38140 38,55 38?0 38185 39,00 3)1 
3832Ff-------------------->f 
'CCTCCAACATGGAGCAGATCATCAAGGCCAAGGCTAACCTGGAGAAGATGTGCCGGACC'I.'TGGAAGACCAGATGAATGAGCACCGGAGCAAGGCGGAGGAGACCCAGCGTTCTGTCAACGACCTCACCAGCCAGC 
GGAGGT'rGTACCTCGTCTAGTAGTTCCGG'rrCCGATTGGACCTCTTCTACACGGCCTGGAACc=TGGTCTACTrACTCGTGGCCTCGTTCCGCCTCCTCTGGGTCGCAAGACAGTTGCTGGAGTGGTCGGTCG 
l<-------------------f3894R 
t--
39,30 39,45 39,60 3Y5 39,90 40,05 40,20 40,35 4015 
GGGCCAAGTTGCAAACCGAGAATGGTGAGCTGTCCCGGCAGCTGGATGAGAAGGAGGCACTGA!rCTCCCAGCTGACCCGAGGCAAGCTCACCTACACCCAGCAGCTGGAGGACCTCAAGAGGCAGCTGGAGGAGG 
CCCGGTTCAACG'I"l'TGGCTC'lCCACTCGACAGGGCCGTCGACCTACTCTTCCTCCGTGACTAGAGGGTCGACTGGGCTCCGTTCGAGTGGATGTGGGTCGTCGACCTCCTGGAGTTCTCCGTCGACCTCCTCC 
l<-------------------f3998R 
40,65 40,80 40,95 41?0 41,25 41,40 4\55 .n1
7o 41[8 
AGGTTAAGGCGAAGAACGCCCTGGCCCACGCACTGCAGTCGGCCCGGCATGACTGCGACCTGCTGCGGGAGCAGTACGAGGAGGAGACGGAGGCCAAGGCCGAGCTGCAGCGCGTCCT'rrCCAAGGCCAACTCGG 
TCCAATTCCGCTTCTTGCGGGACCGGGTGCGTGACGTCAGCCGGGCCGTACTGACGCTGGACGACGCCCTCGTCATGCTCCTCCTCTGCCTCCGGTTCCGGCTCGACGTCGCGCAGGAAAGGTTCCGGT'rGAGCC 
4200 42115 42,30 4145 4260 4275 4290 4305 432 
-
I I I I I I 
AGGTGGCCCAGTGGAGGACCAAG'E'!.TGAGACGGACGCCA!I'TCAGCGGACTGAGGAGCTCGAGGAGGCCAAGAAGAAGCTGGCCCAGCGGCTGCAGGAAGCTGAGGAGGCCGTGGAGGCTGTTAATGCCAAGTGCT 
TCCACCGGGTCACCTCCTGGTTCATACTCTGCCTGCGGTAAGTCGCCTGACTCCTCGAGCTCCTCCGGTTCTTCTTCGACCGGGTCGCCGACGTC=-:t'CGACTCCTCCGGCACCTCCGACAA'rl!ACGGTTCACGA 
43,35 43,50 43,65 43,80 43,95 44110 44,25 44,40 4"15 
CCTCGCTGGAGAAGACCAAGCACCGGCTACAGAATGAGATCGAGGACTTGA!l'GGTGGACGTAGAGCGCTCCAATGCTGCTGCTGCAGCCCTGGACAAGAAGCAGAGGAACTTCGACAAGATCCTGGCCGAGTGGA 
GGAGCGACCTCTTCTGGTTCGTGGCCGATGTCTrACTCTAGCTCCTGAACTACCACCTGCATCTCGCGAGGTTACGACGACGACGTCGGGACCTGTTCTTCGTCTCCTTGAAGCTGTTCTAGGACCGGCTCACCT 
44,70 44,85 45,00 45,15 45,30 4545 45,60 45,75 45( 
I- I 4550P(------------------->( 
AGCAGAAGTATGAGGAGTCGCAGTCGGAGCTGGAGTCCTCGCAGAAGGAGGCTCGCTCCCTCAGCACAGAGCTCTTCAAACTCAAGAACGCCTATGAGGAGTCCCTGGAACATCTGGAGACCTrCAAGCGGGAGA 
TCGTCTTCATACTCCTCAGCGTCAGCCTCGACCTCAGGAGCGTCTTCCTCCGAGCGAGGGAGTCGTGTCTCGAGAAGTrTGAGTTCTrGCGGATACTCCTCAGGGACCTTGTAGACCTCTGGAAGTTCGCCCTCT 
46,05 46(0 46,35 46,50 46,65 46,80 46,95 47,10 4y 
4610P(---------------------->I 
ACAAAAACCTGCAGGAGGAGATCTCCGACTTGACTGAGCAGTrGGGTTCCAGCGGAAAGACTATCCATGAGCTGGAGAAGGTCCGAAAGCAGCTGGAGGCCGAGAAGATGGAGCTGCAGTCAGCCCTGGAGGAGG 
TGTTTrTGGACGTCCTCCTCTAGAGGCTGAACTGACTCGTCAACCCAAGGTCGCCTTTCTGATAGGTACTCGACCTCTTCCAGGCTrTCGTCGACCTCCGGCTCTTCTACCTCGACGTCAGTCGGGACCTCCTCC 
[<-------------------[4659R 
1-
47140 47,55 47?0 47,85 48100 48?5 48,30 48,45 4816 
CCGAGGCCTCCCTGGAGCACGAGGAGGGCAAGATCCTCCGGGCCCAGCTGGAGTTCAACCAGATCAAGGCAGAGATCGAGCGGAAGCTGGCAGAGAAGGACGAGGAGATGGAACAGGCCAAGCGCAACCACCTGC 
GGCTCCGGAGGGACCTCGTGCTCCTCCCGTTCTAGGAGGCCCGGGTCGACCTCAAGTTGGTCTAGTTCCGTCTCTAGCTCGCCTTCGACCGTCTCTTCCTGCTCCTCTACCTrGTCCGGTTCGCGTTGGTGGACG 
f-
48?5 48,90 49105 49,20 49135 49,50 49165 49,80 4919 
4897F[------------------->I 
GGGTGGTGGACTCGCTGCAGACCTCCCTGGACGCAGAGACACGCAGCCGCAACGAGGCCCTGAGGGTGAAGAAGAAGATGGAAGGAGACCTCAATGAGATGGAGATCCAGCTCAGCCACGCCAACCGCATGGCCG 
CCCACCACCTGAGCGACGTCTGGAGGGACCTGCGTCTCTGTGCGTCGGCGTrGCTCCGGGACTCCCACTTCTTCTTCTACCTTCCTCTGGAGTTACTCTACCTCTAGGTCGAGTCGGTGCGGTTGGCGTACCGGC 
' 
1-
5o
1
1o 5o
1
25 5o
1
4o 50,55 50?0 5o1
85 51,00 51,15 5113 
CCGAGGCCCAGAAGCAAGTCAAGAGCCTCCAGAGCTTGTTGAAGGACACCCAGA!t'TCAGCTGGACGATGCAGTCCGTGCCAACGACGACCTGAAGGAGAACATCGCCATCGTGGAGCGGCGCAACAACCTGCTGC 
GGCTCCGGGTCTTCGTTCAGTTCTCGGAGGTCTCGAACAACTTCCTGTGGGTCTAAGTCGACCTGCTACGTCAGGCACGGTrGCTGCTGGACTTCCTCTTGTAGCGGTAGCACCTCGCCGCGTTGTTGGACGACG 
I<-------------------[5072R 
I-
51,45 51,60 51?5 51190 52,05 52,20 52,35 52150 5216 
526 
AGGCTGAGCTGGAGGAGTTGCGTGCCGTGGTGGAGCAGACAGAGCGGTCCCGGAAGCTGGCGGAGCAGGAGCTGATTGAGACTAGTGAGCGGGTGCAGCTGCTGCATTCCCAGAACACCAGCCTCATCAACCAGA 
TCCGACTCGACCTCCTCAACGCACGGCACCACCTCGTCTGTCTCGCCAGGGCCTTCGACCGCCTCGTCCTCGACTAACTCTGATCACTCGCCCACGTCGACGACGTAAGGGTCTTGTGGTCGGAGTAGTTGGTCT 
f-
52180 52195 53110 53125 53,40 53,55 53170 53L8s 5'1_0 
8F(------------------->( 
AGAAGAAGATGGATGCTGACCTGTCCCAGCTCCAGACTGAAGTGGAGGAGGCAGTGCAGGAGTGCAGGAATGCTGAGGAGAAGGCCAAGAAGGCCATCACGGATGCCGCCATGATGGCAGAGGAGCTGAAGAAGG 
TCTTCTTCTACCTACGACTGGACAGGGTCGAGGTCTGACTTCACCTCCTCCGTCACGTCCTCACGTCCTTACGACTCCTCTTCCGGTTCTTCCGGTAGTGCCTACGGCGGTACTACCGTCTCCTCGACTTCTTCC 
I<-------------------I5354R 
54(5 54130 54r5 54160• 54(5 54190 55105 55120 5513 
<-
AGCAGGACACCAGCGCCCACCTGGAGCGCATGAAGAAGAACATGGAACAGACCATTAAGGACCTGCAGCACCGGCTGGACGAAGCCGAGCAGATCGCCCTCAAGGGCGGCAAGAAGCAGCTGCAGAAGCTGGAAG 
TCGTCCTGTGGTCGCGGGTGGACCTCGCGTACTTCTTC'rrGTACCTTGTCTGGTAATTCCTGGACGTCGTGGCCGACCTGCTTCGGCTCGTCTAGCGGGAGTTCCCGCCGTTCTTCGTCGACGTCTTCGACCTTC 
55150 55165 55,80 55195 56(0 56,25 56140 56155 5617 
<= 
CGCGGGTGCGGGAGCTGGAGAATGAGCTGGAGGCCGAGCAGAAGCGCAACGCAGAGTCGGTGAAGGGCATGAGGAAGAGCGAGCGGCGCATCAAGGAGCTCACCTACCAGACGGAGGAGGACATGCAGCCGCAGC 
GCGCCCACGCCCTCGACCTCTJ:'ACTCGACCTCCGGCTCGTCTTCGCGTTGCGTCTCAGCCACTTCCCGTACTCCTTCTCGCTCGCCGCGTAGTTCCTCGAGTGGATGGTCTGCCTCCTCCTGTCCTTTTTGGACG 
1<---------
56,85 57.00 57.15 57.30 57,45 57,60 5Y5 57.90 
I 5io 
<~ 
AGGT'rrTTCAGGACCTGGTAGACAAGCTGCAGCTAAAGGTCAAGGCCTACAAGCGCCAGGCCGAGGAGGCGGAGGAGCAAGCCAACACCAACCTGTCCAAGTTCCGCAAGGTGCAGCACGAGCTGGATGAGGCA 
ACGCCGACGTCCTGGACCATCTGTTCGACGTCGATTTCCAGTTCCGGATGTTCGCGGTCCGGCTCCTCCGCCTCCTCGTTCGGTTGTGGTTGGACAGGTTCAAGGCGTTCCACGTCGTGCTCGACCTACTCCGTC 
---------I5680R 
~ 
58to 58,35 58150 58165 58,80 58195 59(0 59,25 5914 
<== 
GAGGAGCGGGCGGACATCGCCGAGTCCCAGGTCAACAAGCTGCGGGCCAAGAGCCGTGACATTGGCACGAAGGGCTTGAATGAGGAGTAGctttgccacatcttgatctgctcagccctggaggtgccagcaaag 
TCCTCGCCCGCCTGTAGCGGCTCAGGGTCCAGTTGTTCGACGCCCGGTTCTCGGCACTGTAACCGTGCTTCCCGAACTTACTCCTCATCgaaacggtgtagaaotagacgagtcgggacctccacggtcgtttcg 
59,55 59?0 59.85 60.00 60?5 60.30 60,45 60.60 6017 
<--
ccccatgctggagoctgtgtaacagctccttgggaggaagcagaataaagcaattttccttgaagccga 
gggtacgacctcggacacattgtcgaggaaccctccttcgtcttatttcgttaaaaggaacttcggct 
1<--------------------j5975R 
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Abbreviations and Symbols 
A adenine 
A Angstrom 
ABI Applied Biosystems International 
ACD Assembly Conserved Domain (at the C-terminal of the 
myosin heavy chain) 
ACT A 1 skeletal muscle alpha actin gene 
ACTC Actin, a, cardiac muscle gene 
AD autosomal dominant 
AD-VCPMD AD-distal myopathy with vocal cord and pharyngeal 
weakness MPD2 
AD H D attention deficit hyperactivity disorder 
a-MyHC alpha myosin heavy chain polypeptide 
a-SG alpha-sarcoglycan (adhalin) 
a-32p alpha-phosphate of a deoxynucleoside triphosphate 
radiolabelled with phosphorous isotope 32p 
ANRI Australian Neuromuscular Research Institute 
AP M affected pedigree member 
APOE apolipoprotein E 
A R autosomal recessive 
ASP affected sib pair 
B blank 
B A C bacterial artificial chromosome 
~-SG beta-sarcoglycan 
BMD Becker muscular dystrophy 
~-MyHC beta myosin heavy chain polypeptide 
(3-MyHC A1663P substitution of alanine by proline at residue 1663 in 
beta-MyHC 
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BRIC 
bp 
c 
c 
C. elegans 
CANP3 
CAV3 
ceo 
eDNA 
CEPH 
CENP-E 
CHLC 
Ci 
CK 
eM 
CMD 
CMH 
CMH1 
CMH2 
CMH3 
CMH4 
CMHS 
CMH6 
benign recurrent intrahepatic cholestasis 
base pairs 
cardiac 
cytosine 
Caenorhabditis elegans 
calpain-3 gene 
caveolin-3 gene 
central core disease 
complementary DNA 
Centre d'Etude du Polymorphisme Humain 
Human centromeric protein-E 
chi-square statistical test 
Cooperative Human Linkage Center 
Curie 
creatine kinase 
centiMorgan 
congenital muscular dystrophy 
cardiomyopathy hypertrophic/hypertrophic 
cardiomyopathy 
cardiomyopathy hypertrophic 1 , caused by mutations in 
MYH7, the myosin heavy polypeptide 7 cardiac muscle, 
beta gene 
cardiomyopathy hypertrophic 2, caused by mutations in 
TNNT2, the troponin T2, cardiac gene 
cardiomyopathy hypertrophic 3, caused by mutations in 
TPM1, the tropomyosin 1 alpha gene 
cardiomyopathy hypertrophic 4, caused by mutations in 
MYBPC3, the myosin binding protein, cardiac C3 
a 'wastebasket' CMH category for forms of CMH not 
linked to any known loci 
hypertrophic cardiomyopathy associated with Wolff-
Parkinson-White Syndrome 
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CMH7 
CMH9 
CMPD 
CNE 
CNS 
COL6A1 
COL6A2 
COL6A3 
CpG islands 
cpm 
C-terminal 
d 
D-segments 
DAPI 
dATP 
dCTP 
oc 
dGTP 
DMAT 
DM1 
DM2 
DMD 
DMPK 
DNA 
dNTPs 
cardiomyopathy hypertrophic 7, caused by mutations in 
TNN/3, the troponin I, cardiac muscle isoform 
cardiomyopathy hypertrophic 7, caused by mutations in 
TTN, the titin gene 
Connecticut Myopathy Distal (family) 
concentric needle electromyography 
central nervous system 
Collagen 6A 1 gene 
Collagen 6A2 gene 
Collagen 6A3 gene 
short stretches of DNA, often <1 kb, containing CpG 
dinucleotides which are unmethylated. Associated 
with genes at a higher frequency than they are found 
elsewhere in the genome 
counts per minute 
towards the carboxyl end of a polypeptide 
map distance between the markers 
anonymous DNA fragments without gene association 
4', 6 diamidino-2-phenylindole 
deoxyadenosine triphosphate 
deoxycytidine triphosphate 
degrees Celsius 
deoxyguanosine triphosphate 
distal anterior compartment (tibial) myopathy 
myotonic dystrophy 1 
myotonic dystrophy 2 
Duchenne muscular dystrophy 
protein kinase gene with an expanded CTG repeat in its 
3' untranslated region which is associated with myotonic 
dystrophy 
deoxyribonucleic acid 
deoxynucleoside triphosphates 
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D-number 
D-segment 
DOE 
DRPLA 
ds 
6-SG 
dlTP 
DYSF 
e 
ECG 
E. coli 
EDB 
EDMD 
EDTA 
ELC 
EM 
Emb 
ENMC 
EMD 
EMG 
EST(s) 
F 
F 
<I> 
FA 
FACC 
FDC-CDM 
anonymous number, eg patient or sample number 
anonymous DNA fragment 
US Department of Energy 
dentatorubral pallidoluysian atrophy 
double-stranded (DNA) 
delta-sarcoglycan 
deoxythymidine triphosphate 
dysferlin gene 
base of natural logarithms 
electrocardiogram 
Escherichia coli 
extensor digitorum brevis 
Emery-Dreifuss muscular dystrophy 
disodium ethylene diamine tetra-acetate 
essential light chain (of the myosin II hexamer) 
electron microscope 
embryonic muscle 
European Neuromuscular Centre 
Emerin gene 
electromyography 
expressed sequence tags 
familial (as applied to disease) 
forward primer (in PCR or sequencing) 
Yule coefficient 
Fanconi anaemia 
Fanconi anaemia complementation group-e gene 
AD familial dilated cardiomyopathy (FDC), cardiac 
conduction-system disease (CD) and myopathy (M) with 
adult-onset limb-girdle muscular dystrophy [FDC-CDM] 
403 
F-factors. 
FB 
FISH 
5' 
FMR1 
FRAXA/FRAXE 
FSHD 
FVC 
G 
g 
y-SG 
GOB 
gDNA 
3H 
Ho 
h-IBM 
HD 
HGP 
HIV-1 
HMM 
HUGO 
HLA 
HLA-DR2 
HRR 
IBD 
IBM 
18M3 
'fertility' plasmids in bacteria 
factor VIII, haemophilia A, disease gene 
fluorescent in situ hybridisation 
five prime 
fragile~ X gene 
fragile-X syndromes 
facioscapulo-humeral muscular dystrophy 
forced vital capacity 
guanine 
grams 
gamma-sarcoglycan 
Genome Data Base 
genomic DNA 
tritium 
disease and marker locus are unlinked 
disease and marker locus are linked 
hereditary inclusion body myopathy 
Huntington disease 
Human Genome Project 
human immunodeficiency virus 1 
heavy meromyosin fragment of the myosin heavy chain 
Human Genome Organisation 
histocompatibility complex of loci 
HLA allele within the major histocompatibility complex 
haplotype relative risk 
identical by descent 
inclusion body myopathy 
hereditary inclusion-body myopathy associated with a 
mutation in a chromosome 17 MYH gene 
404 
IBS 
IDDM 
IEC 
INI 
IRP 
in situ 
in vitro 
in vivo 
IRE-PCR 
ITGA7 
J 
kb 
identical by state 
insulin-dependent diabetes mellitus 
International Equipment Company 
intranuclear tubular filament inclusions 
CpG Island Rescue PCR 
in location 
in glass/in the test tube 
in a living system 
interspersed repeat element PCR 
integrin-a 7 gene 
Joule 
kilobase 
litre 
lac-z beta-galactosidase gene 
LA MA2 alpha-2 laminin gene 
'A lambda bacteriophage 
'AEMBL3 SP6ff7 human genomic library (CLONTECH) 
'A.Gem 11 human genomic library (Promega) 
LM M light meromyosin proteolytic fragment of the myosin 
heavy chain molecule which comprises the C-terminal 
two-thirds of the rod. Responsible for MyHC self-
association and forms the backbone of the thick filament 
lod (score) the decadic logarithm of the odds that loci are linked 
LGMD limb-girdle muscular dystrophy 
LIPED linkage analysis computer program 
LOOM AD-Markesbery distal myopathy 
LO H loss of heterozygosity 
m connecting meioses 
M molar 
Mb megabase 
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MCA 
MD(s) 
MEl 
MHC 
MIM 
.ul 
.ug 
ml 
mM 
MM 
MMLV-RT 
MPD1 
MPD2 
MAC 
mANA 
MS 
MTM 
MTM1 
MyBP-C 
MYBPC3 
MYH 
MYH6 
MYHl 
MyHC 
MyHC-A 
MYL3 
MYL2 
multiple congenital anomaly (syndromes) 
muscular dystrophy (dystrophies) 
muscle, eye and brain disease 
major histocompatibility complex 
Mendelian inheritance in man 
micro litre 
micrograms 
millilitre 
millimolar 
Miyoshi myopathy 
Maloney murine Leukaemia virus-Reverse Transcriptase 
myopathy, distal1 
myopathy, distal 2 
Medical Research Council 
messenger ribonucleic acid 
multiple sclerosis 
myotubular myopathy 
myotubularin 1 gene 
myosin binding protein-C 
Myosin binding protein, cardiac C3 gene 
myosin heavy chain genes 
myosin heavy polypeptide 6, cardiac muscle, alpha 
gene 
myosin heavy polypeptide 7, cardiac muscle, beta gene 
myosin heavy chain polypeptide (of the myosin II 
hexamer) 
fruit fly Drosophila melanogaster embryonic muscle 
myosin heavy chain 
Myosin, light chain, alkali; ventricular and skeletal slow 
gene 
Myosin, light chain 2; regulatory ventricular gene 
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N 
NCS 
NIH 
NCB I 
ng 
NM 
N-terminal 
NT-3 
OAT 
OMIM 
OPMD 
ORF(s) 
p 
p 
P1 
PABP2 
PAH 
PAC 
parA/parB 
PCR 
PEl 'paper' 
pfu 
pg 
pH 
phage 
PKU 
poly-A 
pREP4 
pter 
unaffected (within pedigree symbol) 
nerve conduction studies 
National Institutes of Health 
National Centre for Biotechnology Information 
nanogram 
non-muscle 
towards the amide end of a polypeptide 
neurotrophin-3-deficient (mice) 
ornithine-d-aminotransferase 
online Mendelian inheritance in man 
oculopharyngeal muscular dystrophy 
open reading frame(s) 
probability/threshold of significance 
short arm (petite) of human chromosomes 
bacteriophage plasmid vector 
poly( A) binding protein 2 gene 
phenylalanine hydroxylase gene/PKU disease gene 
P1-derived artificial chromosomes 
F-factor genes which limit copy number to 1 or 2 per cell 
polymerase chain reaction 
chromatographic acetate strip 
plaque forming units 
picograms 
decadic logarithm of the hydrogen ion concentration 
bacteriophage 
phenylketonuria 
RNA sequence with multiple repeating adenine bases 
eDNA expression shuttle vector 
p terminus of a chromosome 
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PTS(s) 
q 
QMPD 
? 
qter 
A 
RB1 
RED 
REF 
RFLP(s) 
RH panel 
RLC 
rSSCP 
RV(s) 
RNA 
RNase H 
AT 
s 
s 
81 
82 
SBMA 
SCA 
SDS 
SCM 
promoter-tagged site(s) 
long arm of human chromosomes 
Queensland Myopathy Distal (family) 
unknown status (within pedigree symbol) OR 
haplotype/recombination uncertainty (next to haplotype) 
q terminus of a chromosome 
reverse primer (in PCR or sequencing) 
retinoblastoma 1 gene 
repeat expansion detection . 
restriction endonuclease fingerprinting 
restriction fragment length polymorphisms(s) 
radiation hybrid panel 
regulatory light chain (of the myosin II hexamer) 
RNA single-strand conformation polymorphism 
rimmed vacuole(s) 
ribonucleic acid 
enzyme which will produce nicks and gaps in eDNA: 
mANA hybrids, thus creating a series of primers for 
subsequent amplification 
reverse transcriptase 
skeletal muscle 
sporadic 
myosin heavy chain proteolytic subfragment comprising 
the globular head, the convertor domain and an a-helical 
neck region 
myosin heavy chain proteolytic subfragment comprising 
the N-terminal one-third of the MyHC rod region which 
contains a myosin binding protein-C binding site at its N-
terminal end, and a hinge-like region at its C-terminal end 
spinal and bulbar muscular atrophy 
spinocerebellar ataxia 
sodium dodecyl sulphate 
sternocleido-mastoid 
408 
SCAR MD 
Seq Ed 
SG 
SGP 
Sm 
SM buffer 
SMMyHC 
SNP(s). 
SOD1 
sse buffer 
SSCP 
ss 
St 
STE buffer 
STS 
t 
T 
Taq 
Taq polymerase 
TOT 
e 
3' 
TMD 
TNN/1 
TNN/3 
TNNT2 
severe childhood autosomal recessive muscular 
dystrophy 
sequence editor (used for DNA and polypeptide 
sequences) 
sarcoglycan 
sarcoglycanopathy 
smooth muscle 
sodium chloride, magnesium sulphate, Tris Cl buffer 
human smooth muscle myosin heavy chain 
single nucleotide polymorphism(s) 
copper zinc superoxide dismutase 
sodium chloride, sodium citrate buffer 
DNA single-strand conformation polymorphism 
single-stranded {applied to DNA and RNA) 
striated muscle 
sodium chloride, Tris, EDT A buffer 
single-copy, unique 100-250 bp sequence of DNA 
original symbol for recombination fraction/ 
probability of recombination 
thymine 
acronym prefix for thermostable 'Tact DNA polymerase 
extracted from Thermus aquaticus. Also used as a prefix 
to describe the buffer for Taq DNA polymerase 
Taq DNA polymerase 
transmission disequilibrium test 
theta (recombination fraction) 
three prime 
tibial muscular dystrophy (Udd myopathy) 
slow skeletal muscle troponin gene 
troponin I, cardiac muscle isoform gene 
troponin T2, cardiac gene 
409 
TPM1 
TPM2 
TTN 
TrisCI 
tRNA 
TIE 
Tth 
Tth polymerase 
TBE 
u 
u 
UTR 
VDR 
VNTR(s) 
v 
WA 
WAMPD 
WAOPMD 
WDM 
wG 
X 
XL-PCR 
XL-r polymerase 
YAC 
tropomyosin 1 alpha gene 
beta-tropomyosin gene 
titin gene 
chloride stabilised Tris 
transfer RNA 
transthoracic echocardiogram 
acronym prefix for thermostable 'Tttl DNA polymerase 
extracted from Thermus thermus. Also used as a prefix 
to describe the buffer for Tth DNA polymerase 
Tth DNA polymerase 
Tris-borate/EDT A electrophoresis buffer 
unit (physiological) 
unit (enzymatic) 
untranslated region 
Vitamin D Receptor 
variable number tandem repeat(s) 
volts 
Western Australian 
Western Australian Myopathy Distal (family) 
a Western Australian family segregating a putative 
form of oculopharyngeal muscular dystrophy 
Welander distal myopathy 
weeks of gestation 
'times' or multiplied by 
extra-long PCR 
recombinant 'extra-long' DNA polymerase with 
editing/proof reading capacity 
yeast artificial chromosomes 
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